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The majority of antibiotics prescribed for treatment of bacterial infections are β-lactam antibiotics. 
Resistance to these has evolved in a few different ways, notably by regulating permeability and by the 
expression of β-lactamases which hydrolyze the antibiotic before it reaches its target. Three of the 
classes of β-lactamases (classes A, C and D) are serine-β-lactamases (SBLs) and the fourth class 
(Class B) consists of metallo-β-lactamases (MBLs) that rely on one or two zinc ions for their catalytic 
activity. Bacteria producing β-lactamases that are capable of hydrolyzing the β-lactam bond in all of 
the classes of β-lactam antibiotics including penicillins, monobactams, cephalosporins and 
carbapenems are of great clinical concern. As a consequence of the increasing prevalence of 
resistance, there is much interest in the discovery of inhibitors for such clinically important β-
lactamases as well as in the discovery of β-lactam antibiotics that are less susceptible to inactivation 
by β-lactamases.  
Described in this thesis are the kinetic properties of new chromogenic cephalosporin-type 
substrates that are susceptible to hydrolysis by clinically important SBLs and MBLs but that exhibit a 
much more pronounced colour change upon hydrolysis than does the commercially available and 
widely used chromogenic cephalosporin called nitrocefin. Some of these substrates also offer more 
favourable kinetic properties for assaying MBLs in vivo. 
Also in this thesis, biochemical as well as microbiological investigations of several classes of SBL 
and MBL inhibitors are describes as well as one class of cephalosporins that exhibit inhibition of 
MBLs and surprising antibacterial potency against certain clinically significant MBL-producing 
Gram negative bacteria. 
More specifically, 6-phosphonomethylpyridine-2-carboxylates (PMPCs) and a number of 
derivatives thereof, synthesized previously in this research group have been shown in this thesis 
research to be potent inhibitors (low to submicromolar Ki) of the major Class B1 MBLs, IMP-1, 
VIM-2, NDM-1 and SPM-1 as well as the Class B3 MBL L1, all of which are dizinc enzymes,  and 
somewhat less potent inhibitors of the monozinc Class B2 MBL, SFH-1, which is of lesser clinical 
significance.  These compounds that are expected to exhibit metal-binding characteristics were found 
to exhibit a time-dependent inhibition mechanism which fits a kinetic mechanism that is consistent 
with slow binding to the active site and even slower release of the inhibitor without expulsion of the 
metal ions form the MBL active site.  Microbiological investigations were also carried out involving 
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combinations of PMPCs with the carbapenem antibiotic meropenem and demonstrated an ability of 
the PMPCs to lower the MICs of meropenem against of MBL-producing clinical strains of Eschericia 
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and 
Stenotrophomonas maltophilia thus encouraging further research on even more potent PMPCs for 
potential clinical use in combination with carbapenems. 
Another class of MBL inhibitors that was studied consist of cephalosporin derivatives that 
incorporate an aromatic thioester linked to C3ʹ of the cephalosporin core.  It was found that inhibition 
of the Class B3 MBL L1 was likely the consequence largely of the binding of an arylthioacid 
conjugate base to the active site zinc ions after its expulsion from the hydrolysis product of the 
cephalosporin.  This led to a study of the MBL-inhibitory properties of a series of synthetic 
arylthioacids, a class of compounds that have not been well studied as metallo enzyme inhibitors.  
These compounds were found to be poor inhibitors of Class B1 MBLs (IMP-1, VIM-2, NDM-2 and 
SPM-1) but good inhibitors of the B3 MBL L1.  These observations are consistent with inhibition of 
Class B1 MBLs arising not from the arylthicarboxylate released but from binding the cephalosporin-
derived metal-binding species formed upon expulsion of the arylthiocarboylate from the active site. 
A further enzyme kinetic study revealed that synthetic samples of pyridine-2,6-bis(carbothioic) 
acid and 6-thiocarboxy-picolinic acid, previously known as Fe3+-binding siderophores produced by 
some species of Pseudomonas, were good inhibitors of Class B1 and B3 MBLs and also exhibited an 
ability to lower the MIC of meropenem against MBL-producing clinically important Gram negative 
bacteria. 
One cephalosporin called UW-123 with at C3ʹ-arylacylthio group and a siderophore mimic 
attached to the amide group at C7 was studied in some detail microbiologically and found to exhibit 
good standalone antibiotic activity against certain MBL-producing Gram-negative bacteria especially 
those producing the widespread MBL VIM-2.  UW-123 was also shown to be bacteriostatic and to 
bind preferentially to induce filamentation of E. coli cells.  It was found to bind most strongly to PBP 
3 and 1a but also significantly to PBP1b and 4 in P. aeruginosa.  In E. coli, UW-123 bound most 
tightly to PBP3 but also significantly to PBP1a/b and PBP2. 
Finally, the ability of a cyclobutanone mimic of penem antibiotics JJ05-1058, previously prepared 
in this laboratory, to inhibit both SBLs and MBLs was demonstrated and the ability of this compound 
to bind to the low molecular weight penicillin binding proteins was observed suggesting that such 
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compound may have some promise as broad  spectrum MBL/SBL inhibitors and possible also as 
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1.1 Antibiotic Classes and Targets 
1.1.1 Overview of Antibiotics 
Prior to the advent of antibiotics, approximately one third of deaths were the result of bacterial 
infection.1 The discovery of penicillin by Sir Alexander Fleming in 1929 and its subsequent 
identification and use as a clinical therapeutic in 1940 and 1941 respectively by Chain and Florey, 
heralded the age of antibiotics.2–4 The sulfa drugs were discovered in the 1930’s in Germany, and 
represent the first synthetic antibiotics.5 Over the next few decades the discovery and development of 
a wide variety of antibiotics burgeoned, reducing the relative number of deaths from bacterial 
infection substantially.1,6 Among the bacterial pathogens that remain problematic, are the nosocomial 
“ESKAPE” pathogens: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacter species (spp.). These 
pathogens are considered important for the study of antibiotic susceptibility due to the incidence of 
infections from these as well as their pathogenesis, transmission, and resistance.7 These ESKAPE 
pathogens also represent 5 of the 9 pathogens designated by the World Health Organization (WHO) 
as critical or high priority targets for the development of new antibiotics.8 Other high priority 
pathogens on the WHO list are Helicobacter pilori, Campylobacter spp., Salmonellae, and Neisseria 
gonorrhoeae. 
In addition to designating which target pathogens are most in need of new antibiotics, the WHO 
has designated which current antibiotics are most important. Critically important antibiotics have 
been defined as those that are the only therapy (or one of limited available therapies) for serious 
bacterial infections and can either treat bacterial infections that can be transmitted from non-human 
sources or acquire resistance from non-human sources.9 As of 2017, the critically important antibiotic 
classes are aminoglycosides, ansamycins, β-lactams (carbapenems, 3rd, 4th, and 5th generation 
cephalosporins, monobactams, and penicillins), glycopeptides, glycylcyclines, isoniazid, lipopeptides, 
macrolides, oxazolidinones, fosfomycin, polymixins, and quinolones.9 Representative drugs from 




Figure 1.1 Critically important antimicrobials for human medicine. 
The structural diversity of antibiotics seen in Figure 1.1 correlates with target diversity.10 The most 
common target systems are protein synthesis and cellular envelope stability with several molecular 
targets existing within each system. Protein synthesis can be inhibited through binding of antibiotics 
to either the 30S or 50S subunit of the ribosome.11 Destabilization of the cellular envelope can occur 
through several mechanisms targeting either the cell wall or the bacterial membranes. The cell wall 
integrity can be compromised by either capping the polymerizing cell wall subunit or inhibiting the 
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enzymes responsible for subunit synthesis or polymerization.12 The membrane integrity can be 
compromised by pore formation causing membrane depolarization or dissolution by detergent-like 
antibiotics.13,14 
Table 1.1 Mode of action of established antibiotics. 15 
Drug / class Target System Molecular Target 
β-lactams Cellular envelope Penicillin binding proteins 
Fosfomycin Cellular envelope MurA (NAM synthesis) 
Vancomycin Cellular envelope Peptidoglycan 
Daptomycin Cellular envelope (Gram positive) Cytoplasmic membrane 
Colistin Cellular envelope (Gram negative) Outer membrane 
Isoniazid Cellular envelope (Mycobacteria) InhA (Mycolic acid synthesis) 
Quinolones DNA replication Gyrase and Topoisomerase IV 
Ansamycins Transcription RNA polymerase 
Aminoglycosides Protein synthesis 30S ribosomal subunit 
Tetracyclines Protein synthesis 30S ribosomal subunit 
Chloramphenicol Protein synthesis 50S ribosomal subunit 
Macrolides Protein synthesis 50S ribosomal subunit 
Oxazolidinones Protein synthesis 50S ribosomal subunit 
Sulfonamide Folic acid synthesis Dihydropteroate synthetase 
 
Despite the wide array of established antibiotics, the β-lactams are the most prescribed class of 
antibiotic consisting of 50 % of antibiotic usage in Canada in 2017.16,17 There are 4 main structural 
classes of β-lactam antibiotics: penicillins, cephalosporins, carbapenems, and monobactams (Figure 
1.2) which can be distinguished by the size and heteroatom composition of the ring fused to the β-
lactam or by the lack of a fused ring. 
β-Lactam antibiotics exert their antibacterial activity through inhibition of critical cell wall 
synthesis proteins known as penicillin binding proteins (PBPs). PBPs are enzymes that can be 
membrane anchored or associated with peptidoglycan, which catalyze the elongation and crosslinking 
of peptidoglycan to form the rigid component of the cell wall. Each bacterial strain has a different 





Figure 1.2 Representative antibiotics from each major class of β-lactams  with the β-lactam 
functionality highlighted in blue. 
Bacteria have developed resistance to antibiotics through three main mechanisms: target 
modification, antibiotic inactivation, and reduction of drug accumulation.19–21 Resistance to β-lactams 
occurs through all of the aforementioned mechanisms although primarily by antibiotic inactivation 
through the expression of enzymes, known as β-lactamases, that hydrolyze the β-lactam ring.22 There 
are two mechanistic classes of β-lactamases, serine-β-lactamases (SBLs) and metallo-β-lactamases 
(MBLs) both of which are present and problematic in bacterial pathogens.23–26 With the increasing 
prevalence of β-lactamases in pathogenic bacteria, inhibition of β-lactamases through combination 
therapy is vital for reinstating the efficacy of β-lactam antibiotics.27,28  
This introductory chapter provides a brief overview of β-lactam antibiotics and penicillin-binding 
proteins with emphasis on those present in E. coli and P. aeruginosa, followed by a more in depth 
look at β-lactamases and β-lactamase inhibitors. 
1.1.2 β-Lactam Antibiotics 
1.1.2.1 Discovery of Penicillin 
As indicated above, Sir Alexander Fleming is widely credited with the discovery of penicillin 
which arose from a Penicillium notatum contaminant on one of his Staphylococcus culture plates. He 
observed that the bacteria in the vicinity of the mould had lysed and become transparent. Subsequent 
experiments with subcultures of the mould determined that the Penicillium mould was excreting an 
antibiotic into the medium which was responsible for the death of the staphylococci in the original 
plate.2 Although Fleming was the first to understand the significance of these results, he was not the 
first to observe them: John Burdon Sanderson observed a similar phenomenon in liquid media in 
1870 but incorrectly interpreted the results to mean that fungi were airborne but bacteria were not.29 
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Inspired by Sanderson’s observations, Joseph Lister, John Tyndall, and Thomas Henry Huxley also 
explored the antibacterial properties of Penicillium spp. through the 1870’s.30 Lister disproved 
Sanderson’s hypothesis that bacteria could not be airborne and suggested that Penicillium spp. make 
liquid media less favourable for bacterial growth.31 Tyndall then suggested that they made liquid 
media unfavourable by covering the surface of the media, thereby depriving the bacteria of oxygen.32 
Huxley disproved Tyndall’s hypothesis, showing that oxygen deprivation was not the cause of the 
antibacterial effect but rather the mould in solution was making the media unfavourable for growth.33 
Throughout the late-1800’s and early-1900’s, several scientists noted the antibacterial properties of 
moulds and the abilities of extracts of moulds to be used as treatments for bacterial infections, but 
none of them had identified the causative agent for these effects.34 It was Fleming’s work in 1928 that 
finally established that the antibacterial effect of this mould was being caused be a compound 
excreted from Penicillium notatum which was not excreted from other moulds.2 
In the summary of Fleming’s 1929 paper, he suggests that penicillin could be an effective antibiotic 
with clinical applications, although he did not do any studies on infected patients (human or animal).2 
The clinical usefulness of penicillin was established by Chain and Florey in their 1940 paper where 
they showed the efficacy of penicillin in treating mice infected with Streptococcus pyrogenes, 
Staphylococcus aureus, or Clostridium septique (modern name: Clostridium septicuma).4 Human 
trials of penicillin began in January 1941 when a penicillin infusion was injected into a terminally ill 
breast cancer patient to determine toxicity in humans – she showed no adverse effects initially and 
within a few hours developed a high temperature and died. It was determined that the cause of the 
increased temperature was an impurity, not penicillin itself. The first patient treated with penicillin 
was a policeman with combined staphylococcal and streptococcal septicemia who was “desperately 
and pathetically ill”. He showed improvement within the first day and was almost healthy after five 
days. Unfortunately, they had exhausted Florey’s supply of penicillin and could not treat the man any 
further – he died a month later from the infection. After shifting the trials towards children (less 
                                                     
a The strain referred to in Chain et al. 19404 is denoted “Cl. septique Nat. coll. type-cultures No. 458”. The 
NCTC entry for No. 458 is Bordetella bronchiseptica which does not cause the gas gangrene described by 
Chain et al..553 It is probable that this is a typographical error in which the NCTC entry should be No. 547 (548 
does not exist) which is Clostridium septicum (formerly Vibrio septique), the strain used by Henderson and 
Gorer in the paper referenced by Chain et al. in the methods section.554 The change in nomenclature from V. 
septique to C. septicum appears to have occurred in 1935 and references to C. septique occur throughout the 
1940’s (referring to NCTC No. 547).555–558 
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penicillin was required for smaller patients), there was a string of successes in which the patient was 
saved or only died because the treatment was too late.3 Fleming, Chain, and Florey were awarded a 
Nobel Prize in Physiology or Medicine in 1945 for their contributions to the discovery and 
development of penicillin. 
1.1.2.2 Modern β-Lactams 
In the decades that followed Fleming’s discovery of penicillin, a host of other antibiotics were 
discovered and developed.35 The next leap forward in β-lactam antibiotics was discovery of 
cephalosprin C in 1948 from a strain of Cephalosporium (modern name: Acermonium) fungus by 
Guiseppe Brotzu.36 The natural cephalosporins had modest antibacterial activity but had a stable ring 
system that made them ideal for chemical modification which lead to the four generations of semi-
synthetic cephalosporins which were much more potent than their natural counterparts.34,37 In 1976, a 
new family of β-lactams were discovered in extracts from Streptomyces olivaceus, the olivanic acid 
family carbapenems.38 Another family of carbapenems, the thienamycin carbapenems, was 
discovered around the same time from Streptomyces cattleya; although, neither of these families of 
natural carbapenems were stable enough for clinical use.39,40 A semi-synthetic effort in the late-1970’s 
by scientists at Merck yielded imipenem (Figure 1.3), a carbapenem that had a broader spectrum of 
activity than any of the cephalosporins, and was resistant to hydrolysis by many of the enzymes that 
hydrolyze penicillins and cephalosporins.40–42 Imipenem, like thienamycin, is susceptible to 
inactivation by renal dehydropeptidase I (DHP-I) and has to be administered in combination with 
cilastatin, a DHP-I inhibitor, to prevent degradation and the formation of nephrotoxic metabolites.40 
 
 
Figure 1.3 Chemical structures of imipenem and cilastatin. 
To date, there are four major structural classes of β-lactam antibiotics: penicillins (penams), 
cephalosporins (cephems), carbapenems, and monobactams. Other β-lactam classes include penems, 
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cephams, penamycins, oxapenems, cephamycins, oxacephems, oxacephamycins, and carbacephems 
(Figure 1.4).34,43  
 
Figure 1.4 Core structures of β-lactam antibiotic families. 
While antibiotics from all four major classes of β-lactams are still used clinically, many pathogens 
have developed resistance to some or all of them. 
1.1.3 Bacterial Resistance 
In human medicine, antimicrobials are one of the most prescribed drugs, although the Centers for 
Disease Control (CDC) has estimated that as many as 50 % of these prescriptions are unnecessary.44 
As a result of this systemic misuse through over-prescribing, not abiding by treatment regimens, and 
addition to feed stocks for food animals; bacteria have developed resistance to all of the antibiotic 
classes mentioned in Table 1.1.35 The first report of the incidence of bacterial resistance to antibiotics 
was in 1940 when enzyme (β-lactamase)-mediated resistance to penicillin was observed in E. coli.45 It 
has been suggested that the existence of β-lactamases pre-dates the antibiotic era by millions of years 
since penicillin is a naturally occurring antibiotic used in signaling and potentially germ warfare 
among microbes.46,47 In response to spreading resistance, the use of some antibiotics, such as third-
generation cephalosporins and carbapenems, has been restricted to hospitals.48 
Bacteria can acquire resistance through random chromosomal mutation or horizontal gene transfer. 
These adaptations lead to resistance through one of three general mechanisms: target modification, 
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compound modification, or accessibility. Target modification can occur through mutation or 
enzymatic alteration, target bypass or replacement, or target protection through the expression of 
molecules that compete for drug binding. Compound modification often involves the expression of an 
enzyme or group of enzymes that chemically modify the antibiotic compound rendering it inactive 
against its target. Resistance through moderating accessibility is often the result of decreasing 
permeability of the outer membrane by reducing the expression of outer membrane porins (uptake 
proteins), increasing the expression of efflux pumps, or the formation of biofilms.19–21 
Resistance to β-lactams can occur through several of the mechanisms listed above. Methicillin-
resistant Staphylococcus aureus (MRSA) acquires its β-lactam resistance through target replacement 
with the expression of PBP2a, a PBP that is not present in wild type S. aureus and is not inactivated 
by most β-lactam antibiotics.49 Imipenem resistance in Pseudomonas aeruginosa is known to occur 
through decreased production of OprD, an outer membrane porin responsible for the uptake of basic 
amino acids, as well as through the increased expression of multidrug efflux pumps.50–52 The 
predominant mechanism of β-lactam resistance occurs through the production of β-lactamases, 
enzymes that hydrolyze the β-lactam ring thereby inactivating the antibiotic as demonstrated in 
Scheme 1.1. 
 
Scheme 1.1 Generalized hydrolysis of β-lactam by a β-lactamase. 
There are approximately 2000 currently known β-lactamases, of which, several hundred are 
carbapenemases – enzymes capable of hydrolytically inactivating carbapenems.53–55 The most 
problematic carbapenemases are the metallo-β-lactamases (MBLs) which are uninhibited by all 
clinically available β-lactamase inhibitors. Additionally, MBLs are often carried on mobile genetic 
elements with multiple β-lactamases and resistance factors for other antibiotics.56 The increasing 




1.2 Penicillin Binding Proteins 
1.2.1 Bacterial Cell Wall Structure 
The cellular envelopes of bacteria are responsible for creating a stable barrier between the cell and 
its environment that is rigid enough to maintain cell shape and resist lysis in dilute solutions while 
being permeable enough to transport nutrients in and waste out. There are three types of cellular 
envelope: Gram-positive, Gram-negative, and atypical which are broadly classified by Gram staining. 
The cellular envelope of Gram-positive bacteria consists of an inner cell membrane coated in a thick 
layer of peptidoglycan – the rigid component of bacterial cell walls. Gram-negative bacteria have a 
similar inner membrane coated in a much thinner layer of peptidoglycan which is covered by another 
membrane layer referred to as the outer membrane. Both Gram positive and Gram negative cellular 
envelopes have a space between the inner membrane and peptidoglycan known as the periplasm that 
contains numerous proteins in a reducing environment.57 Atypical bacteria lack peptidoglycan either 
as part of their native state (eg. Mycoplasma spp.) or due to degradation of their peptidoglycan (L-
forms).58Atypical bacteria will not be discussed further as they do not respond to β-lactam antibiotics 
due to their lack of peptidoglycan; however, more information on this topic can be found in 
reviews.59–61 
 
Figure 1.5 Gram positive and Gram negative cellular envelope composition. 62,63 Membrane 
graphics were generated using ChemDraw Pro v. 17.0. 
The bacterial cell wall is constructed using several enzymes, key among them, the penicillin 
binding proteins (PBPs). These proteins are responsible for the synthesis and recycling of 
peptidoglycan as well as some regulation of its size and the extent of crosslinking. As should be 
expected, these proteins are primarily located on the periplasmic face of the inner (cytosolic) 
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membrane in complexes with other PBPs and proteins involved in cell shape maintenance and 
septation.64 Some of the smaller PBPs such as E. coli PBP 4 are associated with peptidoglycan instead 
of being membrane bound.65 The localization and function of PBPs as well as other proteins involved 
in cell shape and septation in rod shaped bacteria has been reviewed by den Blaauwen.64 
1.2.2 PBP Functional and Structural Classification 
Historically, penicillin-binding proteins were defined as membrane associated proteins that would 
bind penicillin G. Much of the early work in this field was performed using gel based assays with 14C 
isotopically labelled penicillin G, and as such, the nomenclature for PBPs has been broadly defined 
by molecular weight where the heaviest PBP was denoted PBP 1 and lighter ones followed in 
sequence.66 An appreciable difference in the necessity and functionality of PBPs was observed and 
they were split into two groups: high molecular mass (HMM) and low molecular mass (LMM). The 
naming of PBPs by molecular mass has proven inconvenient as different organisms express different 
quantities of PBPs and functionality is not strictly correlated with mass; thus PBP 2 from one 
organism may have a different function than PBP 2 from another organism. 
1.2.2.1 Reactions Catalyzed by PBPs 
Peptidoglycan (or murein) is a highly crosslinked polymer made from the precursor, lipid II, which 
is synthesized in the cytoplasm before being flipped into the periplasm using a flippase. Lipid II is 
composed of three major groups: the membrane anchor, the glycan backbone, and the pentapeptide, 
as shown in Figure 1.6. The membrane anchor is embedded in the inner membrane, keeping this 
substrate in close proximity to the HMM PBPs which are responsible for its polymerization as they 
are also membrane bound. The polymerization of lipid II into peptidoglycan is achieved by sequential 
additions of the N-acetylmuramic acid-N-acetylglucosamine (NAM-NAG) disaccharide portion of the 
molecule to form a glycan backbone. Finally, the pentapeptide is the portion of peptidoglycan that is 
crosslinked to increase the structural integrity of the cell wall. In the majority of Gram negative 





Figure 1.6 Structure of Lipid II, the peptidoglycan precursor with the membrane anchor 
highlighted in red, the glycan backbone in black, and the pentapeptide in blue.  
There are four reactions that are catalyzed by the various PBPs in the periplasm: glycosyltransfer, 
transpeptidation, DD-carboxypeptidation, and DD-endopeptidation. The glycosyltransferase 
capabilities of certain HMM PBPs polymerize the carbohydrate moiteies of the lipid II substrate to 
make a linear layer of the cell wall. The different layers are crosslinked at the pentapeptide between 
the fourth member of the donor peptide, D-Ala, and the amine on the sidechain of the m-DAP of the 
acceptor peptide using the transpeptidase functionality of HMM PBPs which offers structural stability 
to the cell wall.68 The degree of crosslinking is controlled by LMM PBPs that act as DD-
carboxypeptidases which remove the terminal D-alanine, preventing crosslinking.69,70 A few of the 
LMM PBPs also have DD-endopeptidase activity which hydrolyzes the peptide crosslink as part of 
septation and murein turnover.71,72 The penicillin binding domain of each PBPs use a catalytic serine 
residue and a water molecule in their active site to first form an acyl-enzyme with the substrate which 
is then subsequently attacked by an acceptor (transpeptidase) or hydrolyzed (DD-carboxypeptidase 
and DD-endopeptidase).68 The reactions carried out by PBPs are summarized in Scheme 1.2. For a 
more comprehensive depiction of the reactions involved in bacterial cell wall biosynthesis and 





Scheme 1.2 Reactions catalyzed by PBPs: glycosyl transfer, transpeptidation, 
carboxypeptidation, and endopeptidation. 68,70,73–75 
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The critical role of PBPs in the synthesis of bacterial cell walls makes them an ideal target for 
antibiotics, namely β-lactams. The inhibition of a PBP by a β-lactam occurs when the active site 
serine of the PBP binds and attacks the amide of the β-lactam, forming an acyl enzyme as shown in 
Scheme 1.3. Unlike with its natural substrate, the acyl enzyme formed between a PBP and a β-lactam 
is very slow to hydrolyze with a half-life of around 10 hr, leading to covalent inactivation of the 
PBP.73 
 
Scheme 1.3 Inactivation of PBPs by a β-lactam. 
1.2.2.2 Classification of PBPs 
A classification system for the PBPs was developed by Goffin and Ghuysen based on the 
nomenclature of E. coli PBPs which focused on the functionality and amino acid sequence of HMM 
PBPs.68 This system has been further refined by Sauvage et al. to include classification of LMM PBPs 
and PBPs from Actinomycetes and Cyanobacteria using structure and function as classification 
determinants.18 For simplicity, this section will only cover PBPs in Gram positive and Gram negative 
bacterial pathogens with most attention being paid to E. coli, P. aeruginosa, B. subtilis, S. aureus, and 
S. pneumoniae. Several excellent reviews are recommended for more detailed information on the 
structural and functional classification of PBPs.18,68,73,76 
The high molecular mass PBPs are multimodular, membrane bound proteins that can be classified 
as one of two classes: Class A consists of any PBP with a transglycosylase functionality at the N-
terminal and Class B consists of PBPs with a C-terminal transpeptidase module and an N-terminal 
module that is involved in the cell cycle. The nomenclature of these two classes are based upon the 
numbering of E. coli PBPs for Gram negative organisms, while B. subtilis, E. faecium, and S. 
pneumoniae were used in combination to describe the PBPs for Gram positive organisms.68 B. subtilis 
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will be used where possible as the example for describing PBPs classification in Gram positive 
organisms as it contains the widest variety for a Gram positive organism. 
Class A PBPs are further divided into 7 subclasses based on sequence analysis of the pencillin 
binding (PB) cores and are denoted A1-A7. Subclasses A1 and A2 contain the major bifunctional 
transpeptidases/transglycosylases in Gram negative organisms of which E. coli PBP 1a and 1b are the 
prototypes respectively.77–80 The bifunctional transpeptidases/transglycosylases in Gram positive 
organisms comprise subclasses A3, A4, and A5 as exemplified by B. subtilis PBPs 1, 2c, and 4  
respectively. Subclass A6 contains the “outliers” such as E. coli PBP 1c which contains both modules 
characteristic of Class A PBPs; however, the PB domain is very substrate specific and does not seem 
to act as a transpeptidase.81,82 Finally, subclass A7, which was added by Sauvage, contains 
monofunctional glycosyltransferases such as MgtA from E. coli.83,84 It is worth noting that subclass 
A7 enzymes do not appear in traditional gel based assays as they lack a PB core and that subclass A6 
enzymes may not appear under certain conditions due to their evolutionarily divergent PB core. 
The class B PBPs are multimodular like the class A PBPs with a C-terminal penicillin-binding 
transpeptidase module; however, the non-penicillin binding (nPB) module in class B PBPs is 
implicated in cellular morphology and division rather than transglycosylation.18,64 Five subclasses of 
class B PBPs are present in Gram positive and Gram negative organisms: B1-B5, defined by Goffin 
and Ghuysen using sequence alignment.68 The subclass B1 PBPs are most commonly found in Gram 
positive organisms and are characterized by their low affinity for β-lactams, most famously, PBP 2a 
from methicillin resistant S. aureus. B1 PBPs have been thoroughly reviewed by Zapun et al..85 
Subclass B2 PBPs are predominantly found in Gram negatives, such as E. coli PBP 2, and are 
associated with rod shaped bacteria as the nPB module is specific to the elongase complex.64 
Consequently, selective inhibition of subclass B2 PBPs causes the formation of spherical cells.66,86 
The B3 subclass PBPs, such as E. coli PBP 3 are part of the divisome, and their selective inhibition 
causes filamentation.64,86 The Gram positive counterpart to B3 PBPs are B4 PBPs, such as B. subtilis 
PBP 2b, in that they contribute to cell division.87,88 The B5 PBPs are Gram positive PBPs such as B. 
subtilis PBP 2a, most of which have no known function for the nPB module.68,89,90 B. subtilis PBP 2a 
is known to be involved in maintaining rod shape along with PBP H, another B5 PBP.91 This function 
in elongation cannot be a sole characteristic of B5 PBPs as many cocci express these.18 
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The final class of PBPs are the Class C PBP, commonly referred to as the low molecular mass 
(LMM) or non-essential PBPs. Class C PBPs are monofunctional PBPs that play a role in 
peptidoglycan regulation and recycling through carboxypeptidase and/or endopeptidase 
mechanisms.18,76 As with Class A and Class B PBPs, the nomenclature of Class C PBPs is based on 
the separation pattern of E. coli PBPs; however, there is no differentiation between Gram positive and 
Gram negative organisms in this class. The Class C PBPs are divided into three types: type 4, type 5, 
and type 7.18 Type 4 PBPs, whose archetype is PBP 4 in E. coli, function as both a DD-
carboxypeptidase and a DD-endopeptidase and have been implicated in maintaining normal cell 
morphology and in recycling the cell wall.65,76,92,93 These PBPs do not contain a transmembrane helix 
and are thought to be loosely associated with the cytoplasmic membrane (Gram positive), the inner 
leaflet of the outer membrane (Gram negative) or directly with peptidoglycan since they overproduce 
in the soluble form for E. coli and can be washed off B. subtilis with 1 M KCl.18,65,94–96 In Neisseria 
gonorrhoeae, the type 4 PBP, PBP 3, has been found to be associated with both the outer membrane 
and peptidoglycan.97,98 Type 5 PBPs are often the most abundant PBPs in cells and are the strict DD-
carboxypeptidases.99–101 Functionally, type 5 PBPs have been implicated in normal septum formation 
and in the maintenance of normal cell diameter.92,102,103 In E. coli, this type is represented by PBP 5 
and PBP 6 of which PBP 5 performs the normal regulatory functions of this type, and PBP 6 is 
involved in the onset of stationary phase.69,104,105 The final type of Class C PBPs is type 7 which are 
structurally similar to the penicillin binding domain of type 5 PBPs and as such exhibit the same 
carboxypeptidase/endopeptidase activity but are largely absent in Gram positive organisms.18 Much 
like type 4 PBPs, these are loosely membrane associated and, as of yet, their function in cell cycle or 
morphological regulation is unknown.101,106 In E. coli, this class is represented by PBP 7 and its 
proteolytic product, PBP 8.107 
1.2.3 PBP Expression in Bacterial Strains 
In this study, assays of both E. coli and P. aeruginosa penicillin binding proteins were employed, 
so it is important to discuss which PBPs are present in these organisms, how they compare, and to 
examine any controversy in the literature. Much of the comparison of E. coli and P. aeruginosa PBPs 
was performed by Noguchi et al. in 1979; however, this study was limited to the PBPs that react with 
radiolabeled benzylpenicillin and remain on an SDS PAGE gel.108 Using binding kinetics, thermal 
sensitivity, correlations in β-lactam specificity, and morphological impacts as criteria, they 
determined that E. coli PBPs 1a, 1b, 2, 3, 4, and 5 correspond with P. aeruginosa PBPs 1b, 1a, 2, 3, 4, 
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and 5 respectively.  It was also noted that expression of PBPs may vary between P. aeruginosa strains 
with PBP 2 being nearly invisible on the gels of certain strains, and PBP 3x appearing on others.108  
Recently, P. aeruginosa PBPs have been studied individually, bringing the understanding of the 
function, and in some cases structure, of these proteins to the level of E. coli PBPs. Comparative 
genetic sequence alignment of P. aeruginosa PBP 1a with PBP 1a and 1b from E. coli determined 
that P. aeruginosa PBP 1a most closely correlates with E. coli PBP 1a, not 1b as was previously 
suggested.108,109 Several studies have confirmed that PBP 2, 3, 4, and 5 from P. aeruginosa have the 
same function and similar structures as their E. coli counterparts.99,110–113 Gene names can be used as a 
clearer way to compare PBPs across species as they more closely correlate structure and function than 
electrophoretic mobility, although some inconsistencies in naming still occur. Table 1.2 is a 
compilation of the PBPs present in E. coli and P. aeruginosa with their respective gene names. It is 
worth noting that there is no relationship between the proteins encoded by pbpC in E. coli and P. 
aeruginosa, it is seemingly just an unfortunate naming coincidence.81,114 
Table 1.2 Penicillin binding proteins present in E. coli and P. aeruginosa 76,111 
E. coli Protein Genes P aeruginosa Protein 
PBP 1a ponA PBP 1a 
PBP 1b mrcB PBP 1b 
PBP 1c pbpC†  
PBP 2 pbpA PBP 2 
PBP 3 ftsI PBP 3 
 pbpC† PBP 3x 
PBP 4 dacB PBP 4 
PBP 5 dacA  
PBP 6 dacC PBP 5/6 
PBP 6b dacD  
PBP 7/8 pbpG PBP 7 
†The genes denoted as pbpC are not homologs 
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Aside from the naming coincidence with the pbpC genes in E. coli and P. aeruginosa, there is 
controversy in the literature with respect to the names of the high molecular weight PBPs in P. 
aeruginosa. The first report of P. aeruginosa PBPs labelled them as 1a, 1b, 2, 3, 3’, 4, 4’, 5, and 7/8, 
some of which are only conditionally present, notably 3’ which also goes by the names 3x and 
3a.68,76,108,114,115 While there is some differences between the original labelling of the Class B and C 
PBPs and the current labelling, the nomenclature of these PBPs has become consistent across the 
literature. The point of contention seems to be whether the two Class A PBPs are 1a and 1b or 1b and 
1c. The origin of the 1b/c nomenclature seems to be a publication by Moyá et al. in 2010, in which 
four classic papers about P. aeruginosa PBPs are referenced in the introduction with respect to the 
PBPs present in P. aeruginosa; none of these papers mention PBP 1c and all use the 1a/b 
nomenclature.18,108,116–118 Since the paper by Moyá, several other papers have used the 1b/c 
nomenclature, mostly in reference to the proteins inhibited by ceftolozane (which is the subject of 
Moyá et al. 2010)119–121 Additionally, PBPs 1b and 1c are named in the mode of action description of 
ceftolozane on Drugbank; although, PBP 1c is not listed in the targets section.122 Papers describing 
new experiments on P. aeruginosa PBPs since the release of Moyá et al. 2010 tend to use the 1a/b 
nomenclature, including another paper by Moyá, which may suggest that the 2010 paper had a 
typographical error that has been carried through later literature on the subject.113,116,123,124 Putting this 
to rest, Dhar et al. released a review in 2018 that included a survey of the P. aeruginosa genome 
database, and found no genes corresponding to PBP 1c.76 For this work, the major PBPs in P. 
aeruginosa will be labelled as PBPs 1a, 1b, 2, 3, 4, 5/6 according to the most common nomenclature, 
excluding those that are not visible. 
1.2.4 Role of PBPs in Bacterial Resistance to β-Lactams 
Penicillin-binding proteins contribute to bacterial resistance to β-lactams through either being 
inherently resistant to inhibition by β-lactams or through inducing the production of β-lactamases 
upon inhibition. The most well-known of the β-lactam resistant PBPs is PBP 2a from Staphylococcus 
aureus, a Class B PBP that confers methicillin resistance.125,126 PBP 2a is encoded by the mecA gene 
which is found in a mobile genetic element that integrates into the chromosome of Staphylococci and 
whose origin appears to be Staphyolococcus fleurettii.127,128 β-Lactam resistance by PBP 2a 
acquisition is primarily due to its poor affinity for β-lactams allowing it to compensate for other 
inhibited transpeptidases.129–133Additionally, PBP 2a accounts for 43% of expressed PBPs in 
methicillin resistant S. aureus cells while the number of other PBPs expressed per cell remains 
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constant.134 Similar β-lactam resistant PBPs exist in other bacteria and are covered in several 
excellent reviews.73,85,135  
In bacteria that do not produce inherently resistant PBPs, the inhibition or mutation of certain 
native PBPs has been shown to up-regulate the production of Class C chromosomal β-lactamases 
such as AmpC. Chromosomal ampC genes has been found in many Gram negative pathogens 
including E. coli, P. aeruginosa, K. pneumoniae, E. cloacae, and Serratia marcescens and can be 
constitutively expressed (as in E. coli) or induced by β-lactams.136–139 β-Lactam induced production of 
the β-lactamese AmpC occurs primarily through one of two pathways: AmpR regulation or two 
component CreBC(D) regulation both of which are thoroughly reviewed by Zeng and Lin.140 The 
AmpR regulation pathway involves the inhibition of a LMM PBP (usually PBP 4 or 5) which shifts 
the equilibrium of peptidoglycan recycling, releasing NAG-anhydro-NAM-pentapeptides which are 
transported into the cytoplasm through the AmpG transporter.113,141–144 Once in the cytoplasm, the 
NAG is removed from the NAG-anhydro-NAM-pentapeptides by NagZ and the peptide portion is 
shortened by AmpD, creating a molecule that interacts with the AmpR regulator, derepressing AmpC 
production.139,143–146 The CreBC(D) system has been shown to regulate the expression of OXA-12 and 
other chromosomal β-lactamases in Aeromonas jandaei and to interact with AmpR regulation in PBP 
4 mutants of P. aeruginosa to confer higher β-lactam resistance than the AmpR pathway 
alone.144,147,148 The CreBC(D) two component regulation system responds to PBP 4 inhibition or 
mutation in P. aeruginosa through an unknown signal causing the CreC inner membrane histidine 
kinase to phosphorylate CreB, the response regulator, which induces CreD overexpression in P. 
aeruginosa or induces β-lactamase production in A. jandaei.144,147–149 It is not well understood how 
CreD overexpression influences β-lactam resistance, but it is known to contribute to cell envelope 
stability and biofilm formation.148,150 
Despite the importance of PBPs in conferring and inducing β-lactam resistance, these tend to be 
narrow spectrum resistance mechanisms, making the expression of extended spectrum β-lactamases a 
more important resistance mechanism. 
1.3 β-Lactamases 
β-Lactamases are periplasmic enzymes that efficiently hydrolyze β-lactam antibiotics, conferring 
resistance to the bacterium. There are two general mechanisms by which these enzymes hydrolyze β-
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lactams: using a catalytic active site serine or zinc ions. The serine β-lactamases (SBLs) react with β-
lactams in a mechanism similar to that of PBPs, except they are capable of rapidly hydrolyzing the 
acyl enzyme. A common misconception is that β-lactamases evolved from PBPs as a response to the 
use of β-lactams as antibiotics in humans. It is thought that β-lactamases and PBPs evolved from a 
common DD-peptidase ancestor hundreds of millions of years ago and clinical use of β-lactam 
antibiotics has just selected for resistance, making it more prevalent.151,152 Additionally, the use of β-
lactams in a clinical setting had been shown to accelerate the evolution of β-lactamases with about 
170 β-lactamases having been identified by 1997 and around 2000 having been identified today.53–
55,152 
1.3.1 Role of β-Lactamases in Bacterial Resistance to β-Lactams 
The first observation of a β-lactamase capable of conferring resistance to a bacterium was reported 
in 1940 by Abraham and Chain, although they state in their letter that Fleming had also observed the 
resistance due to these enzymes in his 1929 paper detailing the discovery of penicillin.2,45 Early β-
lactamases were referred to as penicillinases or cephalosporinases depending upon their ability to 
hydrolyze penicillins or cephalosporins respectively. When semisynthetic penicillins were introduced 
in the 1970’s as less β-lactamase susceptible alternatives to natural product penicillins, they were 
lauded for their efficacy against highly resistant pathogens such as Pseudomonas spp., although 
resistance was observed in clinical trials.34,153 Likewise, the third-generation of semi-synthetic 
cephalosporins, such as ceftazidime in 1979, were thought to be highly resistant to hydrolysis by β-
lactamases but some Gram-negative pathogens developed resistance in clinical trials.154,155 Many of 
first identified β-lactamases had relatively narrow-spectrum activity against either penicillins or 
cephalosporins and the few that were capable of hydrolyzing the more stable β-lactams were 
chromosomally encoded.156,157 
In the early 1980’s, enzymes were discovered on transferrable plasmids in Klebsiella spp. isolates 
that were capable of hydrolyzing many of the available β-lactams which represented the first of the 
extended spectrum β-lactamases.156 In the 1980’s, extended-spectrum β-lactamases (ESBLs) were 
considered those capable of efficiently hydrolyzing common semi-synthetic penicillins and first-
generation cephalosporins but exhibiting poor activity against third-generation cephalosporins and 
monobactams.156 The definition of the term ESBL has evolved with the advent of new β-lactams and 
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the identification of β-lactamases with even broader spectrum activity such that it now includes only 
enzymes that are, at least, capable of conferring resistance to penicillins, first-, second- and third-
generation cephalosporins, and monobactams.158 The β-lactam therapy of choice for ESBL-producers 
has been carbapenems for the last few decades, although ESBLs that also hydrolyze carbapenems 
(carbapenemases, e.g. KPC-2) and metallo-β-lactamases have rendered this option less effective.159  
Recently, mobile genetic elements coding for multiple β-lactamases as well as resistance enzymes 
for other classes of antibiotic have been discovered in Gram negative pathogens.160,161 One such K. 
pneumoniae isolate harbouring 4 resistance plasmids was found to be carrying genes for 6 β-
lactamases, conveying resistance to all β-lactams, as well as genes coding for resistance to gentamicin 
(and related compounds), streptomycin, sulfonamides, aminoglycosides, trimethoprim, 
quinolones/fluoroquinolones, macrolides, and fosfomycin in addition to 9 efflux pumps with a wide 
range of specificity.162 Multidrug resistant bacteria are becoming more and more prevalent and have 
moved from being associated only with nosocomial infections to community-acquired infections as 
well.163 The Infectious Disease Society of America has declared that antimicrobial resistance is “one 
of the greatest threats to human health worldwide”, and with over 50% of prescribed antibiotics being 
β-lactams, combatting β-lactam resistance is of the utmost importance.16,17,164 
1.3.2 Classification of β-Lactamases 
The earliest nomenclature for the enzymes that were capable of hydrolyzing penicillins was 
“penicillinase” in accordance with the naming conventions of the time.45 The discovery of 
cephalosporins in the mid-1950’s and the enzymes capable of hydrolyzing them brought about a new 
term – cephalosporinase.165,166 These functional names failed to accurately categorize the enzymes 
that they were describing as they only indicated whether or not that enzyme could hydrolyze that type 
of substrate, omitting enzymes that hydrolyze both cephalosporins and penicillins. Additionally, there 
was no distinction between broad spectrum enzymes that could hydrolyze every member of a class of 
β-lactams and a narrow spectrum one that could only hydrolyze a few members of a class (e.g. Only 
first-generation cephalosporins, but not second-generation).  
After some early efforts to establish a classification system,167–169 Richmond and Sykes came up 
with the first widely accepted classification scheme in 1973.157 This scheme split the known β-
lactamases into five classes denoted by the Roman numerals I-V according to their substrate 
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specificity as well as their sensitivity to inhibition by both cloxacillin and p-chloromercuribenzoate as 
illustrated in Table 1.3.157 Unlike the previous nomenclature, this scheme allows for classification of 
β-lactamases that can hydrolyze both cephalosporins and penicillins and uses additional information 
such as the susceptibility to inhibitors to further subdivide. The classes proposed by Richmond and 
Sykes were subdivided into lettered subgroups according to their relative activities with six 
substrates.157 
Table 1.3 Richmond and Sykes functional classification scheme for β-lactamases. 157 
  Sensitivity to Inhibition 
Class Preferred Substrate Cloxacillin p-chloromercuribenzoate 
I cephalosporin S R 
II penicillin S R 
III cephalosporin/penicillin S R 
IV cephalosporin/penicillin R S 
V cephalosporin/penicillin R R 
 S = sensitive to inhibition, R = resistant to inhibition 
While the Richmond and Sykes classification system was adequate for the time, it introduced 
confusion since Roman numerals were also used in the names of β-lactamases to distinguish between 
two β-lactamases produced by the same organism (e.g. BcI and BcII from Bacillus cereus). Ambler 
proposed a similification of the classification of β-lactamases in 1980 based on their structure and 
changed designations from Roman numerals to letters. The β-lactamases analysed by Ambler fell into 
two groups: Class A and Class B which used an active site serine residue and divalent zinc ions 
respectively to perform the hydrolysis.170 The serine-β-lactamases (SBLs) studied by Amber: PC1, 
BcI, TEM-1, and B. licheniformis 749/C, had a high sequence homology and thus did not require 
further division although Ambler addressed the likelihood of other classes existing.170 Another 
molecular class, Class C, was proposed by Jaurin and Grundström in 1981 to encompass 
chromosomally encoded SBLs from Enterobacteriaceae such as AmpC which had low sequence 
homology with the class A β-lactamases.171 The final molecular class, Class D, was proposed in 1987 
by Ouelette et al. on the basis of the lack of sequence homology between the OXA-type SBLs and the 













enzymes Clav/Tazo EDTA 
1 C Cephalosporins - - Greater hydrolysis of 
cephalosporins than PenG; 
hydrolyze cephamycins 
E. coli AmpC, P99, 
ACT-1, CMY-2, 
MIR-1, DHA-1 
1e C Cephalosporins - - Increased hydrolysis of 
ceftazidime and often other 
oxyimino-β-lactams 
GC-1, CMY-10 
2a A Penicillins + - Greater hydrolysis of PenG 
than cephalosporins 
PC1, BcI 
2b A Penicillins, early 
cephalosporins 
+ - Similar hydrolysis of PenG 
and cephalosporins 
TEM-1, SHV-1 
2be A Extended-spectrum 
cephalosporins 






2br A Penicillins - - Resistance to clav/sul/tazo TEM-30, SHV-10 
2ber A Extended-spectrum 
cephalosporins, 
monobactams 
- - Increased hydrolysis of 
oxyimino-β-lactams 
combined with resistance to 
clav/sul/tazo  
TEM-50 
2c A Carbenicillin + - Increased hydrolysis of 
carbenicillin 
PSE-1, CARB-3 
2ce A Carbenicillin, 
cefepime 
+ - Increased hydrolysis of 
carbenicillin, cefepime, and 
cefpirome 
RTG-4 
2d D Cloxacillin ± - Increased hydrolysis of 
cloxacillin and oxacillin 
OXA-1, OXA-10 
2de D Extended-spectrum 
cephalosporins 




2df D Carbapenems ± - Hydrolyzes cloxacillin or 
oxacillin and carbapenems 
OXA-23, OXA-48 
2e A Extended-spectrum 
cephalosporins 
+ - Hydrolyzes cephalosporins. 
Inhibited by clav but not 
aztreonam 
CepA, L2 





3a B1 Carbapenems - + Broad-spectrum hydrolysis 
including carbapenems but 
not monobactams 
BcII, IMP, NDM, 
VIM, SPM-1 
 B2 Carbapenems - + Broad-spectrum hydrolysis 
including carbapenems but 
not monobactams 
L1, GOB-1, FEZ-1 
3b B3 Carbapenems - + Preferential hydrolysis of 
carbapenems 
CphA, Sfh-1 
4 ? Penicillins - -  SAR-2 
Adapted from 173,174 with representative enzymes focused towards ones used in this work.175–177 clav = 
clavulanic acid, tazo = tazobactam, sul = sulbactam, PenG = penicillin G = benzylpenicillin. 
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Some small updates have been made to the Ambler molecular class classification system since the 
1980’s including subdividing the Class B’s into three subclasses (B1, B2, and B3) based on the amino 
acids used to bind the zincs as well as rearranging the phylogenetic tree of the Class B’s to emphasize 
the relationship between B1 and B2.178,179 
The Ambler molecular classification scheme, along with its many updates, is the most widely used 
classification system to this day because of its simplicity and the limited amount of information 
(primary sequence) needed for classification of new β-lactamases. Throughout the late-1980’s and 
early-1990’s, Bush and Jacoby championed another functional classification system, culminating in 
their 2010 update that divides the β-lactamases into 4 groups (one of which is for “others”) and 17 
subgroups based upon their preferred substrate(s) and their inhibition by clavulanic acid/tazobactam 
and EDTA.173,174,180–182 While this scheme excels at categorizing β-lactamases according to the finer 
details of their function, it is exceedingly complicated and related enzymes can be scattered across 
subgroups (e.g. TEM-type β-lactamases are spread across 4 functional subgroups: 2b, 2be, 2br, and 
2ber), leading to it’s lack of widespread use.173 For the purposes of this work, the Ambler class will 
be referred to as the molecular class and the Bush-Jacoby class will be referred to as the functional 
class. 
The names of β-lactamases are abbreviations that indicate the source organism (Bc = Bacillus 
cereus), the target substrate (IMP = imipenem), the location where a family of β-lactamases was first 
discovered (NDM = New Delhi Metallo-β-lactamase), the name of the patient (TEM = Temoneira), 
or a combination of thereof (CTX-M = cefotaxime, isolated from Munich). The number that follows 
the abbreviation is often assigned sequentially to variants within a family as they are discovered. An 
in depth listing of the nomenclature conventions of β-lactamases was compiled by Jacoby in 2006.183 
1.3.3 Class A β-Lactamases 
When the molecular classes of β-lactamases were first defined, only four Class A SBLs were 
identified: the chromosomally encoded PC-1 from S. aureus, BcI from B. cereus, and 749/C from B. 
linchiformis as well as the plasmid encoded TEM-1 (R-TEM) from E. coli.170 This class tends to 
prefer penicillins as their substrate rather than cephalosporins. Much of the work on this class has 
been on the TEM-type Class A SBLs due to their clinical significance as a result of being plasmid 
encoded. The mobility of plasmids between bacterial strains and species facilitated the rapid 
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dissemination of TEM-1 from one E. coli isolate in Greece in the early 1960s into other 
Entereobacteriaceae, P. aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae worldwide 
in only a few years.184 To this day, TEM-type β-lactamases are responsible for almost 90% of 
ampicillin resistance in Gram negative pathogens.185 
Class A SBLs are composed of two globular domains: one composed entirely of α-helices (pink) 
and another composed of 5 β-strands (green) surrounded by α-helices (blue) as depicted in Figure 1.7. 
The active site sits between the two domains with the β3 strand defining one wall and an Ω-loop 
(Arg164-Asp179) as the other wall shown in green and purple respectively in Figure 1.7.186 An 
oxyanion hole composed of the backbone NH groups of Ser70 and Ala237 orients the substrates 
correctly by binding the carbonyl oxygen of the β-lactam amide.187 The catalytic serine residue, 
Ser70, as well as other critical active site residues such as Lys73, Glu166, and Lys234 are invariant 
among all Class A SBLs. 
 
Figure 1.7 3-Dimensional structure of Class A SBLs, exemplified by KPC-2 .188 This figure was 
generated using UCSF Chimera v. 1.12 from protein databank file 2OV5. 
Early studies on the mechanism of SBLs determined that an acyl enzyme was formed and that it 
was likely that a serine residue, then referred to as Ser44, was the nucleophile.189–193 In the early 
1990’s, X-ray crystallography and site directed mutagenesis were used to further elucidate the 
mechanism and the discussion shifted to whether Glu166 or Lys73 was the general base used to 
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activate Ser70 (formerly Ser44).194,195 The consensus is that the formation of the tetrahedral 
intermediate occurs though a “proton shuttle” mechanism in which the proton from Ser70 is shuttled 
to Glu166 through a water molecule, activating the serine to perform a nucleophilic attack on the 
carbonyl carbon of the β-lactam amide. Likewise, the collapse of the tetrahedral intermediate to the 
acyl enzyme proceeds through a proton shuttle in which the proton from Lys73 is shuttled to the 
substrate nitrogen through Ser130. This shuttle is assisted by Lys234 which increases the acidity of 
Ser130.196 Deacylation occurs through activation of a water molecule by Glu166 which peforms the 
hydrolysis.194 A summary of this mechanism is presented in Scheme 1.4. 
 
Scheme 1.4 Mechanism of penicillin hydrolysis by Class A β-lactamases.  
The largest family of Class A β-lactamases are the TEM family which is comprised of 237 variants 
as of December 2018, spanning 4 functional classes.55Mutations to TEM-1 over the decades have 
broadened the substrate profile of certain TEM-type β-lactamases to include oxyimino-β-lactams such 
as cefotaxime and ceftazidime as is the case for the EBSL TEM-3 from functional class 2be. The 
mutations responsible for this extended substrate profile occur only at a limited number of positions 
on the TEM framework (pink and blue residues in Figure 1.8) with any given variant having only a 
few of these mutations. Some variants, such as TEM-30, do not have an extended substrate profile but 
are resistant to inhibition by mechanism-based inhibitors such as clavulanate and tazobactam and 
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represent another functional class, 2br. Like TEM-type ESBLs, the inhibitor resistant (IR) TEMs 
contain a couple mutation(s) from a small set (yellow and blue residues in Figure 1.8), some of which 
are common in ESBLs as well (blue/bold).184 The frequency and function of the common TEM 
mutations has recently been reviewed by Grigorenko et al..197 Complex mutant TEMs such as TEM-
50 have mutations that confer both the extended substrate profile and inhibition resistance, and 
represent another functional class, 2ber.173  
 
Figure 1.8 Locations of phenotype changing mutations in TEM-1  that contribute to ESBL 
(pink), IR (yellow), or a combination of ESBL and IR phenotypes (blue). The catalytic triad 
(STXK) in the active site is highlighted in grey.184 This figure was generated using UCSF 
Chimera v. 1.12 from protein databank file 5VHI. 
The mutations that confer ESBL character to the TEM variants widen the active site so they can 
better accommodate the larger oxyimino side chains of the third generation cephalosporins or 
improve their alignment in the active site. Inhibitor resistance is a consequence of mutations that 
disrupt the active site through misalignment of Ser70 and Ser130 or disrupting the H-bonding 
network around Ser130. This causes decreased turnover and apparent decreased affinity, particularly 
with inhibitors such as clavulanic acid, altering the balance between acylation and rearrangement.198 
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The second largest family of Class A SBLs is the SHV-family with 228 variants from primarily the 
2b and 2be functional classes with a few 2br variants.55 Unique to this family, the A146V mutationb 
in SHV-38 confers limited carbapenemase activity, but is still categorized in the 2be functional 
class.199 Unlike the TEM-family β-lactamases which are found in many different Gram negative 
pathogens, members of the SHV-family are found primarily in K. pneumoniae and other 
Enterobacteriaceae.176 
Although the TEM- and SHV-type Class A SBLs are clinically important, they are becoming 
overshadowed by another family: the CTX-M’s. Named for their ability to hydrolyze cefotaxime (and 
their first identification in Munich, Germany), this family is entirely composed of ESBLs.183,200 The 
vast majority of the CTX-M-type SBLs belong to the 2be functional class, although recently, a CTX-
M-variant, CTX-M-190, was discovered in a clinical isolate in China and demonstrates significant 
resistance to tazobactam and sulbactam but not clavulanate.201,202 This family of ESBLs has 
disseminated worldwide, primarily in Enterobacteriaceae, in large part due to its presence on 
transferable plasmids.203 Of the 224 identified CTX-M-variants, CTX-M-15 is the most prevalent in 
most parts of the world although CTX-M-14 is most prevalent in Southeast Asia, China, South Korea, 
Japan, and Spain. It has been predicted that in the coming years, CTX-M-27 will out-compete the 
other CTX-M-variants as it confers increased resistance for ceftazidime compared to CTX-M-14 and 
has been shown to be more transmissible in nosocomial E. coli clones compared to CTX-M-15.203 
Other Class A ESBLs include: ACI-1, BEL-type, BES-1, CARB-10, CfxA-type, CGA-1, CIA-type, 
CphA-type, CSP-1, DES-1, ERP-type, FAR-1, GES-type, KLUC-type, LRG-1, LUT-type, OHIO-1, 
OXY-type, PER-type, RAHN-type, SFO-1, SGM-1, SPU-1, TLA-type, and VEB-type.55 As is the 
case for the TEM- and SHV-type SBLs, not all members of a family are ESBLs, but the families 
listed above include at least one ESBL. Despite the wide diversity of ESBLs, CTX-M-, TEM-, and 
SHV-type ESBLs are the most common in clinical pathogens and are consequently the most 
important targets for inhibition.185 
The hydrolysis of cephalosporins is problematic since cephalosporins represent the single most 
prescribed class of antibiotic in Canada but the ESBLs listed above are not capable of hydrolyzing 
carbapenems and as such, those infections can be treated with β-lactams.17 In 1996, a patient in North 
                                                     
b The A146V mutation is also present in SHV-168; however, the mature protein is the same as SHV-38.559  
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Carolina presented with a carbapenem resistant K. pneumoniae infection which marked the first 
instance of a Class A carbapenemase: KPC-1.204 In 2008, a 73-year-old man in a Toronto-area 
hospital presented with the first Canadian case of a KPC-producing infection despite having no 
known risk factors (e.g. recent travel to the USA) – he succomed to the infection before an 
appropriate therapy could be determined.205 KPC-producing Enterobacteriaceae are now found 
worldwide, particularly in the USA, China, South/Central America, the Middle East and 
Mediterranean Europe, with KPC-2 and KPC-3 being the most prevalent variants.206,207 
Class A carbapenemases comprise the 2f functional group with the KPC’s being the most 
prevalent. The members of this group (as of 2007), including NMC-A, GES-, SME-, and IMI-type 
carbapenemases, have been thoroughly reviewed by Walther-Rasmussen and Høiby.208 Of these, the 
GES-type enzymes are generally the least efficient carbapenemases (the authors suggest that they are 
more appropriately 2e than 2f) while NMC-A is the most efficient carbapenemase. Additionally, 
many of these enzymes have higher affinity for meropenem than imipenem (as much as 33-fold 
greater affinity for SME-2).208 Other Class A carbapenemases have been recently discovered 
including FRI-1 and BKC-1 from clinical isolates of E. cloacae and K. pneumoniae respectively, as 
well as FPH-1 from a opportunistic pathogen that rarely causes infection found in a Utah river 
(Francisella philomiragia), VCC-1 from Vibrio cholerae found in shrimp imported to Canada from 
India, and BIC-1 from an environmental Pseudomonas fluorescens sample in France.209–213 
Class A carbapenemases harbour mutations that make the active site wider and shallower. These 
changes are stabilized by a disulfide bond between C69 and C238 which is characteristic of Class A 
carbapenemases. Additionally, the active site residues 237T, 274H, and 220R interact with the 
carboxyl.214 
1.3.4 Class C β-Lactamases 
In Ambler’s original classification system, β-lactamases were divided based on whether they used a 
serine or bound zinc ion(s) to hydrolyze β-lactams.170 All of the SBLs with known sequences at that 
time were coincidentally Class A’s, so when a SBL was sequenced shortly afterwards that had very 
low sequence homology with the Class A’s, another class was established.171 Class C SBLs differ 
functionally from Class A SBLs in that their preferred substrate is cephalosporins rather than 
penicillins (in most cases). This establishes them as their own functional group: group 1.173  
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Many of the Class C SBLs are chromosomally encoded by the ampC gene in Gram negative 
bacteria but tend to be expressed in low levels once expression is induced by a β-lactam. Strains that 
produce high levels of a Class C SBL often harbour mutations in genes involved in the induction 
pathway, particularly ampD or ampR, that cause them to become hyperinducible or constitutive 
hyperproducers.215 The chromosomal AmpC-type β-lactamases tend to be named for the organism 
from which it arises (e.g. E. coli AmpC or P. aeruginosa AmpC) although some have adopted a short 
form where they are referred to by the strain identifier (e.g. P99 from E. cloacae P99).173,216 Plasmid 
mediated AmpC enzymes have also been discovered such as the ACC, BIL, CMY, DHA, FOX, LAT, 
and MIR family β-lactamases.217 The most prevalent plasmid mediated Class C SBLs are related to 
CMY-2, although plasmid mediated Class C SBLs are far less prevalent than those that are coded 
chromosomally in resistant clinical isolates.218 
Hydrolysis of cephalosporins is considered one of the characteristics of Class C SBLs, although 
there are a few that are markedly better at hydrolyzing third-generation cephalosporins such as 
ceftazidime which define the functional group 1e.173 These “extended-spectrum cephalosporinases” 
often have mutations in the Ω-loop, R2 loop, or H-9 helix that open parts of the active site to better 
bind substrates with bulky sidechains.215 The first cephalosporinase discovered to have an extended-
spectrum was GC-1 from E. cloacae GC1 which has a three amino acid (Ala208 Val209 Arg210) 
insertion in the Ω-loop relative to P99 from E. cloacae, increasing its flexibility.219 Other ESBL Class 
C’s include members from the ADC, CMY, EC, OCH, and PDC families and SRT-1.55 
Class C SBLs are structurally similar to Class A SBLs in many ways – they have a similar overall 
fold and many of the active site residues are the same. The canonical numbering system for Class Cs 
differs slightly from Class A, the critical active site residues in Class C are Ser64, Lys67, Lys315, and 
Tyr150 instead of Ser70, Lys73, Lys234, and Ser130 from Class A.220 From a mechanistic standpoint, 
Class A and Class C SBLs are very similar in broad strokes: both use a catalytic serine residue to 
form a tetrahedral acyl-enzyme followed by deacylation using a water molecule found in the active 
site. Looking in greater detail, differences start to arise – the rate limiting step in Class A β-
lactamases is acylation wherease it is deacylation in Class C, the water molecule involved in 
deacylation approaches from opposite faces of the β-lactam, and Class C β-lactamases do not contain 
a residue analogous to Glu166 from Class A.220–223 
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Throughout the years, several groups have attempted to address how Class C β-lactamases function 
without Glu166. It was originally thought that Tyr150 in its anionic form could act as the general base 
for acylation; however, this was disproved by NMR experiments that show that the pKa of Tyr150 is 
greater than 11 and site-directed mutagenesis experiments that showed that Tyr150 is not critical for 
β-lactam turnover.220,224,225 Using hydrid quantum mechanics / molecular mechanics (QM/MM), 
Tripathi and Nair determined that Lys67 acts as the general base for acylation and Tyr150 acts as a 
proton shuttle for the collapse of the tetrahedral intermediate to form the initial acyl enzyme as 
depicted in Scheme 1.5.226 Following formation of the initial acyl enzyme, many cephalosporins 
undego rearrangement to eliminate the R2 group. 
 
Scheme 1.5 Mechanism of cephalosporin hydrolysis by Class C β-lactamases. 226,227 
The mechanism of deacylation has also been debated through the years. As with acylation, Tyr150 
was originally thought to be the general base for activating the water molecule which was disproven 
by NMR experiments220,224 Substrate-assisted catalysis, in which the ring nitrogen activates the water 
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was also considered, although Patera et. al. note that the oxygen of Tyr150 is ideally placed to act as 
the general base if it were in its anionic form.228,229 Tripathi and Nair point out that the NMR studies 
commonly used to eliminate the theories involving Tyr150 were performed on the apo enzyme and do 
not reflect the nature of the enzyme active site when the β-lactam is bound.227 In computational 
studies, the estimated pKa of Tyr150 in the acyl enzyme has supported the idea that it likely exists as 
the phenolate or partially protonated. This, with QM/MM studies supports the deacylation mechanism 
in which the water molecule is activated by Lys67 using Tyr150 as a proton shuttle.227,230 
1.3.5 Class D β-Lactamases 
Among the penicillinases, a small group were set apart by their ability to hydrolyze oxacillin, 
cloxacillin, and other isoxazoyl β-lactams. Once members of this family had been sequenced, they 
were found to have little sequence homology with Class A and C SBLs and were defined as their own 
molecular class: Class D.172 As of 2000, only 20 OXA-variants had been identified;231 however, this 
group has grown exponentially in recent years: 50 variants had been identified by 2005,221 250 by 
2013,232 and there are currently over 700 identified OXA-variants.55 Several excellent reviews have 
been written about the Class D β-lactamases over the years.232–234 
The Class D β-lactamases can be chromosomally encoded or plasmid borne, and are found in many 
Gram negative pathogens, notably A. baumannii and K. pneumoniae.234 The early Class D β-
lactamases are narrow spectrum enzymes, defining functional class 2d, and are often related to OXA-
1, OXA-2, or OXA-10. There are many extended spectrum variants that are closely related to the 
narrow spectrum variants, particularly OXA-10 which define the functional class 2de. Some ESBL 
Class Ds, such as OXA-18, OXA-45, and OXA-53 are not structurally related to the narrow spectrum 
variants.235 As with Class A, there are Class D variants with carbapenemase activity (functional class 
2f). The carbapenemases are further grouped by structural similarity, such as OXA-23-like, OXA-48-
like, OXA-58-like, and OXA-143-like.234 There is no unified numbering system for the amino acid 
sequences of Class D SBLs, so all amino acid numbering in this section will refer to OXA-10 since it 
was the first Class D crystal structure and is one of the best studied in this class. 
Class D β-lactamases share many mechanistic similarities with Class A β-lactamases: a general 
base activates the catalytic serine to form the acyl enzyme, the same general base activates a water 
molecule for deacylation from the α face of the substrate. The general base in Class A β-lactamases, 
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Glu166, is not present in Class D β-lactamases and early crystallographic studies suggested that a 
lysine residue in the active site, Lys70 in OXA-10, acted as the general base.231,236 This suggestion 
was found to be incomplete later that year when it was discovered that the lysine is carboxylated in 
the active form of the enzyme.237 It is widely accepted that the carboxylated lysine acts as the general 
base for both the acylation and deacylation half reactions as depicted in Scheme 1.6. 
 
Scheme 1.6 Mechanism of penicillin hydrolysis catalyzed by Class D SBLs. 238 
Unlike Class A β-lactamases, Class D β-lactamases have a highly hydrophobic active site which is 
thought to promote the carboxylation of the lysine by lowering its pKa and provide favourable 
interactions for substrates with bulky hydrophobic groups such as oxacillin.232 The post-translational 
modification of the active site lysine is known to be reversible, pH dependent, and necessary for 
enzyme activity.239 To prevent spontaneous decarboxylation, the carboxylated lysine is stabilized by 
hydrogen bonds and salt bridges with nearby residues – notably Trp154 and Ser67.232 
Prior to the crystallographic and mechanistic studies, Class D β-lactamases were notoriously 
difficult to work with for kinetic studies due to their biphasic kinetics (burst phase followed by a 
slower steady state) and irreproducibility. The revelation that a critical active site residue needed to be 
carboxylated, and that assay buffers should be supplemented with bicarbonate to mimic physiological 
conditions made kinetic assays reproducible and gave typical progress curves.240 The carboxylated 
lysine was not the only factor that complicates kinetics with Class D β-lactamases, many of the 
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OXA’s are thought to exist as dimers in solution. Paetzel et. al. demonstrated that optimal enzyme 
activity was achieved when OXA-10 was in its dimeric form, and suggested that the biphasic kinetics 
could be, in part, the result of shifting of the dimerization equilibrium.236 For OXA-10, dimerization 
is heavily dependent on the presence of divalent cationic metals; however, this is not true for all 
dimeric OXA’s – OXA-48’s dimerization is metal ion independent.241 Although many OXA’s are 
dimeric (e.g. OXA-2,242 OXA-10,236,237 OXA-13,243 OXA-29,244 OXA-46,245 and OXA-48241) there 
are also several monomeric OXA’s (e.g. OXA-1,246 OXA-24,247 OXA-85,248, and OXA-205249 
1.3.6 Class B β-Lactamases 
The Class B, or metallo-, β-lactamases are characterized by the active site metal ions used to 
perform catalysis and their ability to efficiently hydrolyze carbapenems. Within this class, there are 
three subclasses: B1, B2, and B3 which are primarily differentiated by the amino acid residues used 
to coordinate the zinc ions and the number of those zinc ions in the active form of the enzyme. The 
subclass B1 MBLs, which represent the majority of Class B MBLs, have 3 His residues that 
coordinate Zn1 and an Asp, Cys, and His that coordinate Zn2. A hydroxide molecule is also 
coordinated between the two zinc ions as well, a second water is coordinated to Zn2 such that the 
coordination about Zn1 is tetrahedral and the coordination about Zn2 is trigonal bipyramidal.250–253 
The B1 MBLs also have a unique structural feature: a loop (residues 61-66) that closes over the active 
site and contributes to reaction rate.254 In the B2 MBLs, one of the His residues that coordinates Zn1 
is replaced with an Asn residue, decreasing the binding affinity of that site such that CphA is often a 
monozinc enzyme. The difference between the B1 and B3 MBLs reside primarily in the Zn2 binding 
site where Cys221 is replaced with His121.255,256 A few B3s, such as GOB-1, also have His116 
substituted with a Gln.178,257 Unlike the B1 (and B3) MBLs, the molecule that coordinates Zn1 is a 
water molecule, a water molecule also occupies the Zn2 binding site.258,259 In the functional 
classification scheme, B1 and B3 MBLs occupy group 3a which hydrolyze penicillins, 
cephalosporins, and carbapenems efficiently while group 3b which contains the B2 MBLs only 





Table 1.5 Amino acid residues that coordinate zinc ions in the three subclasses of metallo-β-
lactamases. 
MBL Subclass Zn1 ligands  Zn2 ligands 
B1 His116 His118 His196  Asp120 Cys221 His263 
B2 Asn116 His118 His196  Asp120 Cys221 His263 
B3 His/Gln116 His118 His196  Asp120 His121 His263 
Residues numbered using the standard MBL numbering scheme178,260 
Unlike the previously described classes of β-lactamase, the Class B β-lactamases use an activated 
water molecule coordinated by zinc ion(s) to perform β-lactam hydrolysis rather than a serine residue. 
The MBLs also have a different overall protein fold: they are an αββα sandwich with the active site 
nestled in the crevice between the two β-sheets as depicted in Figure 1.9.26 The structural and 
mechanistic differences between the metallo-β-lactamases and serine-β-lactamases have suggested 
that they evolved independently of one another.  
 
Figure 1.9 Overall MBL αββα fold  with the N-terminal αβ motif in blue and green and the C-
terminal αβ motif in purple and pink.  This figure was generated using UCSF Chimera v. 1.12 
from protein databank file 5N5G, an unpublished structure of VIM-1. 
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The serine-β-lactamases are thought to have evolved from a DD-peptidase similar to the PBPs, 
whereas the MBLs are thought to have evolved from a superclass of zinc hydrolases with a possible 
divergence that differentiated the B3 group from the B1 and B2 groups.151,179,261,262 Other proteins 
from the zinc hydrolase superfamily (sometimes referred to as MBL fold proteins) include 
flavoproteins, glyoxylase II, SNM1 which repairs DNA interstrand crosslinks, and many more.261 
The first metallo-β-lactamase was identified by Abraham and Newton in the mid-1950’s when it 
was realized that the penicillinase they were pursuing from Bacilus cereus 569H was a mixture of two 
enzymes termed BcI and BcII.263,264 The first of these, BcI, is a Class A penicillinase discussed briefly 
in 1.3.3. The second, BcII, was found to be a metal-dependent cephalosporinase that lost activity 
upon treatment with EDTA.265 For decades, BcII was the only known MBL until L1 was discovered 
in Pseudomonas maltophilia (also known as Xanthomonas maltophilia, now Stenotrophomonas 
maltophilia) in 1982.266 Shortly after, two more MBLs were identified: CcrA from Bacteroides 
fragilis and CphA from Aeromonas hydrophilia.267,268 All of the early MBLs: BcII (B1), L1 (B3), 
CcrA (B1), and CphA (B2) were chromosomally encoded so despite their ability to efficiently 
hydrolyze cephalosporins and carbapenems, they were not considered clinically important. Recently, 
L1 has become considered much more clinically relevant since S. maltophilia has become 
increasingly prevalent (third most common non-fermentative Gram negative pathogen after P. 
aeruginosa and A. baumannii) and highly resistant to most antibiotics.269 
In 1991, the first mobile MBL, IMP-1 (B1), was identified in a P. aeruginosa isolate from Japan 
encoded in a class 1 integron.270 Since then, 70 IMP variants have been identified in several Gram 
negative pathogens including other Pseudomonas spp., Klebsiella spp., Citrobacter spp., 
Acinetobacter spp., and E. cloacae. Pathogens expressing IMP are found worldwide, but are most 
prevalent in southeast Asia and Australia.271–276 Another major family of transferrable MBLs was 
identified in 1997 in a P. aeruginosa isolate from Verona, Italy – VIM-1 (B1).277 The VIM-family of 
MBLs has quickly become the most prevalent MBL in Europe in a variety of Gram negative pathogen 
with over 50 VIM-variants having been identified to date.55,278 
A relatively new family of MBLs, the NDMs, has risen to fame in recent years over their ability to 
confer resistance to almost every clinically used β-lactam, presence on highly multidrug resistant 
plasmids, and rapid dissemination into nosocomial and community acquired pathogens. The first 
report of a pathogen harbouring NDM-1 came in 2009 from a K. pneumoniae strain in New Delhi that 
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expressed NDM-1 (B1 MBL), CMY-4 (Class A SBL), and an erythromycin esterase. In that same 
report, they also noted that an E. coli strain isolated from the patient’s feces was also carrying and 
NDM-1 gene, leading to speculation about in vivo conjugation.279 Two years after the first report, 
NDM-1 was found found in clinical isolates worldwide, primarily E. coli, K. pneumoniae, A. 
baumannii, and P. aeruginosa, and in environmental isolates in India (many of which are potential 
human pathogens).56,280,281 NDM-1-producing isolates often produce other resistance proteins – one 
was shown to have genes for 3 SBLs, as well as aminoglycoside, fluoroquinolone, sulfonamide, 
trimethoprim, fosfomycin, macrolide, chloramphenicol, and rifampin resistance.56,282,283 
Through the 2000’s and early 2010’s, several novel MBLs were discovered in the chromosomes of 
pathogens such as FEZ-1 (B3)284 and SFH-1 (B2)285 or on mobile genetic elements such as integrons 
or tranferable plasmids such as SPM-1 (B1/B2 hybrid),286,287 GIM-1 (B1),288 SIM-1 (B1),289 KHM-1 
(B1),290 DIM-1 (B1),291 AIM-1 (B3),292 and FIM-1 (B1).293 Of these, only SPM-, GIM-, and FIM- 
producing pathogens are reported with any regularity in epidemiological surveys of metallo-β-
lactamase-producers with VIM-, IMP-, and NDM-producers being far more prevalent.207,294–297 
The hydrolytic mechanisms of MBLs are divided into dizinc (B1/B3) and monozinc (B2). For both 
groups, the predominant questions address the identity and nature of the nucleophile and the identity 
of the proton source for protonating the ring nitrogen. The history and key studies in this area have 
been thoroughly reviewed by Meini et. al..298 
The primary candidates for the nucleophile in dizinc MBLs are Asp120 (which coordinates Zn2) or 
the water/hydroxide bound between the zinc ions.250,299,300 The consensus is that Zn1 lowers the pKa 
of the water molecule enough that it exists as a hydroxide ion which acts as the nucleophile for the 
ring opening.298 Asp120 was seriously considered as the proton source for the second step of the 
mechanism; however, this would require transient dissociation from Zn2. Also, studies with BcII and 
L1 mutants have demonstrated that Asp120 is not the proton source.301–303 It has been suggested that 
the proton source is most likely the non-hydrolytic water molecule that coordinates Zn2 and that the 
two tautomeric products of carbapenems occur through protonation of different resonance 





Scheme 1.7 Hydrolysis of carbapenems by B1 and B3 MBLs. 298 
There has been much less controversy regarding the B2 mechanism – the water molecule bound in 
the Zn1 binding site is activated by His118, forming a hydroxide that attacks the amide.258,259 As with 
the dizinc MBLs, the water that coordinates Zn2 acts as the proton source which can protonate either 
resonance structure to form the two carbapenem tautomers.298 A summary of the mechanism of 
carbapenem hydrolysis by B2 MBLs can be found in Scheme 1.8. 
 
Scheme 1.8 Hydrolysis of carbapenems by B2 MBLs. 298 
1.3.7 Established Methods for Assaying β-lactamases 
Early methods for assaying β-lactamase activity used traditional analytical chemistry techniques 
adapted to this unique system such as pH indicators, iodometric titration, or manometric quantitation 
of the CO2 evolved. Upon hydrolysis by as β-lactamase, penicillin becomes penicillanic acid which 
can be quantified using pH indicators such as phenyl red using spectrophotometry.304 Later methods 
were developed that used a pH meter to monitor penicillanic acid formation.305 The iodometric 
titration exploited the ability of penicilloic acid to reduce iodine, turning the blue starch/iodine 
complex clear. The earliest version of the iodometric assay involved adding a known excess of the 
starch/iodine indicator after hydrolysis had preceeded for a set amount of time, and determining the 
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amount of unreduced indicator by titration with thiosulfate.306 Later versions of this assay added the 
β-lactamase to a solution containing both the indicator and the substrate and monitoring the colour 
change from blue to clear spectrophotometrically in either a continuous or discontinuous 
manner.307,308 The manometric method quantifies the hydrolysis of penicillin in sodium bicarbonate 
by the CO2 evolved from the bicarbonate in response to the pH change caused by penicillanic acid.309 
The hydrolysis of all β-lactam antibiotics causes a shift in the absorption peak in the UV-range. In 
the early 1970’s, a novel cephalosporin, termed nitrocefin, was developed that showed a visible 
colour change from yellow to red upon hydrolysis.310 This allowed for the direct quantitation of the 
hydrolysis of a cephalosporin using spectrophotometry. By the mid-1970’s UV-spectrophotometers 
had become affordable enough for direct quantitation of β-lactam hydrolysis by spectrophotometry.311 
Since then, several chromogenic substrates have been developed, including PADAC, CENTA, and 
Chromacef for visual or spectrophotometric determination of β-lactamases, although nitrocefin 
remains the standard for chromogenic substrates.312–315  
In the early 2000’s a fluorogenic cephalosporin was developed that releases an umbelliferone 
fluorophore upon hydrolysis for use in cell imaging and localization studies.316 Recently, another 
fluorogenic cephalosporin, FC4, was developed that releases a 7-hydroxycoumarin fluorophore. FC4 
was found to be an excellent substrate for fluorescence based kinetic assays of MBLs and has also 
found limited use with SBLs.317,318 
1.4 β-Lactamase Inhibitors 
1.4.1 β-Lactams as β-Lactamase Inhibitors 
The first inhibitor of β-lactamases was actually a β-lactam itself: cephalosporin C which was found 
to be resistant to inactivation by a penicillinase in 1955.165 Cephalosporin C was later shown to 
protect benzylpenicillin (Penicillin G) from hydrolysis by a penicillinase by competitive inhibitionof 
the enzyme.263 The inhibition of β-lactamases by β-lactams relies entirely upon the substrate 
specificity of the different classes of β-lactamase. Many of the early β-lactamases were narrow-
spectrum Class A SBLs, and consequently were able to efficiently hydrolyze penicillins but not 
cephalosporins. As such, β-lactams that are inhibitory towards β-lactamases due to unfavourable 
substrate specificity are often referred to as “poor” or “slow” substrates. 
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Methicillin was the first semi-synthetic penicillin developed that was resistant to hydrolysis by 
some penicillinases and acted as a competitive inhibitor of others.319 Other penicillins, such as 
nafcillin, cloxacillin, and quinacillin were also determined to inhibit β-lactamases (Figure 1.10).320–322 
A structural study by Fink et al. in 1987 suggested that inhibition of β-lactamases by methicillin and 
related compounds was due to steric interactions of the bulky aromatic sidechains causing the acyl 
enzyme to adopt a conformation that cannot be deacylated.322 
 
Figure 1.10 Penicillins that are inhibitory towards some SBLs. 
Some cephalosporins and carbapenems are capable of inhibiting Class A and Class C β-lactamases 
through rearrangements that stabilize the acyl enzyme. With cephalosporins, this rearrangement 
occurs if X is a sufficiently good leaving group and favours elimination over deacylation (Scheme 
1.9A) which has been kinetically observed with the Class A SBLs PC1 and RTEM-2 as well as the 
Class C SBLs E. cloacae 908 R and P99.323–326 The elimination product of ceftazidime has been 
captured in crystal structures of AmpC (C) where steric clashes prevented the correct conformation 
for deacylation and in deacylation impaired mutants of CTX-M-14 (A) and OXA-160 (D).327–329 
Carbapenems are known to demonstrate biphasic kinetics with Class A SBLs, a phenomenon that was 
attributed to tautomerization of the acyl enzyme from a Δ2-pyrroline to a Δ1-pyrroline (Scheme 
1.13B) as observed using NMR methods.330–332 In crystal structures of carbapenems bound to TEM-1 
(A), SHV-1 (A), and AmpC (C) the Δ1-pyrroline tautomer is not observed but rather the rotation of a 
carbonyl formed upon acyl enzyme formation out of the oxanion hole (Scheme 1.13C).333–335 This 
rotation disrupts the ideal geometry for acyl enzyme hydrolysis, leading to a long-lived acyl-enzyme 




Scheme 1.9 Inhibition of SBLs by cephalosporins and carbapenems. 
Although metallo-β-lactamases are typically efficient carbapenemases, a series of carbapenems, the 
1β-methylcarbapenems, have been discovered that are poor substrates for MBLs and potent 
inhibitors. The most potent in this series, J-110,441, was inhibitory towards TEM-1 (A), IMP-1 (B1), 
BcII (B1), CcrA (B2), L1 (B3), and a Class C cephalosporinase from E. cloacae with KIs ranging 
from 0.0037 μM to 2.54 μM. This compound was found to be a modest antibiotic against several 
MBL-producing strains but was potently synergistic with imipenem, reducing the MIC as much as 
64-fold.336 Unfortunately, this mechanism of MBL inhibition by J-110,441 has not been elucidated 
and the compound has not led to a clinically useful MBL inhibitor. 
1.4.2 Serine-β-Lacamase Inhibitors 
Most of the β-lactamases discovered early in the history of β-lactam antibiotic use, particularly 
those that were prevalent in clinical isolates, were serine-β-lactamases. As a result of this, much of 
the early work to find a clinically useful β-lactamase inhibitor focused on SBL inhibition. The first 
success came with the mechanism-based inhibitors, clavulanate, sulbactam, and tazobactam (Figure 
1.11) which are inhibitory towards many of the Class A SBLs and some Class D SBLs. Much of the 
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work over the next few decades focused on transition state analogs such as the boronates and 
phosphonates, although none of these made it into clinical use. More recently, the 
diazobicyclooctanes were discovered in the mid-2000’s which inhibit Class A, C and some Class D 
SBLs – these have been approved for clinical use since 2015.337,338 Finally, a cyclic boronate, 
Varborbactam, was approved for clinical use in combination with meropenem in August of 2017 as a 
inhibitor of Class A and C SBLs. 
1.4.2.1 Mechanism Based Inhibitors 
Clavulanic acid was the first of the mechanism-based inhibitors to be discovered in the late-1960’s 
but was not disclosed until the late-1970’s as part of a program by Beecham pharmaceuticals to 
identify natural product β-lactmase inhibitors.38,339 This compound was a potent inhibitor of 
penicillinases (Class A SBLs) but was ineffective against the chromosomal cephalosporinases (Class 
C SBLs).340 Shortly after the disclosure of clavulanic acid, a sulfone derivative of penicillin, 
sulbactam, was discovered by Pfizer which had a similar spectrum of inhibitory activity as clavulanic 
acid but slightly inferior potency.341,342 Nearly a decade later, tazobactam, a triazole-substituted 
derivative of sulbactam was prepared by a group led by R. Micetich at SynPhar labs in Edmonton, 
Alberta, and was determined to have increased potency against Class C SBLs while also improving 
upon sulbactam’s inhibition of Class A SBLs.342,343 
 
Figure 1.11 Mechanism-based serine-β-lactamase inhibitors. 
The mechanism by which these compounds inhibit SBLs has been thoroughly studied and appears 
in many reviews. The most complete analysis of the mechanism was done by Brown et al. in 
1996.23,344–349 As summarized in Scheme 1.10, the first step for inhibition by these compounds is 
similar to the hydrolysis of β-lactams by SBLs: the catalytic serine (Ser70) attacks the β-lactam bond 
to form the acyl enzyme. From this point, the enzyme can deacylate, releasing the free enzyme, or 
rearrange to form the imine intermediate. The imine can then tautomerize to form the cis or trans 
enamine which is transiently inhibitory or alternatively can react with another serine (Ser130), 
irreversibly crosslinking the active site and inactivating the β-lactamase. Other side reactions 
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including decarboxylation of the imine or enamines, and hydrolysis of the imine to an aldehyde which 
is slowly hydrolyzed can also occur. 
 
Scheme 1.10 Inhibition of Class A SBLs by mechanism-based inhibitors eg. clavulanate. 344,346,348 
Other mechanism-based inhibitors such as other sulfone derivatives of penicillin,350–352 6-halo 
penicillins,189,353–355 and alkylidene penams356–360 have also been studied but have not been brought 
into clinical use. 
 
Figure 1.12 Other mechanism-based inhibitors: penicillanic acid sulfones, 6-halo penicillins, 
and alkylidene penams. 189,350,351,354,356,358 
1.4.2.2 Diazabicyclooctanes 
The major drawback of the clinically available mechanism-based inhibitors is that they only inhibit 
some Class A and C SBLs which greatly limits their usefulness for highly resistant pathogens. A new 
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class of inhibitor, the diazabicyclooctanes (DBOs), was discovered in the mid-2000’s that were 
nanomolar inhibitors of Class A and C SBLs including extended spectrum SBLs not inhibited by 
clavulanate nor the penicillanic acid sulfones (e.g. KPCs) and some Class D SBLs.337,361,362 The first 
inhibitor from this class to be approved for clinical use is Avibactam (formerly AVE1330A or 
NXL104) although another, Relebactam, is in phase 3 clinical trials.338,363 Earlier this year, a DBO 
(WCK 4234) was published in the literature that has KI’s comparable to avibactam for critical Class 
A and C SBLs but greatly improved activity against Class D SBLs such as OXA-10 and OXA-24 
which are uninhibited by Avibactam and Relebactam.364 
 
Figure 1.13 A selection of the diazabicyclooctanes that are clinically available or in 
development. 365 
The mechanism of SBL inhibition by DBOs (Scheme 1.11) is simple at first glance; the catalytic 
serine (Ser70) attacks the diaza group carbonyl carbon, breaking the amide bond on the sulfate side to 
form the inhibited acyl enzyme.366 The details of this mechanism make it very interesting: in the 
structure of the active inhibitor, the lone pair of electrons on the bridgehead nitrogen are constrained 
and cannot exist in amide resonance making the carbonyl more reactive than expected from an amide. 
Once the ring is opened, as in the acyl enzyme shown in Scheme 1.11, the nitrogen lone pair is no 
longer geometrically constrained and exists in amide resonance. This makes the amide linkage in the 
acyl enzyme relatively unreactive towards nucleophilic attack by the water in the SBL active site 




Scheme 1.11 Avibactam mediated inhibition of SBLs and other reactions with Avibactam 
catalyzed by β-lactamases. 361,366,367 
Acylation of the catalytic serine can slowly reverse in many SBLs to regenerate the active inhibitor. 
Some SBLs, such as KPC-2, are capable of hydrolyzing and inactivating Avibactam by desulfonating 
(through either a one or two step mechanism), then hydrolyzing the imine, followed by carbamate 
hydrolysis but these are slow processes shown in Scheme 1.11.361 MBLs are not inhibited by DBOs, 
but have been shown to slowly inactivate the DBOs through the hydrolysis depicted in Scheme 1.11. 
The subsequent desulfonation in the MBL mechanism was only observed at low levels and it was not 
conclusively determined whether or not it was the result of enzymatic catalysis.367 
1.4.2.3 Transition State Analogs and β-Lactam Mimics 
Mechanism based inhibitors and DBOs both inhibit though the opening of an amide ring (either β-
lactam or DBO) forming a stable acyl-enzyme complex. Not all inhibitors of SBLs require a cyclic 
amide, others function by forming a covalent complex with the active site serine that mimics the 
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tetrahedral intermediate formed during catalysis or mimics the natural substrate without being able to 
complete the catalytic cycle.  
The earliest β-lactamase inhibitor to be discovered was boric acid in 1978 which inhibited BcI (A) 
with a KI of 1 mM.368 Boronate inhibitors were vastly improved in the 1980’s with simple aromatic 
boronic acids such as 1-1 and 1-2 from Figure 1.14 that inhibited Class A and C SBLs with KI’s as 
low as 0.5 μM.369–371 Increasing the complexity of boronic acids to include two R groups (one of 
which is derived from a cephalothin R group – highlighted in blue) such as 1-3, improved the potency 
of these inhibitors to 60 nM (IC50) against Class A SBLs.372 Cyclization of the boronate improved 
potency even more with Vaborbactam (RPX7009) inhibiting Class A and C SBLs with KI’s as low as 
30 nM.373 Vaborbactam was first reported and patented in 2010 and was approved for clinical use in 
combination with meropenem in 2017.374,375 Recently, boronic acid inhibitors have also been shown 
to be inhibitory towards a Class D SBL, OXA-24/40, although the inhibition is much less potent than 
against Class A and C SBLs.376 The inhibition of Class A, C, and D SBLs by phosphonates (1-4) and 
both cyclic and linear phosphates (1-5 and 1-6 respectively) have been thoroughly studied by the Pratt 
group; however the kinetics are reported in terms of rate constants making it difficult to compare their 
efficacy to that of other inhibitors reported in terms of KI or IC50.377–386  
 




Many β-lactam mimics have been studied in the context determining the pharmacophore of β-
lactam antibiotics and diversifying pharmacophores, some of which (imidazolidinones and 
cyclobutanones) were determined to be inhibitory towards β-lactamases. The topic of β-lactam 
mimics has been well reviewed by Jungheim and Ternansky in 1993 and cyclobutanones in particular 
have been recently reviewed by Devi and Rutledge.387,388 The first cyclobutanones (such as 1-7 from 
Figure 1.15) were synthesized by Gordon et al. in 1981 and were found to have no inhibitory activity 
towards R-TEM β-lactamase.389 A few years later, Lowe and Swain prepared a series of 
cyclobutanones, including 1-8, that inhibited R-TEM and B. cereus 568/H β-lactamases in a slow, 
time-dependent manner but they did not report a value that indicates inhibitory potency.390 Most 
recently, Johnson et al. from the Dmitrienko laboratory described the synthesis of 
dichlorocyclobutanones such as JJ05-1058 and JJ05-802, that weakly inhibited all classes of β-
lactamases with the best activity being demonstrated against Class C. 
 
Figure 1.15 Cyclobutanones: β-lactam mimics that are inhibitory towards β-lactamases. 389–391 
Both the transition-state analogs and the cyclobutanones inhibit SBLs by forming a reversible 
covalent acyl enzyme with the catalytic serine (Ser70) of the β-lactamase that mimics the tetrahedral 
transition-state of β-lactam binding as shown in Scheme 1.12. Crystal structures of Vaborbactam, 1-4, 
and JJ05-802 bound to the active sites of SBLs have been obtained which confirm the formation of a 
covalent bond between the catalytic serine and the inhibitor as well as the release of the p-nitrophenyl 
group from the phosphonate.373,379,391 A crystal structure of JJ05-1085 bound to the active site of the 




Scheme 1.12 Covalent adducts formed by boronates, phosphonates, and cyclobutanones that 
mimic the transition-state of β-lactam acyl-enzyme formation with serine-β-lactamases. 373,379,391 
1.4.3 Metallo-β-Lactamase Inhibitors 
Metallo-β-lactamases have become increasingly prevalent in recent years, and their broad substrate 
specificity confers resistance to many of the β-lactam antibiotics. Unlike the SBLs which can be 
inhibited by clavulanate, sulbactam, tazobactam, and the DBOs (Figure 1.11 and Figure 1.13 
respectively), MBLs do not yet have a clinically available inhibitor. Many MBL inhibitors have been 
reported in the literature since the mid-1990’s, although none of them have been developed for 
clinical use. Combination therapy of aztreonam with avibactam is currently being explored by Pfizer 
in phase 3 clinical trials as a potential treatment for complicated intra-abdominal infections and 
pneumonia (ventilator associated or hospital acquired) involving bacteria that co-express SBLs and 
MBLs.393 This strategy exploits a gap in the MBL substrate profile, their inability to hydrolyze 
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monobactams, while protecting the antibiotic from the SBLs that can degrade it with avibactam. In 
vitro studies on over 60 000 clinical isolates from 40 countries have shown that the aztreonam and 
avibactam combination is a potent combination against MBL-producing Enterobacteriaceae and P. 
aeruginosa.394 Despite the promise of a treatment for MBL-producing infections in the near future, 
the pursuit of an MBL inhibitor (for combination therapy with carbapenems) continues to be an 
important area of research. The following section covering MBL inhibitors is by no means exhaustive 
but covers many of the main themes in MBL inhibitor development; several excellent reviews exist in 
the literature.27,395–398 Common strategies for MBL inhibition involve completely or patially de-
metallating the active site with chelators, binding the zinc ions with dicarboxylates or sulphur groups 
without metal ion removal. Inhibitors have either been designed rationally or been discovered by 
screening natural product or known chemical libraries for activity using high-throughput methods. 
1.4.3.1 Demetallating chelators 
When trying to inactivate a protein that uses metal ions to perform its catalytic function, an obvious 
strategy is to remove the metal from the protein. For decades, this has been used in the classification 
of β-lactamases as MBLs since only the MBLs would be inactivated by EDTA.399 Although EDTA is 
adequate as a characterization tool, EDTA inactivation of MBLs often requires hours of incubation 
which, in combination with its promiscuity, makes it a poor drug candidate. Other common 
commercial chelators such as o-phenanthroline, PAR, TPEN, and DPA have been investigated as 
inactivators of IMP-1 although even the most effective of these inactivators, DPA, had only removed 
one zinc ion from 13% of the IMP-1 moelcules after 3 hours of incubation.400  
 
Figure 1.16 Demetallating inhibitors of MBLs. 400–402 
More recently, a natural product, Aspergillomarasmine A (AMA), was found to be a potent 
inactivator of NDM-1 and VIM-2, capable of removing one zinc ion from NDM-1 in as little as one 
hour. While AMA was shown to potentiate meropenem against NDM and VIM producing bacterial 
strains, it was much less effective against strains that produce AIM, IMP, or SPM – type MBLs, 
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making it a relatively narrow-spectrum MBL inactivator.401 The same group also discovered the 
potential for spiro-indolino-thiadiazoles (SIT) to inactivate MBLs with IC50s for NDM-1 as low as 6.6 
μM. Despite the favourable response from NDM-1, VIM-2 and IMP-7 were unaffected by even the 
most potent compound from this series, SIT-Z5, likely due to their zinc ions being more tightly 
bound.402–405 Demetallating chelators pose problems for clinical use since compounds that are potent 
enough to pull the zinc ions out of MBLs will potentially have toxicity problems in humans and those 
that are weak enough to be non-toxic have very narrow-spectrum activity. As a potentially less toxic 
alternative to demetallating chelators, inhibitors that can bind the zincs rather than remove them are 
desirable. 
1.4.3.2 Dicarboxylates 
The earliest MBL inhibitors in this class were the succinic acid derivatives, the most potent of 
which is 1-9 (Figure 1.17).This compound was reported to be an extremely potent inhibitor of IMP-1 
with an IC50 of 3 nM, although neither the article nor the patent that disclose this compound address 
its ability to inhibit other MBLs.406,407 Further analogs of the succinic acids have been pursued by 
chemists at Merck who have proven that these compounds can potentiate meropenem against E. coli 
strains transformed with an IMP-1 expressing plasmid, although none of those compounds approach 
the potency of 1-9.408 Olsen et al. explored the inhibitory potency of analogs of 1-9 with BcII and L1 
and did not observe inhibition, suggesting that these compounds may not have a sufficiently broad-
spectrum to be clinically useful.409 
 
Figure 1.17 Dicarboxylate inhibitors of MBLs. 406,410–414 
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The succinic acid derivatives have flexibility in the bond connecting the carboxylic acid groups, 
although this is not necessary as several conformationally rigid dicarboxylates have been found to be 
MBL inhibitors. DPA (2,6-PA), which is capable of abstracting one zinc ion from IMP-1 at long 
incubation times, also inhibits MBLs in a time dependent competive manner at short incubation 
times.400,415 Horsfall et al. demonstrated that other substitution patterns of DPA are also inhibitory, 
notably 2,4-PA which inhibits the B2 MBL CphA with a KI of 5 μM but has little effect on B1 and B3 
MBLs. Their study also demonstrated that the monocarboxylate, 2-picolinic acid, is capable of 
partially inhibiting all MBL subclasses at 100 μM.410 Feng et al. explored nitrogen containing 
heterocycles as MBL inhibitors, and found that those with carboxylate groups on either side of the 
nitrogen (such as 1-10) were inhibitors of all MBL subclasses with IC50s of compound 1-10 ranging 
from 0.64 μM to 7.1 μM.413 
Although the nitrogen in the picolinic acid derivatives is advantageous for zinc binding (see 
Chapter 3 for more details), it is not a necessary feature for the aromatic dicarboxylate inhibitors. 
Researchers at Meiji Seika pharmaceuticals have demonstrated that dicarboxylate inhibitors derived 
from phthalic acid such as 1-11 and 1-12 are capable of inhibiting IMP-1. Although the IC50s for 1-11 
and 1-12 (0.97 μM and 0.27 μM respectively) indicate that these are much more potent than the DPA 
derivatives, they have only been tested against IMP-1, so it is unknown whether or not these represent 
broad-spectrum MBL inhibitors.411,414,416 
Another discovery in this area at Meiji Seika pharmaceuticals is ME1071, a maleic acid derivative 
that has been demonstrated inhibit IMP-1, VIM-2, and NDM-1. The inhibition constants determined 
for ME1071 remains consistent between publications for IMP-1 (KI = 0.41 μM or 0.46 μM); 
however, that of VIM-2 varies greatly (KI = 120 μM or 1 μM), while that of NDM-1 has only been 
reported once (KI = 24 μM). When correlated with the bacterial data, it becomes clear that this 
compound is most active against IMP variants and least active against NDM variants.412,417 
1.4.3.3 Sulphur Containing Inhibitors 
The affinity of sulphur compounds for zinc ions is one of the fundamental relationships in biology, 
allowing for zinc binding to proteins through cysteine containing zinc fingers, the Lewis acidity of 
zinc ions in proteins, some forms of redox activity, and much more.418 This relationship can also be 
exploited for inhibition of proteins, such as MBLs, that use zinc in their catalysis.  
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The most common sulphur moiety used in MBL inhibitors is the thiol (Figure 1.18) which often 
accompanies a carboxylate. Early mercaptocarboxylates identified as MBL inhibitors included 
compound 1-13 and R-thiomandelic acid, both of which were inhibitors of multiple subclasses of 
MBL with submicromolar IC50s and KIs respectively.251,419 In 2003, members of the Dmitrienko lab 
tested the inhibitory potential of 23 commercial thiols, the most potent of which was mercaptoacetic 
acid against IMP-1 and also inhibited BcII 5/B/6 and CcrA. This study concluded that thiols with an 
α-carboxylate (or similar anionic group) were classical competitive inhibitors, while those without an 
anionic group behave as time-dependent competitive inhibitors under neutral conditions due to the 
deprotonation necessary to make the most stable EI complex. Additionally, it was observed that 
esterifying the carboxylates, adding an amine, and using an aromatic molecule as the core structure all 
reduced inhibitory potency against IMP-1.420 Jin et al. found that using aliphatic chains to distance the 
thiol from an aromatic group increased potency as compound 1-14 from Figure 1.18 exhibits IC50s of 
1.2 μM and 1.1 μM with IMP-1 and VIM-2 respectively while the equivalent compound with only 
one carbon between the phenyl ring and the carboxylate had IC50s of 16.4 μM and 14.3 μM 
respectively.421 
 
Figure 1.18 Thiol inhibitors of MBLs. 251,419–425 
The most thoroughly studied MBL inhibitor is captopril, a known inhibitor of angiotensin-
converting enzyme (ACE) in humans that has been used for many years to treat hypertension.426 Two 
stereoisomers of captopril have been used in most investigations: D-captopril (Figure 1.18) and L-
captopril, referring to the stereochemistry of the proline ring. Crystal structures of MBLs have been 
acquired with both stereoisomers bound; however, the D-isomer is frequently the more potent 
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inhibitor (2- to 61- fold more potent) and consequently generates higher occupancy crystal structures 
of the enzyme-inhibitor complexes.423,427 Although D-captopril is able to inhibit enzymes in all 
subclasses of MBL, some MBLs such as SPM-1 (B1) and FEZ-1 (B3) are resistant to inhibition.256,423 
Additionally, D-captopril does not bind to all MBLs in the same manner: the sulphur atom binds 
between the zinc atoms in all MBLs except in the monozinc CphA (B2) in which the carboxylate 
binds the zinc atom as seen in Figure 1.19E. Binding even differs within subclasses, for example the 
B1 MBLs BcII (Figure 1.19A) and VIM-2 (Figure 1.19B) bind in very similar modes with the proline 
ring stacked over the His residue that coordinates Zn2 (His240) and the carbonyl H-bonded to 
Asn210 whereas in IMP-1 (Figure 1.19C) the Asn210 interaction is weaker (4.4 Å as opposed to <3 
Å) but the tryptophan on the capping loop, Trp45, makes the proline stacking tighter.423 The most 
different of the B1 MBL structures is BlaB (Figure 1.19D) in which the proline ring sits over one of 
the histadine residues that coordinates Zn1 (His118) rather than the His residue that coordinates Zn2 
(His 240).428 The two structures of B3 MBLs differ greatly since L1 (Figure 1.19F) is inhibited by D-
captopril with a KI of 8 μM, corresponding to D-captopril binding the active site tightly, whereas 
FEZ-1 (Figure 1.19G) is only weakly inhibited with a KI of 400 μM and in the crystal structure, D-




Figure 1.19 D-Captopril bound to various MBLs from all subclasses : B1 MBLs (A) BcII, (B) 
VIM-2, (C) IMP-1, (D) BlaB, the B2 MBL (E) CphA with the putative Zn1 binding site 
highlighted in blue, and the B3 MBLs (F) L1, and (G) FEZ-1 (This figure was generated using 
UCSF Chimera v. 1.12 from protein databank files 4C1C, 4C1E, 4C1G, 1M2X, 2QDS, 2FU8, 
and 1JT1 respectively).255,256,423,428,429 All structures are oriented with Zn1 (or equivalent binding 
site) towards the bottom of the image. 
Recent work on thiol inhibitors of MBLs has focused on taking advantage of their ability to inhibit 
all subclasses of MBL and reducing the in vivo toxicity. The mercaptophosphonate 1-15 (Figure 1.18) 
addressed cross-class inhibition of MBLs by introducing a phosphonate which coordinates the zinc 
ion of CphA in a tetrahedral geometry while also making contacts with nearby His and Lys residues 
(PDB: 3IOG) while the thiol is predicted to bind the zincs in the B1 and B3 enzymes as observed for 
D-captopril.424 The bisthiazolidines, particularly L-CS319 (Figure 1.18), were shown to inhibit all 
subclasses of MBL with KIs ranging from 0.26 μM to 41 μM with most KIs being in the low 
micromolar range for the 7 tested MBLs (B1: NDM-1, VIM-2, IMP-1, BcII; B2: Sfh-1; B3: L1, 
GOB-18). Crystal structures of Sfh-1 (B2) and L1 (B3) were obtained with L-CS319 and showed the 
 
 54 
thiol equidistant between the zinc ions in the L1 strucutre (PDB: 5EVK) and the carboxylate 
coordinating the zinc ion in Sfh-1 (PDB: 5EW0), consistent with the binding modes of D-captopril.425 
Unpublished structures of the B1 MBLs BcII, NDM-1, and VIM-2 with L-CS319 bound (PDB: 
4NQ5, 4U4L, 4U4A) have been acquired and demonstrate the expected mode of binding: the thiol 
replacing the bridging hydroxide. 
 
Scheme 1.13 Activation of rhodanine to a mercaptocarboxylate MBL inhibitor. 430,431 
One of the challenges of using thiols as MBL inhibitors is that thiols can inhibit critical human 
metallo-proteins such as ACE and some can cause toxicity as a result of their reactivity.432,433 
ML302F is a potent MBL inhibitor that is intended to be administered as ML302 with the thiol 
protected. ML302F was found to inhibit 6 B1 MBLs (NDM-1, VIM-1, VIM-2, SPM-1, IMP-1, and 
BcII) with sub-micromolar IC50s and was not inhibitory towards a small panel of human metallo-
enzymes including ACE. The authors suspect that ML302 is converted to ML302F by MBLs; 
however, their experiments to confirm this were inconclusive due to the potent inhibitory effect of 
ML302F. As expected, ML302F binds to VIM-2 with the thiol bridging the zinc ions with the 
carboxylate also interating with Zn2 and several of the surrounding residues.430,431 Although 
protecting the thiol of ML302F should reduce potential toxicity (as demonstrated by no toxicity 
against human HeLa cells up to 100 μM)430, rhodanines are known to be promiscuous inhibitors and 
may cause problems in complex systems such as humans.434 
The next most common sulphur containing functionality used in MBL inhibitors is the thioester as 
seen in compounds 1-16, 1-17, and 1-18 in Figure 1.20, the idea being that the thioester could be 
recognized as the amide of a β-lactam substrate, particularly when the β-carbon from the sulphur is a 
carboxylate.435 Each of these compounds was reported as an MBL inhibitor in the late 1990’s, and 
today would not be considered potent enough to publish. Compound 1-16 inhibited L1 (B3) and 
CphA (B2) with reasonable potency (IC50 = 10 μM, 30 μM respectively) but was not capable of 
significantly inhibiting BcII (B1) nor CfiA (B1).435 The same group demonstrated that compound 1-
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17 inhibited BcII and CfiA with IC50s of 23 μM and 724 μM respectively in the presence of 1 μM 
zinc and all inhibition was abolished when the Zn2+ concentration was increased to 100 μM. Although 
it was weakly effective against B1 MBLs, this inhibitor was very potent against L1 with an IC50 of 
less than 1.9 μM in high and low zinc conditions.436 Compound 1-18 was developed by Merck 
scientists as a potent IMP-1 inhibitor (IC50 = 0.0004 μM), although their publications are inconsistent 
about the stereochemistry of the active inhibitor.437,438 The stereochemistry denoted in Figure 1.20 is 
consistent with the Greenlee paper which actually addresses the differences in the activity of the R 
and S isomers.437 The extreme potency of 1-18 against IMP-1 (B1) did not translate to the only other 
MBL tested, CcrA (B1), which has an IC50 of only 180 μM.437,438 No crystal structures have been 
published with a thioester inhibitor bound to an MBL. 
 
Figure 1.20 Thioester and other non-thiol MBL inhibitors that contain sulphur. 435–437,439–442 
Other MBL inhibitors have been discovered with sulphur containing moieties, some of which fit 
better into the other categories laid out in this section such as the demetallating chelator SIT-Z5 from 
Figure 1.16 and the dicarboxylate 1-10 from Figure 1.17.402,413 Inspired by the inhibition of MBLs 
with DPA and thiols, Roll et al. investigated the inhibition of CcrA (B1) and L1 (B3) with thioacid 
and methyl thioester derivates of DPA and found that PDTC (Figure 1.20) is the most potent inhibitor 
of these two MBLs with IC50s of 0.14 μM and 0.6 μM respectively.439 Faridoon et al. used fragment-
based screening to suggest that 3-mercapto-1,2,3-triazoles and N-acylated thiosemicarbazides could 
be inhibitory towards IMP-1. After investigation of several compounds from each group, they 
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determined that the triazoles were not inhibitory and the thiosemicarbazoles were moderate inhibitors. 
The most potent inhibitor from this series, 1-19 in Figure 1.20, inhibited IMP-1 with a KI of 14 μM 
which is comparable to the inhibitory potency of L-captopril.440  
Two groups of inhibitors have been published with sulfones as a key feature of their structure: the 
N-arylsulfonyl hydrazones (1-20 in Figure 1.20) and sulfonyl triazoles (1-21 in Figure 1.20).441,442 
The N-arylsulfonyl hydrazones were developed as IMP-1 inhbitors, the most potent of which (1-20) 
inhibited IMP-1 with an IC50 of 1.6 μM. These inhibitors were unfortunately not broad-spectrum as 
many in this series were unable to inhibit BcII 5/B/6, and even 1-20 only elicited 30 % inhibition at 
25 μM.441 The sulfonyl triazoles were discovered as VIM-2 inhibitors using high-throughput 
screening of a click-chemistry library, the most potent compound in this series, 1-21, inhibited VIM-2 
in a competitive manner with a KI of 0.41 μM (IC50 = 3.3 μM) but was uninhibitory towards IMP-
1.442 Compound 1-21 was used as a lead to develop a more potent inhibitor which was able to inhibit 
VIM-2 with a KI of 0.01 μM but all 47 compounds developed in this series were uninhibitory towards 
IMP-1.443 
1.4.3.4 Other Metallo-β-Lactamase Inhibitors 
Identification of structurally unique inhibitors of MBLs occurs primarily through screening large 
databases of natural products, pharaceuticals, and chemical collections from pharmaceutical 
companies. Scientists from GlaxoSmithKline screened their natural products database and identified 
three tricyclic natural products as MBL inhibitors, the most potent of which is SB236049 which 
inhibits BcII (B1) and CfiA (B2) with IC50s of 0.3 μM and 2 μM respectively. This compound was 
not as effective against IMP-1 (IC50 = 151 μM) and all three compounds in this series were inactive 
against L1 (B3).444 Chemists at Merck screened their chemical collection to identify biphenyl 
tetrazoles as inhibitors of MBLs, the most potent derivative of which was L-161,189 which inhibited 




Figure 1.21 Structurally unique MBL inhibitors. 442,444,445 
Minond et al. screened a collection of pharmacologically active compounds to identify inhibitors of 
VIM-2. They found mitroxantrone (Figure 1.21), a DNA intercalator and topoisomerase IIα inhibitor 
used to treat advanced multiple sclerosis and certain cancers, to be an uncompetitive inhibitor of 
VIM-2 (KI = 1.5 μM) and uninhibitory towards IMP-1.442,446–449 The other pharmacologically active 
compound identified from the screen as a VIM-2 inhibitor was para-chloromercuribenzoate (pCMB) 
which is known to react with cysteine residues. pCMB inhibits both VIM-2 and IMP-1, likely by 
covalently modifying the cysteine that coordinates Zn2 (Cys172 in VIM-2, Cys158 in IMP-1).260,442 
Inhibitors of metallo-β-lactamases vary widely in structure and specificity. Many of the inhibitors 
presented in this section were only tested against one or two MBLs and do not offer any insight into 
whether or not they would be useful as broad-spectrum inhibitors. Of those that were tested widely, 
the thiol (particularly the mercaptocarboxylates) and dicarboxylate functionalities had the broadest 
spectrum of inhibition. The mercaptophosphonate 1-7 in Figure 1.18 introduces a phosphonate into a 
thiol inhibitor, a novel solution to the problem of thiols being less inhibitory towards B2 MBL. The 
dithioacid derivative of DPA (PDTC) in Figure 1.20 is also an interesting approach to that problem, 
potently inhibiting both a B2 and B3 MBL. The phosphonate and thioacid moieties are understudied 
in the literature considering their potential to be broadly inhibitory: this thesis addresses furthering the 
understanding of the prospects for these functionalities in MBL inhibitors (see Chapter 3 and Chapter 
4 respectively).  
1.4.4 Dual Serine- and Metallo-β-Lactamase Inhibitors 
Although it is useful to inhibit either SBLs or MBLs, this poses a challenge for clinical applications 
against pathogens that produce both types of β-lactamases. It is challenging enough to get 
combination therapies involving only two compounds approved but is significantly more difficult to 
get approval for a three-compound combination (antibiotic, SBL inhibitor, MBL inhibitor). Ideally, a 
dual serine- and metallo-β-lactamase inhibitor would be administered in combination with a broad-
spectrum β-lactam (such as meropenem) which would protect it from all β-lactamases. The only dual 





Figure 1.22 Structural evidence for cyclic boronate inhibition of SBLs and MBls  exemplified by 
CB-1 bound to the SBL CTX-M-15 (A) and CB-2 bound to the B1 MBL VIM-2 (B). This figure 
was generated using UCSF Chimera v. 1.12 from protein databank files 5T66 and 5FQC.450,451 
Kinetic studies on the cyclic boronates CB-1 and CB-2 have determined that while both show 
activity against SBLs and MBLs, CB-1 is more potent against SBLs and CB-2 is more potent against 
MBLs.451 Crystal structures of CTM-M-15 (PDB: 5T66) and OXA-10 (PDB: 5FQ9) have been 
determined with CB-1 bound, and VIM-2 (PDB: 5FQC) and BcII (PDB: 5FQB) have been 
determined with CB-2 bound (Figure 1.22).450,451 The crystal structures of the SBLs illustrated that the 
inhibition of SBLs occurs through nucleophilic attack of the boronate by the catalytic serine (Ser73 in 
CTX-M-15) forming a covalent adduct.450 In binding the MBLs, such as VIM-2, CB-2 was found to 
coordinate Zn1 with both boronate hydroxyl groups and Zn2 with the oxygen in the ring.451 Although 
the cyclic boronate pharmacophore is capable of being inhibitory towards both SBLs and MBLs, not 
all cyclic boronates behave in this manner. The newly FDA approved β-lactamase inhibitor 
Vaborbactam (Figure 1.14) is a cyclic boronate with activity against only Class A and C β-lactamases 
as covered in 1.4.2.3.375 
1.5 Clinical Significance of β-Lactamase Inhibition 
Combination therapy with the mechanism-based inhibitors has proven to be a useful strategy for 
combating β-lactam resistance in bacteria that express certain SBLs although resistance to these 
inhibitors is already prevalent. The recent introductions of Avibactam and Vaborbactam into clinical 
use have addressed resistance from many, but not all, SBLs including some ESBLs. These solutions 
to an ever-growing problem provide hope that β-lactams can remain a viable option for antimicrobial 
therapy for decades to come. The biggest threat to β-lactams as a therapeutic option is the 
increasingly widespread expression of MBLs which are capable of breaking down last-line of defense 
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β-lactams, such as the carbapenems, and are unaffected by the current SBL inhibitors. Metallo-β-
lactamase inhibitors are necessary for the future of antimicrobial therapy, especially in the light of 
increasingly common multidrug resistant pathogens. Ideally, novel β-lactamase inhibitors should aim 
to inhibit both SBLs and MBLs since it is not uncommon for resistant pathogens to express multiple 
β-lactamases from both mechanistic families. 
Inhibition of PBPs and β-lactamases – specifically metallo-β-lactamases – is crutial for treating 
increasingly problematic resistant pathogens. This work explores the potential use of several classes 
of MBL inhibitors and inhibitor releasing cephalosporins in increasing the efficacy of clinical 





Phylogenetic Analysis, Purification, and Biochemical 
Characterization of β-Lactamases 
2.1 Introduction 
The objective of the research described in this chapter was to overexpress and purify adequate 
amounts of a variety of β-lactamases for kinetic testing and to characterize their ability to hydrolyze 
chromogenic cephalosporins as well as their stability to organic co-solvents commonly used in kinetic 
assays. While the hydrolysis of any β-lactam can be detected using spectrophotometry, it is 
advantageous to use chromogenic substrates that exhibit larger changes in absorbance in the visible 
range rather than the UV range upon hydrolysis of the β-lactam bond. This means that these 
substrates can be assayed in affordable 96-well plates made of polystyrene rather than those made 
from quartz or expensive UV-transparent plastics. An additional benefit of the assay wavelength 
being relatively high is that it is uncommon for other compounds in the assay, such as cosolvents or 
inhibitors, to interfere with the assay as they typically absorb only in the UV range. 
 




In the 1970s and early 1980s, several chromogenic β-lactams were developed (eg. nitrocefin, 
PADAC, and CENTA (Figure 2.1)). PADAC is no longer commercially available and nitrocefin has 
become the chromogenic substrate of choice.310,312–314,452 A drastic increase in the cost of nitrocefin in 
the early 2000’s motivated another surge of chromogenic β-lactam development resulting in 
Chromacef and the fluorogenic FC4 (Figure 2.1).315,317,453  
 
Scheme 2.1 Panbio homogeneous immunoassay technology. 454 
The Dmitrienko group, in collaboration with Panbio, undertook the development of a series of 
chromogenic cephalosporins that could be used in a homogeneous immunoassay pictured in Scheme 
2.1. In a homogeneous immunoassay, β-lactamase fragments that are independently inactive are 
tethered to an antibody and a disease specific antigen. Upon binding to IgM from a patient’s sample, 
the β-lactamase fragments are brought together into their active form, catalyzing the hydrolysis of a 
chromogenic cephalosporin.454 The substrates used for this assay need to have a more distinct colour 
change than provided by nitrocefin hydrolysis and must be more cost effective. The Dmitrienko lab 
pursued several strategies to make a better chromogenic cephalosporin, finally yielding the UW series 
of substrates: UW-57, UW-58, and UW-154 (Figure 2.2). 
 
Figure 2.2 Chromogenic β-lactamase substrates synthesized by the Dmitrienko group. 
 
 62 
The UW series of substrates have the advantage of a shorter and more cost effective synthetic 
method while maintaining similar kinetic parameters to nitrocefin with many β-lactamases. In some 
cases, the kinetic parameters of the UW substrates make them better for kinetic assays than nitrocefin 
through either raising the KM sufficiently to make substrate depletion less of a problem in assays 
performed at KM concentrations, or higher kcat values which require less enzyme to achieve 
reasonable rates, allowing savings on precious enzyme stocks. 
2.2 Methods 
Unless otherwise stated, all spectrophotometric readings were done using a SpectraMax 190 plate 
reader (Molecular Devices, Sunnyvale, CA) with SoftMax 6.0 (Molecular Devices, Sunnyvale, CA) 
software. Analysis of kinetic data was performed using GraphPad Prism 5.00 for Windows 
(GraphPad Software, San Diego, CA). The 96-well plates were always clear, flat bottomed, 
polystyrene plates and were purchased from either Corning (Corning, NY) or Greiner Bio-One 
(Monroe, NC) for enzyme kinetics. Plates for bacteria experiments were purchased from either 
Corning (Corning, NY) or Sarstedt (Nümbrecht, Germany). Initially, cation adjusted Mueller Hinton 
broth powder was purchased from Sigma (Burlington, MA) when problems with inconsistency were 
encountered between batches late in 2017, the supplier was changed to BD (Franklin Lakes, NJ). 
Other bacterial media components were purchased from BioBasics (Markham, ON). Most buffer salts 
were purchased from BioShop (Burlington, ON), phosphate buffer salts from Alfa Aesar (Haverhill, 
MA), and other chemicals from companies now owned by MilliporeSigma (Burlington, MA) such as 
EMD and Sigma. The dialysis membrane used throughout was SpectraPor dialysis membrane with a 
6-8 kDa molecular weight cutoff from the Spectrum labs division of Repligen (Waltham, MA). 
2.2.1 Protein Sequence Alignment 
The protein sequences of IMP-1, NDM-1, and VIM-2 were acquired from the NCBI Database in 
FASTA form and entered into the BLAST Explorer functionality of phylogeny.fr which searched the 
NCBI database prior to 9 Nov 2017 for similar, non-redundant protein sequences.455,456 The 100 
closest matches were displayed and the whole protein sequence for every variant within that family 
was selected to make a phylogenetic tree using the “One Click” tool. A check was done to ensure all 
variants with sequences in the NCBI database as of 20 Jan 2018 were in the data set, and any variants 
that were missing were manually added to the data set prior to tree generation. The “One Click” 
analysis tool aligned sequences using MUSCLE, curated these results with Gblocks, determined 
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phylogenetic relationships with PhyML. The phylogenetic tree was rendered with TreeDyn.457–461 The 
sequence alignment was downloaded as a Clustal file then formatted using BioEdit v. 7.0.5.3.462 
Formatting of the phylogenetic tree was done using both the TreeDyn web applet on phylogeny.fr and 
the TreeDyn v. 198.3 desktop program. 
2.2.2 Enzyme Purification 
Characterization of the inhibition of serine- and metallo-β-lactamases by PMPCs (Chapter 3) 
necessitated the purification and acquisition of a variety of enzymes. Pure protein samples of the 
MBLs IMP-1, L1, and SFH-1 as well as the SBL OXA-23 were generous gifts from Dr. James 
Spencer of the School of Cellular and Molecular Medicine at the University of Bristol. Dr. Spencer 
also provided expression plasmids for VIM-1 and OXA-48. Two batches of pure SPM-1 were 
obtained; one from Dr. Spencer, and the other from Dr. Christopher Schofield of the Department of 
Chemistry at the University of Oxford. The experiments presented in this thesis were performed with 
Dr. Schofield’s SPM-1 preparation. NDM-1 with the first 41 amino acids truncated including the 
signal peptide and the 13 amino acids that follow it, from the Schofield group at the University of 
Oxford was used thoughout these studies.317 Dr. Natalie Strynadka of the Department of Biochemistry 
and Molecular Biology at the University of British Columbia provided the expression plasmid for 
CTX-M-15 and pure NDM-1 stocks that were used in preliminary experiments not presented in this 
work. Expression plasmids for VIM-2, GC-1, and KPC-2 were provided by Dr. Patrice Nordmann of 
L’Université Paris-Sud, Dr. Michiyoshi Nukaga of Josai International University in Togane City, 
Chiba, Japan, and Dr. Focco van den Akker of Case Western Reserve University respectively. 
Purification of proteins was carried out with the assistance of Dr. Geneviève Labbé and various 
undergraduate research students as part of their projects. 
2.2.2.1 Preparation for Protein Purification 
Media for Bacterial Cultures 
Luria-Bertani (LB) and Terrific broth (TB) were made using standard recipes from Molecular 
Cloning Laboratory Manual 2nd Ed. with tryptone, yeast extract, and NaCl. Salts for buffering TB 
were prepared separately from the media and added after autoclaving.463 
Calcium chloride competent E. coli for Transformation 
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LB broth (5 mL) was inoculated with 50 μL E. coli cells (BL21, BL21 DE3, or BL21 PLysS as 
appropriate) and incubated overnight at 37 oC shaking at 225 rpm. The overnight culture was 
inoculated into fresh LB in a ratio of 1:20 (culture:media) and shaken at 225 rpm at 37 oC until the 
OD was between 0.25 and 0.3 (approximately 1.5 hr) the chilled on ice for 15 min. Cells were 
isolated by centrifugation in sterile 50 mL conical vials at 1600 xg for 10 min at 4 oC. The 
supernatant was decanted and discarded. Cells were resuspended and pooled in 30 mL cold 0.1 M 
CaCl2 and allowed to accommodate for 30 min on ice. Centrifugation and resuspension were repeated 
twice as previously described. The final resuspension was performed with 6 mL cold 0.1 M CaCl2 in 
15 % glycerol which was then aliquoted and flash frozen on dry ice for storage at -80 oC. 
2.2.2.2 Analysis of Protein Purification 
Nitrocefin Activity Assay 
Aliquots of protein collected during purification were diluted as appropriate in the buffer used in 
the respective purification step and incubated in a flat bottom 96 well plate at 30 oC for 5-10 min 
before addition to nitrocefin (final concentration 100 μM for GC-1, and 25 μM for CTX-M-15). The 
activity was determined by monitoring this reaction at 482 nm for 5 min at 30 oC and measuring the 
initial rate. At least two replicates of this assay were generally performed. 
Bradford Assay 
A standard curve of bovine serum albumin (BSA) from 0.05 mg/mL to 0.5 mg/mL was made fresh 
each day. Four technical replicates of standards and appropriately diluted samples were 
simultaneously incubated with Bradford reagent (BioRad, Hercules, CA) in a 96 well plate for 5 min 
at room temperature. The absorbance was then read at 595 nm using either a Powerwave XS2 
(BioTek) plate reader or the SpectraMax 190. 
SDS PAGE 
Protein samples or diluted protein samples were added to 5x SDS PAGE loading buffer (0.25 M 
Tris-HCl, 10 % SDS, 5 % 2-mercaptoethanol, 30 % glycerol, 0.02 % bromophenol blue, pH 6.8) then 
boiled for 5 min. If condensation was observed on the lid of the tubes, they were centrifuged briefly. 
The prepared sample (10-20 μL) was loaded onto 12.5 % polyacrylamide:bisacrylamide gel and run 
at 200 V with a low molecular weight protein standard (GE Healthcare UK, Buckinghamshire, UK or 
BioBasic, Markham, ON) in at least one of the wells. Gels were stained with Coomassie Blue 
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(BioRad, Hercules, CA) containing stain (50 % (v/v) methanol, 10 % (v/v) acetic acid, 0.025 % (w/v) 
Coomassie Blue R-250) then destained with 50 % methanol, 10 % acetic acid. Gels were soaked in 
water prior to visualization using either the white plate with a Gel Doc EZ Imager (BioRad, Hercules, 
CA) or a camera. Purification of all β-lactamases in this chapter was monitored using SDS PAGE. 
Gels from individual purifications will not be presented in this work, only a summary gel. 
Mass Spectrometry 
The molecular weights of purified proteins were determined by electrospray ionization mass 
spectrometry (ESI-MS) in positive ion mode at the University of Waterloo Mass Spectroscopy 
Facility. Pure proteins with their affinity tags cleaved were exchanged into 20 mM ammonium acetate 
using Amicon Ultra Ultracel 10 K membrane centrifugal filters (Millipore). VIM-2 and KPC-2 were 
then appropriately diluted in 1:1 MeOH:H2O, 0.2 % FA and injected into the Micromass Q-TOF 
Ultima Global mass spectrometer equipped with a Z-spray electrospray ionization source 
(Micromass) with the aid of a syringe pump. CTX-M-15, GC-1, NDM-1 (received from the Schofield 
group at Oxford), SPM-1 (received from the Spencer group at Bristol), L1 (also received from 
Spencer), and OXA-48 were appropriately diluted in 1:1 MeOH:H2O, 0.1 % FA then injected into the 
Thermo Scientific Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific Inc.) by 
electrospray ionization with the aid of a syringe pump. Protein deconvolution was done using Thermo 
Protein Deconvolution v. 1.0 (Thermo Fisher Scientific Inc.). 
2.2.2.3 CTX-M-15 
The transformation and purification of CTX-M-15 was done with the assistance of Jessica Duong 
as part of her undergraduate research. 
Transformation 
The cloning of CTX-M-15 into a pET28 vector with a thrombin cleavable N-6His tag was 
performed by Dr. Strynadka’s lab before being sent to the Dmitrienko lab. The CTX-M-15 plasmid 
was transformed into CaCl2 competent E. coli BL21 DE3 cells by incubating them together for 40 
min on ice before heat shocking at 42 oC for 1.5 min. The cells were allowed to recover from 
transformation with the addition of 200 μL of LB media then incubated for 2 hours at 37 oC. 
Transformants were plated on LB agar supplemented with 50 μg/mL kanamycin and incubated 
overnight at 37 oC then stored at 4 oC until ready to proceed to liquid cultures. 
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Growth of Liquid Cultures for CTX-M-15 Expression 
One colony from the CTX-M-15 transformation was inoculated into 50 mL TB media 
supplemented with 50 μg/mL kanamycin which was incubated at 37 oC overnight, shaking at 200 
rpm. Two 4 L flasks containing 1 L TB media supplemented with 50 μg/mL kanamycin were 
inoculated with 10 mL each of the overnight culture then incubated at 37 oC, shaking at 220 rpm until 
the culture had reached an OD600 of approximately 0.9 (this should have been 0.6, but was 
overgrown). Expression of CTX-M-15 was then induced with 1 mM isopropyl β-D-1 
thiogalactopyranoside (IPTG) overnight, shaking at 200 rpm at room temperature. Cells were 
harvested by centrifugation in a JA-10 rotor at 6000 xg for 20 min at 4 oC yielding 25.7 g of pellet. 
The pellet was then washed twice with 54 mL of 0.85 % NaCl and cells were harvested again by 
centrifugation in a F34-6-38 rotor at 6000 xg for 5 min at 4o C then flash frozen on dry ice and stored 
at -80 oC. Cell pellets were thawed then resuspended in 20 mL of Lysis buffer (50 mM Tris HCl, 300 
mM NaCl, 20 mM imidazole, 10 % (v/v) glycerol, 0.2 % NP-40, 1 mg/mL lysozyme, 2 μg/mL DNase 
I, pH 8.0) and lysed using a large probe on a Heat Systems Ultrasonic processor W-255 sonicator set 
to 50 % cycle and 50 % power 5 times for 30 sec each with 1 min rest on ice between bursts. Cellular 
debris was separated from the lysate by centrifugation at 20 000 xg for 60 min at 4 oC using a JA-25.5 
rotor. The supernatant was retained and stored at 4 oC overnight.  
Affinity Chromatography 
An Omnifit column housing filled with HisPurTM Ni-NTA Superflow Agarose (Thermo Scientific) 
was mounted on a BioCad Sprint Perfusion Chromatography system and equilibrated with 1 column 
volume of CTX-M-15 Elution buffer (50 mM Tris HCl, 300 mM NaCl, 300 mM imidazole, 10 % 
(v/v) glycerol, pH 8.0) then 12 column volumes of CTX-M-15 Chelating buffer (50 mM Tris HCl, 
300 mM NaCl, 20 mM imidazole, 10 % (v/v) glycerol, pH 8.0) through 2 different lines at 1 mL/min. 
The lysate was filtered through at 0.2 μm syringe filter to sterilize and remove any particulates before 
loading onto the column. Over the course of 3 purifications, 9.5 mL of lysate was applied to the 
column through the pump at 0.5 mL/min then that line was flushed with CTX-M-15 Chelating buffer 
for 2 column volumes. The column was then washed with 5 column volumes of CTX-M-15 Chelating 
buffer at 1 mL/min. CTX-M-15 was eluted from the column using a gradient from 100 % CTX-M-15 
Chelating buffer to 100 % CTX-M-15 Elution buffer over 5 column volumes with an additional 
column volume of CTX-M-15 Elution buffer at the end to ensure complete elution. Fractions were 
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collected every 3 min starting from the loading of the protein onto the column. The 2-3 fractions from 
each day that contained the highest CTX-M-15 activity by nitrocefin assay were pooled and dialyzed 
into 50 mM HEPES pH 7.2 until both the imidazole and NaCl concentrations were calculated to be 
below 10 nM. Dialyzed CTX-M-15 was concentrated using an Amicon Ultra-15 centrifugal filter 
with a 10 kDa molecular weight cutoff then stored in 50 % (v/v) glycerol at -20 oC. 
Thrombin Cleavage of His Tag 
Cleavage of the His tag from CTX-M-15 was performed using a Thrombin Cleavage Capture kit 
(Novagen) which uses biotinylated thrombin and streptavidin agarose. An 80 μL aliquot of 
concentrated CTX-M-15 was incubated with 20 μL 1:100 diluted thrombin in Thrombin Cleavage 
Buffer (20 mM Tris HCl, 150 mM NaCl, 2.5 mM CaCl2, pH 8.4) at room temperature for 4 hr. The 
reaction was stopped with the addition of 25 μL streptavidin agarose slurry and incubated for 30 min 
at room temperature to bind all of the thrombin. Cleaved CTX-M-15 was eluted using a spin filter at 
1000 xg for 10 min then stored at -20 oC in 50 % (v/v) glycerol. 
2.2.2.4 KPC-2  
PCR Amplification of KPC-2 
The gene for KPC-2 was amplified from a KPC-2 containing pBr322 vector supplied by Dr. Focco 
van den Akker to introduce restriction sites for insertion into pET28a.214 Two sets of primers were 
used to code for an N-terminal 6-His tag: one that adds the His tag onto the signal peptide of KPC-2 
and another one that adds the His tag directly onto KPC-2 without coding for the signal peptide. 
Polymerase chain reactions (PCR) were prepared using a PWO DNA polymerase kit (Roche) with 1 
mM dNTP mixture, 0.25 μM of the Nde1 forward primer and EcoR1 reverse primer, 1 μL or 5 μL of 
KPC-2 template, and 2.5 units of PWO polymerase in 10 mM Tris HCl, 25 mM KCl, 5 mM 
(NH4)2SO4, 2 mM MgSO4, pH 8.85 then vortexed and centrifuged briefly. PCR was initiated with a 2 
min denaturation at 95 oC, followed by 34 cycles consisting of denaturation at 92 oC for 15 sec, 
annealing at 65 oC for 30 sec, and elongation at 72 oC for 1 min. The final cycle of PCR ended with a 
7 min elongation at 72 oC. PCR products were purified on a 1% agarose gel in TAE (40 mM Tris, 20 
mM acetic acid, 1 mM EDTA, pH 8.3) where bands were excised, and DNA was isolated using a 
Quiagen Gel Extraction kit. 
Cloning KPC-2 into pET28a 
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Both PCR products (His-SP-KPC-2 and His-KPC-2) and a pET28a vector were digested with 
FastDigest EcoR1 and FastDigest Nde1 in FastDigest Green buffer (Fermentas). The digestion of the 
PCR products was incubated for 1 hr at 37o C while the digestion of the vector was only incubated for 
10 min at 37 oC before purification on 1 % agarose gel in TAE where bands were excised, and 
digested DNA was isolated using a Qiagen Gel Extraction kit. The digested pET28a vector was 
ligated with each of the two digested PCR products using T4 DNA Ligase for 2 hr at 37 oC.  
From this point on, the purification of KPC-2 was taken over by the undergraduate research student 
Melinda Lam under the supervision of Dr. Laura Marrone. 
Transformation 
The two KPC-2 containing plasmids, His-SP-KPC-2 and HIS-KPC-2, were transformed into 50 μL 
of CaCl2 competent E. coli BL21 DE3 cells by incubating cells and plasmid on ice for 30 minutes 
followed by heat shock at 42 oC for 20 seconds. Transformation reactions were placed back on ice for 
2 min then allowed to recover in 950 μL of LB media for 1 hr at 37 oC while shaking. Transformants 
were plated on LB agar supplemented with 50 μg/mL kanamycin and incubated at 37 oC overnight. 
Small scale expression tests of these transformants indicated that the construct without a signal 
peptide was not active and this avenue was not pursued further.  
Growth of Liquid Cultures for KPC-2 Expression 
Initial cultures were prepared by inoculating 5 mL of LB media supplemented with 50 μg/mL 
kanamycin with His-SP-KPC-2 transformants then incubating these overnight at 37 oC while shaking. 
The entirety of this initial culture was used to inoculate 0.5 L LB media supplemented with 50 μg/mL 
kanamycin which was then grown at 37 oC, shaking at 220 rpm overnight. Small scale tests indicated 
that expression of KPC-2 was best when not induced with IPTG so this step was forgone. Bacterial 
cells were harvested by centrifugation at 6000 rpm for 15 min at 4 oC then subjected to periplasmic 
lysis at room temperature for 10-15 min in 50 mM HEPES, 0.5 M NaCl, pH 7.5 and 0.1 μg of 
lysozyme. DNase I and RNase I were added to the lysate to degrade any DNA and RNA released by 
sphereoplast lysis then the periplasmic lysate was isolated from spheroplasts and cellular debris by 
centrifugation at 12 000 xg for 10 min.  
Chromatographic Purification of KPC-2 
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Periplasmic lysate was loaded onto a nickel affinity column but did not bind due to cleavage of the 
signal peptide and consequently the His tag during cellular processing. The flow through from the 
affinity column was dialyzed into 20 mM Tris-HCl, 50 mM NaCl, pH 8.7 and loaded onto a Poros 
20HQ anion exchange column (Poros) at 2 mL/min using the BioCad Sprint High Perfusion 
Chromatography system. Again, KPC-2 did not bind to the anion exchange column and the flow 
through was then loaded onto a Poros 20S cation exchange column but did not bind due to 
inappropriate pH conditions. The flow through from the Poros 20S column was dialyzed into 10 mM 
acetate pH 5.0 and loaded again onto the Poros 20S cation exchange column at 2 mL/min using the 
BioCad Sprint. The column was washed with acetate buffer then KPC-2 was eluted using a gradient 
of NaCl from 0 to 1 M in buffer over 32 mL. Fractions were tested for activity using nitrocefin as a 
substrate using the procedure in 2.2.2.2 and some fractions were stored at -20 oC in 50% glycerol 
while the remainder was frozen on dry ice and stored at -80 oC. Fraction 4, which exhibited the 
highest activity and was the only fraction with just one band by SDS PAGE, was used for all kinetic 
studies. 
2.2.2.5 VIM-1 
The purification of VIM-1 was performed primarily by the undergraduate research student Karan 
Malik under the co-supervision of Dr. Geneviève Labbé and myself as part of his undergraduate 
thesis project. 
Transformation 
Cloning of codon-optimized VIM-1 with a carboxypeptidase A cleavable C-6His tag into pOPIN 
vector E and the N-terminal signal sequence expressed was performed by Dr. Spencer’s lab and given 
to the Dmitrienko lab as a generous gift. The VIM-1 containing plasmid was transformed into 50 μL 
of E. coli BL21 DE3 cells by incubating them together on ice for 30 min then heat shocking at 42 oC 
for 45 sec and resting them on ice for 2 min. Transformants were allowed to recover in 900 μL LB 
media at 37 oC for 2 hr before being plated on LB agar supplemented with 100 μg/mL ampicillin and 
incubated at 37 oC overnight. 
Growth of Liquid Cultures for VIM-1 Expression 
A single colony of from the plate of VIM-1 transformants was used to inoculate 50 mL of LB 
media supplemented with 100 μg/mL ampicillin and incubated at 37 oC, overnight, shaking at 250 
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rpm. Two flasks with a 4 L capacity containing 1 L of LB media supplemented with 100 μg/mL 
ampicillin were each inoculated with 20 mL of overnight culture and shaken at 225 rpm and 37 oC. 
As the OD600 of the culture reached 0.4, expression of VIM-1 was induced with 1 mM IPTG for 4 
hours shaking at 225 rpm and 37 oC. Cells were harvested by centrifugation at 6000 rpm for 20 min at 
4 oC; nitrocefin tests determined that the majority of the VIM-1 activity was in the supernatant.  
Affinity Chromatography 
VIM-1 containing supernatant was filtered through a 0.45 μm filter to remove particulates, then 
imidazole was added to the solution to a final concentration of 20 mM. A HisPurTM Ni-NTA 
Superflow Agarose (Thermo Scientific) in an Omnifit column housing mounted on a BioCad Sprint 
Perfusion Chromatography system was equilibrated with VIM-1 Chelating buffer (50 mM Tris-HCl, 
300 mM NaCl, 20 mM imidazole, 10 % (v/v) glycerol, pH 8.0) before 200 mL VIM-1 supernatant 
was loaded onto the column at 4 mL/min through the pump. The column was washed with 90% VIM-
1 Chelating buffer and 10 % VIM-1 Elution buffer (50 mM Tris-HCl, 300 mM NaCl, 150 mM 
imidazole, 10 % (v/v) glycerol, pH 8.0) until the OD280 was reading less than 0.1. VIM-1 was eluted 
from the column using VIM-1 Elution buffer then dialyzed 50 mM Tris-HCl, 150 mM NaCl, pH 8.0 
at 4 oC.  Pure His-tagged VIM-1 was stored in 50 % glycerol at -20 oC. Due to time constraints and 
low yield, the tag was not cleaved; however, the kinetic parameters of His-VIM-1 did not differ 
significantly from literature values.464 The concentrations of VIM-1 fractions were determined by 
A280 (ε = 29910 M-1cm-1) using NanoDrop (Thermo Scientific) instead of Bradford due to low 
concentrations. The concentration of the final VIM-1 stock was determined by Bradford as described 
in 2.2.2.2. 
2.2.2.6 VIM-2 
Dr. Geneviève Labbé cloned VIM-2 out of the pNOR 2001 vector provided by Dr. Patrice 




The cloning of GC-1 into the high expression plasmid pCS100 was performed and published by Dr. 
M. Nukaga prior to it being obtained by the Dmitrienko lab.219 The recommended E. coli strain for 
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purification from this plasmid was AS266-51 which is an ampC deficient C600 with a mutant ampD 
to prevent AmpC contamination of the GC-1.219,466 When transformations of GC-1 containing 
pCS100 were attempted into competent E. coli AS266-51, colonies formed on 50 μg/mL 
chloramphenicol LB agar plates; however, activity was not observed upon growth and induction in 
LB broth. In later trials, a side by side transformation of 5 μL of pCS100-GC-1 into E. coli AS266-
51, E. coli BL21 DE3, and E. coli BL21 PLysS was performed by incubating the plasmid with CaCl2 
competent cells for 30 min on ice before heat shocking at 42 oC for 45 sec. Cells were returned to ice 
before the addition of 950 μL of LB. Cells were allowed to recover for 1 hr at 37 oC. Transformants 
were then plated on LB agar supplemented with 50 μg/mL chloramphenicol and incubated at 37 oC 
overnight. It was determined from induction of small scale liquid cultures that BL21 DE3 was the 
best strain for growing GC-1 despite the potential for a minor AmpC contaminant. 
Growth of Liquid Cultures for GC-1 Overexpression 
A single colony of pCS100-GC-1 transformed E. coli BL21 DE3 was used to inoculate 70 mL TB 
broth supplemented with 50 μg/mL chloramphenicol which was incubated at 37 oC shaking at 225 
rpm overnight. Six flasks with a 4 L capacity containing 1 L of TB broth supplemented with 50 
μg/mL chloramphenicol were then inoculated with 10 mL each of the overnight culture which were 
incubated at 37 oC shaking at 190 rpm until they reached an optical density at 600 nm of 
approximately 0.6. As each flask reached the desired optical density, it was induced with 1 mM IPTG 
and returned to incubator overnight. Cells were harvested by centrifugation at 6000 rpm for 20 min at 
4 oC in a JA-10 rotor yielding 54.6 g of pellet. The activity of both the supernatant and a crude lysis 
of the pellet (using 0.1 mg/mL lysozyme incubated for 10 min at room temperature) were determined 
using a nitrocefin based activity assay as described in 2.2.2.2. It was determined that the majority of 
the GC-1 activity was in the supernatant. 
Fractionation by Ammonium Sulfate 
Solid ammonium sulfate was dissolved in the supernatant to a final concentration of 70% (w/v) at 
room temperature then stirred at 4 oC for 2 days. The precipitated proteins were extracted by 
centrifugation at 13500 xg for 60 min at 4 oC in a JA-10 rotor. The extracted proteins, including GC-
1, were then slowly resuspended at 100 rpm in 8 mL of 50 mM NaPi pH 7.0 per gram of pellet at 4 
oC. Any remaining precipitated proteins were extracted by centrifugation at 13500 xg for 60 min at 4 
oC then discarded after the presence of GC-1 in the supernatant was confirmed using the nitrocefin 
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assay described above. The supernatant (230 mL) was dialyzed against 50 mM NaPi pH 7.0 at 4 oC 
until the ammonium sulfate concentration was calculated to be below acceptable limits for ion 
exchange. 
Ion Exchange Chromatography 
The dialyzed protein solution was diluted in an equal volume of 50 mM MES pH 5.0 then the pH 
was adjusted to approximately 5.0 with 6 N HCl. The acidified protein was then filtered through a 
0.45 μm filter to ensure no particulates remained in the solution. A POROS CM-Sepharose column 
mounted on a BioCad Sprint Perfusion Chromatography system was equilibrated in 50 mM MES pH 
5.0 then loaded at 3 mL/min with the acidified protein ensuring the flow through did not have β-
lactamase activity. The column was then washed with 3 column volumes of 50 mM MES pH 5.0 at 3 
mL/min followed by 1 column volume each of 50 mM MES, 30 mM NaCl pH 5.0 and 50 mM MES, 
50 mM NaCl pH 5.0 at 5 mL/min. A final wash was performed with 2.5 column volumes of 50 mM 
MES, 100 mM NaCl pH 5.0. GC-1 was eluted from the column using a salt gradient from 50 mM 
MES, 100 mM NaCl pH 5.0 to 50 mM MES, 500 mM NaCl pH 5.0 over 4 column volumes at 5 
mL/min. Fractions containing the highest GC-1 activity by the nitrocefin assay were pooled and 
concentrated using Amicon Ultra-15 membrane filters with a 10 kDa molecular weight cutoff. An 
equal volume of glycerol was added to the concentrated GC-1 for storage at -20 oC. 
Size Exclusion Chromatography 
Dr. Geneviève Labbé performed the size exclusion chromatography to increase the purity of the 
GC-1 preparations by first dialyzing the glycerol stock into 50 mM MES, 0.2 M NaCl pH 5.5. The 
dialyzed GC-1 was then concentrated using a Pall Macrosep Advance Centrifugal device with a 10 
kDa molecular weight cutoff down to 1.5 mL (2 mL after filter was rinsed). The concentrated GC-1 
solution was centrifuged at 14 000 rpm for 5 min to remove dust and particulates before injecting it 
onto a Superdex 200 26/60 size exclusion column mounted on an AKTA Explorer HPLC system. 
GC-1 was eluted using isocratic 50 mM MES, 0.2 M NaCl, pH 5.5 at 2 mL/min. Collected fractions 
with the highest β-lactamase activity by nitrocefin assay were pooled and concentrated using another 
Pall Macrosep Advance Centrifugal device with a 10 kDa molecular weight cutoff. Concentrated GC-




The purification of OXA-48 was performed primarily by Alicia Tjahjadi as part of her 
undergraduate thesis project under the co-supervision of Dr. Geneviève Labbé and myself. 
Transformation 
Cloning of codon-optimized OXA-48 with a 3C Protease cleavable N-6His tag into pOPIN vector 
F without expression of the signal sequence was performed by Dr. Spencer’s lab and given to the 
Dmitrienko lab as a generous gift. The OXA-48 containing plasmid was transformed into 50 μL of 
CaCl2 competent E. coli BL21 DE3 cells by incubating them together on ice for 30 min before heat 
shocking them at 42 oC for 45 sec then resting them on ice for 2 min. Transformants were allowed to 
recover in 950 μL of LB for 2 hr at 37 oC and then were plated on LB agar supplemented with 100 
μg/mL ampicillin which was incubated at 37 oC overnight. 
Growth of Liquid Cultures for OXA-48 Expression 
A single colony from the plate of OXA-48 transformants was used to inoculate 50 mL of LB broth 
supplemented with 100 μg/mL ampicillin in a 250 mL flask and incubated overnight at 37 oC, shaking 
at 250 rpm. Two flasks with a 4 L capacity containing 1 L of LB media supplemented with 100 
μg/mL ampicillin were each inoculated with 20 mL of overnight culture and incubated at 37 oC, 
shaking at 225 rpm. Once an OD600 of approximately 0.6 was reached, expression of OXA-48 was 
induced with 1 mM IPTG and incubated at 25 oC, shaking at 225 rpm overnight. Cells were harvested 
by centrifugation at 3000 xg for 20 min at 4 oC. Cell pellets (11.4 g total) were resuspended in 40 mL 
of OXA-48 Lysis buffer (50 mM Tris-HCl, 300 mM NaCl, 20 mM imidazole, 10 % (v/v) glycerol, 
0.2 % (v/v) NP-40, 0.02 % (v/v) 1-thioglycerol, pH 8.0) then lysed using a large probe on a Heat 
Systems Ultrasonic processor W-255 sonicator set to 50 % cycle and 50 % power 5 times for 30 sec 
each with a 1 min rest on ice between bursts. Cellular debris was separated from the lysate by 
centrifugation at 48 000 xg for 60 min at 4 oC and the supernatant was retained. 
Affinity Chromatography 
OXA-48 chromatography was performed in two runs each with the lysate of a different flask. 
Imidazole was added to each lysate to a final concentration of 20 mM before being loaded at 2 
mL/min onto HisPurTM Ni-NTA Superflow Agarose (Thermo Scientific) in an Omnifit column 
housing mounted on a BioCad Sprint Perfusion Chromatography system that had been equilibrated 
 
 74 
with OXA-48 Chelating buffer (50 mM Tris-HCl, 300 mM NaCl, 20 mM imidazole, 10 % (v/v) 
glycerol, 0.01 % (v/v) 1-thioglycerol, pH 8.0). The column with OXA-48 bound was washed at 3 
mL/min with OXA-48 Chelating buffer then at 4 mL/min with 90 % OXA-48 Chelating buffer and 10 
% OXA-48 Elution buffer (50 mM Tris-HCl, 300 mM NaCl, 150 mM imidazole, 10 % (v/v) glycerol, 
0.01 % (v/v) 1-thioglycerol, pH 8.0) over a total of 55-80 mL. His-tagged OXA-48 was eluted from 
the column with 100 % OXA-48 Elution buffer while 10 mL fractions were collected until no activity 
was detected in fractions by nitrocefin assay. Fractions containing the highest OXA-48 activity were 
dialyzed into OXA-48 Storage buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM EDTA, 20 % (v/v) 
glycerol, pH 8.0). 
Cleavage of His-tag 
The most active fraction from the two days (day 1 fraction 2) was chosen for tag cleavage. His-
tagged OXA-48 and His-tagged 3C Protease were both dialyzed at 4 oC using SpectraPor dialysis 
membranes with a molecular weight cutoff of 8-10 kDa into Dialysis buffer (50 mM Tris-HCl, 150 
mM NaCl, pH 8.0). The dialyzed OXA-48 was incubated with 1 mg of 3C Protease per 100 mg of 
OXA-48 at 4 oC overnight to allow complete cleavage of the N-terminal tag. The protein mixture was 
loaded onto Ni-NTA Superflow Agarose (Thermo Scientific) in an Omnifit column housing mounted 
on a BioCad Sprint Perfusion Chromatography system that had been equilibrated with Dialysis buffer 
at 4 mL/min. OXA-48 was collected in the flow through over 4 fractions then the 3C Protease was 
eluted from the column with Protease Elution buffer (50 mM Tris-HCl, 300 mM NaCl, 150 mM 
imidazole, pH 8.0). Pure OXA-48 with the His-tag cleaved was dialyzed as above, then stored at -20 
oC in 50 % glycerol. 
2.2.3 Characterization of Chromogenic Substrates 
Chromogenic β-lactams: nitrocefin, UW-57, UW-58, and UW-154, were synthesized as an E/Z 
mixture by Dr. Ahmed Ghavami as previously described, and their structures (Figure 2.3) and purity 
were confirmed by 1H NMR, 13C NMR, and ESI-MS.453  Powders of these substrates were dissolved 
in DMSO as a necessary step to isomerize completely to the E isomer to a final concentration of 40 
mM and stored at -20 oC. If it was suspected that stocks had started to degrade (usually after years in 





Figure 2.3 Chromogenic β-lactamase substrates synthesized by the Dmitrienko group. 
2.2.3.1 Molar Extinction Coefficient Determination 
Substrates were diluted to 100 μM in 50 mM HEPES pH 7.2 supplemented with 50 μg/ml BSA, 
0.01 % Triton X-100, and 100 μM ZnCl2. One sample of this was read directly while the other was 
completely hydrolyzed using 90 nM VIM-2 for 10 min. Spectral scans were performed using a Cary 
50 spectrophotometer in quartz cuvettes from 250-750 nm in triplicate. The wavelength 
corresponding to the greatest difference between the absorbance of the product and the substrate was 
determined. A range of substrate concentrations from 1 μM to 100 μM were prepared in 50 mM 
HEPES pH 7.2 supplemented with 50 μg/mL BSA and 0.01 % Triton X-100. Hydrolyzed substrates 
were made by incubating with 27 nM VIM-2 until fully hydrolyzed. Greiner 96-well plates were 
loaded with 200 μL volumes of both hydrolyzed and unhydrolyzed substrates then read at the 
wavelength to be used for kinetics (NC, 482 nm; UW-57, 520 nm; UW-58, 534 nm; UW-154. 533 
nm). 
2.2.3.2 Substrate and Product Stability 
Substrates were prepared as in 2.2.3.1 and the stability of both substrate and product were assessed 
by taking scans from 325-750 nm (NC, UW-57, UW-58) in a SpectraMax 190 plate reader or from 
250-750 nm in a Cary 50 spectrophotometer at 0 hr, 3 hr, 24 hr, and 96 hr. The 96-well plate 
containing 200 μL samples of NC, UW-57, and UW-58 substrate and product was lidded and sealed 
with Parafilm between reads to minimize evaporation.  
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2.2.4 Biochemical Characterization 
The stability of β-lactamases to DMSO is a critical piece of information since most inhibitors and 
substrates require DMSO as a cosolvent. As such, an upper limit for the total DMSO concentration 
allowed was determined for all β-lactamases except SFH-1 which was assumed to behave similarly to 
other MBLs. β-Lactamases were also routinely characterized with chromogenic substrates upon 
purification or arrival. Kinetic characterization of KPC-2, IMP-1, NDM-1, SPM-1, VIM-2, L1, and 
GC-1 with NC and the UW substrates were performed by Dr. Genevieve Labbe.453  
2.2.4.1 DMSO Stability 
The stability of all of the SBLs used in his work (CTX-M-15, KPC-2, GC-1, OXA-23, and OXA-
48) and most of the MBLs (IMP-1, NDM-1, SPM-1, VIM-1, VIM-2, and L1) in DMSO 
supplemented buffer was assessed to give an upper limit to the allowed DMSO concentration in 
substrate assays as well as later inhibition assays. The enzyme and substrate concentrations used in 
this assay are detailed in Table 2.1. Class A, B, and C β-lactamases were prepared in 50 mM HEPES 
pH 7.2 supplemented with 50 μg/mL BSA and 0.01 % Triton X-100 then incubated with varying 
DMSO concentrations from 0.05-9.5 % for 10 min at 30 oC. Class D β-lactamases were prepared in 
100 mM NaPi, 2.1 mg/mL NaHCO3, pH 7.0 supplemented with 50 μg/mL BSA and 0.01 % Triton X-
100 then incubated with DMSO concentrations from 0.2-9.5% as described above. The assay was 
initiated in a 96-well plate by adding 190 μL of this mixture to 10 μL of nitrocefin then shaken for 5 
sec prior to monitoring the absorbance at 482 nm every 7 sec for 5 min and the initial rate was 
determined.  
Table 2.1 Enzyme and substrate concentrations used for DMSO stability studies. 
β-lactamase Class Enzyme Concentration NC Concentration 
(μM) 
CTX-M-15 A 140 pM 20 
KPC-2 A 190 pM 8 
IMP-1 B1 170 pM 3.5 
NDM-1 B1 570 pM 1 
SPM-1 B1 7.5 nM 1 
VIM-1 B1 1.5 nM 20 
VIM-2 B1 290 pM 15 
L1 B3 580 pM 5 
GC-1 C 380 pM 15 
OXA-23 D 570 pM 50 
OXA-48 D 72 pM 80 
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2.2.4.2 Kinetic Parameter Determination 
CTX-M-15 
The determination of kinetic parameters for CTX-M-15 was performed for both the tagged and 
cleaved versions of the protein in both HEPES and phosphate buffers. CTX-M-15 (tagged: 44 pM, tag 
cleaved: 152 pM) was prepared in 50 mM HEPES pH 7.2 or 100 mM NaPi pH 7.2 supplemented with 
50 μg/mL BSA and 0.01 % Triton X-100 then incubated for 10 min at 30 oC in a 96-well plate. The 
reaction was initiated by addition of CTX-M-15 mix to 16 concentrations of substrate (500 μM – 1 
μM) in triplicate then shaking for 5 sec before monitoring the absorbance every 6-7 sec for 5 min 
(NC: 482 nm, UW-57: 520 nm, UW-58: 534 nm, UW-154: 533 nm) and determining initial rates. 
Rates were converted into molar units using Beer’s Law and molar extinction coefficients for the 
hydrolysis of each substrate determined in 2.2.3.1 (NC: 11 470 M-1cm-1, UW-57: 10 630 M-1cm-1, 
UW-58: 12 420 M-1cm-1, UW-154: 10 870 M-1cm-1) then fitted to equations for Michaelis-Menten 
kinetics (Equation 2.1) or substrate inhibition (Equation 2.2) as appropriate where v is the rate of 
product formation and [S] is the concentration of substrate.467 












Kinetic parameters for VIM-1 were determined using methods similar to that of CTX-M-15 using 
50 mM HEPES pH 7.2, a tagged VIM-1 final concentration of 1.6 nM for NC and 640 pM for the 
UW substrates and a substrate concentration range from 500 μM to 0.5 μM. 
SFH-1 
Kinetic parameters for SFH-1 were determined using methods similar to that of CTX-M-15 using 
50 mM HEPES pH 7.2, SFH-1 final concentrations of 9 nM (nitrocefin) and 1.8 nM (UW substrates), 




Kinetic parameters for OXA-23 were determined using methods similar to that of CTX-M-15 using 
100 mM NaPi, 2 mg/mL NaHCO3, pH 7.0; OXA-23 final concentrations of 600 pM (nitrocefin), 1.2 
nM (UW-57, UW-154), and 3 nM (UW-58); and a substrate concentration range from 500 - 0.5 μM. 
OXA-48 
Kinetic parameters for OXA-48 were determined using methods similar to that of CTX-M-15 using 
100 mM NaPi, 2 mg/mL NaHCO3, pH 7.0; OXA-48 final concentrations of 87 pM (nitrocefin), 347 
pM (UW-57), 173 pM (UW-58, UW-154); and a substrate concentration range from 500 μM to 5 μM. 
2.3 Results 
2.3.1 Metallo-β-Lactamase Protein Sequence Alignment 
Alignments of the protein sequences of NDM-1, IMP-1, and VIM-2 with other variants from each 
family was done using a variety of web-based programs on phylogeny.fr. This was not done for SPM-
1 or L1 as they are no other MBL variants in their families.  
2.3.1.1 NDM Family Alignment 
The amino acid sequence of the NDM family of MBLs is highly conserved resulting in a 




Figure 2.4 Phylogenetic tree of NDM Variants generated using phylogeny.fr and TreeDyn. 
Most of the 19 variants within the NDM family are within 1-2 amino acids of NDM-1 with the 
exception of NDM-10 and NDM-18 which differ by 5 amino acids. A full list of the amino acid 
changes in the variants relative to NDM-1 can be found in Table 2.2.  
The complete sequence alignment for NDM-1 and all of its variants can be found in Appendix E. 
The most common mutation found among the variants is the M154L mutation which is present in 9 of 
the 19 variants. Mutation of D130 to either G or N is also fairly common. Other mutations were either 









Table 2.2 Amino acid differences between NDM-1 and other NDM variants. 




NDM-5 V88L, M154L 
NDM-6 A230V 
NDM-7 D130N, M154L 
NDM-8 D130G, M154L 
NDM-9 E152K 
NDM-10 R32S, G36D, G69S, A74T, G200R 
NDM-11 M154V 
NDM-12 M154L, G222D 
NDM-13 D95N, M154L 
NDM-14 D130G 
NDM-15 M154L, A230V 
NDM-16 R264H 
NDM-17 V88L, M154L, E170K 
NDM-18 D48_L49insQRFGD 
NDM-19 D130N, M154L, A230V 
2.3.1.2 VIM Family Alignment 
Whereas NDM family contains only 19 variants including NDM-1, the VIM family contains 55 
variants making it likely that there will be more than just 1 or 2 amino acids difference between 
variants. As seen in the phylogenetic tree in Figure 2.5, there are two main branches of the tree; those 
that are VIM-1 like, and those that are VIM-2 like. There are 25 amino acids different between VIM-
1 and VIM-2: F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, I200V, Y201H, R205S, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A. 
Within the two groupings, variation is fairly consistent with only a few amino acids differing between 
variants in that group. It is worth noting that VIM-7 is widely divergent from both the VIM-1 like and 
VIM-2 like variants. The complete sequence alignment as well as a table summarizing the amino acid 




Figure 2.5 Phylogenetic Tree of VIM variants generated by phylogeny.fr and TreeDyn. 
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2.3.1.3 IMP Family Alignment 
The IMP family is the largest of the MBL families with 70 assigned variants. Of these 70 variants, 
IMP-36, IMP-39, IMP-50, and IMP-65 do not have protein sequences in the NCBI database and IMP-
47 has the same amino acid sequence as IMP-8, so IMP-47 was left out of the phylogenetic analysis. 
The phylogenetic tree generated from this analysis, seen in Figure 2.6, is much more branched than 
that of the NDM variants or the VIM variants, indicative of the wide sequence variety in this family. 
The small subset of IMP variants found near IMP-1 on the phylogenetic tree are very similar; 
however, at the extremities of the tree, variants can differ by over 50 amino acids from IMP-1. The 
full protein sequence alignment and a table summarizing the amino acid changes relative to IMP-1 




Figure 2.6 Phylogenetic tree of IMP family variants generated by phylogeny.fr and TreeDyn. 
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The analysis of the relationships between NDM-1, IMP-1, VIM-2, and their respective variants 
indicates that there is little sequence similarity between MBL families. The NDM variants are all 
closely related differing by only a few amino acids between NDM-1 and any given NDM variant. 
Due to both its sequence similarity and clinical significance NDM-1 should be a suitable 
representative of this family. The VIM family contains two major groupings: VIM-1-like and VIM-2-
like. One variant from each these groupings should be represented in screening to check if both 
branches respond similarly to substrates and inhibitors - VIM-1 and VIM-2 were selected. The 
amount of variability in the IMP family makes it unreasonable to test representatives of each branch 
of the phylogenetic tree, so IMP-1 was used as it is among the most prevalent in clinical isolates and 
is readily available.276 
2.3.2 Protein Purification 
2.3.2.1 CTX-M-15 Purification 
His tagged CTX-M-15 was purified by affinity chromatography before tag cleavage with thrombin. 
This was an efficient purification in which 12 % of the active protein from the crude was collected in 
fractions that were used for concentration and cleavage (Table 2.3). The reduction of CTX-M-15 
from the 829 mg present in the lysate to the 34 mg eluted from the Ni-NTA column can be explained 
though its use in method development and its presence in fractions that were not pooled. The apparent 
loss of CTX-M-15 from the thrombin cleavage is due to only a small portion of the protein having 
undergone tag cleavage. The remainder of the tagged CTX-M-15 was stored at -20 oC in glycerol for 
possible His-tag cleavage in the future. 
Table 2.3 CTX-M-15 purification table 
 Total activity 
(μmol/min) 






Lysate 14000 100 829 17.1 1 
Ni-NTA 1700 12 34 49.4 2.9 
Concentration 1600 11 34 45.7 2.7 




2.3.2.2 KPC-2 Purification 
The cloning of KPC-2 into a plasmid to introduce a His-tag was futile as the tag was removed during 
cellular processing along with the signal peptide. The active flow through from the Poros 20HQ 
column was not formally assayed with NC, run on SDS PAGE, nor aliquoted for future checks. As a 
result of this lack of testing, it is unknown whether or not this step contributed to purification; 
although, it is likely that it is responsible for the removal of some anionic proteins. This in 
conjunction with the purification by the Poros 20S column resulted in > 95 % pure protein by SDS 
PAGE (Figure 2.7).  
Table 2.4 KPC-2 purification table. 
 Total activity 
(μmol/min) 






Lysate 54 100 4.4 12 1 
Poros 20HQ - 20S 0.25 0.46 0.40 0.62 0.05 
2.3.2.3 VIM-1 Purification 
VIM-1 was not overexpressed well in E. coli BL21 DE3 cells; however, what protein was expressed 
was found predominantly in the media since the signal peptide was included in the construct. The 
media was loaded onto a Ni-NTA affinity column and VIM-1 eluted across 3 fractions, one of which 
was further concentrated yielding 0.5 mg VIM-1 (Table 2.5). Potentially much more VIM-1 could 
have been purified from the remaining 1.8 L of media; however, the amount that was produced was 
adequate for the present study. 
Table 2.5 VIM-1 purification table 
 Total activity 
(μmol/min) 






Media Supernatant 38.9 100 92 0.42 1 
Ni-NTA  0.84 2.2 0.56 0.84 3.5 
Concentration 0.61 1.6 0.51 0.61 2.8 
2.3.2.4 GC-1 Purification 
Early testing of the lysate fractions (media, periplasm, and cytosol) determined that most of the 
GC-1 was exported into the media when it was overexpressed. Since the GC-1 construct did not 
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include an affinity tag, a 70% ammonium sulfate cut was used to precipitate GC-1 which was then 
resolubilized, removing 200 mg of various proteins (Table 2.6). This mixture was then purified by ion 
exchange and cleaned by size exclusion chromotography yielding 2.5 mg of pure GC-1. 
Table 2.6 GC-1 purification table. 
 Total activity 
(μmol/min) 






Media Supernatant 65319 100 660 99 1 
Ammonium Sulfate 
Soluble Fraction 
26024 39.8 460 57 0.6 
CM Sepharose 11962 18.3 9.2 1293 13 
Sephadex 200 1859 2.8 2.5 774 7.5 
 
Early attempts at purification of KPC-2, IMP-1, and VIM-2 were performed using classical 
purification techniques such as those used in this GC-1 purification. Each of those purifications failed 
with all of the protein being lost on either the ion exchange or size exclusion columns. Considering 
this early experience, it came as a surprise that this purification proceded relatively well, yielding 2.5 
mg of pure GC-1. The good yield of GC-1 as compared to those earlier purifications is likely because 
the GC-1 purification was performed using an FPLC system while the others were performed using 
gravity columns.  
2.3.2.5 OXA-48 Purification 
 OXA-48 was overexpressed well and was contained within the cells since no signal peptide was 
present in the construct. A lack of characterization at the time of purification necessitated the sample 
of frozen lysate being tested 3 years after the purification was completed. It is probable that this delay 
skewed the results since the target protein has been exposed to proteolytic enzymes for an extended 
period. For this reason, the non-physical values for % yield (2.5 million %) and fold purification (270 






Table 2.7 OXA-48 purification table.  
 Total activity 
(μmol/min) 
Total Protein (mg) Specific activity 
(μmol/min/mg) 
Lysate 0.34* 350 0.00097* 
Ni-NTA  16700 52 180 
His-tag cleavage 8300 32 260 
*3 year delay in analysis of this sample. Proteolytic degradation is likely. 
2.3.2.6 SDS PAGE of Purified β-Lactamases 
A summary SDS-PAGE gel of all pure β-lactamases used in this thesis is presented in Figure 2.7 with 
the enzymes purified in this laboratory on the left side of the gel and any gifted enzymes on the right 
side of the gel. The β-lactamases purified at U Waterloo: KPC-2, VIM-1, VIM-2, and OXA-48, were 
determined to be >95 % pure by SDS-PAGE as is evident by the presence of only a single band in 
each well. CTX-M-15 and GC-1 samples appear to have minor contaminants, the CTX-M-15 
contaminant is likely His-tagged CTX-M-15. Many of the β-lactamases received from other 
researchers: NDM-1, SPM-1, SFH-1, L1, and OXA-23 were also determined to be >95 % pure. Some 
small contaminant bands are evident in the IMP-1 sample and can likely be attributed to HRV 3C 
protease and IMP-1 with an uncleaved His-tag that were not successfully removed from the sample. 
 
Figure 2.7 SDS-PAGE of pure β-lactamases. 1 LMW Marker, 2 CTX-M-15, 3 KPC-2, 4 VIM-1, 
5 VIM-2, 6 GC-1, 7 OXA-48, 8 LMW Marker, 9 IMP-1, 10 NDM-1, 11 SPM-1, 12 SFH-1, 13 L1, 
14 OXA-23, 15 LMW Marker. 
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2.3.2.7 Confirmation of β-Lactamase Identity by Mass Spectrometry 
The masses of proteins purified in this laboratory were confirmed by ESI mass spectrometry. In 
addition, samples of NDM-1, SPM-1, and L1 were tested. This was used to confirm the successful 
removal of the His-tags from CTX-M-15 and OXA-48 using thrombin and 3C protease respectively. 
By the same logic, this confirms that the His tag was cleaved from KPC-2 during cellular processing 
and was not present during purification.  
Table 2.8 Masses of pure β-lactamases as predicted using Expasy ProtParam and determined 
by mass spectroscopy 
β-Lactamase Predicted Denatured 
Mass (Da) 
Mass Determined by 
Mass Spectrometry (Da) 
CTX-M-15 28 407 28 406 
KPC-2 28 720 28 719 
NDM-1 24 318 24 317 
VIM-2 25 515 25 515 
SPM-1 27 884 27 883 
L1 28 706 28 703 
GC-1 39 573 39 572 
OXA-48 28 301 28 300 
 
Some of the β-lactamases provided by other labs were also analyzed by ESI mass spectrometry as 
either preliminary experiments for other work or to determine the specifics of the sample sequence 
given to us. The mass of NDM-1 was determined because the sample provided to us was denoted as 
Δ36 NDM-1 which implied that the first 36 amino acids were truncated; however, that did not match 
any constructs published by that group. Upon determination of the mass, it was confirmed that the 
first 41 amino acids including the signal peptide were excluded from the construct, consistent with the 
published construct.317 
In addition to the masses presented in Table 2.8, the native mass of SPM-1 was also determined to 
be 28 009 Da (theoretical: 28 015 Da)468 which is consistent with 2 Zn ions in the active site. This 
was performed in ammonium acetate buffer instead of 1:1 H2O:MeOH 0.1 % formic acid. 
2.3.3 Characterization of Chromogenic Substrates 
The colour change observed in the chromogenic β-lactams is produced by the hydrolysis of the β-




Scheme 2.2 Hydrolysis of nitrocefin by β-lactamases. 
Hydrolyzed and unhydrolyzed versions of the 4 substrates used in this work were plated at various 
concentrations on a 96-well plate to illustrate the colour change (Figure 2.8). Nitrocefin shows a 
characteristic change from yellow to red, UW-57 goes from yellow to red/brown, and both UW-58 
and UW-154 turn from yellow to purple. This colour change can be exploited for kinetic analysis of 
β-lactamases capable of hydrolyzing cephalosporins (ESBLs, Class C SBLs, and MBLs). 
 
Figure 2.8 Visual appearance of 200 μL of increasing concentrations of unhydrolyzed and 
hydrolyzed chromogenic substrates synthesized by the Dmitrienko lab  (A: 10 μM, B: 25 μM, 
C:50 μM, D: 75 μM, E: 100 μM, F: 200 μM). 1: unhydrolyzed NC, 2: hydrolyzed NC, 3: 
unhydrolyzed UW-57, 4: hydrolyzed UW-57, 5: unhydrolyzed UW-58, 6: hydrolyzed UW-58, 7: 
unhydrolyzed UW-154, 8: hydrolyzed UW-154. 
At the same concentrations, both the unhydrolyzed and hydrolyzed forms of the UW substrates are 
more more readily detectable visually. Additionally, the colour change of the UW substrates is more 
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distinctive since they are on opposite sides of the colour wheel instead of going to a neighbouring 
colour (red-orange). 
2.3.3.1 Molar Extinction Coefficient 
The wavelength at which the greatest difference between substrate and product curves occurred, 
λmax, was determined using spectral scans of both the unhydrolyzed and hydrolyzed versions of the 
substrates produced by the Dmitrienko lab (Figure 2.9). The λmax is the optimal wavelength for kinetic 
analysis as it is where the highest sensitivity occurs. The λmax was determined to be 482 nm for NC, 
520 nm for UW-57, 534 nm for UW-58, and 533 nm for UW-154.  







































































Figure 2.9 Spectral scans of chromogenic substrates before and after hydrolysis  with the 
unhydrolyzed represented by a yellow and the hydrolyzed represented in red/purple for 
nitrocefin (A), UW-57 (B), UW-58 (C), and UW-154 (D) at 100 μM. This figure was generated 
using GraphPad Prism v. 5.03. 
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Estimates for the molar extinction coefficients for the product can be determined from these scans: 
NC ε482 = 15 990 M-1cm-1, UW-57 ε520 = 16 520 M-1cm-1, UW-58 ε534 = 16 590 M-1cm-1, and UW-154 
ε533 = 17 140 M-1cm-1; however, it is more accurate to determine the molar extinction coefficients 
from several different concentrations of substrate. In order to simplify further calculations, the molar 
extinction coefficient of a 200 μL volume in a standard flat bottom 96-well plate (Greiner Bio One) 
was determined and used for future calculations as well as the molar extinction coefficient in 
conventional units as listed in Table 2.9. For the purposes of this work, it is most appropriate to use 
the difference between molar extinction coefficient of the product and substrate, Δε. The differences 
between the estimates and the calculated extinction coefficients illustrate the inaccuracy of single 
point determinations and may have been exacerbated by these being from different batches of 
different ages. 
Table 2.9 Molar extinction coefficients for UW substrates 
  Molar extinction coefficient (M-1well-1) 
Pathlength Substrate Substrate Product Difference 
200 μL in Costar 
655101 96-well 
plate (0.571 cm) 
NC 679 ± 8 7230 ± 50 6550 ± 50 
UW-57 350 ± 10 6420 ± 30 6070 ± 40 
UW-58 392 ± 5 7490 ± 19 7090 ± 20 
UW-154 533 ± 2 6740 ± 20 6200 ± 20 
  Molar extinction coefficient (M-1cm-1) 
1 cm NC 1190 ± 10 12 660 ± 80 11 470 ± 90 
 UW-57 620 ± 20 11 240 ± 50 10 630 ± 80 
 UW-58 686 ± 8 13 110 ± 30 12 420 ± 40 
 UW-154 933 ± 3 11 800 ± 30 10 870 ± 30 
 
2.3.3.2 Substrate and Product Stability 
The stability of both the unhydrolyzed and hydrolyzed versions of each substrate was assessed 
using spectral scans at 0 hr, 3 hr, 24 hr, and 96 hr (Figure 2.10). The unhydrolyzed versions of the 
substrates tend to be stable within the time frame of a day of assays and start to degrade within 24 hr. 
The apparent hydrolysis of the substrates at 96 hr can be observed for NC, UW-57, and UW-58. The 
products of the substrate hydrolysis are much less stable than the unhydrolyzed substrate often 
showing a significant decrease in maximal absorbance at only 3 hr (with the exception of nitrocefin). 
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Figure 2.10 Stability spectra of 100 μM chromogenic substrates before and after hydrolysis.  
NC (A: unhydrolyzed, B: hydrolyzed), UW-57 (C: unhydrolyzed, D: hydrolyzed), UW-58 (E: 
unhydrolyzed, F: hydrolyzed), and UW-154 (G: unhydrolyzed, H: hydrolyzed) at 0 hr (red), 3 




2.3.4 Biochemical Characterization 
2.3.4.1 DMSO Stability 
The relative activity of β-lactamases incubated for 10 min in various concentrations of DMSO is 
presented in Figure 2.11 with stability being defined as a <10 % reduction in activity relative to a no 
DMSO added control (0.05 %- 0.2 % DMSO present in NC). Of the SBLs, CTX-M-15, OXA-23, and 
OXA-48 are only stable up to 2 % DMSO while KPC-2 and GC-1 are stable up to 5 % DMSO. VIM-
1 is the least DMSO stable of the MBLs, dipping below the acceptable activity reduction after only 1 
% DMSO. The other MBLs are much more stable with SPM-1 and VIM-2 being stable up to 2.5 % 
DMSO, IMP-1 and L1 being stable up to 5 % DMSO, and NDM-1 appearing to be activated in the 
presence of DMSO. This suggests that in most cases, the presence of 2 % DMSO is tolerated well by 
β-lactamases. 













































Figure 2.11 DMSO sensitivity of β-lactamases  separated into (A) SBLs and (B) MBLs with a 
cutoff line at 10 % activity reduction. This figure was generated using GraphPad Prism v. 5.03. 
2.3.4.2 Determination of Kinetic Parameters 
The determination of kinetic parameters was done by non-linear regression of the Michaelis-
Menten plots fitting to either Michaelis-Menten (Equation 2.1) or substrate inhibition (Equation 2.2) 
equations as appropriate. The hydrolysis of NC and UW substrates in 50 mM HEPES pH 7.2 and 100 
mM NaPi pH 7.2 by both tagged and cleaved CTX-M-15 is presented in Figure 2.12. These graphs 
show that the tagged CTX-M-15 is more prone to substrate/product inhibition in both buffer systems 
as seen by the reduction in rate of hydrolysis at high substrate concentrations. Substrate/product 
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inhibition is also observed when the His-tag cleaved CTX-M-15 but only in the HEPES buffer 
system. The concentration of DMSO in these experiments was kept constant. 
HEPES NaPi 
Cleaved Tagged Cleaved Tagged 

















































































































































































































































































Figure 2.12 Michaelis-Menten plots of CTX-M-15 kinetic parameter determination.  Each point 
represents three replicate measurements, error bars are often smaller than the markers. This 
figure was generated using GraphPad Prism v. 5.03. 
The kinetic parameters determined by the non-linear regression of the graphs in Figure 2.12 can be 
found in Table 2.10. It is evident that while substrate/product inhibition in HEPES is a slight problem 
for CTX-M-15 with the tag cleaved, the KI is at least 10x greater than the KM for all substrates except 
UW-154 where they are both about 25 μM. Overall, the KM and kcat for NC is about 3 times greater 
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than those for the UW substrates (particularly UW-57 and UW-58) and the kcat/KM is similar for all 
substrates within a given set of conditions. 




Buffer Substrate KM (μM) KI (μM) kcat (s-1) kcat/KM 
(μM-1s-1) 
Cleaved HEPES NC 17.3 ± 0.8 580 ± 40 580 ± 10 33 ± 2 
  UW-57 5.6 ± 0.4 1110 ± 140 120 ± 2 21 ± 1 
  UW-58 5.8 ± 0.6 2400 ± 800 78 ± 2 13 ± 1 
  UW-154 24 ± 8 25 ± 8 640 ± 150 30 ± 10 
 NaPi NC 35.7 ± 0.9 1400 ± 90 716 ± 8 20.1 ± 0.5 
  UW-57 10.0 ± 0.2  223.6 ± 0.7 22.4 ± 0.3 
  UW-58 11.2 ± 0.3  270 ± 2 24.1 ± 0.7 
  UW-154 12.1 ± 0.2  280 ± 1 23.2 ± 0.5 
Tagged HEPES NC 12 ± 1 150 ± 20 3270 ± 150 250 ± 30 
  UW-57 5.9 ± 0.6 1600 ± 400 790 ± 30 130 ± 20 
  UW-58 3.5 ± 0.6 330 ± 60 400 ± 20 110 ± 20 
  UW-154 4.3 ± 0.2 730 ± 60 1120 ± 20 260 ± 20 
 NaPi NC 57 ± 4 600 ± 70 9700 ± 400 170 ± 10 
  UW-57 15.4 ± 0.5 2100 ± 200 2780 ± 30 181 ± 6 
  UW-58 18.8 ± 0.8 930 ± 80 3580 ± 70 190 ± 9 
  UW-154 30 ± 3 150 ± 20 4660 ± 290 160 ± 20 
Combinations without a KI value were fitted to Equation 2.1 rather than Equation 2.2. 
The kinetic parameters of all other β-lactamases used in this thesis have also been determined for 
NC and the UW substrates. Many of these experiments were published by Dr. Geneviève Labbé using 
the β-lactamase preparations described above and have been included in Table 2.11.453 Michaelis-
Menten plots for the β-lactamases not included in the publication by Ghavami et al. are presented in 
Figure 2.13 and show typical Michaelis-Menten behaviour with the exception of OXA-48 and VIM-1 
which display substrate/product inhibition. 
The kinetic parameters for the SBLs used in this thesis against NC and UW substrates are listed in 
Table 2.11. Generally, KPC-2 and GC-1 β-lactamases have the lowest KM values for NC and the 
highest KM values for UW-154, a trend that is mirrored in the kcat values. This KM trend does not hold 
for Class D β-lactamases which have significantly higher KM values for NC than any other tested 
substrate by 3 – 4 fold. The kcat values for the Class D SBLs scale with the KM values as seen in KPC-
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Figure 2.13 Michaelis-Menten plots of VIM-1, SFH-1, OXA-23, and OXA-48 kinetic parameter 
determination.  Each point represents three replicate measurements, error bars are often 
smaller than the markers. This figure was generated using GraphPad Prism v. 5.03.  
The KI values for this inhibition tend to be at least 10x greater than the KM values (except for UW-57 
where KI is only about 4x larger than the KM) so they should not be problematic for kinetic 
experiments performed at KM concentrations of substrate. The catalytic efficiencies (kcat/KM) of all 
substrates tend to be fairly consistent for each SBL. 
The kinetic parameters for the MBLs with NC and the UW substrates (Table 2.12) tend to follow 
the same trend seen for the SBLs. The KM values for all substrates tend to be fairly consistent and any 
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variation is generally mirrored in the kcat values leading to consistent catalytic efficiencies. The only 
exceptions to this are the NC values for SPM-1, SFH-1, and L1 in which the KM is slightly (1.1 to 
1.5-fold) smaller than it is for other substrates and the kcat is significantly (5 to 10-fold) smaller 
leading to much lower catalytic efficiencies.  
Table 2.11 Kinetic parameters of serine-β-lactamases (except CTX-M-15) against NC and UW 
substrates. 
Enzyme Class Substrate KM (μM) KI (μM) kcat (s-1) kcat/KM  
(μM-1s-1) 
KPC-2a A NC 8.1 ± 0.2  520 ± 3 64 ± 2 
  UW-57 12.6 ± 0.2  463 ± 2 36.8 ± 0.6 
  UW-58 14.1 ± 0.3  607 ± 3 43.1 ± 0.9 
  UW-154 20.9 ± 0.5  799 ± 7 38 ± 1 
GC-1a C NC 15.4 ± 0.8 390 ± 20 920 ± 20 60 ± 4 
  UW-57 35 ± 4 130 ± 20 1700 ± 100 49 ± 6 
  UW-58 20.3 ± 0.7 390 ± 20 1460 ± 30 72 ± 3 
  UW-154 35 ± 2 270 ± 30 2200 ± 90 63 ± 4 
OXA-23 D NC 51 ± 2  95 ± 1 1.86 ± 0.08 
  UW-57 6.3 ± 0.2  8.85 ± 0.06 1.41 ± 0.05 
  UW-58 15.2 ± 0.2  24.44 ± 0.07 1.60 ± 0.02 
  UW-154 15.7 ± 0.3  23.2 ± 0.1 1.48 ± 0.03 
OXA-48 D NC 82 ± 2 980 ± 50 1650 ± 20 20.0 ± 0.6 
  UW-57 9.2 ± 0.2  242.8 ± 0.8 26.3 ± 0.7 
  UW-58 21.5 ± 0.5  351 ± 2 16.3 ± 0.4 
  UW-154 20.5 ± 0.4  3787 ± 1 18.8 ± 0.4 
aThese assays were performed by Dr. Geneviève Labbé and were reported by Ghavami et al.453  
Combinations without a KI value were fitted to Equation 2.1 rather than Equation 2.2. 
As was seen for the SBLs, some enzymes are subject to substrate/product inhibition; in this case 
VIM-1, SPM-1 and NDM-1. For SPM-1 and NDM-1, the KMs are extremely low and the KI values 
for the inhibition are around 100x higher. This substrate/product inhibition should not be a problem 
for inhibition kinetics performed near KM but should be kept in mind for those performed in excess 
substrate (usually only 10x KM). This consideration is irrelevant for NDM-1 as it is only inhibited by 
UW-57 and inhibition kinetics were performed with NC. For VIM-1, only UW-58 and UW-154 







Table 2.12 Kinetic parameters of metallo-β-lactamases with NC and UW substrates 
Enzyme Class Substrate KM (μM) KI (μM) kcat (s-1) kcat/KM 
(μM-1s-1) 
IMP-1a B1 NC 3.5 ± 0.2  236 ± 3 67 ± 4 
  UW-57 2.5 ± 0.1  229 ± 2 92 ± 4 
  UW-58 3.0 ± 0.1  235 ± 2 78 ± 3 
  UW-154 6.8 ± 0.2  576 ± 5 85 ± 3 
NDM-1a B1 NC 0.88 ± 0.06  43.7 ± 0.5 50 ± 3 
  UW-57 1.43 ± 0.09 1300 ± 100 120 ± 2 84 ± 5 
  UW-58 2.15 ± 0.09  185 ± 1 86 ± 4 
  UW-154 2.6 ± 0.1  237 ± 2 91 ± 4 
SPM-1a B1 NC 1.2 ± 0.1 630 ± 90 4.9 ± 0.1 4.1 ± 0.4 
  UW-57 1.5 ± 0.1 270 ± 20 25.8 ± 0.5 17 ± 1 
  UW-58 2.3 ± 0.2 210 ± 20 51 ± 1 22 ± 2 
  UW-154 2.6 ± 0.2 130 ± 10 58 ± 2 22 ± 2 
VIM-1 B1 NC 31.5 ± 0.6  25.2 ± 0.1 0.80 ± 0.02 
  UW-57 71 ± 2  74.3 ± 0.6 1.04 ± 0.03 
  UW-58 120 ± 10 450 ± 70 113 ± 9 1.0 ± 0.1 
  UW-154 90 ± 9 280 ± 30 88 ± 6 1.0 ± 0.1 
VIM-2a B1 NC 13.9 ± 0.3  471 ± 3 33.9 ± 0.8 
  UW-57 12.5 ± 0.5  369 ± 4 30 ± 1 
  UW-58 15.1 ± 0.3  529 ± 3 35.0 ± 0.7 
  UW-154 17.5 ± 0.9  590 ± 10 34 ± 2 
SFH-1 B2 NC 120 ± 10  1.60 ± 0.05 0.013 ± 0.001 
  UW-57 200 ± 10  23.2 ± 0.5 0.115 ± 0.006 
  UW-58 220 ± 10  24.5 ± 0.6 0.112 ± 0.007 
  UW-154 132 ± 4  13 ± 1 0.10 ± 0.01 
L1a B3 NC 5.5 ± 0.5  69 ± 1 13 ± 1 
  UW-57 8.5 ± 0.1  279 ± 1 32.8 ± 0.4 
  UW-58 15.2 ± 0.4  388 ± 3 25.5 ± 0.7 
  UW-154 16.7 ± 0.6  425 ± 6 25 ± 1 
aThese assays were performed by Dr. Geneviève Labbé and were reported by Ghavami et al.453  
Combinations without a KI value were fitted to Equation 2.1 rather than Equation 2.2. 
The kinetic parameters determined in this chapter, particularly the KM s, will be used to inform the 




The phylogenetic analysis of NDM variants showed that they are all closely related to NDM-1, 
often only differing by 1 or 2 amino acids. Each of the amino acids that differ across the NDM 
variants have been highlighted in green in the NDM-1 structure in Figure 2.14.  
 
Figure 2.14 NDM-1 crystal structure with residues that are changed among the variants 
highlighted in green. This figure was generated using UCSF Chimera v. 1.12 from protein 
databank file 3SPU Chain A. 
Of the mutable residues, G222 and E152 are the closest to the active site (within 7 Å of Zn1) and 
are most likely to cause a difference in substrate hydrolysis or inhibition. The E152 mutation has been 
studied in NDM-9 and results in a 3-fold increase in the affinity (KM) and 2-fold increase in 
hydrolytic activity (kcat) for meropenem while decreasing the affinity for nitrocefin 6-fold and its 
hydrolytic activity 2-fold relative to NDM-1.469 The G222 mutation, which is located on the mobile 
loop that comes over the active site, was studied in NDM-12 which also contains an M154 mutation. 
In the NDM-12 variant, the affinity of meropenem is largely unchanged relative to NDM-1 but the 
hydrolytic activity is decreased 3-fold. In microbial experiments, this showed little difference in MICs 
against transformed E. coli DH5α; often only 1 two-fold dilution different for a varied collection of β-
lactams which is often considered to be within standard error for this type of experiment.470 M154 is 
also quite close to the active site (within 10 Å of Zn1) and is the most prevalent mutation being found 
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in 10 of the 19 NDM variants. A study of 4 variants with the M154 mutation (NDM-4, NDM-5, 
NDM-7, and NDM-8) concluded that this mutation does not have significant effects on the kinetics 
except that substrate inhibition becomes apparent at high concentrations of nitrocefin.471 The small 
changes in kinetic parameters that result from these mutations as well as their physical location 
suggests that they should not significantly affect the binding of inhibitors. Generally, these variants 
are similar enough that if a representative of the family (NDM-1) is susceptible to an inhibitor, then 
all variants should be susceptible to a similar extent. 
 
Figure 2.15 Overlay of VIM-1 and VIM-2 crystal structures with variable residues within 10 Å 
of the Zn atoms highlighted  in a darker colour and labelled relative to VIM-2. This figure was 
generated using UCSF Chimera v. 1.12 from the following protein databank files: VIM-1 (blue, 
PDB: 5N5G), VIM-2 (tan, PDB: 4BZ3). 
The phylogenetic tree in Figure 2.5 shows that the VIM variants can be split into two major and 
three minor groups: VIM-1-like and VIM-2-like being the major groups, and VIM-12-like, VIM-13-
like, and VIM-7 being the minor groups. Many of the mutations that occur in this family occur in the 
signal peptide region (1-20 aa) and are not present in the mature protein. The mutations between 
VIM-2 and VIM-1 within 10 Å of the Zn atoms, I200V, Y201H, and R205S, have been highlighted in 
Figure 2.15. A crystal structure of VIM-1 bound to hydrolyzed meropenem (PDB: 5N5I) has also 
been obtained and of the three mutations listed above, only S205 falls within 5 Å of the hydrolysis 
product. In VIM-2, when this is an Arg residue, the polarity of the amino acid is reversed and comes 
much closer to the amide oxygen on the side chain of meropenem. This would change the kinetics of 
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meropenem hydrolysis between VIM-1 and VIM-2 as one has favourable contacts with the product 
and the other has unfavourable contacts. 
A comparison of substrate and inhibition kinetics between VIM-2 and four VIM-1 like variants 
(VIM-1, VIM-4, VIM-5, and VIM-38) was reported by Makena et al. and determined that these 
variants behave similarly with various substrates but differ greatly in their behaviour with 
isoquinoline-based metal chelators.472 This similarity between the substrate kinetics of VIM-1 and 
VIM-2 was also observed in this lab where their KM values for nitrocefin are relatively close (31 μM 
and 13.9 μM453 respectively). From an epidemiological standpoint, VIM-1 is by far the most prevalent 
VIM variant in clinical isolates although VIM-2 is also found in multiple isolates.278 VIM-1 is 
woefully understudied as a protein with crystal structures having been released very recently and two 
publications with original kinetic data (one of which uses VIM-1 with an uncleaved C-terminal His-
tag).464,472 Conversely, VIM-2 is extensively studied and is often the go-to VIM for studies with 
MBLs. The observation by Makena that they do not necessarily behave in a similar manner with 
inhibitors in addition to the structural observations, suggest that VIM-1 should be included in initial 
screens of inhibitors to determine whether or not VIM-2 alone will be an adequate representative of 
the VIM family for the inhibitors in this study.472  
On first inspection of the phylogenetic tree in Figure 2.6, the IMP variants do not appear to have 
any major groupings like the VIM family with the exception of the grouping around IMP-1. A 2014 
analysis of the diversity of IMP variants identified 5 main branches of the phylogenetic tree; however 
only 42 IMP variants were identified at that time, and there are now 70 identified IMP variants and 
the phylogenetic tree has increased in complexity.473 A study by Matsumura et al. on the global 
epidemiology of IMP producing clinical isolates showed that IMP-1 and IMP-4 (which only has 10 
amino acids different from IMP-1) are the most prevalent IMP variants.276 Purification and 
characterization of an adequate number of IMP variants was beyond the scope of the present study 
and so characterization of substrates and inhibitors were limited to IMP-1 due to its clinical 
significance and availability. 
None of the purifications in this chapter were the same as one another. Of the proteins purified in 
this work, the yield of final usable protein was greatest for OXA-48 which yielded 32 mg of pure 
protein from 2 L of liquid culture once the tag was cleaved. A similar yield of CTX-M-15 could be 
achieved as there is 34 mg of concentrated tagged protein; however, as a result of the limited supply 
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of thrombin at the time of this investigation, only a small portion of the protein was subjected to tag 
cleavage. Other His-tagged β-lactamases did not give high yields for various reasons: VIM-1 did not 
overexpress well in the cells and only a small portion of the available culture was used in purification, 
and KPC-2 did not bind to the Ni-NTA column leading us to believe that the His-tag was cleaved in 
the cells, a hypothesis later confirmed by ESI-MS. GC-1, the only β-lactamase that was never tagged, 
yielded 2.5 mg of pure protein after ammonium sulfate precipitation, ion exchange, and size exclusion 
chromatography. The SDS-PAGE presented in Figure 2.7 confirms the purity of each β-lactamase 
used in this thesis, and the masses in Table 2.8 confirm their identity. Each of these preparations 
yielded an adequate amount of protein for the kinetics presented in this thesis although the tagged 
purifications (like CTX-M-15) were by far preferred to untagged purifications (like GC-1) due to the 
ease of the purification. 
The four substrates produced in this laboratory (NC, UW-57, UW-58, and UW-154) were deemed 
adequate for the study of the β-lactamases used in this work as they each demonstrate a maximal 
difference between the substrate and product spectra in the visible range, making them condusive to 
use in polystyrene 96-well plates. These substrates also proved to be stable within the time constraints 
of a normal day of assays (as long as 3 hr at room temperature) and the relative instability of the 
product should not interfere with assays as most are only run for 5-10 min. To minimize any possible 
deterioration of the substrate, they will be kept on ice after dilution until they are ready to be used. 
While each of the substrates can be hydrolyzed by all of the β-lactamases used in this thesis, some 
are better than others in specific cases. Most assays presented in this thesis will be run using 
nitrocefin as the substrate due to its widespread use in the literature, facilitating comparison. The 
exception to this is SFH-1 which behaves similarly with UW-57 and UW-58 but has a kcat 15-fold 
lower than NC which translates into more SFH-1 being required to achieve readable rates with NC. 
Due to the extremely limited supply of SFH-1 and the amount of it required for any given assay, it 
will be assayed with UW-58 for inhibition studies. 
It was important to establish how tolerant the various β-lactamases are to DMSO since the majority 
of the inhibitors used in this work are soluble in DMSO. The cutoff for stability was set at 10 % 
activity reduction since that is considered in the literature to be the acceptable error for enzyme 
kinetics and has been used as a cutoff in similar experiments.474–476 All β-lactamases were stable up to 
at least 2% DMSO with the exception of VIM-1 which was only stable up to 1 % DMSO. This will 
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be considered the upper limit of DMSO concentration eventhough some β-lactamases are stable at 
DMSO concentrations much higher than 2 %.  
As can be seen in Table 2.13, the values for various kinetic parameters with nitrocefin vary widely 
in the literature for SBLs. CTX-M-15 and KPC-2 are widely studied Class A β-lactamases in 
enzymatic assays and the KM determined in our lab fits within the expected range for KPC-2 but is 2-
fold lower than any of the literature KMs for CTX-M-15. Conversely, our kcat for CTX-M-15 is 
consistent with literature values while our kcat for KPC-2 is about 10x those found in the literature. 
The class D SBLs, OXA-23 and OXA-48 are generally studied with meropenem as opposed to 
nitrocefin; however, our values for KM fall within the expected variance based on the spread seen in 
the literature for Class A SBLs. The kcat for OXA-23 obtained in this study is much lower than the 
literature value (93 s-1 and 1500 s-1 respectively) but considering the literature value is for a OXA-23-
MBP fusion protein, differences are expected.477 The two literature values for the OXA-48 KM vary 
four fold and our value falls halfway between them, although the reported kcat values range from 143 
s-1 to 1610 s-1.241,478 GC-1 has been previously studied with cephalothin, cefuroxime, ceftazidime, 
benzylpenicillin, ampicillin, and aztreonam; however, studies with nitrocefin have only been 
performed by members of the Dmitrienko lab, so there is no literature value for comparison.219,479 
Table 2.13 Literature values for serine-β-lactamase kinetic parameters with nitrocefin. 
Enzyme Class KM (μM) kcat (s-1) kcat/KM (μM-1s-1) Source 
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Similar to the SBLs, the literature values for the kinetic parameters of MBLs with nitrocefin vary 
widely. The KM and kcat values obtained by members of the Dmitrienko lab for NDM-1, VIM-2, and 
L1 are consistent with literature values. The literature values for NDM-1 vary by more than an order 
of magnitude, likely because its KM approaches the lower limit for detection of NC by 
spectrophotometry (rates cannot be determined for NC concentrations below 0.5 μM). The KM of 
IMP-1 from the Dmitrienko lab is approximately 2-16-fold lower than literature values although, the 
kcat is fairly consistent.  
Table 2.14 Literature values for metallo-β-lactamase kinetic parameters with nitrocefin. 
Enzyme Class KM (μM) kcat (s-1) kcat/KM (μM-1s=1) Source 
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SPM-1 also gave a lower KM when compared to literature values as well as a higher kcat leading to 
catalytic efficiency that is as much as 100 x greater than literature (4.1 vs 0.04).317 The obtained KM 
of SFH-1 is consistent with literature value (120 μM and 106 μM respectively); however, we obtained 
a much higher kcat value.491 Despite our determination of a high kcat for SFH-1, it is still too low for 
efficient use in kinetic assays using NC which is why UW-58 was used as it has a higher kcat. 
The VIM-1 purified in this laboratory was found to exhibit stability issues in certain storage 
conditions, one of the least stable conditions was used for this determination and likely contributed to 
the discrepancy between the kinetic parameters determined here and the literature. A Michaelis-
Menten parameter determination was performed for NC with the ideal storage condition and gave 
values consistent to the literature (KM 18.6 μM, kcat 48 s-1, kcat/KM 2.6 s-1μM-1) however, this was done 
with 2 technical replicates with only 7 concentrations of NC. This suggests that any further studies 
performed with VIM-1 should pay closer attention to the stability problem with this MBL. 
The values for the various kinetic parameters obtained in this laboratory (either in this study or in 
Ghavami 2015)453 will be used to inform later experiments as they are most representative of the 
conditions and constructs used. 
2.5 Future Work 
As it currently stands, all of the chromogenic substrates in the literature are cephalosporins which 
limits their usefulness since not all β-lactamases are capable of hydrolyzing cephalosporins. A 
chromogenic version of a penicillin and a carbapenem could be used in conjugation with one of the 
cephalosporins as a diagnostic tool to visually determine if a bacterial strain is resistant to any or all 
of these β-lactam subclasses. This could additionally make kinetics more affordable for β-lactamases 
that do not hydrolyze cephalosporins well such as SFH-1, OXA-23, OXA-48, and some non-ESBL 
class A and C β-lactamases since lower concentrations would likely be used for assays performed at 
KM concentrations. Development of chromogenic substrates based on other β-lactam scaffolds would 
also require acquisition or purification of more class A and C β-lactamases: ideally AmpC, P99, 




Inhibition of Metallo-β-Lactamases by Phosphonomethyl Pyridine 
Carboxylates 
3.1 Introduction 
The objective of this chapter is to assess the inhibitory potency of pyridine-based inhibitors of 
metallo-β-lactamases and the potential applications of this inhibition in combination therapy. 
Previous studies in collaboration with this laboratory concerning the inhibition of bacterial and fungal 
Class II fructose-1,6-bisphosphate aldolase demonstrated that 6-phosphonomethyl-pyridine-2-
carboxylates (PMPCs) are moderately inhibitory (IC50 57-130 μM).493 Early docking studies 
suggested that these compounds may also be inhibitory towards MBLs, a hypothesis which was 
bolstered by literature reports of picolinic acid derivatives and phosphonates inhibiting MBLs. 
Dipicolinic acid (DPA) has been used for decades in the identification and characterization of β-
lactamases as MBLs, the logic being that if a β-lactamase was inactivated by a metal-binding agent 
such as DPA, it must be an MBL.494 The characterization of IMP-1 and VIM-1 at the turn of the 
millennium with multiple chelators showed that DPA is one of the more effective inactivators of these 
MBLs. Upon further exploration of this inactivation, the authors determined that DPA forms a 
transient ternary complex with the metal-containing enzyme.403,464 A few years later, a study was 
performed on IMP-1 to assess the efficacy of a wide range of chelators and to explore the potential 
activity of its monozinc form. The most potent IMP-1 chelator from this study, DPA, was shown to 
be able to extract one of the zinc ions from the IMP-1 active site only when applied in large excess 
for 10-24 hours. When treated for only 3 hours, 87% of the di-zinc form of IMP-1 remained, 
suggesting that metal ion removal is slow and the inhibition observed at short incubation times is not 
the result of Zn extraction.400 When SPM-1 was characterized in 2003, it was determined that DPA 
bound preferentially to one of the Zn ions over the other, unlike IMP-1 and VIM-1 whose kinetics 
suggest equal affinity for both Zn ions.403,464,489 Later structural studies on SPM-1 determined that it is 
structurally a B1/B2 hybrid, which, with the earlier observation suggest that different subclasses of 
MBLs may react differently with DPA.287,489 
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The many reports of MBL inhibition or inactivation by DPA inspired development of DPA based 
inhibitors. Horsfall et al. studied the inhibitory potency of other pyridinedicarboxylic acids (PDCA) 
such as 2,3-PDCA, 2,4-PDCA, 2,5-PDCA, and 3,4-PDCA in addition to the standard 2,6-PDCA 
(DPA) and picolinic acid (PA) against MBLs from all three subclasses using imipenem as a reporter 
substrate. They found that the Class B2 MBL, CphA, was most potently inhibited by these 
compounds after 30 minutes of pre-incubation at room temperature, but the inhibition was generally 
weak (uninhbited by 100 μM 2,3-PDCA, 2,5-PDCA, and 3,4 PDCA and 8 %, 12%, and 38% residual 
activity when inhibited by 100 μM of PA, DPA, and 2,4-PDCA respectively). Additionally, they 
determined that inhibition of CphA by these compounds was pH dependent and occurred through a 
competitive mechanism.410 Thioacid and thioester derivatives of DPA have also been found to be 
inhibitory towards Class B3 MBLs, CcrA and L1, but not SBLs.439 This will be explored in more 
detail in Chapter 4. The most in depth work on the inhibitory action of DPA analogs was reported by 
Chen et al. in 2017 after the present study of MBL inhibition by PMPCs was completed and details 
the synthesis of 47 DPA analogs as well as their inhibitory potency against NDM-1. The most potent 
inhibitor from this study (compound 2 in Figure 3.1) gave in IC50 for NDM-1 of 0.08 μM was also a 
good inhibitor for IMP-1 and VIM-2 with IC50s of 0.24 μM and 0.21 μM respectively.495 
 
Figure 3.1 MBL inhibitors based off the DPA core structure.  2,4-PDCA,410 1,439 and 2495 are the 
most potent novel inhibitors from their respective publications. 
The known phosphonate β-lactamase inhibitors are primarily mechanism based SBL inhibitors. 
The first of these, the phosphonate monoesters such as compound 3 from Figure 3.3, was reported in 
1991 by the Pratt group at Wesleyan as an inhibitor of three Class A SBLs: PC1, BC1, and a TEM-
type.377 This inhibitor series was then found to also inhibit the Class C SBL P99 and a crystal 
structure of it bound to the active site of PC1 was generated.378,379 The PC1 crystal structure 
confirmed the hypotheses that the phosphonate monoesters inactivate SBLs by forming a covalent 
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bond between the phosphorous atom and the catalytic serine residue (Ser70) and that inhibitor 
potency is dependent upon leaving group stability.379  
 
Figure 3.2 PC1 from S. aureus covalently inactivated by a phosphonate monoester  (compound 
3 from Figure 3.3). This figure was generated using UCSF Chimera v. 1.12 from the protein 
databank file 1BLH.379 
More analogs of the phosphonate monoesters were generated to explore the requirements of the 
part of the molecule that bonds to the serine residue, yielding compound 4 from Figure 3.3. 
Compound 4 was found to be 20 fold more potent against the TEM-type SBL, 20 fold less potent 
against P99, and maintain similar potency with PC1.380 Once it was thoroughly established that 
phosphonates could be SBL inhibitors, two publications probed the possibility of phosphates as SBL 
inhibitors. Compounds such as compound 7 from Figure 3.3 were found to inhibit OXA-1, P99, and a 
TEM-type with a suggested mechanism that differs from the phosphonate monoesters: the serine OH 
attacks the carbon of the ester rather than the phosphorous atom.385,386 Further studies also identified 
bicyclic and monocylic phosph(on)ates as inhibitors of P99, a TEM-type SBL, OXA-1, and OXA-10 
with the bicyclics acting by a mechanism similar to the phosphates expect with the rings being 




Figure 3.3 Phosph(on)ate based inhibitors of β-lactamases.  The SBL inhibitors 3377,378, 4380, 5381, 
6383, and 7385,386 are the most potent inhibitors from their respective publications. Compounds 8 
and 9 are phosphonate based MBL inhibitors.424 
The only series of phosphonate inhibitors of MBLs published to date (with the exception of those 
studied in this chapter) are the mercaptophosphonates, the most potent of which is compound 8 from 
Figure 3.3. These compounds act as competitive inhibitors of representatives from all three subclasses 
of MBL: VIM-4 (B1), CphA (B2), and L1(B3), being most potent against the monozinc MBL, CphA. 
This study also determined two crystal structures of CphA, one of compound 8 bound to CphA and 
one of compound 9 bound to CphA. Compound 8 was found to bind to the active site with 2 of the 
phosphonate oxygens interacting with the zinc ion while compound 9 bound such that the thiol was 
interacting with the zinc ion.424 This illustrates that when two moieties, a phosphonate and a thiol, are 
competing to interact with zinc, the two contacts made by the phosphonate oxygens are collectively 
stronger than the single contact from the thiol. 
3.2 Methods 
Materials used in this chapter were the same as those listed in Chapter 2 unless otherwise stated. 
3.2.1 Enzyme Kinetics 
3.2.1.1 Inhibitor Screening 
A library of PMPCs was made by organic chemists in the Dmitrienko group, primarily by Dr. 
Anthony Krismanich, and their structures and purity were confirmed by 1H NMR, 13C NMR, and MS. 
A table containing the structures, molecular weights, laboratory codes, and common acronyms of 
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these compounds can be found in Appendix A, an abridged figure can be found in Figure 3.4. PMPC-
3 and PMPC-4 were prepared as racemic mixtures and were tested as such. Synthetic picolinate 
derivatives, were prepared as 100 mM stocks in DMSO with the exception of: PMP and DPMP which 
were prepared as 50 mM stocks in 50 mM HEPES pH 7.2. Commercial picolinate derivatives, DPA, 
PA, and 6-MPA (Sigma), were prepared in DMSO, the same as synthetic picolinate derivatives. All 
inhibitor stocks were stored at -20 oC and were remade when necessary. 
 
Figure 3.4 Structures of picolinic acid derivatives used in this chapter. 
Enzyme stocks for class A, B, and C β-lactamases were prepared in 50 mM HEPES pH 7.2 
supplemented with 50 μg/mL BSA and 0.01 % Triton X-100 while the stocks for class D enzymes 
were prepared in 100 mM NaPi, 2.1 mg/mL NaHCO3, pH 7.0 supplemented with 50 μg/mL BSA and 
0.01 % Triton X-100. Enzyme specific conditions are listed in Table 3.1; the total DMSO 
concentration was kept below 2 %.  
Enzyme stocks were pre-incubated with a small selection of inhibitor concentrations from 1 mM, 
500 μM, 100 μM, 10 μM, and 1 μM in addition to the appropriate DMSO control in triplicate for 10 
min at 30 oC in flat bottomed microplates. After pre-incubation, inhibited enzyme stock was added to 
nitrocefin/UW-58 concentrations at or near the KM to a final volume of 200 μL and was monitored at 
482 nm (NC) or 534 nm (UW-58) every 5-7 sec for 5 min (30 min for SFH-1) using a SpectraMax 
190 plate reader (Molecular Devices, Sunnyvale, CA). The initial rate of each reaction was 
determined using SoftMax 6.0 software (Molecular Devices, Sunnyvale, CA) over a minimum of 5 









Substrate KM (μM) 
Enzyme 
Conc. in assay 
[Substrate] 
in assay (μM) 
KPC-2 A NC 8.1 ± 0.2453 211 pM 8 
GC-1 C NC 15.4 ± 0.8453 41 pM 15 
OXA-48 D NC 81 ± 2 79 pM 80 
IMP-1 B1 NC 3.5 ± 0.2453 186 pM 3.5 
NDM-1 B1 NC 0.88 ± 0.06453 620 pM 1 
SPM-1 B1 NC 1.2 ± 0.1453 8.17 nM 1 
VIM-1 B1 NC 19 ± 1 1.15 nM 15 
VIM-2 B1 NC 13.9 ± 0.3453 313 pM 15 
SFH-1 B2 UW-58 220 ± 10 1.86 nM 100 
L1 B3 NC 5.5 ± 0.5453 637 pM 5 
 
3.2.1.2 IC50 Determination 
A more thorough analysis of inhibition was performed for enzyme/inhibitor concentrations that 
showed at least 50 % inhibition at 100 μM. Assays were performed as described in 3.2.1.1 using 7 or 
14 different concentrations of inhibitor. Inhibitor concentrations were determined using data from the 
inhibitor screen ensuring both plateaus and the hill of the plot were well defined. Each measurement 
was performed on 3-4 separate days unless otherwise indicated. Initial rates were normalized then 
fitted to Equation 3.1 using GraphPad Prism version 5.00 for Windows (GraphPad Software, San 
Diego, CA) by non-linear least squares regression.  




Where y is the normalized initial rate, [I] is the log of the inhibitor concentration, and s is the Hill 
slope. Measurements and uncertainties from each day were averaged using the statistical method 
described in Appendix B. 
3.2.1.3 Determination of Inhibition Constant, KI 
Assays to determine the KI for the most potent enzyme/inhibitor combinations were performed in 
50 mM HEPES pH 7.2 supplemented with 50 μg/mL BSA and 0.01 % Triton X-100 in 96-well flat 
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bottomed microplates at a final volume of 200 μL. Enzyme mixture was added to nitrocefin (>>KM) 
containing dilutions of inhibitor as determined from IC50 experiments in triplicate; specific conditions 
can be found in Table 3.2. Assay was monitored at 482 nm every 6 sec for 10 min at 30 oC in a 
SpectraMax 190 plate reader (Molecular Devices, Sunnyvale, CA). 
Table 3.2 Conditions of time-dependent KI determination. 
Enzyme [Enzyme] in assay [NC] in assay 
IMP-1 60 pM 25 μM 
NDM-1 600 pM 15 μM 
VIM-2 39.2 pM 100 μM 
L1 308 pM 50 μM 
 
Progress curves were fitted to Equation 3.2 by non-linear regression using GraphPad Prism version 
5.00 for Windows (GraphPad Software, San Diego, CA) to determine kobs, the apparent first-order 
rate constant at steady state, for each inhibitor concentration.496,497 





Where [P]t is the concentration of product at time t, vo is the initial rate, vs is the steady state rate, 
and C is a constant used to mitigate any background absorbance. The values of kobs were then plotted 
against their respective concentration of inhibitor [I] to determine which mechanism described in 
Scheme 3.1 this data fits. The resulting linear plot defined by Equation 3.3 suggests that the data fits 
Scheme 3.1A. 




Where k-o is the dissociation rate constant of EI, the enzyme:inhibitor complex, and KIapp is the 
apparent inhibition constant. The value of KIapp can be determined by dividing the value of the y-
intercept, k-o, by the value of the slope, k-o/KIapp.  KI was then determined using the value of KIapp and 
Equation 3.4. 
Equation 3.4    𝑲𝑰
𝒂𝒑𝒑






Finally, kon and koff, the association and dissociation rate constants of EI can be determined using 
Equation 3.5, where koff = k-o from Equation 3.3. 




3.2.2 Microbial Experiments 
3.2.2.1 Bacterial Strains  
Detailed information regarding the clinical isolates and control strains used in this study can be 
found in Appendix C. The Pseudomonas putida strain expressing VIM-2 (UWB24), Escherichia coli 
strain expressing both CTX-M-15 and NDM-1 (UWB75), Pseudomonas aeruginosa strain expressing 
VIM-2 (UWB78), and E. coli strain expressing both CTX-M-15 and IMP-1 (UWB93), were obtained 
from the collection of clinical isolates at Calgary Laboratory Services, Calgary, Alberta and were 
provided by Dr. Johann Pitout and Dr. Dylan Pillai. A Klebsiella pneumoniae strain expressing 
NDM-1 (UWB116), was provided by Dr. Allison McGeer from Mount Sinai Hospital in Toronto, 
Ontario. 
3.2.2.2 Minimum Inhibitory Concentration (MIC) Determination 
MIC values for meropenem with the bacterial strains in 3.2.2.1 were assayed by broth 
microdilution several times in cation adjusted Mueller Hinton broth (MHB) (Sigma) according to the 
Clinical Laboratory Standards Institute (CLSI) guidelines.498 Overnight cultures in MHB were grown 
shaking at 225 rpm and 37 oC then diluted to approximately 0.5 McFarland as measured by OD600. 
The 0.5 McFarland culture was diluted 100-fold in MHB, making the inoculum. Microtiter plates 
containing media and two-fold dilutions of meropenem were inoculated with equal volumes of 
inoculum to a final volume of 200 μL. The growth control (100 μL) that was diluted 1000-fold was 
plated on Mueller Hinton agar (MHA). Microtiter plates were shaken for 10 sec before being 
incubated overnight at 37 oC in humid conditions; agar plates were also incubated overnight at 37 oC. 
MICs were determined by measuring the OD600 using a Powerwave XS2 (BioTek) plate reader with 
an absorbance of 0.07 considered the breakpoint for growth then confirmed visually.  
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3.2.2.3 Potentiation of β-lactam Antibiotics by PMPCs 
Potentiation experiments were performed using the method described in 3.2.2.2 with a gradient of 
two-fold dilutions of inhibitor, dissolved in DMSO, in the microtiter plates perpendicular to the 
meropenem gradient. 
3.3 Results 
3.3.1 Enzyme Kinetics 
3.3.1.1 Inhibitor Screening 
The inhibitors used in this chapter were first screened against all of the purified β-lactamases 
available in the Dmitrienko lab to test for inhibition as well as to give a rough estimate of the IC50. To 
maximize the possibility of seeing inhibition, the inhibitors were preincubated with the enzyme for 10 
minutes prior to being added to nitrocefin at concentrations near KM. These screens were performed 
in the presence of Triton X-100 to reduce the probability of observing inhibition as a result of 
aggregation. 
The data shown in Table 3.3 indicates that DPA, all of the PMPCs, and DPMP are reasonably 
potent inhibitors of both B1 and B3 MBLs. The representative B2 MBL, SFH-1, was not inhibited to 
the same degree by the PMPCs as the other MBLs but its response to DPA was consistent. The 
PMPCs that significantly inhibited SFH-1 were PMPC-3 and PMPC-4 which both reduced its activity 
by just over 50 % at 10 μM. NDM-1 also demonstrated comparable sensitivity with PMPC-3 and 
PMPC-4. Other MBLs were most potently inhibited by PMPC-4 with VIM-1, and VIM-2 being 
inhibited by more than 50 % at 1 μM. PMPC-1 is consistently a more potent inhibitor than DPA, and 
PMPC-2 is comparable to it against NDM-1, SPM-1, VIM-1, SFH-1, and L1. With IMP-1 and VIM-
2, PMPC-2 is less effective at 10 μM than PMPC-1 was, suggesting that the carboxylate at the 3 
position of the pyridine ring may interfere with binding for some MBLs. PA, 6-MPA, and PMP are 
poor inhibitors that only show activity at the highest concentrations and therefore do not warrant 
further study. The IC50 of PA with VIM-2 will be determined to get an idea of how this compares in 








Table 3.3 Screening of PMPCs and related commercial compounds against MBLs 
  % Inhibition 
  IMP-1 NDM-1 SPM-1 VIM-1 VIM-2 SFH-1 L1 
DPA 
100 μM 93.0 91.2 81.1 72.9 97.9 91.9 92.2 
10 μM 46.1 82.7 30.0 52.4 84.3 59.7 62.2 
1 μM 17.4 32.3 18.8 -14.5 9.9 4.4 -2.7 
PA 
100 μM 19.7 46.4 44.1 37.4 74.6  46.4 
10 μM 16.5 37.7 18.1 -12.6 26.4  12.5 
1 μM 17.2 25.9 22.1 -19.9 8.2  -0.6 
6-MPA 
100 μM 20.5 32.7 18.0 -11.7 8.5  8.0 
10 μM 25.9 36.4 14.2 -3.5 4.7  -5.0 
1 μM -13.7 7.0 8.5 -9.5 2.4  -3.7 
PMPC-1 
100 μM 98.4 99.0 81.7 87.5 101.2 61.6 77.4 
10 μM 66.2 97.6 26.1 76.2 93.7 41.7 90.8 
1 μM 2.3 53.4 25.1 39.9 24.7 22.0 32.0 
PMPC-2 
100 μM 89.0 101.6 84.0 79.3 97.2 57.7 105.5 
10 μM 12.4 91.6 41.4 86.4 39.5 40.6 82.3 
1 μM 0.4 61.5 19.0 42.8 11.9 26.1 24.0 
PMPC-3 
100 μM 95.9 101.3 88.7 87.5 96.1 85.2 90.9 
10 μM 63.6 108.2 41.2 80.0 78.6 54.0 87.0 
1 μM 26.1 69.7 26.7 33.9 14.7 37.0 32.1 
PMPC-4 
100 μM 96.7 100.2 106.5 103.9 101.1 71.6 100.5 
10 μM 92.0 103.0 70.3 90.8 99.7 51.1 92.9 
1 μM 24.6 84.3 21.8 61.3 64.7 35.1 39.6 
PMP 
1 mM 60.7 45.3 14.9  85.0  40.4 
100 μM 8.5 -14.3 14.4  32.7  2.0 
10 μM -3.1 -8.3 10.0  0.4  -3.6 
DPMP 
1 mM 96.7 98.6 73.9  99.3  97.5 
100 μM 54.3 97.3 38.4  88.8 33.6 83.5 
10 μM 1.0 87.3 16.9  35.0 19.7 33.8 
Bolded values are >50 % inhibited. 
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A selection of SBLs was screened to ascertain whether or not these are metallo-enzyme specific 
inhibitors. As seen in Table 3.4, these compounds do not inhibit SBLs at concentrations comparable 
to their inhibition of MBLs.  
Table 3.4 Screening of PMPCs and related commercial compounds against SBLs. 
  % Inhibition 
  KPC-2 GC-1 OXA-48 
DPA 
500 μM 28.1 6.5 0.7 
100 μM -5.0 -16.4  
10 μM -8.1 -13.7  
PA 
500 μM 10.3 1.3 2.3 
100 μM -2.4 -7.9  
10 μM -12.1 -12.9  
6-MPA 
500 μM 12.3 -1.4 1.1 
100 μM -6.4 -11.2  
10 μM -5.7 -3.7  
PMPC-1 
500 μM 33.2 25.1 0.6 
100 μM 4.6 -3.9  
10 μM 1.0 -5.2  
PMPC-2 
500 μM 14.5 42.8 1.6 
100 μM 6.0 1.1  
10 μM -1.1 -14.1  
PMPC-3 
500 μM 13.9 34.8 3.2 
100 μM 3.8 4.2  
10 μM -4.6 -6.3  
PMPC-4 
500 μM 56.7 47.2 4.8 
100 μM 19.4 14.3  
10 μM -4.6 0.7  
PMP 
1 mM 24.0 17.7  
500 μM 12.2 9.7 -2.4 
DPMP 
1 mM 22.2 25.9  
500 μM 19.6 16.1 -2.1 
 
Some inhibition can be detected at 500 μM for KPC-2 and GC-1, with the greatest effect being 
observed with PMPC-4 (57 % and 47 % inhibition respectively). The inhibition of SBLs by PMPCs 
was not considered potent enough to warrant further study. 
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3.3.1.2 IC50 Determination 
A more in-depth screen of MBL inhibition by PMPCs was performed by determining IC50s when 
the inhibitor was preincubated with enzyme for 10 min prior to addition to nitrocefin. Trends in the 
efficacy of inhibitors for each enzyme can best be demonstrated by the dose response curves in Figure 
3.5. Generally, DPMP (and PA and PMP where applicable) are the poorest inhibitors as seen by their 
curves being shifted to the right of the others. Little difference can be seen between PMPC-1, PMPC-
3, and PMPC-4 against most enzymes, although PMPC-4 is notably more potent than the others 
against VIM-2. Of the PMPCs, PMPC-2 is the least potent, falling well to the right of the curves of 
other PMPCs for IMP-1, VIM-1, and VIM-2.  
In most cases, the curve shape and Hill slope is fairly consistent for the different inhibitors against 
any given enzyme with the exception of DPA with SFH-1 and DPMP with both SPM-1 for which the 
































































































Figure 3.5 Dose response curves of MBLs with PMPCs and related compounds.  The 
enzyme/inhibitor combinations in Table 3.5 are presented here with the inhibitors represented 
as follows: DPA (▬), PA (▬), PMPC-1 (▬), PMPC-2 (▬), PMPC-3 (▬), PMPC-4 (▬), PMP 
(▬), and DPMP (▬). The graphs in this figure were generated using GraphPad Prism v. 5.03. 
The data in Table 3.5 is a numeric representation of the graphs in Figure 3.5 which allows for 
comparison between enzymes. From this it can be seen that NDM-1 is the MBL that is most 
susceptible to inhibition by PMPCs with IC50 values of 0.31 μM to 0.55 μM for the PMPCs, all of 
which are lower than the IC50 values for any other enzyme/inhibitor combination. SPM-1 and SFH-1 
are poorly inhibited relative to the other MBLs with SFH-1 being less susceptible to inhibition than 
SPM-1. The B1 MBLs are inhibited most potently by PMPC-4 with PMPC-1 being less than 2-fold 
less potent than PMPC-4 against all B1 MBLs except VIM-2. Unlike the B1 MBLs, the B2 MBL, 
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SFH-1, was most potently inhibited by PMPC-3 than PMPC-4 (IC50s of 0.56 μM and 7.3 μM 
respectively) and PMPC-1 is 5-fold less potent than the most potent inhibitor, PMPC-3. The B3 MBL 
L1, is very similarly inhibited by all of the PMPCs such that the 95% confidence intervals for each 
PMPC inhibitor encompasses the IC50 values of all of the other PMPC inhibitors. As was suggested 
from the screening experiments, PA, PMP, and DPMP are relatively weak inhibitors of MBLs. Using 
VIM-2 as a model system (since it showed some susceptibility to all inhibitors in screening), PMP is 
the weakest inhibitor followed by PA, and DPMP with IC50 values of 170 μM, 32 μM, and 18 μM 
respectively. With IMP-1, VIM-2, and SFH-1, PMPC-2 is a weaker inhibitor than DPA suggesting 
that this is not necessarily a good compound on which to base further structural optimization. 
Table 3.5 IC50’s of PMPCs against MBLs 
 IC50 (μM) 
(95% Confidence Interval) 
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(150-190) 
  






 18 * 
(17-19) 
 33 * 
(31-34) 
* From a single experiment of three technical replicates.  
 From these data, it was determined that the inhibition should be better characterized for 
enzyme/inhibitor combinations with low IC50 values. The enzyme/inhibitor combinations selected for 
this analysis were IMP-1, NDM-1, VIM-2, and L1 with the inhibitors DPA, PMPC-1, PMPC-3, and 
PMPC-4. The stock of purified VIM-1 was extremely limited and still has the C-terminal His tag 
attached, thus it was excluded from further study. 
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3.3.1.3 Determination of the Inhibition Constant  
Preliminary assays performed without preincubation of the inhibitor with the enzyme showed 
progress curves that exhibit asymptotes, particularly at high concentrations of inhibitor. This is 
indicative of time-dependent inhibition (sometimes referred to as slow-binding inhibition), which can 
be described by either of the mechanisms in Scheme 3.1.496 In mechanism A, the inhibitory complex, 
EI, forms in a single, slow step; whereas in mechanism B, the inhibitory complex forms then 
isomerizes slowly to the EI* complex. 
 
Scheme 3.1 Enzyme inhibition mechanisms that can exhibit time-dependent inhibition. 
Progress curves from either mechanism of time-dependent inhibition can be fit to Equation 3.2, 
resulting in the coloured fit curves seen in Figure 3.6. From this analysis, the kobs can be determined, 
and plotted against the concentration of inhibitor, [I], to generate a secondary plot which allows us to 
distinguish between mechanism A and B. If the inhibition is occurring by mechanism A, the 
secondary plot has a linear relationship described by Equation 3.3; whereas if the inhibition is 
occurring by mechanism B, the secondary plot will be hyperbolic.  
Plots of the progress curves of IMP-1, NDM-1, VIM-2, and L1 inhibited by PMPC-1 are found in 
Figure 3.6 and the error bars are representative of the error between the three replicate measurements 
on the same day. The secondary plots generated from these progress curves for each MBL/inhibitor 
combination was linear, indicating that these compounds inhibit the MBLs by a one-step mechanism 
such as mechanism A from Scheme 3.1.  
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KI = 0.5 ± 0.1
R2 = 0.9760
KI = 1.1 ± 0.2
R2 = 0.9944
KI = 0.067 ± 0.010
R2 = 0.9893





Figure 3.6 Time-dependent KI graphs for PMPC-1 against representative MBLs : IMP-1 (A), 
NDM-1 (B), VIM-2 (C), and L1 (D). The graphs in this figure were generated using GraphPad 
Prism v. 5.03. 
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The graphs corresponding to those in Figure 3.6 for DPA, PMPC-3, and PMPC-4 can be found in 
Appendix D. 
The KI values in Table 3.6 were determined from further analysis of the linear regression of the 
secondary plots. Consistent with the IC50 data, PMPC-4 is the most potent inhibitor as it has the 
lowest KI for each enzyme; as much as 14.2 times more potent than PMPC-1. The general trends for 
inhibitor potency within each enzyme system seen in the IC50 data also holds up here, although the 
scaling is not consistent (ie. PMPC-4 was 8-fold more potent than DPA against NDM-1 in terms of 
IC50 values, however the KI is almost 100-fold lower). The KI values for PMPC-1 and PMPC-3 are 
generally similar while the KI values for DPA are 1.5-49 times greater than those of PMPC-1. Finally, 
NDM-1 is most sensitive to PMPCs with KI values from 34 nM to 74 nM. 
Table 3.6 KI of DPA, PMPC-1, -3, and -4 against select MBLs. 
 KI (µM) 
 DPA PMPC-1 PMPC-3 PMPC-4 
IMP-1 2.8 ± 0.4 1.1 ± 0.2 1.5 ± 0.1 0.4 ± 0.2 
NDM-1 3.3 ± 0.6 0.067 ± 0.010 0.074 ± 0.008 0.034 ± 0.006 
VIM-2 0.8 ± 0.3 0.54 ± 0.05 0.61 ± 0.04 0.038 ± 0.009 
L1 1.1 ± 0.3 0.5 ± 0.1 0.41 ± 0.10 0.4 ± 0.1 
 
The first order rate constant for the dissociation of the EI complex, koff, for each enzyme/inhibitor 
combination was determined from the y-intercept of the secondary plot. The second order rate 
constant for the association of the EI complex, kon was calculated from the known values of koff and 
the KI; the results of these analyses are found in Table 3.7.  
Table 3.7 On and off rates of metallo-β-lactamase inhibition by PMPCs. 
 kon (M-1sec-1) 
koff (sec-1) 
 DPA PMPC-1 PMPC-3 PMPC-4 
IMP-1 500 ± 100 
0.0014 ± 0.0002 
1400 ± 300 
0.0015 ± 0.0002 
980 ± 90 
0.00147 ± 0.00008 
4000 ± 2000 
0.0014 ± 0.0006 
NDM-1 1300 ± 300 
0.0043 ± 0.0003 
51 000 ± 9000 
0.0034 ± 0.0003 
54 000 ± 8000 
0.0040 ± 0.0004 
110 000 ± 20 000 
0.0036 ± 0.0002 
VIM-2 5000 ± 2000 
0.004 ± 0.001 
8000 ± 800 
0.0043 ± 0.0002 
9100 ± 700 
0.0055 ± 0.0002 
70 000 ± 20 000 
0.0027 ± 0.0005 
L1 1200 ± 400 
0.0013 ± 0.0003 
6000 ± 2000 
0.0029 ± 0.0005 
5000 ± 1000 
0.0019 ± 0.0004 
5000 ± 2000 




The koff values for the various inhibitors against any one enzyme are fairly consistent, ranging from 
0.0013 sec-1 to 0.0055 sec-1, while the kon values vary greatly. The kon values for PMPC-4 are 2-7.5-
fold larger than the inhibitor with the next highest kon for B1 MBLs. This indicates that the EI 
complex forms fastest with PMPC-4, and the koff values show that it dissociates at approximately the 
same rate as the other inhibitors, resulting in stronger inhibition. This trend does not hold up with L1 
which has very similar kon values across the PMPCs (5000 M-1sec-1 – 6000 M-1sec-1). The lack of 
increased kon for PMPC-4 with L1 is consistent with the KI and IC50 data which suggests that PMPC-4 
does not hold a particular advantage over the other PMPCs against L1, unlike the B1 MBLs.  
3.3.2 Potentiation of meropenem against MBL producing Gram negatives 
It is one thing to inhibit enzymes in vitro, but another thing entirely to penetrate the Gram-negative 
cell wall and restore antibiotic potency. Five strains MBL producing clinical isolates including two E. 
coli strains, two Pseudomonas spp., and a K. pneumoniae were selected to determine whether or not 
the PMPCs could potentiate meropenem activity in vivo. Strains UWB93 and UWB75 co-express the 
SBL CTX-M-15 which does not significantly hydrolyze meropenem and thus should not significantly 
contribute to the meropenem MIC when the MBL is inhibited.  
The Clinical Laboratory Standards Institute (CLSI) defines Enterobactericiae (E. coli and K. 
pneumoniae) as susceptible to meropenem when the MIC is at or below 1 mg/L and as resistant at or 
above 4 mg/L. Pseudomonas spp. are considered susceptible to meropenem at or below 2 mg/L and 
are resistant at or above 8 mg/L. The data in Table 3.8 indicates that DPA tends to bring the MIC of 
meropenem into susceptible range with two-fold less inhibitor than PMPCs although it tends to 
require 16 mg/L DPA or more to achieve susceptibility. PMPC-4 is the least effective of the tested 
inhibitors against each strain and only brings UWB93 and UWB116 into the susceptible range, others 
showed a decrease in MIC at high concentrations of PMPC-4, but not enough to be clinically useful. 
UWB116 is particularly sensitive to potentiation by PMPCs with meropenem MICs entering the 
susceptible range with only 16-32 mg/L of inhibitor. None of the tested inhibitors had intrinsic 






Table 3.8 Sensitization of MBL producing Gram negatives to meropenem by DPA and PMPCs. 
Strain β-lactamase 
Meropenem 
MIC (mg/L) Inhibitor 


















4 DPA 4 4 2 1 0.25 <0.03 
PMPC-1 4 4 4 2 0.5 0.25 
PMPC-2 4 4 4 4 2 0.5 
PMPC-3 4 4 4 4 2 0.5 
PMPC-4 4 4 4 2 2 0.5 




128 DPA 128 128 64 16 <0.5 <0.5 
PMPC-1 128 128 64 32 4 <0.5 
PMPC-2 128 128 64 64 16 4 
PMPC-3 128 128 128 64 32 2 
PMPC-4 128 128 128 64 64 8 
K. pneumoniae 
UWB116 
NDM-1 32 DPA 16 4 0.5 <0.125 <0.125 <0.125 
PMPC-1 16 8 4 0.25 <0.125 <0.125 
PMPC-2 16 8 2 0.5 <0.125 <0.125 
PMPC-3 8 8 1 <0.125 <0.125 <0.125 
PMPC-4 16 8 2 0.5 <0.125 <0.125 
P. putida 
UWB24 
VIM-2 128 DPA 128 128 128 64 4 2 
PMPC-1 128 128 128 64 32 4 
PMPC-2 128 128 128 128 64 32 
PMPC-3 128 128 128 128 64 32 
PMPC-4 128 128 128 128 64 32 
P. aeruginosa 
UWB78 
VIM-2 128 DPA 64 64 64 32 8 4 
PMPC-1 128 128 64 64 16 8 
PMPC-2 128 128 128 64 64 16 
PMPC-3 128 128 128 128 64 8 
PMPC-4 128 128 64 64 64 16 
Bolded MIC values are susceptible to meropenem according to CLSI guidelines.500 
Italicized MIC values are intermediate (neither resistant nor susceptible) to meropenem according to CLSI 
guidelines.500 
3.4 Discussion 
Previous studies have indicated that DPA is an effective inhibitor of both IMP-1 and NDM-1.400,495 
Due to the structural similarity of DPA and the PMPCs, it was considered likely that the PMPCs 
would also inhibit MBLs. The initial synthesis of PMPC-1 and PMPC-2 was directed at inhibition of 
Class II fructose-1,6-bisphosphate aldolase, a metallo-enzyme.501  
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The PMPCs and related pyridine compounds are poor inhibitors of SBLs, only inhibiting KPC-2 
and GC-1 at the highest tested concentration, 500 μM. In most cases, this inhibition is modest, 
reducing the activity of these enzymes by 10-40 % relative to the uninhibited control. The only tested 
compound that managed to elicit a response of greater than 50 % inhibition against SBLs was PMPC-
4 which is also the most potent inhibitor against the MBLs. 
The MBLs are potently inhibited by PMPCs, and to a lesser extent by other picolinic acid 
derivatives depicted in Figure 3.4. Of the commercial picolinic acid derivatives: PA, DPA, and 6-
MPA, the most potent inhibitor of MBLs is DPA. The improved activity of DPA over PA indicates 
that the presence of the carboxylate at the 6-position is beneficial as it decreases the IC50 by 6 to 
greater than 20-fold. A study on the inhibitory activity of commercial picolinate derivatives against 
MBLs by Horsfall et al. showed that 100 μM DPA was able to reduce the activity of IMP-1 to 2 % 
relative to an uninhibited control in the absence of added zinc while 100 μM PA was only able to 
reduce the activity by 31%.410 In the presence of 100 μM ZnCl2, the inhibition of IMP-1 by DPA is 
substantially diminished (72 % residual activity at 100 μM DPA) suggesting that DPA in solution 
with Zn2+ is being sequestered and is not available for inhibition.410 The data presented by Horfall et 
al. is consistent with the data presented in Table 3.3 for DPA in which 7 % activity remains after 
incubation with 100 μM DPA but is not consistent with the data for PA (80.3 % residual activity at 
100 μM PA). The data in Horsfall et al. with VIM-2 and L1 are not comparable as they appear to be 
run in the presence of 100 μM ZnCl2, although this is not explicitly detailed in the Methods section of 
their paper.410 Substitution of the carboxylate on DPA at the 6 position with a methyl group 
completely abolishes activity, suggesting that the presence of a polar group at the 6-position is 
favourable for inhibition.  
The inhibition is further improved when the 6-carboxylate is substituted by a phosphonomethyl 
group, decreasing the IC50 values by another 2.6-7-fold. Substitution of both DPA carboxylates by 
phosphonomethyl groups as in DPMP leads to a reduction in activity for all MBLs except NDM-1 
which has comparable IC50 values for DPA and DPMP (2.59 μM and 2.03 μM respectively). 
Furthermore, if the carboxylate from PMPC-1 is excluded (PMP) the inhibitory activity is completely 
abolished, emphasizing the importance of the carboxylate at the 2-position.  
Within the PMPCs, two substitution sites were explored: the 3-position of the pyridine ring 
(PMPC-2), and the methylene group of the phosphonate (PMPC-3 and PMPC-4). The addition of a 
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carboxylate to PMPC-1 at the 3-position of the ring to form PMPC-2 provides no improvement in the 
inhibition of NDM-1 or L1 and increases the IC50 2-11-fold against IMP-1, SPM-1, and VIM-2. This 
suggests that the addition of an anionic group to the 3-position of the pyridine ring increases 
specificity but does not improve the potency of these inhibitors. The addition of either a small polar 
group (PMPC-3) or large hydrophobic group (PMPC-4) to the methylene group of the PMPC-1 
phosphonate did not significantly affect the inhibition in terms of IC50 with the exception of the 2.8-
fold decrease in the IC50 from PMPC-1 (1.29 μM) to PMPC-4 (0.464 μM) for VIM-2. It should be 
noted that PMPC-3 and PMPC-4 were synthesized as racemic mixtures so they may be twice as 
potent as reported if the binding to the active site is selective for only one enantiomer. 
The two VIM variants, VIM-1 and VIM-2, showed similar IC50 values for most of the compounds 
tested. The only compound for which their IC50’s varied significantly was PMPC-2 which is also the 
only compound in this set that may have two modes of inhibition: one as a PMPC and the other as a 
phthalate. Phthalates (specifically 3-(4-hydroxypiperidin-1-yl)-aminophthalic acid) are known to 
inhibit B1 MBLs by coordinating one carboxylate group, which would be equivalent to the 
carboxylate at the 2 position in PMPCs, with the two active site Zn ions and the other carboxylate (the 
3 position in PMPC-2) interacts with Lys161 in IMP-1 (Figure 3.7A). Crystallographic studies done 
in collaboration with Dr. Jim Spencer (University of Bristol) yielded structures of IMP-1 with PMPC-
1 and L1 with PMPC-1 and PMPC-3. In the IMP-1 structure, PMPC-1 coordinates its pyridine 
nitrogen and carboxylate with Zn2. The carboxylate also hydrogen bonds with Lys161, the 
phosphonate hydrogen bonds to the bridging water/hydroxide and interacts weakly with Ser80 in 
IMP-1, and the aromatic ring has an edge-face interaction with Trp28 (Figure 3.7C).414,415 The 
potential for two binding modes for PMPC-2 may explain the discrepancy in the potency trend 
mentioned above. If PMPC-2 preferentially binds in a manner similar to PMPC-1, it is expected that 
the IC50 would be similar to the other PMPCs as it is for NDM-1, L1, and VIM-1 since they should be 
making the same contacts. If PMPC-2 preferentially binds in a manner similar to the phthalates, this 
may result in significantly different IC50 as seen with IMP-1, SPM-1, and VIM-2 since the contacts 
made in the active site are completely different. This dichotomy greatly complicates the kinetics as 
inhibition may be a result of multiple binding modes, each with differing affinities.   
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Figure 3.7 Binding of 3-(4-hydroxypiperidin-1-yl)-aminophthalic acid and PMPC-1 to the active 
site IMP-1.  (A) 3-(4-hydroxypiperidin-1-yl)-aminophthalic acid bound to IMP-1 with contacts 
from the groups also present in PMPC-2 shown (PDB 3WXC). (B) Overlay of the binding of the 
two inhibitors. (C) PMPC-1 bound to IMP-1 with contacts that would also be present in PMPC-
2 (PDB 5HH4). This figure was generated using Chimera v. 1.12 from the aforementioned 
protein databank files. 
Structural studies of PMPC-1 and PMPC-3 with L1 yielded some unexpected results. Despite the 
kinetics suggesting that IMP-1 and L1 are inhibited by the same mechanism, crystal structures in 
Figure 3.8 show that in L1, the phosphonate of the PMPC replaces Zn2 while in IMP-1 both Zn ions 
are retained (Figure 3.7). The removal of one zinc ion from L1 is uncommon and has only been 
previously reported when a L1 crystal was soaked for 10 min with 10 mM EDTA.255 Studies have 
been performed in the literature to determine the dissociation constant (KD) of Zn2 in both L1 and 
IMP-1 and suggest that Zn2 is more tightly bound in IMP-1 than in L1 (KD of 0.7 μM at pH 5.61 and 
2.6 μM at pH 7.0 respectively).302,502  
 
Figure 3.8 Crystal structures of PMPCs bound to L1 , namely PMPC-1 (A, green) and PMPC-3 
(C, purple) with a comparative overlay of the two structures (B) to illustrate similarities in the 
mode of binding. This figure was generated using Chimera v. 1.12 from PDB: 5HH5 and 5HH6. 
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It has been shown that the KD of Zn2 depends heavily on pH and while these two KDs were not 
determined at the same pH, the KD of IMP-1 was determined at a range of pHs (4.33-5.61) and 
decreases as pH increases.302 This suggests that if the trend holds, 0.7 μM may by an over estimation 
of the KD of Zn2 in IMP-1 at pH 7 which may explain why it retains its Zn while L1 does not in the 
crystallization experiments with PMPC-1. Additionally, the KD values were determined for the 
proteins in solution, and they may be significantly different with respect to one another in the 
crystalline state. The replacement of Zn2 in L1 by the phosphonate group of the PMPCs results in a 
very strong interaction between one of the phosphonate oxygens and Zn1 (1.8 Å). This interaction is 
notably stronger that the interactions between Zn1 and the three His residues that coordinate it to the 
active site (2.1 Å average). Additionally, the two PMPCs, PMPC-1 and PMPC-3 bind to L1 in the 
same manner, overlaying on each other almost perfectly as seen in Figure 3.8B. 
 
Figure 3.9 Binding of the S-enantiomer of PMPC-3 to the active site of L1. This figure was 
generated using Chimera v. 1.12 from the protein databank file 5HH6. 
Unlike PMPC-1 which has no stereocenters, the C6 methine group of PMPC-3 is chiral and was 
synthesized as a racemic mixture. The crystal structure of L1 with PMPC-3 bound shows that the 
binding of PMPC-3 to the active site is stereospecific for the S-enantiomer. By mapping the protein 
surface, as in Figure 3.9, it can be seen that the 6’-hydroxyl group points towards the opening of the 
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active site and that the R-enantiomer would likely have unfavourable contacts with the protein 
surface. The relative openness of this part of the binding pocket indicates that large substituents such 
as that of PMPC-4 would be well tolerated but their binding would also be stereospecific. Due to the 
stereoselectivity of the L1 active site, it is probable that the IC50 and KI values for PMPC-3 and 
PMPC-4 should be half that which was detailed above. It is uncertain whether or not the other MBLs 
require the same enantiomer as L1 for inhibition by PMPC-3 and PMPC-4.  
In the case of binding of PMPC-4 to IMP-1, it is clear from qualitative modelling that the bulky N-
thienoyl-N-benzyl groupcan only be accommodated in the binding site if the stereochemistry is of the 
R configuration. This is due to the prediction of very bad contacts with the zinc ions and the bridging 
hydroxide ion if the stereochemistry is of the S configuration. Thus, it is reasonable to suggest that 
only the R-isomer of PMPC-4 contributes to inhibition and that the effective IC50 and KI values with 
IMP-1 should be half what is reported above. 
In the case of PMPC-3, the hydroxyl group in the S-isomer makes close contacts with the bridging 
hydroxide as well as with the aspartate carboxylate that is a ligand to Zn2. These may however be 
tolerated since they may involve hydrogen bonding interactions. In the R-isomer, no contacts are 
predicted between the hydroxyl group and the protein. Thus it is possible that both stereoisomers 
contribute to the observed enzyme inhibition. 
In early experiments performed with no pre-incubation with the inhibitors (DPA, PMPC-1, PMPC-
3, and PMPC-4) and three B1 MBLs (IMP-1, NDM-1, and VIM-2) and one B3 MBL (L1) exhibited 
burst kinetics wherein there is an initial fast rate and a slower steady state rate (Figure 3.10). The 
burst kinetics are most evident in mid-range inhibitor concentrations of the progress curves in Figure 
3.6 and are not caused by substrate depletion as only 10 % or less of the substrate is consumed at the 
end of a 10 min assay. This, in conjunction with the observation that IC50’s taken at different 
preincubation times stabilize at 10 min (data not shown), indicates that DPA and the PMPCs inhibit 



























































































Figure 3.10 Fits of initial and steady state rates on representative progress curves of MBLs 
inhibited by PMPC-1 (25 μM for IMP-1, 1 μM for NDM-1, 5 μM for VIM-2, and 7.5 μM for 
L1). The graphs in this figure were generated using GraphPad Prism v. 5.03. 
Time dependent kinetics can be the result of either slow-binding or slow-tight-binding. The 
possibility of slow-tight-binding inhibition was excluded since the concentrations of inhibitor 
required to see inhibition are in great excess relative to the concentration of the MBL being 
inhibited.496 Secondary plots of the rate of change between the initial rate, vo and the steady state rate, 
vs, denoted as kobs, and the concentration of inhibitor were used to determine that inhibition occurs 
through the formation of an EI complex, and that that complex does not isomerize further. 
Determination of the inhibition constant, KI, showed that PMPC-1, PMPC-3, and PMPC-4 were 
similarly potent against IMP-1, VIM-2, and L1 with PMPC-4 being the most potent. NDM-1 is the 
most susceptible to inhibition by the PMPC’s with KI values ranging from 34-74 nM. The KI values 
for DPA against each of the MBLs is larger than those of the PMPCs by 1.3-45-fold indicating that 
the PMPCs are more effective inhibitors of MBLs than DPA.  
Slow binding inhibitors exhibit lower rates of association (kon) than classical inhibitors which tend 
to have association rates of 106-108 M-1sec-1 and in order to be effective inhibitors, the dissociation 
rates (koff) must be even slower.496 The dissociation rates determined for DPA, PMPC-1, PMPC-3, 
and PMPC-4 are very consistent across the MBLs as they all tend to be on the order of 10-3 sec-1. 
Since the dissociation rates are so consistent, any differences in the efficacy of an inhibitor is 
predicated by the association rate, which can vary by a hundred-fold for different inhibitors against 
the same enzyme. The kon are highest for NDM-1 and approach being fast enough for classical 
kinetics with PMPC-4 (106 M-1sec-1). This is consistent with the structural characteristics of NDM-1 
in that it has the largest and most open active site allowing it to bind larger inhibitors faster than 
enzymes with tighter active site like IMP-1 which has the slowest association rates for every 
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inhibitor. In most cases, PMPC-4 has the fastest kon which may be due to the hydrophobic group on 
the C6-methine carbon since it will contribute to a lower extent of hydration of the phosphonate 
group.  
The benefits of PMPC-4 for inhibiting MBLs does not translate into improved sensitization of 
MBL producers to meropenem most likely since it may not cross the outer membrane as well as the 
smaller compounds DPA and PMPC-1. The two VIM-2 producing Pseudomonas strains, UWB24 and 
UWB78, are very resistant to sensitization by DPA and the PMPCs. Although MIC reduction was 
observed with each of the tested compounds against these two strains, only one of them could be 
brought into the susceptible range and it required 128 mg/L DPA to do it. Sensitization of the two E. 
coli strains, UWB93 and UWB75, was most effective for DPA which made them susceptible at 32 
mg/L and 64 mg/L respectively. PMPC-1 was not far behind requiring only 2-fold more compound to 
make the strains susceptible to meropenem while other PMPCs required at least another 2-fold more 
compound. The most susceptible strain was the K. pneumoniae strain UWB116 which could be 
sensitized to the susceptible range by only 16 mg/L of either DPA or PMPC-3 and 32 mg/L of all 
other PMPC compounds. 
Overall, the PMPCs are potent inhibitors of class B1 and B3 MBLs with little to no inhibitory 
activity against any class of SBL. This inhibition occurs by a time-dependent, one-step, competitive 
mechanism in which the rate of dissociation of the EI complex is fairly consistent and the affinity of 
the inhibitor for the MBL active site is determined largely by the rate of association, kon. SAR studies 
suggest that negatively charged groups at both the 2 and 6 positions of the pyridine ring are required 
for inhibition, and the PMPC configuration at these positions is more potent than the dicarboxylate or 
diphosphonomethyl configurations. Modification of the methylene group in the PMPCs was tolerated 
well and resulted in increased affinity. Of the compounds with modifications of the methylene group, 
PMPC-4 is the most potent inhibitor despite it being a racemic mixture; however, this potency does 
not translate in microbial growth inhibition experiments as PMPC-4 was only able to sensitize two of 
the 5 tested Gram negatives into the susceptible range although MIC reduction was seen for all 5 
strains. DPA and PMPC-1 are the two most effective compounds in sensitizing the bacteria likely due 
to their size and polarity; this charge/size consideration should be taken into account for development 
of future PMPC analogs. 
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3.5 Future Work 
One of the possible explanations for the discrepancy between the kinetic results and the 
crystallography with respect to the replacement of Zn2 in L1 is that it may be due to the zinc ion 
affinities differing in the crystalline state in comparison to the solution state. To establish whether or 
not the zinc ion is abstracted in solution state, mass spectrometry experiments will be attempted. 
Preliminary studies on SPM-1 have demonstrated that the dizinc form of the enzyme can be detected 
as the primary species by ESI-MS under non-denaturing conditions. It is likely that L1 could also be 
detected by native ESI-MS as the dizinc enzyme. If L1 retains 2 Zn ions when treated with PMPCs 
prior to analysis by ESI-MS, then the replacement is a crystallographic artifact; however, a mono-Zn 
L1 by this method does not confirm the crystal structure as the interaction of the Zn may have been 
weakened enough by the PMPC to allow it to dissociate in the MS. If a mono-Zn spectrum was 
obtained, further studies using ICP-MS, as described by King et al., would be required to determine if 
Zn2 is actually being removed from the active site.401 
Experiments performed in this chapter used racemic mixtures of PMPC-3 and PMPC-4; however, 
the crystal structure of L1 with PMPC-3 demonstrated stereoselectivity for the S-enantiomer. It 
should be noted that the stereoselectivity of the crystalline form of the enzyme may not be 
representative of the stereoselectivity of the solution state enzyme. As such, enantiomerically pure 
(both R and S) samples of PMPC-3 and PMPC-4 should be synthesized as tested with the MBLs to 
determine if the S-enantiomer is the active inhibitor for all of them as well as how potent the pure 
stock is. Once the issue of the stereochemistry at the C6-methylyne group is sorted out, new analogs 
in the PMPC series can be rationally developed using the crystal structures of IMP-1 and L1 with 
PMPCs bound.  
The crystal structure of PMPC-1 bound to IMP-1 suggests a number of strategies for enhancing the 
affinity of the PMPCs for MBL active sites. As indicated in Figure 3.11C, a substituent on C3 would 
extend out of the active site so substituents that would increase the uptake into cells could be attached 
here. The results with PMPC-2 demonstrate that the addition of an anionic group to this position is 






Figure 3.11 Binding of PMPC-1 to the active site of IMP-1, highlighting opportunities for 
development of future PMPCs. (A) Schematic of the binding interactions involved in PMPC-1 
binding to IMP-1. (B) The hydrophobic pocket of IMP-1 highlighted in purple. (C) Positions on 
the PMPC core that could be modified to optimize binding to B1 MBLs. This figure was 
generated using Chimera v. 1.12 from the protein databank file 5HH4. 
Substituents at C4 and in the α-orientation on the C6 methine would not be well tolerated due to 
steric clashes with Trp64 and the zinc ions/ligands respectively. Hydrophobic substitutions on C5 or 
in the β-orientation on the C6 methine would point towards the hydrophobic pocket highlighted in 
purple in Figure 3.11B. This hydrophobic pocket is well conserved within the B1 MBLs, so these 





Thioacids and 3ʹ-Acylthio-Cephalosporins as B3 Inhibitors 
4.1 Introduction 
Cephalosporins such as cefotaxime and ceftazidime account for 12% of all antibiotic prescriptions 
in Canada and are considered highly important by the WHO.9,16,17 Over the past few decades, 
cephalosporin resistance has become increasingly prevalent to the point where early generation 
cephalosporins are no longer prescribed for Gram negative infections.44 The first report of an ESBL-
producer was in 1983 in Germany which was followed by reports of ESBL-producers around the 
world in the late-80’s.503,504 Resistance to extended spectrum cephalosporins (generations 3-5) in 
Canadian hospitals has been monitored since 1995 by the Canadian Nosocomial Infection 
Surveillance Program and it was determined that 116 ESBL producers in 12 Canadian hospitals in a 
one year period (Sept 1999- Sept 2000).505 Shortly thereafter, a study in Calgary showed that ESBLs 
were becoming increasingly prevalent in community acquired infections.506 The most prevalent 
ESBLs are CTX-M-15-like, SHV-type, and KPC-type, although MBLs such a NDM-1 are increasing 
in prevalence.17,507 Recently avibactam (see Figure 1.13), an inhibitor effective against SBLs, has 
been approved by the FDA which (at least temporarily) solves that part of the ESBL problem.508 
In a collaboration between the Dmitrienko lab and Panbio Inc. in Australia discussed in 2.1 several 
strategies to develop a novel chromogenic β-lactamase substrate including one strategy that involved 
the release of a thioacid as described in Scheme 4.1 were explored. In this strategy, a 3ʹ-
acylthiocephalosporin is hydrolyzed by a β-lactamase, followed by a rearrangement that expels a 
thioacid which in turn, reacts with a tetrazolium salt in the presence of 1-methoxy phenazine 





Scheme 4.1 Formazan dye strategy for a chromogenic cephalosporin. 
The formazan dye strategy was not successful in making a chromogenic cephalosporin, since the 
3ʹ-acylthiocephalosporins were poor substrates for β-lactamases. As part of their characterization, 
early compounds in this series, including UW-19 (Scheme 4.1), were found to protect meropenem 
from hydrolysis by metallo-β-lactamases. In the enzyme assays depicted in Figure 4.1, co-
administration of UW-19 with meropenem extended the half-life of meropenem three-fold while 
another compound in this series, AK075, extended its half-life 5.5-fold. To confirm whether or not 
this was a characteristic of cephalosporins, ceftiofur and moxalactam were tested for comparable 
activity and were determined that they do not protect meropenem. This interesting and potentially 
advantageous behaviour inspired a synthetic effort that resulted in over 70 novel cephalosporins 
which were assessed based on their synergy with meropenem in microbiological experiments. While 
some experiments were performed to elucidate the reason that these cephalosporins protected 





Figure 4.1 Protection of meropenem hydrolysis by synthetic and commercial cephalosporins.  
The novel cephalosporins UW-19 and AG075 protect meropenem from hydrolysis by IMP-1, 
extending its half-life 3-fold and 5.5-fold respectively (A). The commercial cephalosporin 
ceftiofur and oxacephamycin moxalactam are not capable of conferring the same protection to 
meropenem (B). 
The mechanism presented in Scheme 4.1 suggests that after the cephalosporin is hydrolyzed by a β-
lactamase, the hydrolysis product expels an aromatic thioacid as its conjugate base. There are a 
number of examples in the literature of thiols and thioesters being potent inhibitors of MBLs as 
reviewed by McGeary et al.397 but relatively few examples of the interaction of thioacids with MBLs. 
Tsang et al. have reported that the thioacid formed upon hydrolysis of an 8-thioxo-cephalosporin is an 




Figure 4.2 Generation of a MBL inhibitor from 8-thioxo-cephalosporins. 509 
More recently, researchers at Pfizer Global R&D reported using a high throughput bioassay to 
screen 19,366 natural product extracts including those from actinomycete cultures to identify two 
potent inhibitors of  the  Class B1 MBL CcrA (from Bacterioides fragilis) and the Class B3 MBL L1 
from (S. maltophilia) PMTC and PDTC.439 
 
Figure 4.3 Potent inhibitors of CcrA and L1 determined from natural product screen. 439 
The goals of the research described in this Chapter were as follows: 
1) Estimate the potential of aromatic thiocids as inhibitors of MBLs 
2) Determine the potency of PMTC and PDTC as inhibitors of clinically important MBLs 
3) Gain insights in to the mechanism of inhibition of MBLs by 3ʹ-acylthiocephalosporins 
4) Gain insights into the potency and mechanism of a 3ʹ-acylthiocephalsoporin, UW-123 (Table 
4.2), that has significant activity as a stand-alone anditbiotic against MBL-producing clinical 
isolates. 
4.2 Methods 
Materials used in this chapter were the same as those listed in Chapter 2 unless otherwise stated. 
Thiobenzoic acid (TBA) is the only inhibitor that was not synthesized in this lab but was purchased 
from Sigma. 
4.2.1 Synthetic Thioacids and 3ʹ-acylthiocephalosporins 
A library of thioacids was synthesized by Dr. Ahmed Desoky and Dr. Glenn Abbott in the 
Dmitrienko group using a new synthetic method shown in Scheme 4.2, and their structures and purity 




Scheme 4.2 Abridged method for thioacid synthesis. 
A table containing the structures, molecular weights, laboratory codes, and common acronyms of 
these compounds can be found in Appendix A, an abridged depiction can be found in Table 4.1. 
Table 4.1 Structures of phenyl thioacids presented in this chapter 
 
 R1 R2 R3 R4 R5 
TBA H H H H H 
TA-1 H H Br H H 
TA-2 H OMe H H H 
TA-3 Cl H Cl H H 
TA-4 Cl H Cl H Cl 
TA-5 H NO2 H H H 
TA-6 H NO2 H NO2 H 
TA-7 H H NHAc H H 
TA-8 H H NHBoc H H 
 
Samples of PMTC, PDTC, and I-PDTC, a benzene variant of PDTC, were synthesized using the 
same strategy. 
 
Figure 4.4 Structure of pyridine based thioacids and related compounds presented in this 
chapter. 
The primary goal for the study of the thioacids was to determine whether or not they are inhibitory 
towards β-lactamases when released from a cephalosporin. While it is useful to know the in vitro 
inhibitory properties of the thioacids, ultimately, the potency of the cephalosporin against β-lactamase 
producing bacteria is more important. In order to assess this potency, a series of 3ʹ-
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acylthiocephalosporins were made by Dr. Desoky and other organic chemists in the Dmitrienko 
group. In total, over 70 compounds in this series were made. Only a small subset of these compounds 
are presented in this work. The 3ʹ-acylthiocephalosporins presented in this work, found in Table 4.2, 
were all made by Dr. Ahmed Desoky and their structures have been confirmed using the methods 
described for the compounds in Table 4.1. 
Table 4.2 Structures of cephalosporins presented in this chapter 
 























The R1 sidechains for TE-5 and UW-123 were chosen to optimize uptake into Gram negative 
bacteria. For TE-5, the R1 sidechain is the same as that from ceftazidime – a highly successful 
antibiotic against clinically important Gram negative pathogens.9 The R1 sidechain of UW-123 is a 
catechol siderophore mimic intended to increase uptake into Pseudomonas strains through Fe3+ 
uptake porins. This sidechain has also been used in BAL30072, a monobactam in Phase 3 clinical 
trials for treatment of Gram negative infections, especially Pseudomonas aeruginosa.510 Catechol-
type siderophores such as enterobactin and pyoverdine are known to facilitate iron uptake in E. coli, 
 
 140 
K. pneumoniae, and P. aeruginosa which suggests that these siderophore mimics may increase uptake 
in other bacterial pathogens as well as in Pseudomonas.511 
4.2.2 β-Lactamase Enzyme Kinetics 
4.2.2.1 Thioacid Solubility 
Thioacids were dissolved in DMSO using a combination of vortexing and sonicating to make 100 
mM, 50 mM, or 25 mM stocks. The stock concentration was chosen for each thioacid was the highest 
concentration where all solid appeared to dissolve. Upon freezing, these stocks precipitated and the 
resulting solid would not dissolve back into the DMSO so they were used as fine suspensions. To test 
whether or not the solubility of these compounds could be improved by deprotonation of the thioacid, 
5 mM solutions of TA-1 were prepared from the precipitated freezer stocks in the presence of 0, 1, 
and 6 molar equivalents of NaOH. Each of the solutions was then diluted to 50 μM in DMSO and to 
100 μM in 50 mM HEPES pH 7.2 the latter is intended to mimic kinetic assay conditions. The pH of 
each of the prepared solutions of TA-1 was determined using colorpHast® pH 0-14 indicator strips 
(EM-Reagents, Gibbstown, NJ). 
4.2.2.2 Inhibitor Screening 
The assays in this section were performed as described in 3.2.1.1 for CTX-M-15, KPC-2, GC-1, 
OXA-48, IMP-1, NDM-1, SPM-1, VIM-2, and L1 with the following stipulations: 
The phenyl thioacids were screened against L1 in the presence and absence of one molar equivalent 
of NaOH to assess differences and determine the best conditions to be used with other β-lactamases. 
Screening of the other β-lactamases against the synthetic phenyl thioacids (TA-1 – TA-8) listed in 
Table 4.1 was carried out in the presence of NaOH. Later studies with the inhibitors presented in 
Figure 4.4 were also carried out with one molar equivalent of NaOH to assist in complete dissolution. 
4.2.2.3 IC50 Determination 
The assays in this section with PMTC, PDTC, and I-PDTC were performed as described in 3.2.1.2 
with the most concentrated stock being prepared with one molar equivalent of NaOH. 
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4.2.3 Antimicrobial Susceptibility 
4.2.3.1 Bacterial Strains 
Detailed information regarding bacterial strains can be found in Appendix C. The bacterial strains 
used by Merck are part of their collections. 
4.2.3.2 MIC Determination 
MICs were determined using methods described in 3.2.2.2. Some compounds were prepared as 
DMSO stocks, in which case the final concentration of DMSO was 1.25 %. Commercial antibiotics 
that were used for comparison: meropenem (Mero) (A. G. Scientific, San Diego, CA), imipenem 
(Imi), ceftazidime (CAZ) (Sigma), cephotaxim (CTX) (Sigma). Later experiments with UW-123 were 
performed in the presence and absence of a serine-β-lactamase inhibitor. In the case of the 
experiments performed in the Dmitrienko lab, this inhibitor was either BLI-489 or avibactam (Figure 
4.5), in the Merck panels, it was an undisclosed inhibitor from the same functional class as avibactam. 
 
Figure 4.5 Serine-β-lactamase inhibitors used in microbiological experiments in the Dmitrienko 
lab. 337,512 
4.2.3.3 Checkerboard Synergy Assay 
Checkerboard synergy assays were performed against meropenem as described in 3.2.2.3 with final 
DMSO concentrations of 1.67 %. To ensure complete dissolution of the thioacids, one molar 
equivalent of NaOH was added to the initial DMSO stock. Some compounds precipitated in MH 
media, in these cases, after growing overnight at 37 oC in a 96-well plate, 10 μL from each well was 
spotted onto MH agar then incubated overnight to assess the viability of any remaining bacteria. By 
comparing the minimum bactericidal concentrations (MBCs) generated by spot plate for meropenem 
and the same MICs measured by OD600, correlation between the two techniques was established. 
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Fractional inhibitory concentrations (FICs) were determined using Equation 4.1 with the caveat 
that if one compound does not have an MIC in the range of the experiment, it is assumed to be the 
next dilution above the limit. 







The determined FIC values indicate what type of relationship exists between the two compounds as 
listed in Table 4.3. 
Table 4.3 Relationships indicated by FIC 
FIC Relationship 
≤ 0.5 Synergistic 
0.5 < FIC ≥ 1 Additive 
1 < FIC > 2 Indifferent 
≥ 2 Antagonistic 
 
4.2.4 Mode of Action 
The experiments performed in this section were adapted from Moya et al. and Page et al..116,513 
4.2.4.1 Time-Kill Kinetics 
The UW-123 used in these experiments was from a different stock than the one used in the MIC 
experiments above. An MIC was determined for the strain being used and was found to be different 
from the one above. These experiments were set up using the MIC of this stock: 1 mg/L.  
4.2.4.1.1 Monitoring by Optical Density 
MH agar plates were streaked with a wild type E. coli (UWB59) and incubated at 37 oC overnight 
then stored at 4 oC. Single colonies were used to inoculate 1 mL of MH broth which was shaken at 
250 rpm overnight at 37 oC. O/N cultures of E. coli (UWB59) were diluted 1/100 in MH broth and 
grown to an OD600 of approximately 0.2 in an incubator at 37 oC and 250 rpm. Dilutions of antibiotic 
were prepared at 4x, 2x, 1x, 0.5x, 0.25x, and 0x MIC in MH with 1.25% DMSO. Cultures were then 
added to 96 well plates by a 1/20 dilution with the antibiotic preparations. Plates were shaken in the 
plate reader for 10 sec on low speed then read at 600 nm every hour for 8 hours and again at 24 hours 
then incubated at 37 oC between reads. Same day experiments were performed in quadruplicates with 
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only MH in the wells on the edge of the plate. Three separate day replicates were performed. 
Normalization of data was performed by subtracting the absorbance of the sterility control from that 
of the wells with bacteria and antibiotic at that concentration and time to eliminate background 
effects. 
4.2.4.1.2 Monitoring by Colony Forming Units 
The setup of this experiment was similar to that detailed in 4.2.4.1.1 except that the growth 
component of the assay was performed in snap cap tubes with a final volume of 1 mL instead of in a 
microplate with a 200 μL final volume using only 2x, 1x, 0.5x, 0.25x, and 0x MIC. The tubes were 
shaken at 250 rpm for the duration of their incubation at 37 oC with aliquots taken at 0 hr, 0.5 hr, 1 hr, 
2 hr, 4 hr, 8 hr, and 24 hr. Aliquots were immediately diluted and plated on MH agar then incubated 
at 37 oC overnight. Several dilutions were plated for each time and concentration combination to 
ensure at least one readable plate was obtained, totaling 119 agar plates. Due to the amount of 
supplies required to perform this experiment, only a single replicate was performed. 
4.2.4.2 Phase Contrast Microscopy 
The setup of this experiment was similar to that of 4.2.4.1.1 with the 1/100 dilution of cultures 
being made in both MH broth and MH broth supplemented with 0.3 M sucrose. Likewise, dilutions of 
antibiotic (128 mg/L – 0.0625 mg/L) were also made in MH broth in the presence and absence of 0.3 
M sucrose. After 2 hr of incubation at 37 oC in a microplate, 100 μL was taken from each well and 
pelleted at 5000 rpm for 5 min in an Eppendorf 5415 C centrifuge and the supernatant was decanted. 
The pellets were kept on ice until about 0.5 μL of the pellet (resuspended in the small amount of 
retained supernatant) was visualized under oil immersion at 1000x magnification on a Zeiss Axioskop 
2 plus phase contrast microscope. 
4.2.4.3 Penicillin Binding Protein Competitive Binding Assay 
4.2.4.3.1 Preparation of PBP Containing Membrane Fragments 
P. aeruginosa Membrane Fragments 
Procedures for PBP membrane preparation and Bocillin binding assay were adapted from Moyá et 
al..116 P. aeruginosa PA01 cells were obtained from Dr. Stephen Seah of the University of Guelph 
and designated UWB96. An overnight culture of PA01 cells was prepared by inoculating two tubes 
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containing 2 mL Luria Bertani (LB) broth with scrapings from a glycerol stock and shaking them at 
250 rpm, 37 oC, overnight (16-20 hr). The 4 mL of PA01 overnight culture were used to inoculate 500 
mL LB broth which was then incubated at 37 oC, shaking at 185 rpm until the OD600 reached 1 (~5 
hr). Cells were then centrifuged in a JA-10 rotor at 4400 xg for 10 min at 4 oC and the supernatant 
was discarded. The pellets were washed in 150 mL of Buffer A (20 mM KH2PO4, 140 mM NaCl, pH 
7.5) then centrifuged again at 4400 xg for 10 min at 4 oC and the supernatant was discarded. The cells 
in the pellet were then lysed using a large probe on a Heat Systems Ultrasonic processor W-255 
sonicator set to 50 % cycle and 50 % power 5 times for 30 sec each with 1 min rest on ice between 
bursts. The lysate was then centrifuged in a JA-25.5 rotor at 12 000 xg for 10 min at 4 oC and the 
supernatant and pellets were retained separately and frozen on dry ice then stored at -80 oC. The 
supernatant was thawed and transferred into 10 mL Oak Ridge polypropylene tubes with a nylon 
screw cap for use in a T-1270 rotor of a Sorvall WX100 Ultra centrifuge. Samples were centrifuged at 
150 000 xg for 1 h at 4 oC and the supernatant was discarded. The pellets were resuspended in 1 mL 
Buffer A and pooled. Total membrane protein concentration was determined by Bradford assay as 
described in 2.2. The P. aeruginosa PBP membrane preparation was then aliquoted, frozen on dry ice, 
and stored at -80 oC.  
E. coli Membrane Fragments 
A similar but modified procedure was used for the isolation of membrane fragments from E. coli 
(ATCC 25922, UWB 102). An overnight culture of E. coli cells was prepared by inoculating 5 mL of 
LB broth with scrapings from a glycerol stock and shaking them at 200 rpm, 37 oC, overnight (16-20 
hr). The 5 mL of E. coli overnight culture was used to inoculate 1 L LB broth which was then 
incubated at 37 oC, shaking at 200 rpm until the densely grown. Cells were then centrifuged in a f10 
4x1000 LEX rotor in a Sorvall RC 6+ centrifuge at 4400 xg for 10 min at 4 oC and the supernatant 
was discarded. The pellets were washed in 150 mL of Buffer B (20 mM NaH2PO4, 140 mM NaCl, pH 
7.5) then centrifuged again at 4400 xg for 10 min at 4 oC and the supernatant was discarded. The cells 
in the pellet were resuspended in 40 mL of Buffer B, then lysed using a small probe on a Microson 
Ultrasonic Cell Disruptor set to 5 power, 5 times for 30 sec each at 4 oC with 1 min rest on ice 
between bursts. The lysate was then centrifuged in a f13 14x50cy rotor at 12 000 xg for 5 min at 4 oC 
and the pellets were retained separately and frozen on dry ice then stored at -80 oC. The supernatant 
was transferred into 70 mL Beckman polypropylene tubes with an aluminum screw cap for use in a 
Type 45 Ti rotor of a Beckman-Coulter Class S Optima L-90K Ultracentrifuge. Samples were 
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centrifuged at 134 032 xg (34 000 rpm) for 1 h at 4 oC with maximum acceleration and slow 
deceleration then the supernatant was discarded. The pellets were resuspended in 1 mL Buffer B then 
aliquoted and flash frozen on dry ice to be stored at -80 oC. Upon testing this preparation, it was too 
dilute to quantify PBP 2 or 3 – the following procedural additions were to generate a more 
concentrated stock. The retained pellet from the sonication was thawed and suspended in another 40 
mL Buffer B then lysed more completely using a large probe on a Heat Systems Ultrasonic processor 
W-255 sonicator set to 50 % cycle and 50 % power 5 times for 30 sec each with 1 min rest on ice 
between bursts. The lysate was then centrifuged in an f13 14x50cy rotor at 10 000 xg for 5 min at 4 
oC. The supernatant was decanted into 70 mL Beckman polypropylene tubes with an aluminum screw 
cap and balanced against a pooled solution of the previous aliquots, with Buffer B. Both samples 
were centrifuged at 134 032 xg (34 000 rpm) for 1 h at 4 oC with maximum acceleration and slow 
deceleration in a Type 45 Ti rotor. Each pellet was resuspended in 20 mL of Buffer B, then they were 
pooled together and centrifuged again at 134 032 xg for 1 h at 4 oC with maximum acceleration and 
slow deceleration in a Type 45 Ti rotor. The pellet was then soaked in 500 μL of Buffer B overnight 
at 4 oC to allow complete resuspension before aliquoting and freezing on dry ice for storage at -80 oC. 
Total membrane protein concentration was determined by Bradford assay as described in 2.2.  
4.2.4.3.2 PBP Competitive Binding Assay 
Two-fold dilutions of UW-123 ranging from 128 mg/L to 0.0039 mg/L were prepared in Buffer B 
(20 mM NaPi, 140 mM NaCl, pH 7.5) and DMSO such that the final concentration of DMSO in each 
sample was 1.28 % while aliquots of the PBP membrane preparation were thawed on ice. The PBP 
membrane preparation (10 μL) was incubated with a 3x concentrated stock of UW-123 (5 μL) for 30 
min at 37 oC after vortexing. In a darkened room, 5 μL of the fluorescent penicillin, Bocillin 
(Thermo), was added and returned to the incubator for 30 min at 37 oC after vortexing. Samples were 
prepared for SDS-PAGE by adding 5 μL of 5x SDS-PAGE Buffer to each sample, vortexing, and 
boiling for 3 min before spinning down any condensation. Each sample (20 μL) as well as 5 μL of 
low molecular weight marker was loaded onto two 10 % SDS-PAGE gel which were run at 80 V in 
the dark until the blue dye front had reached the bottom of the gel. Gels were uncased directly onto a 
Pharos (BioRad, Hercules, CA) gel reading system and visualized at λex= 488 nm and λem= 530 nm. 
Band densities were determined using Image Lab software (BioRad, Hercules, CA) and were 
normalized and fitted to Equation 3.1 using GraphPad Prism 5.00 for Windows (GraphPad Software, 
San Diego, CA) with the added constraint that the bottom plateau is set to 0 since it is not well 
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defined. Gels were then stained with Coomassie Blue R-250 (BioRad, Hercules, CA) containing stain 
overnight then destained with 50 % methanol, 10 % acetic acid in water. Coomassie stained gels were 
visualized on a Gel Doc EZ Imager (BioRad, Hercules, CA). 
4.3 Results 
Preliminary studies aimed at probing the mechanism of MBL inhibition by 3ʹ-
acylthiocephalsopsorins were carried out by Dr. Laura Marrone in this research group.  She 
discovered that, for UW-19, the IC50 for inhibition of nitrocefin hydrolysis by IMP-1 was 3.1 μM. 
Following this, a complete hydrolysis of UW-19 was carried out using the SBL KPC-2 and the 
hydrolysis product was separated from the enzyme.  The hydrolysis product, at 60 μM was found to 
cause 48% reduction in the catalytic activity of IMP-1.  In a separate experiment, thiobenzoate itself 
(TBA) at 60 μM was found to reduce the catalytic activity of IMP-1 by 56%.  Thus, neither 
thiobenzoate alone nor the hydrolysis products, presumed to be TBA and the cephalosporin-derived 
elimination product (shown in Scheme 4.1) were sufficiently effective as inhibitors to explain the 
inhibitory potency of UW-19. 
This led to the proposal the the inhibition by UW-19 was likely a consequence of tight binding of 
the intact cephalosporin (low KM, estimated to be 0.07 μM) followed by slow release of the 
cephalosporin-derived elimination product from the active site resulting in a low kcat.514  
4.3.1 Released Phenyl Thioacids as β-Lactamase Inhibitors 
In an effort to ascertain if the inhibitory activity of 3ʹ-acylthiocephalosporins could be altered by 
substitutions on the thioacids, a selection of phenyl thioacids were tested for their inhibitory activity 
towards β-lactamases. These compounds are not very soluble directly in either DMSO or water at pHs 
that can be readily withstood by the β-lactamases, necessitating the addition of NaOH.  
To determine if the addition of NaOH would cause a significant pH change in the stocks and 
assays, the pH of 5 mM and 50 μM DMSO stocks of TA-1 were determined when prepared with one 
and six molar equivalents of NaOH and without. As demonstrated in Table 4.4, when 5 mM TA-1 
was prepared without NaOH, it was neutral (pH 7) whereas the TA-1 that was prepared with 1 
equivalent of NaOH was slightly basic (pH 8). When an excess of NaOH was used in TA-1 stock 
preparation, the solution becomes more basic (pH 9). Upon 100-fold dilution in DMSO without 
additional NaOH, each of these stocks became pH 9.  
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Table 4.4 pH of DMSO stocks of TA-1 when prepared with and without NaOH. 
[TA-1] (mM) equivalents of NaOH pH 
5 0 7 
5 1 8 
5 6 9 
0.05 0 9 
0.05 1 9 
0.05 6 9 
 
It was important to know if the addition of NaOH would change the conditions of the kinetic 
assays. To this end, the 5 mM stocks of TA-1 prepared with 0, 1, and 6 equivalents of NaOH were 
diluted 50-fold in 50 mM HEPES pH 7.2 as they would be in kinetic assays. Once diluted, both 
solutions of 100 μM TA-1 were pH 7 confirming that the addition of NaOH to the thioacid stock does 
not change the pH of the kinetic assays. This experiment was not repeated for 50 μM stocks, although 
the results of the 100 μM TA-1 prepared with excess NaOH suggest that the HEPES will be able to 
buffer the 50 μM stocks as well. 
4.3.1.1 Inhibitor Screening 
A very preliminary screen suggested that the Class B3 MBL L1 would be the most susceptible of 
our β-lactamases to inhibition by thioacids, so it was chosen as the test system to determine whether 
or not stocks should be prepared with NaOH. A range of concentrations  (100 μM, 10 μM, and 1 μM) 
of each thioacid listed in Table 4.1 were screened for inhibiton of L1 when the stocks were prepared 









Table 4.5 Phenyl thioacid screening against L1 when prepared in the presence and absence of 
NaOH (presented as % inhibition). 
 0 equivalents NaOH 1 equivalent NaOH 
[TA] 100 μM 10 μM 1 μM 100 μM 10 μM 1 μM 
TBA -14.2 24.1 19.7 86.1 40.4 12.1 
TA-1 25.4 42.4 36.6 91.2 61.4 13.4 
TA-2 26.6 10.0 18.2 5.7 45.4 23.3 
TA-3 13.9 20.8 10.3 91.7 51.1 8.1 
TA-4 -18.9 -18.1 -12.2 19.6 0.4 -3.0 
TA-5 68.4 50.5 23.8 86.9 70.0 17.5 
TA-6 67.4 44.4 16.7 91.5 72.8 15.5 
TA-7 1.7 3.3 6.0 -4.7 8.9 3.9 
TA-8 16.6 8.5 3.0 34.9 6.7 1.8 
Bolded values indicate >50 % inhibition. 
The data in Table 4.5 suggest that phenyl thioacids are more inhibitory when prepared in the 
presence of 1 molar equivalent of NaOH. Regardless of whether or not the stocks were made with 
NaOH, thioacids containing nitro group(s), TA-5 and TA-6, are the most potent L1 inhibitors. These 
were the only compounds to reduce the activity of L1 by more than 50% when NaOH was not used to 
aide in dissolution, and to elicit >70% inhibition at 10 μM when NaOH was used. The other phenyl 
thioacids that significantly inhibited L1 were TA-1 which had a bromine at C4, and TA-3 which has 
chlorines at both C2 and C4. 
Inspection of the data collected without the addition of NaOH shows unusual trends for some 
thioacids: TBA, TA-1, TA-3, and TA-7 are more inhibitory at 10 μM than they are at 100 μM. It is 
probable that while the solutions are clear and the no scatter is observed in the absorbance, these 
thioacids may be forming colloids at 100 μM, reducing their availability for the L1 active site. The 
only case of this when the thioacids were treated with NaOH is TA-2 which has an OMe group at C3. 
Studies on other β-lactamases were carried out using phenyl thioacid stocks that have been prepared 







Table 4.6 Phenyl thioacid inhibitor screening against SBLs 
  % Inhibition 
Inhibitor Concentration CTX-M-15 KPC-2 GC-1 OXA-48 
TA-1 
100 μM -2.8 -1.5 13.0 2.3 
10 μM -2.9 -5.6 3.6 1.0 
1 μM 1.1 1.7 0.9 0.6 
TA-2 
100 μM -0.5 -3.2 84.0 -10.2 
10 μM 2.2 -9.3 19.4 -1.7 
1 μM -2.8 -0.8 2.9 -1.4 
TA-3 
100 μM 1.0 -0.9 56.9 1.9 
10 μM 1.3 3.3 16.5 2.0 
1 μM 0.7 1.9 0.4 1.4 
TA-4 
100 μM 10.0 -3.2 4.7 1.1 
10 μM 10.1 -12.2 1.7 2.4 
1 μM 1.7 -4.8 3.0 -5.1 
TA-5 
100 μM -1.8 -5.9 51.6 2.5 
10 μM 1.3 -5.2 18.2 -1.5 
1 μM -1.5 0.0 1.6 -2.5 
TA-6 
100 μM -2.6 -15.1 40.8 3.0 
10 μM -2.6 -11.3 9.4 1.1 
1 μM -0.3 -2.7 -4.8 0.9 
TA-7 
100 μM 7.2 -5.3 61.2 2.9 
10 μM 6.0 -18.3 63.4 1.5 
1 μM -2.8 -0.7 17.6 4.4 
TA-8 
100 μM 8.8 0.6 10.6 1.5 
10 μM 5.4 -4.2 3.9 -0.1 
1 μM 1.5 -4.4 3.8 -0.8 
Bolded values indicate >50 % inhibition. 
The SBLs used in this screen were generally not inhibited by the thioacids with the exception of 
GC-1 as seen in Table 4.6. GC-1 was found to be most susceptible to inhibition by TA-7 which has a 
NHAc group at C4 and slightly susceptible to TA-2, TA-3, and TA-5 which have a C3 OMe, a C2 
and C4 Cl, and a C3 NO2 respectively. The SBLs commonly found in the clinical isolates used in this 
study, CTX-M-15, KPC-2, and OXA-48, show no response with their perceived deviation from 0 % 






Table 4.7 Phenyl thioacid inhibitor screening against MBLs. 
  % Inhibition 
Inhibitor Concentration IMP-1 NDM-1 SPM-1 VIM-2 L1 
TA-1 
100 μM 33.0 -21.5 27.0 13.5 91.2 
10 μM 6.9 -13.6 -1.1 3.5 61.4 
1 μM 3.9 -4.7 0.8 2.1 13.4 
TA-2 
100 μM 32.8 22.8 38.4 12.1 5.7 
10 μM 1.4 12.1 4.7 -4.9 45.4 
1 μM 7.2 16.7 4.8 -2.0 23.3 
TA-3 
100 μM 18.3 -13.5 -1.7 8.7 91.7 
10 μM 8.3 -5.0 -5.0 4.7 51.1 
1 μM -3.6 -4.0 -2.7 0.4 8.1 
TA-4 
100 μM 0.5 -11.5 -3.3 -7.7 19.6 
10 μM 2.7 -7.7 -2.5 -8.9 0.4 
1 μM 4.4 2.0 7.0 -5.7 -3.0 
TA-5 
100 μM 49.9 -0.6 19.9 37.5 86.9 
10 μM 9.9 -5.2 18.2 11.3 70.0 
1 μM 0.8 -7.4 -9.2 3.2 17.5 
TA-6 
100 μM 78.8 5.0 35.9 61.4 91.5 
10 μM 19.9 -13.4 -1.0 3.5 72.8 
1 μM 6.0 -10.1 -2.5 -2.3 15.5 
TA-7 
100 μM 38.2 53.6 29.0 17.3 -4.7 
10 μM 19.6 69.2 37.9 19.4 8.9 
1 μM 7.2 18.7 8.4 8.9 3.9 
TA-8 
100 μM 2.7 6.2 -1.6 -1.8 34.9 
10 μM -0.1 -5.8 1.6 -3.7 6.7 
1 μM 1.6 -1.2 9.8 0.5 1.8 
Bolded values indicate >50 % inhibition. 
The phenyl thioacids were also screened against MBLs as potential inhibitors using similar 
methods. The data in Table 4.7 shows that the B1 MBLs are slightly more inhibited than the SBLs at 
the highest concentrations of phenyl thioacids. IMP-1 and VIM-2 were 78.8% and 61.4 % inhibited 
by TA-6 (3,5-dinitro) respectively, consistent with L1 which is also inhibited most potently by TA-6. 
NDM-1 was only inhibited by more than 50% by TA-7 (4-NHAc) which is more consistent with GC-
1 than L1 which was uninhibited by this thioacid. Throughout Table 4.7 there are examples of the B1 
MBLs starting to show slight inhibition (~30%) at 100 μM with TA-1, TA-2, TA-5, TA-6, and TA-7. 
While it is encouraging that these can be inhibited by phenyl thioacids, the inhibition is too weak to 
be clinically relevant. In addition to those presented below, the Class B2 MBL SFH-1 was screened 
with TA-1 and was not significantly inhibited up to 316 μM. 
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4.3.1.2 Meropenem potentiation by phenyl thioacids 
The most potent L1 inhibitors (TA-1, TA-5, and TA-6) were assayed for potentiation of 
meropenem against 10 S. maltophilia strains. Of these strains, 7 are known to produce both the Class 
B3 MBL L1 and the Class A SBL L2, 2 produce only L2, and one has not been sequenced to identify 
coded β-lactamases. These compounds were not found to be soluble in MH broth at 1.25 % (TA-1, 
TA-5) or 1.67% (TA-6) DMSO, necessitating spotting 10 μL from each well onto MH agar to 
distinguish between growth and precipitate as depicted in Figure 4.6. 
 
Figure 4.6 MH agar spot plates of thioacid potentiation of meropenem against L1 and L2 
producing S. maltophilia (UWB 45) for 128 mg/L TA-1 (B), TA-5 (C), or TA-6 (D). Plate A is the 
unsupplemented control. The values along the perimeter of the agar plates indicate the 
concentration of meropenem in the sample starting from 128 mg/L in the upper right corner 
progressing downwards then left in 2-fold serial dilutions to 0.25 mg/L. The sample labelled “0” 
is the inhibitor and the sample labelled “gr” is the growth control which contains neither 
meropenem nor thioacid. 
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Prior to spotting on MH agar, MICs were determined using the standard combination of OD600 and 
visual inspection. The MIC values for meropenem from this analysis served as a control to determine 
whether or not the agar spotting (MBC) was representative of the MICs determined by standard 
methods. Using UWB45 as an example, the MIC for meropenem alone was determined to be 128 
mg/L using standard methods and the agar spot plate showed an MBC of 128 mg/L, validating that 
the spot plates are representative of meropenem MICs in solution. The plates in Figure 4.6 
demonstrate that TA-1 is able to reduce the MBC of meropenem against UWB45 from 128 mg/L to 
64 mg/L, TA-5 reduces the MBC to 32 mg/L, and TA-6 reduces the MBC to 16 mg/L. The 
potentiation of meropenem by these phenyl thioacids was also determined against other S. maltophilia 
strains (Table 4.8). 
Of the 10 S. maltophilia strains assayed in this section, three (UWB26, 29, and 44) did not grow 
due to problems with the inoculum. The remaining strains had good agreement between their 
meropenem MIC and MBC. UWB46 and UWB48 had a 2-fold difference between these 
measurements likely due to the OD600 measurement not guaranteeing that there is no growth in 
solution, just that is not turbid enough to be above to cutoff absorbance of 0.07, so growth could be 
reflected on the agar plate but not the OD600 reading. Atypical growth was observed and noted for 
seven samples in which growth was observed as colonies rather than a homogeneous spot which may 
be a result of resistant mutants or very few viable cells in that sample. 
Table 4.8 Potentiation of meropenem against S. maltophilia strains by TA-1, TA-5, and TA-6 as 
determined using agar spot plate technique. 












33 L1, L2 4 8 1 1* 2* 
34 L1, L2 >32 >32 32* >32* >32* 
39 L1, L2 256 256 128* 256 128 
45 L1, L2 128 128 64 32 16 
46 L1, L2 64 128 32 64 128 
48 L2 128 >128 64* >128 >128 
49 L2 >32 >32 >32 >32 >32 
*colonies at the highest meropenem concentration with growth 
Strains that produce only L2 (UWB48 and 49) were largely unaffected by the presence of the 
phenyl thioacids. The exception to this is when UWB48 was treated with 128 mg/L TA-1 and the 
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MIC of meropenem was reduced at least 4-fold. For most of the L1-producing strains, TA-1 was the 
most effective phenyl thioacid in potentiating meropenem yielding at least a 2-fold reduction in MBC. 
The most susceptible strain to potentiation was UWB 33 whose meropenem MBC was reduced 8-fold 
in the presence of TA-1 and TA-5, and 4-fold in the presence of TA-6. While the potentiation of 
meropenem by these compounds may be underwhelming in comparison to that of the PMPCs 
described in Chapter 3, this assay requires the phenyl thioacids to cross the outer membrane and find 
its target without getting diverted by other potential targets. The intended application of these 
thioacids would involve them being delivered to their targets as part of a 3ʹ-acylthiocephalosporin and 
released upon hydrolysis, reducing the likelihood of off target interactions and potentially increasing 
their potency. 
4.3.1.3 MICs of 3ʹ-acylthiocephalosprins against Stenotrophomonas maltophilia 
To assess the intended thioacid delivery system, the 3ʹ-acylthiocephalosprins, and the impact of 
substitutions on the thioacid leaving group in vivo, a selection of 3ʹ-acylthiocephalosporins with a 
simple phenylacetyl or 3-fluorophenylacectyl on the C7-amido nitrogen group and a variety of 
thioacid leaving groups at C3” were used in this study. While the most potent thioacids were the 3-
nitro (TA-5) and 3,5-dinitro (TA-6) substituted phenyl thioacids, cephalosporins with these groups on 
the right-hand side were not available at the time of testing. Two S. maltophilia strains that are known 
not to produce L1 but produce the other β-lactamase present in each of these strains, L2, was used as 
a control. Three commercial β-lactams were also tested, meropenem (Mero), ceftazidime (CAZ), and 
cefotaxime (CTX), to give a relative measure of the potency of the novel cephalosporins. The only β-
lactam for which there is a CLSI guideline for resistance is ceftazidime which is seldom used as a 









Table 4.9 MICs of 3ʹ-acylthiocephalosporins and control β-lactams against β-lactamase 
producing strains of S. maltophilia. 
  MIC (mg/L) 
UWB β-Lactamases Mero CAZ CTX TE-1 TE-2 TE-3 TE-4 TE-5 UW-123 
26 L1, L2 256 256 256 >128 >128 >128 >128 64 16 
29 NS 64 32 128 64 >128 128 64 8 4 
33 L1, L2 4 16 8 64 128 >128 128 4 32 
34 L1, L2 8 8 16 64 128 128 64 4 2 
39 L1, L2 128 128 256 128 >128 >128 128 16 16 
43 L1, L2 32 16 16 32 128 64 32 4 0.5 
44 L1, L2 <1 <1 <1 128 64 64 32 2 0.25 
45 L1, L2 64 64 128 32 >128 >128 128 16 4 
46 L1, L2 32 4 32 64 128 128 64 4 2 
48 L2 64 <1 16 128 >128 >128 >128 8 1 
49 L2 16 2 16 64 128 128 64 4 2 
NS – not sequenced, the presence of β-lactamases is unknown 
Bolded MIC values are susceptible to β-lactams according to CLSI guidelines.500 
Italicized MIC values are intermediate (neither resistant nor susceptible) to β-lactams according to CLSI 
guidelines.500 
The simple 3ʹ-acylthiocephalosporins, TA-1 – 4 are generally poor antibiotics for S. maltophilia 
strains with MICs no lower than 32 mg/L. Of these compounds, TE-1 and TE-4 are the most potent 
against this panel although studies with other bacterial strains and variable right-hand side groups 
have distinguished the 2,4-dichloro substitution pattern as the most potent as a standalone antibiotic. 
Through optimization of the group on the left-hand side, the potency of these compounds was 
improved from TE-4, though TE-5, to UW-123. TE- 5 is more potent than meropenem against 9 of 
the 11 S. maltophilia strains in Table 4.9 and UW-123 is generally 2 to 4-fold more potent than TE-5 
and is only less potent than meropenem against one strain, UWB33.  
In addition to being poor antibiotics against S. maltophilia strains, the early 3ʹ-
acythiocephalosporins, TE-1 through TE-4, were ineffective at potentiating meropenem beyond a 2-
fold MIC improvement as seen in Table 4.10. Although little potentiation of meropenem by these 
compounds is observed in terms of MIC reduction, the combination of the two antibiotics did 
significantly decrease the density of the cultures in the wells. This was particularly evident towards 
the higher ends of both the cephalosporin and meropenem concentration ranges. The discrepancies 
between the meropenem MICs reported in Table 4.9 and those in Table 4.10 are likely due to more 
bacteria being present in the inoculum when the latter was prepared. Ideally, there should be 500 000 
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CFU/mL in the inoculum and while the colony counts for the experiment described in Table 4.10 
(UWB26: 850 000 CFU/mL, UWB45: 320 000 CFU/mL, and UW49: 830 000 CFU/mL), they were 
not considered out of range, nor were those for the experiment in Table 4.9 (UWB26: 590 000 
CFU/mL, UWB45: 260 000 CFU/mL, and UWB49: 190 000 CFU/mL). For most organisms, minor 
differences like this in the colony counts do not significantly impact the MICs; however, the S. 
maltophilia strains in this lab have been found to be difficult in this respect in the past. 
Table 4.10 Potentiation of meropenem by 3ʹ-acylthiocephaloporins (Ceph) against β-lactamase 
producing strains of S. maltophilia. 
Strain β-lactamase Ceph 
Ceph MIC 
(mg/L) 















UWB 26 L1, L2 TE-1 >128 512 512 512 512 512 256 256 
TE-2 >128 512 512 512 512 512 256 256 
TE-3 >128 512 256 256 256 256 256 256 
TE-4 >128 512 512 512 512 512 256 256 
UWB 45 L1, L2 TE-1 >128 128 128 128 128 128 64 64 
TE-2 >128 128 128 128 128 128 128 128 
TE-3 >128 128 128 128 128 128 128 64 
TE-4 >128 128 128 128 128 128 128 64 
UWB 49 L2 TE-1 >128 >64 >64 >64 >64 >64 >64 64 
TE-2 >128 >64 >64 >64 >64 >64 >64 >64 
TE-3 >128 >64 >64 >64 >64 >64 >64 >64 
TE-4 >128 >64 >64 >64 >64 >64 >64 64 
Bolded values indicate potentiation relative to meropenem control. 
Optimization of the 3ʹ-acylthiocephalosporins involved over 70 novel cephalosporins in pursuit of 
an MBL resistant β-lactam antibiotic that could be co-administered with meropenem. These 
compounds were screened using a meropenem synergy assay with MBL producing Gram negative 
pathogens. From this significant synthetic and microbiological effort, one compound distinguished 
itself for its potency as a standalone antibiotic against not only S. maltophilia, but other MBL 
producers as well and its moderate synergistic activity with meropenem: UW-123. 
4.3.2 MICs of UW-123 
In order to assess UW-123’s potential as a standalone antibiotic, several MIC panels were 
performed in the presence and absence of an SBL inhibitor by both our lab and Merck. 
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4.3.2.1 UW panel of Bacterial Strains 
Table 4.11 MICs of UW-123 in the presence and absence of 4 mg/L BLI-489 against select 
bacteria from the UW collection. 
    MIC (mg/L) 
    UW-123 CAZ Mero 
Bacterial Strain UWB MBL SBL with BLI no BLI   
A. baumannii 94  OXA-23 8 >128 >128 32 
 95  OXA-23 8 >128 >128 32 
E. coli 59     0.25 0.125 0.125 0.125 
 57  CMY-2 0.125 2 32 <0.06 
 75 NDM-1 CTX-M-15 >128 >128 >128 128 
  91 NDM-1   >128 >128 >128 >128 
K. pneumoniae 60   4 4 0.5 <0.06 
 11  KPC-2 32 >128 >128 32 
 16  KPC-3 64 >128 >128 32 
 88  KPC-2, SHV-12 64 >128 >128 >128 
 87  CTX-M-15, OXA-48 16 32 128 2 
 86  OXA-48 2 4 8 16 
 56  CMY-2 8 8 32 0.06 
 82 VIM-1  32 32 >128 64 
 83 VIM-1  64 128 >128 128 
P. aeruginosa 62     8 8 2 1 
 25 IMP-7  >128 >128 >128 >128 
 31 IMP-5  2 4 32 64 
  78 VIM-2   4 4 32 64 
S. maltophilia 26 L1 L2 2 2 16 >128 
 
The antibiotic potency of UW-123 relative to ceftazidime (CAZ) and meropenem was first assessed 
with 20 strains from the UW bacterial collection. These 20 strains were selected for their expression 
of an assortment of β-lactamases, both MBL and SBL, as well as a few wild types for comparison. 
For the purposes of antibiotic development, an MIC of 32 mg/L or higher (red) is not useful while an 
MIC of 4 mg/L or less (green)  in combination with a β-lactamase inhibitor is considered 
susceptible.500,518 
Some of the bacterial strains tested for antibiotic susceptibility are completely resistant to all of the 
tested antibiotics regardless of whether or not an SBL inhibitor was co-administered such as UWB25, 
75, 91 while others such as UWB11, 16, 82, 83, and 88 showed a response to the presence of SBL 
inhibitor but did not fall below 32 mg/L. The wild types (UWB59, 60, 62) did not show reduction of 
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the UW-123 MIC in the presence of the SBL inhibitor, confirming that it is a true wild type and does 
not produce an SBL. Conversely, all of the strains that produce only SBLs (except UWB56) showed 
improved UW-123 MICs in the presence of the SBL inhibitor. This improvement can be as much as 
16-fold as it as for UWB57 whose MIC dropped from 2 mg/L to 0.125 mg/L with the addition of 4 
mg/L BLI-489. The strains that produced MBLs were much more sensitive to UW-123 than they 
were to either ceftazidime and meropenem with the most pronounced difference being against the 
IMP-5 and VIM-2 producing strains of P. aeruginosa (UWB31, 78). This effect could be a result of 
UW-123 being insensitive to MBLs or turning over very slowly in MBLs and thus losing less 
antibiotic to hydrolysis by MBL than other β-lactams. Unlike strains that produced IMP and VIM β-
lactamases, those that produced NDM-1 were not anymore susceptible to UW-123 than they were to 
ceftazidime or meropenem which may be a result of the MICs being out of range or NDM-1 being 
insensitive to UW-123. 
To determine whether or not UW-123 could also be potentiated by the clinical SBL inhibitor 
avibactam, three MBL producing strains (UWB75, 78, and 93) were assayed with both UW-123 and 
ceftazidime against various concentrations of avibactam. The strains were chosen because they are 
the most β-lactam resistant strains for each NDM, IMP, and VIM producers in the UW collection. 
The standard administration of avibactam in microbiological assays is 4 mg/L; however, higher 
concentrations can be assayed to explore the possibility of better synergy at higher concentrations.  
 
Table 4.12 MICs of UW-123 against select strains from UW collection and its potentiation by 
avibactam. 
     Cephalosporin MIC (mg/L) 







E. coli 75 NDM-1 CTX-M-15 UW-123 >128 128 64 
    CAZ >1024 >1024 >1024 
 93 IMP-1 CTX-M-15 UW-123 >128 64 64 
    CAZ 1024 512 256 
P. aeruginosa 78 VIM-2  UW-123 4 8 8 




Two of the MBL producers co-express CTX-M-15, a common SBL in clinical pathogens. The 
strains that produced the SBL showed improved sensitivity to UW-123 when co-administered with 4 
mg/L of avibactam and administration of 8 mg/L avibactam did not offer a significant advantage over 
4 mg/L as demonstrated in Table 4.12. The strain that only produced an MBL did not show 
significant change in the MIC in response to the administration of either concentration of avibactam. 
This is consistent with the previous result that BLI-489 does not potentiate UW-123 against VIM-2 
producing P. aeruginosa (UWB78). As was also seen in Table 4.11, UW-123 is consistently much 
more potent than ceftazidime against these MBL producers regardless of whether or not an SBL 
inhibitor was co-administered. 
4.3.2.2 Merck panel of Bacterial Strains 
UW-123 was found to be superior to both meropenem and ceftazidime against the MBL producing 
strains from the UW collection but required an SBL inhibitor to improve potency against strains that 
express SBLs. The UW collection does not have a lot of variation within each of the MBL families, 
so a sample of UW-123 was sent to Merck for testing against IMP, NDM, and VIM producing strains. 
The Merck testing was performed on 25 MBL producing strains each of the families mentioned above 
using ceftazidime and imipenem as comparators. The BLI used in these experiments was not 
disclosed but is known to be a DBO like avibactam but is not the DBO that they were pursuing for 
FDA approval.   
IMP producing strains 
Many of the IMP producing strains in the Merck panel were not sequenced at high enough resolution 
at the time of these assays to determine the specific variant with the exception of the five K. 
pneumoniae strains that produce IMP-26. The lack of specific typing to the IMPs also suggests that 
the screening may have missed any SBLs in many of these strains. Contrary to expectations, a few of 
the IMP producing strains in Table 4.13 demonstrate an antagonistic relationship between the BLI 







Table 4.13 MICs of UW-123 in the presence and absence of an undisclosed avibactam-like 
inhibitor against a Merck panel of IMP producers. 
        MIC (mg/L) 
    UW-123 CAZ Imi 
Bacterial strain Identifier MBL SBL with BLI* no BLI     
C. freundii CL 5724 IMP  32 2 128 2 
K. pneumoniae MB 9713 IMP   16 >32 >128 8 
 MB 9248 IMP-26 CTX-M-15 16 >32 >128 1 
 MB 9249 IMP-26 CTX-M-15 16 >32 >128 2 
 MB 9245 IMP-26  16 32 >128 2 
 MB 9247 IMP-26  32 32 >128 2 
 MB 9721 IMP-26  4 >32 >128 2 
P. aeruginosa CL 5673 IMP AmpC-ind 4 1 >128 128 
 CL 5730 IMP AmpC-ind 2 2 >128 32 
 CL 5679 IMP  8 8 >128 32 
 CL 5727 IMP  16 16 >128 4 
 CL 5728 IMP  16 16 >128 >128 
 CL 5729 IMP  16 16 >128 64 
 CL 5732 IMP  8 8 >128 8 
 CL 5733 IMP  >32 >32 >128 128 
 CL 5734 IMP  8 4 >128 8 
 CL 5737 IMP  >32 >32 >128 128 
 CL 5742 IMP  32 >32 128 32 
 MB 9708 IMP  2 4 64 16 
 CL 5745 IMP  16 8 >128 16 
P. putida MB 9707 IMP   >32 >32 >128 >128 
S. marcescens CL 5725 IMP  >32 >32 >128 >128 
 CL 5726 IMP  >32 >32 >128 >128 
 CL 5738 IMP  8 2 >128 4 
  CL 5741 IMP   16 16 >128 16 
 
Previous experiments with UW-123 in combination with an SBL inhibitor showed no more than a 
2-fold increase in MIC when compared to UW-123 alone which is considered within the allowed 
uncertainty of the experiment. The Merck strains, on the other hand, exhibit as much as a 16-fold 
increase in MIC when UW-123 is in combination with the BLI suggesting that there must be an 
unfavourable interaction between the two compounds against certain bacterial strains. Additional 
information was not provided as to whether or not this is a common observation with those strains. 
As was also seen in Table 4.11, UW-123 seems to be better than ceftazidime against every strain; 
however, when comparing to imipenem, the advantages of UW-123 shine through against P. 
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aeruginosa. Approximately two thirds of the P. aeruginosa strains were more susceptible to UW-123 
than imipenem, even without the addition of the BLI which did little to nothing for this subset. The 
IMP producing strains of K. pneumoniae tend to be more sensitive to imipenem than UW-123 as well 
as more responsive to the BLI than the P. aeruginosa strains. The addition of BLI brought the MICs 
of UW-123 nearer to those of imipenem for most K. pneumoniae strains. The tested strains of S. 
marcescens were similarly susceptible to UW-123 and imipenem which is in and of itself 
encouraging that a cephalosporin can be equally potent as a carbapenem. 
NDM producing strains 
The only NDM variant represented in the NDM panel from Merck is NDM-1 because it is by far the 
most clinically important variant (and was at the time of this panel the only one found in clinical 
isolates). Many of the NDM producing strains co-express at least one SBL, necessitating the use of 
the SBL inhibitor since UW-123 is known to be susceptible to SBLs. This increases the complexity of 
the problem since none of the clinically available classes of SBL inhibitors actually inhibit all SBLs. 
The most common SBLs in this panel, CTX-M-15 and CMY-2, have been previously found to be 
susceptible to avibactam, and should be similarly susceptible to other inhibitors of that class.361,519 
The data in Table 4.14 suggest that UW-123 is not as effective against NDM-1 producers as it was 
against IMP producers: imipenem is much more effective against most of the strains in this panel that 
UW-123 regardless of whether or not the BLI is present. This is consistent with the observation from 
Table 4.11 that UW-123 was completely ineffective against NDM-1 producers. Both NDM-1 
producing E. coli strains used in the UW panel gave out of range or top of range MICs for each of the 
tested antibiotics which prevented meaningful conclusions from being drawn; however, the 
overwhelming result from the Merck panel is that NDM-1 producing strains of E. coli are much more 








Table 4.14 MICs of UW-123 in the presence and absence of an undisclosed avibactam-like 
inhibitor against a Merck panel of NDM-1 producers. 
        MIC (mg/L) 
    UW-123 CAZ Imi 




BLI     
A. baumannii CLB 30003A NDM-1  >32 >32 >128 128 
E. coli CLB 30022 NDM-1 CMY-2 16 16 >128 2 
 
CLB 30048 NDM-1 CTX-M-15 32 >32 >128 >128 
 
CLB 30005 NDM-1 CTX-M-15, CMY-2 32 >32 >128 8 
 
CLB 30009 NDM-1 CTX-M-15, CMY-2 32 >32 >128 8 
 
CLB 30016 NDM-1 CTX-M-15, CMY-2 >32 >32 >128 8 
 
CLB 30026 NDM-1 CTX-M-15, CMY-2 >32 >32 >128 8 
 
CLB 30028 NDM-1 CTX-M-15, CMY-2 >32 >32 >128 16 
 
CLB 30042 NDM-1 CTX-M-15, CMY-2 32 >32 >128 8 
  CLB 30008 NDM-1   16 16 >128 8 
E. cloacae CLB 30004 NDM-1 CTX-M-15, ACT/MIR >32 >32 >128 4 
 
CLB 30018 NDM-1 CTX-M-15, ACT/MIR >32 >32 >128 4 
 
CLB 30030 NDM-1 
CTX-M-15, ACT/MIR, 
OXA-181 
2 >32 >128 16 
 
CLB 30031 NDM-1 
CTX-M-15, ACT/MIR, 
OXA-181 
2 >32 >128 16 
 
MB 9867 NDM-1 TEM-1, CTX-M-15 4 >32 >128 4 
K. pneumoniae CLB 30046 NDM-1 CMY-2 32 32 >128 16 
 
CLB 30039 NDM-1 CTX-M-15 >32 >32 >128 16 
 
CLB 30001 NDM-1 CTX-M-15, CMY-2 16 >32 >128 16 
 
CLB 30006 NDM-1 
CTX-M-15, CMY-2, 
DHA 
>32 >32 >128 64 
 
CLB 30012 NDM-1 CTX-M-15, DHA-1 32 >32 >128 8 
 
CLB 30019 NDM-1 CTX-M-15, DHA-1 32 >32 >128 8 
 
CLB 30010 NDM-1 DHA-1 16 16 >128 8 
 
CLB 30034 NDM-1 SHV-12, CTX-M-15 32 32 >128 8 
  CLB 30011 NDM-1 SHV-2A, DHA-1 32 >32 >128 2 
M. morganii CLB 30047 NDM-1 DHA-1 16 >32 >128 8 
 
The only subset that yielded promising results from the NDM Merck panel was the E. cloacae 
strains: three of the five strains showed a reduction in the MIC of UW-123 in the presence of BLI that 
made it similarly potent to imipenem. This suggests that it may not be NDM-1 that is causing the lack 
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of sensitivity to UW-123 but rather other features of pathogenic Enterobacteriaceae that are 
preventing it from reaching its target. This trend was also observed in the UW panel as well as the 
IMP panel in which clinical isolates of K. pneumoniae and E. coli are much less susceptible to UW-
123 than other strains, even in the presence of a BLI.  
VIM producing strains 
Table 4.15 MICs of UW-123 in the presence and absence of an undisclosed avibactam-like 
inhibitor against a Merck panel of VIM producers. 
        MIC (mg/L) 
    UW-123 CAZ Imi 
Bacterial strain Identifier MBL SBL with BLI* no BLI     
C. freundii MB 9163 VIM-1  4 16 >128 2 
 MB 9864 VIM-32 CMY-81 32 32 >128 8 
E. cloacae MB 9787 VIM-1 ACT/MIR 4 1 >128 4 
 MB 9158 VIM-1  8 8 >128 4 
 MB 9160 VIM-1  0.125 2 >128 4 
  MB 9178 VIM-5   >32 >32 >128 4 
K. pneumoniae MB 9773 VIM-1 KPC-2 4 16 >128 64 
 MB 9151 VIM-1  0.5 0.5 >128 64 
 MB 9152 VIM-1  1 2 >128 16 
 MB 9153 VIM-1  1 8 >128 32 
 MB 9155 VIM-1  16 8 >128 32 
 MB 9156 VIM-1  1 1 >128 64 
 MB 9159 VIM-1  0.5 0.5 >128 64 
 MB 9161 VIM-1  4 32 >128 32 
 MB 9166 VIM-1  2 4 >128 2 
 MB 9171 VIM-26  1 0.5 >128 32 
 MB 9172 VIM-26  0.25 1 >128 64 
 MB 9175 VIM-27  8 16 >128 64 
  MB 9177 VIM-5   4 >32 >128 16 
P. aeruginosa MB 9732 VIM  8 8 64 >128 
 MB 9758 VIM  >32 >32 >128 >128 
 MB 9344 VIM-2  16 16 16 16 
 MB 9345 VIM-2  4 4 16 128 
 MB 9346 VIM-2  32 >32 64 >128 




The Merck panel of VIM producers includes at least 6 VIM variants and 3 of the strains also 
express an SBL. Despite the lack of SBLs in these strains, 11 strains responded to the BLI and 
reduced the MIC of UW-123. The VIM panel was the most susceptible of the Merck panels to UW-
123 with 10 of the 25 strains having MICs of 4 mg/L or less without BLI and 16 of 25 with BLI as 
seen in Table 4.15. This is a distinct improvement over the 6 of 25 IMP producers with UW-123 
MICs of 4 mg/L or lower. Similar to other panels, ceftazidime was ineffective against almost all 
strains making any response to UW-123 a vast improvement over other cephalosporins.  
The K. pneumoniae strains from the IMP and NDM panels were less susceptible to UW-123 than 
imipenem both in the presence and absence of the BLI. In the VIM panel, only two of the 13 K. 
pneumoniae strains were less susceptible to UW-123 than imipenem in the absence of BLI while the 
addition of BLI brings the MIC of UW-123 to or lower than that of imipenem for all of them. 
Likewise, all of the P. aeruginosa strains in the VIM panel were more or equally susceptible to UW-
123 than both ceftazidime and imipenem regardless of whether or not it was assayed with the BLI. 
4.3.3 Bacterial Synergy of UW-123 with Meropenem 
Compounds in this series were developed to be co-administered with a carbapenem as a protective 
agent against MBLs. UW-123 was the best antibiotic from this series; however, early synergy 
screening assays with meropenem were often out of range.  




















K. pneumoniae  
UWB11 
KPC-3 >32 64 32 32 64 32 32 64 0.27 
K. pneumoniae 
UWB16 
KPC-2 >32 128 32 32 32 32 32 32 0.28 




>32 128 128 128 128 128 64 64 0.75 
P. aeruginosa 
UWB31 
VIM-2 8 64 32 32 16 - - - 0.13 
P. aeruginosa 
UWB78 
VIM-2 4 64 32 16 - - - - 0.35 
S. maltophilia 
UWB26 
L1, L2 2 128 128 64 32 - - - 0.25 
*Synergistic (FIC ≤ 0.5), Additive (0.5 < FIC ≤ 1), Indifferent (1 < FIC < 2), Antagonistic (FIC ≥ 2) 
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The synergy of UW-123 and meropenem was assayed against 6 β-lactamase producing strains 
using a microplate checkerboard synergy assay. UW-123 was able to potentiate meropenem against 
K. pneumoniae and P. aeruginosa strains at even the lowest concentrations (1 mg/L) as seen in Table 
4.16. For the chosen E. coli and S. maltophilia strains, higher concentrations of UW-123 were 
required to decrease the MIC of meropenem against those bacteria. This combination of antibiotics 
demonstrates synergy against the S. maltophilia strain but not the E. coli against which they are 
additive. It is possible that not all E. coli strains will be resistant to synergistic effects of these two 
antibiotics as UWB75 among the most resistant strains in our collection. 
4.3.4 Mode of Action Studies of UW-123 
To get a better understanding of how UW-123 works as an antibiotic, a series of experiments were 
performed to establish whether or not it is lethal to cells, what (if any) morphological changes occur 
in response to treatment, and the specific target(s) and potency against common pathogens.  
4.3.4.1 Time Kill Curves 
β-Lactam antibiotics are widely accepted to be bactericidal as treatment with therapeutic 
concentrations results in cell lysis. Studies have shown that this bactericidal activity is concentration 
dependent such that lower concentrations of β-lactam are bacteriostatic if only one critical PBP is 
inhibited while higher concentrations are bactericidal as a result of inhibition of multiple PBPs.520,521 
In this work, time-kill curves for UW-123 were first generated by OD600 to establish the expected 
behavior at specific timepoints then by CFU to determine viability. The time-kill curve produced by 
reading the culture density, depicted in Figure 4.7A shows a reproducible “bump” in the curve at 
around 3 hr corresponding to morphological change. This method of assaying growth in the presence 
of antibiotic is good as a starting point for comparing different classes of antibiotics (data no shown) 
but gives little insight into the viability of the cells in the culture 
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Figure 4.7 UW-123 time kill curves against wild type E. coli  (UWB 59) monitored by (A) OD600 
and (B) CFUs. The graphs in this figure were generated using GraphPad Prism v. 5.03. 
Plating UW-123 treated cultures at various timepoints on MH agar gives insight into cell viability 
after antibiotic treatment. Bactericidal activity is defined as a 3-log unit reduction in the number of 
viable cells relative to the starting timepoint of the untreated control. The experiment in Figure 4.7B 
started with 107 viable cells per mL of liquid culture. At 4 hours, the number of viable cells in 1 mL 
of culture had fallen to its minimal value of 105.5 when treated with either 1 or 2 mg/L UW-123 (1x 
and 2x MIC respectively), a 1.5 log unit reduction. This suggests that higher concentrations of UW-
123 would be required to induce a bactericidal effect and that at these concentrations, UW-123 
behaves as a bacteriostatic antibiotic. Later experiments performed with other β-lactam antibiotics 
showed that bactericidal activity occurs at 4x MIC and greater (data not shown). 
4.3.4.2 Morphology 
Inhibition of certain HMM PBPs results in characteristic morphological changes which can be 
observed by phase contrast microscopy. The OD600 measurement of the time-kill curves of many 
antibiotics suggested that most morphological changes occurred at 2-3 hr after treatment as indicated 
by a transient “bump” in the curves. This prompted the decision to stop the growth at 2 hr and 
determine the morphology of the cells by phase contrast microscopy. This form of microscopy was 
chosen over fluorescence or traditional light microscopy because it does not require staining or fixing 
of the bacteria and it has been used to determine bacterial morphologies in the literature.117,513,522 A 
DMSO control was performed to ensure that any morphological changes were the result of the 
antibiotic rather than the solvent. Additionally, aztreonam and meropenem were tested as controls for 




Table 4.17 Sucrose stabilized, β-lactam treated E. coli under 1000x magnification by phase 
contrast microscopy. 

















Cell density should not be considered in analysis of these microscopy images; samples were not 
prepared quantitatively. 
The treatment of cells with 1.25 % DMSO did not induce significant morphological changes – 
Table 4.17 illustrates that some cells may have elongated slightly which that may be within normal 
variation when compared to the untreated control. As expected, inhibition of PBP 3 in E. coli by 
aztreonam induced filamentation at concentrations above the MIC (0.0156 mg/L) but not below the 
MIC. Some elongation can be observed below the MIC but is minimal compared to the filamentation 
above the MIC. Inhibition of PBP 2 in E. coli by meropenem induced the expected spheroplasting of 
the cells. The addition of 0.3 M sucrose to the MH broth is supposed to stabilize osmotically unstable 
spheroplasts.522 When E. coli cells were treated with 0.0156 mg/L meropenem in the presence and 
absence of sucrose, the sucrose free media yielded many spheroplasted cells while the sucrose media 
yielded only cellular debris (data not shown).  
UW-123 induced filamentation at all assayed concentrations (128 mg/L – 0.0625 mg/L); however, 
normal morphology cells can be observed in samples treated with 0.25 mg/L or less UW-123 as seen 
in Table 4.17. Contrary to the effect of sucrose on meropenem treated cells, UW-123 treated cells 
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grown in the presence of sucrose were much more stable at concentrations in excess of the MIC such 
as 128 mg/L, maintaining the groups of filaments observed for 1 mg/L in Table 4.17 as opposed to 
the only one cell could be found in the culture treated with 128 mg/L UW-123 in the absence of 
sucrose (data not shown). The formation of filaments by treatment with UW-123 suggests that UW-
123 primarily inhibits subclass B3 PBPs, specifically PBP 3 in E. coli. 
4.3.4.3 Competition of UW-123 with Bocillin for PBP Binding 
To confirm the hypothesis that UW-123 acts as an inhibitor of subclass B3 PBPs, membrane 
fragments from two wild-type Gram negative organisms, E. coli and P. aeruginosa, were isolated. 
The wild-type E. coli strain used in this experiment is an ATCC control strain, unlike the one used 
above and was acquired after the previous experiments were performed. Membrane fragments from 
this particular E. coli strain were required for work not presented in this thesis and some of which was 
used to assay UW-123. In addition to E. coli, membrane fragments from P. aeruginosa were isolated 
due to the marked increase in potency of UW-123 over ceftazidime and meropenem against P. 
aeruginosa strains from our lab.  
P. aeruginosa PBPs 
Variable concentrations of the isolated membrane fragments from P. aeruginosa were assayed 
using the SDS-PAGE Bocillin assay described in 4.2.4.3.2 to determine the optimal concentration of 
fragment to use in the assay (data not shown). Multiple SDS-PAGE gels of varying acrylamide 
contents (10%, 12.5%, and 15%) were also tested to ensure optimal separation. The optimal 
conditions for this assay were determined to be 1.4 mg/mL protein per well, run on a 10% SDS-
PAGE gel. Using these conditions, the membrane fragments were first incubated with UW-123, 
allowing adequate time for the covalent bonds to form, then Bocillin was added and incubated for the 
same amount of time allowing selective labelling of uninhibited PBPs. Identification of PBPs used 




Figure 4.8 SDS-PAGE of UW-123 bound to P. aeruginosa PBPs competing with Bocillin. Gel A 
is the Bocillin fluorescent read, Gel B is the Coomassie stained read. The lanes correspond to 
the following concentrations of UW-123: 2) 0 mg/L; 3) 128 mg/L; 4) 64 mg/L; 5) 32 mg/L; 6) 16 
mg/L; 7) 8 mg/L; 8) 4 mg/L; 9) 2 mg/L – streak in the lane thus discluded; 10) 1 mg/L; 11) 0.5 
mg/L; 12) 0.25 mg/L; 13) 0.125 mg/L; 14) 0.0625 mg/L; 15) 0.0313 mg/L; 16) 0.0156 mg/L; 17) 
0.0078 mg/L; 18) 0.0039 mg/L; 19) 0 mg/L. Lanes 1 and 20 contained low molecular weight 
marker. 
The visualization of the fluorescence is dependent upon the covalent binding of Bocillin to the 
various PBPs, and a decrease in intensity of any band relative to the control is indicative of UW-123 
competing for the active site of that PBP. As can be seen in Figure 4.8A, UW-123 binds to P. 
aeruginosa PBP 1a and PBP 3 at low concentrations and PBP 1b and PBP 4 at slightly higher 



































































































































































Figure 4.9 Dose response curves of the relative competitive binding of UW-123 to PBPs from P. 




The weak intensity of PBP2 in the gels resulted in a high degree of uncertainty in the measurement 
of the band densities resulting in scatter and poor curve fitting (Figure 4.9). Looking at the gel in 
Figure 4.8A, it is evident that PBP2 was not inhibited by UW-123 since the corresponding band 
appears to be only slightly weaker in intensity when treated with 128 mg/L UW-123 (well 2) than 
when treated with no UW-123 (well 1). The curve fitting of PBPs 1a, 1b, 3, and 4 was good, although 
PBP 1a and PBP 3 required constraints for the upper plateau since it was not well defined. The fitting 
of the dose response curves from Figure 4.9 yielded the IC50s presented in Table 4.18.  
Table 4.18 IC50s of the competitive binding of UW-123 to PBPs from P. aeruginosa with 
Bocillin. 
PBP IC50 (mg/L) 
1a 0.13 ± 0.05 
1b 0.6 ± 0.1 
2 NI 
3 0.027 ± 0.005 
4 0.8 ± 0.3 
5/6 NI 
NI – Not significantly inhibited 
As expected, the most potently inhibited PBP was the subclass B3 PBP 3 with an IC50 of 0.027 
mg/L. The other PBPs were an order of magnitude less potently inhibited than PBP 3 with IC50s 
ranging from 0.13 mg/L to 0.8 mg/L indicating that the antibiotic potency is primarily due to PBP 3 
inhibition in P. aeruginosa. 
E. coli PBPs 
In the same manner as for the P. aeruginosa PBP assay, the optimal conditions for the E. coli PBP 
assay were determined to be 0.32 mg/mL protein per well, run on a 10% SDS-PAGE gel. Unlike the 
P. aeruginosa PBPs, PBP 1a and 1b could not be resolved for E. coli. Close inspection of the gels in 
Figure 4.10A shows two bands at this position; however, they did not migrate uniformly and cannot 
be isolated from one another for band density analysis. Additionally, the signal for PBP 5/6 is so 
intense that it may impact the readings for PBP 4 since these two bands are not well resolved. It 
should be noted that the visualization in Figure 4.10A has been optimized for PBP 2 and PBP 3 - the 





Figure 4.10 SDS-PAGE of UW-123 bound to E. coli PBPs competing with Bocillin. Gel A is the 
Bocillin fluorescent read, Gel B is the Coomassie stained read. The lanes correspond to the 
following concentrations of UW-123: 2) 0 mg/L; 3) 128 mg/L; 4) 64 mg/L; 5) 32 mg/L; 6) 16 
mg/L; 7) 8 mg/L; 8) 4 mg/L; 9) 2 mg/L; 10) 1 mg/L; 11) 0.5 mg/L – water entered sample during 
boiling; 12) 0.25 mg/L; 13) 0.125 mg/L; 14) 0.0625 mg/L; 15) 0.0313 mg/L; 16) 0.0156 mg/L; 17) 
0.0078 mg/L; 18) 0.0039 mg/L; 19) 0 mg/L. Lanes 1 and 20 contained low molecular weight 
marker. 
As above, the visualization of the fluorescence is indicative of covalently bound Bocillin in the 
active sites of the various PBPs, and a decrease in intensity of any band relative to the control is 
indicative of UW-123 competing for the active site of that PBP. As can be seen in Figure 4.10A, UW-
123 binds to E. coli PBP 3 at low concentrations and PBP 1a/b and PBP 2 at higher concentrations. 
































































































































Figure 4.11 Dose response curves of the relative competitive binding of UW-123 to PBPs from 
E. coli with Bocillin.  The graphs in this figure were generated using GraphPad Prism v. 5.03. 
The affinity of UW-123 for the active sites of PBP 1a/b and PBP 2 appear to be similar with both 
curves having midpoints between 0.1 and 1 mg/L. PBP 3 was much more susceptible to inhibition by 
UW-123 with only the lowest assayed concentration (0.0039 mg/L) representing the upper plateau. 
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As was expected, there is a lot of scatter in the PBP 4 data; however, visual inspection of the gel 
confirms that the band intensity is consistent throughout most of the wells, only decreasing at the 
highest UW-123 concentrations. Likewise, little inhibition of PBP 5/6 was observed, although the 
intensity of these bands steadily decreased with increasing UW-123.  
The dose-response plots in Figure 4.11 were fitted using nonlinear regression to determine the IC50s 
presented in Table 4.19. The curves for PBP 4 and PBP 5/6 did not go low enough (PBP 4 and PBP 
5/6 were not inhibited enough) to determine an IC50 with certainty. 
Table 4.19 IC50s of the competitive binding of UW-123 to PBPs from E. coli with Bocillin. 
PBP IC50 (mg/L) 
1a/b 0.45 ± 0.08 
2 1.0 ± 0.2 
3 0.02 ± 0.01† 
4 NI 
5/6 NI 
NI – Not significantly inhibited 
†Top of curve not well defined, constrained to 110 (comparable to top of curve for 1a/b and 2) 
As the morphological data suggested, PBP 3 is the most potently inhibited E. coli PBP and it level 
of inhibition is comparable to that of PBP 3 from P. aeruginosa – both 0.02-0.03 mg/L. Likewise, the 
inhibition of PBP 1 a/b from E. coli is close to the average inhibition of the Class A PBPs from P. 
aeruginosa (0.45 mg/L and 0.37 mg/L respectively). Unlike P. aeruginosa, significant inhibition of 
PBP 2 from E. coli was observed, although it is weaker than the inhibition of PBP 3 and the Class A 
PBPs.  
4.3.5 Pyridine thioacids – a more potent alternative to phenyl thioacids 
Phenyl thioacids are at best moderate inhibitors of MBLs, by increasing the potency of the released 
thioacid inhibitor the efficacy of these cephalosporins could be further improved against MBL 
producing strains. From Chapter 3, we know that pyridine rings with negatively charged groups at the 
2 and 6 positions are potent inhibitors of all subclasses of MBLs. Additionally, Roll et al. have 
demonstrated that pyridine thiocarboxylates (also referred to as pyridine thioacids) are potent 
inhibitors of B3 MBLs; however, their analysis did not include other MBL subclasses.439 This section 
explores the potential inhibitory activity of two pyridine thiocarboxylates, PMTC and PDTC, and the 
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benzene derivative of PDTC, I-PDTC (structures depicted in Figure 4.4) against a variety of β-
lactamases.  
4.3.5.1 Inhibitor Screening 
Like the phenyl thioacids, the pyridine thiocarboxylates required the addition of NaOH to the 
stocks to ensure complete dissolution - this was most pronounced for I-PDTC. These compounds 
were first screened for SBL inhibition to establish whether or not they are universal β-lactamase 
inhibitors. As expected, CTX-M-15, KPC-2, and OXA-48 are not inhibited by any of the tested 
compounds as seen in Table 4.20. Some mild inhibition of CTX-M-15 was observed with I-PDTC at 
100 μM, but this is not enough inhibition to warrant further study. 
Table 4.20 Pyridine thioacid inhibitor screening against SBLs. 
  % Inhibition 
Inhibitor Concentration CTX-M-15 KPC-2 GC-1 OXA-48 
PMTC 100 μM -0.3 -2.1 54.3 -0.4 
10 μM 1.2 -2.9 44.1 -0.9 
1 μM -0.5 -1.2 5.6 0.3 
PDTC 100 μM 3.8 3.0 69.5 1.2 
10 μM -3.1 -3.0 37.6 -1.1 
1 μM -2.1 -2.8 1.4 1.1 
I-PDTC 100 μM 37.1 -5.1 85.4 6.4 
10 μM 2.2 -3.4 50.2 -1.5 
1 μM -1.1 -0.5 6.3 -2.4 
Bolded values are >50 % inhibited. 
As was also observed for the phenyl thioacids in Table 4.6, GC-1 is the only SBL that is 
significantly susceptible to inhibition by this subset of thioacids. The data in Table 4.20 shows that I-
PDTC is the most potent inhibitor of GC-1 from this series, suggesting that the pyridine core is not 
necessary or beneficial for GC-1 inhibition. GC-1 is also indifferent to the number of thiocaboxylate 
groups on the molecule as evidenced by the negligible difference between the inhibitory potency of 
PMTC and PDTC.  
Although the pyridine core was not advantageous for GC-1 inhibition, it yielded very potent MBL 
inhibition as demonstrated in Table 4.21. The most potent inhibitor in this series appears to be PMTC 
which completely inhibits IMP-1, NDM-1, and VIM-2 at all assayed concentrations and demonstrated 
>50% inhibition at all concentrations for SFH-1 and L1. PDTA is slightly less effective, inhibiting 
 
 175 
most MBLs by about 73 % at 1 μM as opposed to the >95% seen with most B1 MBLs at 1 μM 
PMTC. SPM-1 is less potently inhibited that other B1 MBLs, demonstrating complete inhibition at 10 
μM PMTC and only 42% inhibition at 1 μM while the other B1 MBLs are still completely inhibited 
at 1 μM.  
Table 4.21 Pyridine thiocarboxylate inhibitor screening against MBLs 
  % Inhibition 
Inhibitor Concentration IMP-1 NDM-1 SPM-1 VIM-2 SFH-1 L1 
PMTC 
100 μM 99.8 99.2 99.5 99.9 96.7 99.7 
10 μM 99.9 100.0 99.5 99.9 96.1 99.9 
1 μM 97.3 96.8 42.5 99.6 62.4 84.2 
PDTC 
100 μM 98.6 94.1 101.9 99.9 93.6 100.2 
10 μM 100.0 99.7 90.2 99.8 96.9 99.0 
1 μM 71.5 73.1 45.9 74.5 73.6 78.2 
I-PDTC 
100 μM 61.8 27.2 54.8 31.8 41.2 61.3 
10 μM 12.7 5.3 0.3 -0.6 13.1 35.1 
1 μM 6.5 7.3 -7.3 -0.6 -4.4 22.7 
 Bolded values are >50 % inhibited. 
The inhibitor with a benzene core, I-PDTC, only inhibits MBLs at the highest assayed concentrations. 
The drastic drop in inhibitory potency from PDTC to I-PDTC suggests that the pyridine core is 
essential of potent inhibition.  
4.3.5.2 IC50 Determination 
A wider range of PMTC and PDTC concentrations were assayed with GC-1, the B1 MBLs, and L1 
to give a more accurate measure of inhibition. These assays were performed with three technical 
replicates but was only performed once to allow enough material for bacterial studies. The dose 












































































Figure 4.12 Dose response curves of MBLs and GC-1 inhibited by PMTC and PDTC (red and 
blue respectively). The graphs in this figure were generated using GraphPad Prism v. 5.03. 
It is evident from the dose response curves in Figure 4.12 that PMTC and PDTC are very similarly 
potent inhibitors against all assayed enzymes as the curves are overlapping throughout the vertical 
portion of the curve. This steepness of this region is well conserved for each enzyme; however, there 
is a distinct difference between enzymes. The curves for IMP-1 and VIM-2 are much steeper (Hill 
slope >4) than SPM-1 and L1 (Hill slope ~1.3) with NDM-1 and GC-1 having intermediate slopes 
which may be indicative of differing inhibition mechanisms for the different enzymes.499 
Fitting of these dose response curves to Equation 3.1 yielded the IC50 values listed in Table 4.22. 
These data confirm that PMTC and PDTC have similar potency with IC50 values differing by no more 
than 25% (SPM-1). It is probable that with more repeats of this experiment, the IC50 values for PMTC 
and PDTC will fall within the uncertainty of one another. Despite the differences observed in the 
steepness of the dose response curves, the pyridine thiocarboxylates exhibit consistent potency across 
the MBLs with IC50 values ranging from 0.41 μM to 0.79 μM for the assayed MBLs with the 
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exception of SPM-1 which was slightly less susceptible to inhibition. A dose response curve was also 
generated for SFH-1; however, the assayed concentrations were not low enough to obtain the upper 
plateau region. The estimates for the IC50 of these compounds against SFH-1 are consistent with those 
of the majority of the MBLs (0.70 μM and 0.47 μM for PMTC and PDTC respectively). 
Table 4.22 IC50s of pyridine thiocarboxylates against class B and C β-lactamases. 
  IC50 (μM) 
β-lactamase Class PMTC PDTC 
GC-1 C 4.61 ± 0.08 4.2 ± 0.1 
IMP-1 B1 0.79 ± 0.02 0.63 ± 0.02 
NDM-1 B1 0.45 ± 0.02 0.50 ± 0.02 
SPM-1 B1 1.33 ± 0.06 1.01 ± 0.06 
VIM-2 B1 0.60 ± 0.01 0.48 ± 0.02 
L1 B3 0.41 ± 0.02 0.48 ± 0.02 
 
In addition to being potent MBL inhibitors, PMTC and PDTC are inhibitors of GC-1, albeit a 10-
fold less potent than against MBLs. Despite the reduced potency against GC-1 relative to the MBLs, 
PMTC and PDTC are similarly potent against GC-1 with IC50s of 4.61 μM and 4.2 μM respectively. 
This inhibition broadens the spectrum of targets from solely MBLs to MBLs and some SBLs. To 
further explore the potential of the pyridine thiocarboxylates as β-lactamase inhibitors, they were 
assayed as an adjuvant to potentiate meropenem against β-lactam resistant pathogens. 
4.3.5.3 Potentiation of meropenem by pyridine thiocarboxylates 
The potentiation of meropenem was assayed using a microplate checkerboard assay with two-fold 
dilutions of meropenem along the long axis of the plate and two-fold dilutions of the inhibitor along 
the short axis. The addition of sodium hydroxide to stock solutions of pyridine thiocarboxylates was 
required for complete dissolution prior to dilution in MH broth. A small amount of precipitate was 
observed in the wells corresponding to the highest concentration of the inhibitors after overnight 
growth. Spotting on agar plates was not used to differentiate between growth and precipitate in these 
assays because comparison to other wells containing the same concentration of inhibitor allowed for 
visual differentiation. 
Each of the strains in Table 4.23 demonstrate potentiation of meropenem by the pyridine 
thiocarboxylates at the highest assayed concentrations as evidenced by a 4-fold or greater reduction in 
 
 178 
the MIC. The most susceptible strain was the IMP-1 and CTX-M-15 producing E. coli, UWB 93, 
which was reduced to intermediate inhibition by only 4 mg/L PDTC and 8 mg/L PMTC. This strain 
was made completely susceptible to meropenem (MIC of 1 mg/L or less) in the presence of 16 mg/L 
PDTC and 64 mg/L PMTC. Most other strains were only brought into intermediate or susceptible 
range but the highest concentrations of adjuvant. This is a significant accomplishment for UWB 75 
and UWB 24 which have meropenem MICs of 128 mg/L and require a 32 to 64-fold reduction of 
their MIC to enter the intermediate range.  




MIC (mg/L) Inhibitor 


















4 PMTC 4 2 2 2 0.5 0.25 
PDTC 2 2 1 0.25 0.25 0.125 




128 PMTC 128 64 64 64 8 4 
PDTC 64 64 64 16 4 2 
K. pneumoniae 
UWB116 
NDM-1 32 PMTC 16 16 8 8 2 0.25 
PDTC 16 16 8 8 2 0.25 
I-PDTC 32 16 16 16 16 8 
P. putida UWB24 VIM-2 128 PMTC 128 128 128 128 64 4 
PDTC 128 128 128 64 4 2 
P. aeruginosa 
UWB78 
VIM-2 128 PMTC 128 128 128 128 32 32 
PDTC 128 128 128 64 32 32 
Bolded MIC values are susceptible to β-lactams according to CLSI guidelines.500 
Italicized MIC values are intermediate (neither resistant nor susceptible) to β-lactams according to CLSI 
guidelines.500 
The most effective compound at potentiating meropenem is PDTC which elicits the same MIC 
reductions with at least 2-fold less compound for most bacterial strains. The only strain where the two 
pyridine thiocarboxylates are equivalent was UWB 116, this was also the only strain for which I-
PDTC was assayed. The benzene core of I-PDTC abolishes much of the potency of PDTC, such that 
PDTC elicits a 32-fold greater reduction in MIC than I-PDTC at 128 mg/L. Additionally, I-PDTC 





4.4.1 Phenyl Thioacid Inhibitors of B3 MBLs 
The phenyl thioacids proved to be moderate inhibitors of L1 but inhibited few other β-lactamases. 
This inhibition was improved substantially when the most concentrated DMSO stock of the inhibitor 
was prepared in the presence of one molar equivalent of NaOH. Upon addition of the NaOH, it is 
assumed that the thiocarboxylate group is deprotonated.  Although the initial DMSO solution did not 
seem to contain precipitate, it is possible that the aromatic thioacids are in an aggregated state and 
that deprotonation breaks up the aggregate resulting in a higher effective concentration of the 
conjugate base of the thioacid to act as an inhibitor.   
The phenyl thioacids with halogen substituents on the aromatic ring TA-1, TA-3, and TA-4 
demonstrated decreased potency at high concentrations when prepared in the absence of NaOH. 
Preliminary dose response curves of these compounds under the same conditions gave unusual “U-
shaped” curves (data not shown). Most of the literature regarding U-shaped dose response curves 
involves hormesis, the overcompensation of cells or organisms in response to deviation from 
homeostasis, which does not apply to in vitro enzyme assays.523 In this case, it is likely that the U-
shaped dose response curves are indicative of the halogenated phenyl thioacids forming aggregates or 
colloids at high concentrations resulting in  reduced availability of the free inhibitor for binding to the 
enzyme active site.524  
The most potent set of phenyl thioacid inhibitors of L1 were those with one or more nitro group on 
the phenyl ring, TA-5 (at C3) and TA-6 (at C3 and C5), while the second most potent set of inhibitors 
has a halogen at C4, TA-1 (Br at C4) and TA-3 (Cl at C2 and C4). TA-4 which has an additional 
chlorine at C6 is a poor inhibitor.  It is not clear if this effect is steric or electronic. TA-2 which has a 
methoxy group (inductively electron withdrawing but pi-electon donating) at C3 is a poor inhibitor of 
L1. This suggests that it is beneficial to have π-electron with drawing groups (e.g. NO2) meta to the 
thioester rather than a π-electron donating groups (e.g. OMe).  
Upon testing with a broader panel of MBLs, TA-6 which has nitro groups at C3 and C5 had the 
greatest breadth of inhibitory activity as it inhibited IMP-1 and VIM-2 by more than 50% at 100 μM 
and showed limited activity with SPM-1. Other trends seen with L1 do not hold up: TA-2 and TA-7 
are more potent against the B1 MBLs than both TA-1 and TA-3, suggesting that the hydrophobic 
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substituent is preferred over the halogens in these MBLs. This may be the result of the C3 substituent 
weakly interacting with the loop that closes over the B1 active sites. NDM-1 does not behave the 
same way as other B1 MBLs with these inhibitors, it is only significantly inhibited by TA-7 which 
may be a result having a much more flexible loop than IMP-1 or VIM-2.  
Unlike the PMPCs, the phenyl thioacids are capable of inhibiting at least one of the SBLs, GC-1, 
although the Class A and Class D SBLs were not affected. The mode of inhibition of GC-1 by 
aromatic thioacids is unclear. 
In bacterial studies, the phenyl thioacids were able to potentiate meropenem against L1 producing 
strains of S. maltophilia. Most strains were more potentiated by TA-1 than either of the phenyl 
thioacids with nitro substituents. This is contrary to the observation that the nitro substituents 
improved the inhibitory potency of the phenyl thioacids in enzyme kinetic assays and suggests that 
TA-1 may cross the outer membrane better than TA-5 or -6 or it may have fewer off-target 
interactions. Since meropenem is a bactericidal antibiotic, the MBCs were reflective of the MICs with 
no more than a 2-fold difference between the MIC and MBC of meropenem. This suggests that since 
the thioacids are not antibiotics themselves and should not disrupt the ability of meropenem to kill 
bacteria, the MBC reduction would also be reflected in the MICs if they were readable. The only 
point in the MBC experiment where it becomes uncertain whether or not they are reflective of MICs 
is when the growth spots are only colonies. Due to the low count of viable bacteria in these spots, it is 
likely that these wells would not have reached the growth cutoff. This is most pronounced against 




Figure 4.13 Spot plates of UWB 33 on MH agar to determine the MBCs of thioacid potenticated  
meropenem when treated with no adjuvant (A), 128 mg/L TA-1 (B), 128 mg/L TA-5 (C), and 
128 mg/L TA-6. 
The inhibition of L1 by the phenyl thioacids may be the result of the thiocarboxylate sulfur atom 
replacing the catalytically essential hydroxide ion that is normally shared as a ligand by the the two 
Zn2+ ions in the active site. This behavior, depicted in Figure 4.14, has been previously demonstrated 
for the sulfur atom of  numerous thiols including D-captopril, N-(3-mercaptopropanoyl)-D-alanine, 







Figure 4.14 Binding of thiols to the L1 active site : D-captopril (PDB: 2FU8), N-
mercaptopropanoyl)-D-alanine (PDB: 2QDT), bisthiazolidine (PDB: 5EVB). This figure was 
generated from the aforementioned protein databank files using Chimera v. 1.12. 
4.4.2 3ʹ-Acylthiocephalosporins as delivery systems for phenyl thioacid inhibitors of 
L1 
Precipitation of an adjuvant is not ideal for assays since the true accessible concentration of the 
compound is unknown. The challenges of determining the potentiation of meropenem by the phenyl 
thioacids would be a problem for potential drug development; however, the intended application of 
these compounds is through a 3ʹ-acylthiocephalosporin. Unlike the phenyl thioacids, the synthetic 
cephalosporins were completely soluble, and use of a cephalosporin as a delivery system ensures that 
the thioacid is release at its target. The release of the thioacid at its target circumvents any solubility 
problems, reduces the potential for off-target reactions, and the thioacid should be in the active, 
deprotonated form. Simple 3ʹ-acylthiocephalosporins with leaving groups at C3ʹ similar to the 
thioacids discussed above were less effective at potentiating meropenem against S. maltophilia strains 
than the thioacid alone. This suggests that these cephalosporins may be having difficulty crossing the 
outer membrane or that they are poor substrates that are not being turned over enough to release an 
adequate amount of inhibitor.  
S. maltophilia is known to be a highly antibiotic resistant pathogen with low outer membrane 
permeability, efficient efflux mechanisms, and chromosomally encoded β-lactamases (L1 and L2).525–
527 This resistance is particularly prevalent for β-lactams due to the chromosomally encoded β-
lactamases such that only 26.5% of S. maltophilia isolates from a Greek hospital were susceptible to 
either ceftazidime and treatment with β-lactams is only recommended when the patient exhibits 
adverse effect to other antibiotics such as trimethoprim/sulfamethoxazole.515,517 This is what makes 
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the antimicrobial potency of TE-5 and UW-123 against β-lactamase producing strains of S. 
maltophilia interesting: S. maltophilia strains that co-produce L1 and L2 have been widely reported to 
be immune to β-lactam monotherapy (with sporadic reports of limited ceftazidime efficacy).279,526–534 
4.4.3 UW-123 
The most potent standalone antibiotic to come from the extensive medicinal chemistry effort of 
developing the 3ʹ-acylthiocephalospoins was UW-123. The increased potency of this compound 
relative to the other 3ʹ-acylthiocephalosporins is most likely a result of more efficient uptake into the 
bacteria due to the siderophore mimic in the amido sidechain on the C7 nitrogen. In assays where 
UW-123 was not co-administered with any other antibiotic or adjuvant, it was shown to be less 
effective against strains that express extended spectrum SBLs. This is, in part, due to these enzymes 
being excellent at hydrolyzing cephalosporins, but more importantly, it is due to the phenyl thioacids 
not being inhibitory towards Class A and Class D SBLs. The vast majority of bacterial strains in the 
Dmitrienko lab inventory that produce SBLs produce either Class A or Class D ESBLs, so efficacy of 
UW-123 against strains producing Class C SBLs, particularly Class C ESBLs, was not established.  
4.4.3.1 Efficacy of UW-123 against bacterial pathogens 
In the UW panel, UW-123 was more potent than either ceftazidime or meropenem against strains 
that produce only MBLs due to the inhibition of the MBL by the released thioacid inhibitor. The only 
case where this was not true was against strains that produce NDM-1. These strains, UWB 75 and 91, 
are highly resistant to all β-lactam antibiotics and require potent inhibition of NDM-1 for sensitization 
as demonstrated by the PMPCs in Table 3.8. Since the phenyl thioacids were not inhibitory towards 
B1 MBLs in vitro, least of all NDM-1, it is probable that they are also not inhibitory in vivo, leading 
to the insensitivity of these strains to UW-123.  
The insensitivity of NDM-1 producers was also observed in the Merck panel of NDM-1 producers 
in Table 4.14 in which UW-123 was less potent than either ceftazidime or imipenem against all 
strains in the absence of BLI. While many of the NDM-1 producing strains demonstrated a reduction 
in UW-123 MIC in the presence of BLI consistent with the widespread SBL co-expression, only 3 of 
the strains were sensitized enough to be considered susceptible. Unlike NDM-1 producers which were 
not susceptible (MIC ≤ 4 mg/L) to UW-123 alone, both the IMP and VIM producing strains from the 
Merck panels had 6 and 9 strains that were susceptible to UW-123 without the aid of a BLI.  
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The VIM panel was the most susceptible of the Merck panels to UW-123 and was also the most 
responsive to the addition of the BLI, increasing the number of susceptible strains from 9 to 15 of 25 
upon its addition (Table 4.15). This demonstrates that the VIM-producing strains in the UW panel in 
Table 4.12 are not necessarily representative of all VIM-producers as the K. pneumoniae VIM-1 
strains (UWB 82 and 83) were highly resistant to UW-123 while the VIM-2 producing P. aeruginosa 
(UWB 78) was only moderately susceptible. Although the Merck panel of VIM-producers contained 
at least 6 VIM variants, these were heavily weighted towards VIM-1-like variants with only 4-6 of the 
25 strains being from the VIM-2 branch of the family. Unfortunately, all of the potential strains that 
produce a VIM-2-like variant were P. aeruginosa strains with no VIM-1-like variants being 
represented in this organism so although the VIM-2 strains were less susceptible to UW-123, it is not 
certain whether that is a characteristic of P. aeruginosa or the VIM-2-like variants. 
Across both the NDM and VIM panels from Merck, the BLI performed as expected, reducing the 
MIC of UW-123 against a few of the strains. In the VIM panel, there was an occasional discrepancy 
in which UW-123 became less effective in the presence of the BLI, although this only happened in 3 
of the 25 strains and only one of those was actually a significant (increase of ≥ 4-fold in MIC). The 
IMP-1 panel had more of these anomalies with 5 of the 25 strains demonstrating this behavior and 
three of those being a significant decrease in efficacy. It is possible that this BLI has off-target 
interactions in some strains (such as inducing the expression of an SBL or efflux pump) that increase 
the resistance of the cell to UW-123 or β-lactams in general. 
In assays with a small set of β-lactamase-producing bacteria from the Dmitrienko lab collection, 
UW-123 was found to behave synergistically with meropenem against most strains (Table 4.16). The 
only strain against which they did not show synergy was UWB75, and E. coli that produces both 
NDM-1 and CTX-M-15. This is consistent with the results from the Merck panel of NDM-1-
producers, suggesting that UW-123 is highly susceptible to NDM-1 and does not reach its target in 
the cell in high concentrations. 
4.4.3.2 Mode of action of UW-123 
At the assayed concentrations, UW-123 is a bacteriostatic antibiotic at concentrations as high as 2x 
MIC that induces filamentation in E. coli cells. Other literature cephalosporins such as CXA-101 and 
ceftazidime have also been found to be bacteriostatic at 2x MIC, approaching but not attaining a 3-log 
unit reduction at 8 hr.116 In those studies, a bactericidal load of antibiotic was achieved at 8 hour 
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incubation with 4x MIC and only slightly surpassed the 3-log unit cutoff. This, in addition to the 
observation that when the killing curve is collected using OD measurements, the 4x MIC sample has 
much less growth at 24 hr than the 2x MIC sample (Figure 4.7) suggests that going to higher 
concentrations in the agar plate count experiments would likely yield a set of conditions under which 
UW-123 is bactericidal.  
The morphological changes associated with inhibition of PBP 2 and PBP 3 in E. coli were 
confirmed using meropenem and aztreonam respectively. These experiments were carried out in the 
presence of 0.3M sucrose to increase the likelihood of observing delicate morphologies through 
osmotic stabilization. Consistent with the literature, inhibition of PBP 2 by meropenem created 
spheroplasts and inhibition of PBP 3 by aztreonam induced filamentation (Table 4.17).535 
Cephalosporins, such as ceftazidime, have also be known to induce filamentation through PBP 3 
inhibition.535 The filamentation of E. coli cells in the presence of UW-123 is indicative of a β-lactam 
antibiotic that inhibits subclass B3 PBPs such as PBP 3 in E. coli.  
 Studies to quantify the binding of UW-123 to the PBPs of E. coli and P. aeruginosa confirmed that 
UW-123 inhibits the B3 PBP, PBP3, most potently in each organism. 
4.5 Future Work 
The success of UW-123 as a more potent cephalosporin against MBL producing Gram negative 
pathogens suggests that this is an area of study that warrants further pursuit. 
The data presented in section 4.3.1.1 suggest that the phenyl thioacids are moderate inhibitors of L1 
and have some inhibitory activity against IMP-1 and VIM-2. The kinetic studies in this section 
operated under the assumption that NaOH only deprotonates the thioacid and does not cause any side 
reactions in DMSO. A thorough literature search has not yielded any studies that have been carried 
out under these conditions. To confirm whether or not the addition of NaOH is just deprotonating or 
changing the structure of the phenyl thioacids, structural studies (such as 1HNMR or MS) would need 
to be performed on the reaction mixture over time as a decrease in colour intensity is observed.  
The proposed mechanism for the 3ʹ-acylthiocephalosporins suggests that upon hydrolysis, a 
rearrangement occurs that results in the release of a thioacid, a phenomenon that has yet to be 
confirmed. Reaction mixtures of either base hydrolyzed or enzyme hydrolyzed 3ʹ-
acylthiocephalosporin could be analyzed by ESI-MS to determine whether or not the thioacid is 
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released. This study could also be used to determine whether or not the enzyme active site contributes 
to the rearrangement. If a thioacid is released, further studies kinetic studies to better quantify the 
inhibition (IC50) and to determine the mechanism by which inhibition occurs would be warranted. 
Much like the phenyl thiocaids, there is more kinetics work to be done with the pyridine thioacids: 
additional replicates of the IC50s should be done to establish reproducibility and mechanistic studies 
should be pursued. Additionally, the Dmitrienko group has acquired an expression plasmid for His-
tagged AmpC which should be used to generate pure AmpC protein and tested for inhibition with 
PMTC and PDTC to determine whether or not the inhibition of GC-1 is characteristic of Class C 
SBLs or if it is GC-1 specific. 
The the pyridine thioacids were found to be potent β-lactamase inhibitors; however, they pose both 
solubility and reactivity problems in a clinical setting. Delivery of these compounds, particularly the 
dithioacid, PDTC, using a cephalosporin has been considered with a bis-PDTC-cephalosporin (Figure 
4.15) having been synthesized. 
 
Figure 4.15 Bis-PDTC-cephalosporin 
 Some preliminary experiments have been conducted with this compound and it was found to be 
ineffective alone and in combination with avibactam (only for UWB 75, 93) against 5 MBL 
producing Gram negatives (UWB: 24, 26, 75, 78, 93). For each of these, the MIC of the bis-PDTA-
cephalosporin was >128 mg/L alone and came down to 128 mg/L when in combination with 4 mg/L 
avibactam against UWB 93. It is likely that this compound is too large to adequately penetrate the 
outer cell membrane of Gram negative bacteria since it is 860 Da. Another strategy for delivery of 
these compounds may need to be considered such as attempting to deliver only the monothioacid, 





Other β-Lactamase Inhibitors 
5.1 Introduction 
In the late 1960’s and early 1970’s a number of reports appeared in the literature concerning the 
inhibition of serine proteases by electrophilic carbonyl compounds such as aldehydes and 
trifluoromethylketones.536–538 It was argued the such inhibitors formed hemiacetal or hemiketal 
adducts with the enzyme active site serine hydroxyl group and that such adducts interacted 
particularly favourably with the enzyme active site since they were mimics of either the tetrahedral 
intermediate involved in the catalytic mechanism or mimics of the structurally related transition state 
involved in forming them. (Scheme 5.1)  Hence, such compounds were referred to as transition state 
analogues. 539–541 
 
Scheme 5.1 Comparison of hemiketal formation with TS and intermediate in acyl enzyme 
mechanism. 
Inspired by these observations, this laboratory as well as several other academic and industrial 
research laboratories explored the concept of creating cyclobutanones that mimic β-lactam antibiotics 
as potential inhibitors of β-lactamases as well as potential antibiotics that bind to penicillin binding 




Figure 5.1 Examples of cyclobutanone mimics of β-lactam antibiotics. 389,542–546 
In this group, racemic CYB-1: (1S,4S,5S)-7,7-dichloro-6-oxo-2-thiabicyclo[3.2.0]heptane-4-
carboxylic acid (Figure 5.1) was prepared and tested as a potential inhibitor of the Class A SBL Bc-I 
from  Bacillus cereus.  This compound exhibited no SBL inhibition at concentrations up to 1 mM.  
Likewise, the cyclobutanones prepared in this context by others were not potent inhibitors of Class A 
SBLs nor good antibiotics. Since at that time potent SBL inhibitors such as clavulanic acid and 
penicillanic acid sulfones such as sulbactam (Figure 1.11) were coming into clinical use, all research 
concerning the cyclobutanones as SBL inhibitors was abandoned. 
With the emergence of clinically important bacteria that produce new SBLs exhibiting 
carbapenemase activity and that are poorly inhibited by clavulanate and the penicillanic acid sulfones, 
as well as the carbapenem-hydrolyzing MBLs in the late 90’s, this laboratory began to revisit the 
cyclobutanones as potential inhibitors of both the SBLs and the MBLs.  Computational, spectroscopic 
and crystallographic studies in this group led to the realization that the cyclobutanone-type penicillin 
mimic A (Figure 5.2) had a strong preference for an endo conformation of the five-membered ring 
which forces the essential carboxylate group into a pseudo-axial orientation that is not favourable for 





Figure 5.2 Conformations of C3-substituted cyclobutanones and the steric interactions of the 
hydrates.  The colour-coded (Cl = green, S = yellow, O = red, C = grey, H = white) ball-and-
stick ORTEP plots were generated using Mercury 3.7 software and are based on atomic 
coordinates from original X-ray crystallographic data generated by Dr. Abdeljalil Assoud in 
the Department of Chemistry X-ray crystallographic laboratory at the University of Waterloo. 
It was also discovered that the preferred conformation of the five-membered ring could be 
controlled by introduction of a heteroatom in the α-orientation (Figure 5.2) which creates an anomeric 
effect between the heteroatom and the sulfur lone pairs of electrons leading to a preference for the 
exo-conformation and a spatial orientation of the carboxylate group that is more favourable for 
binding to β-lactamases. The compounds incorporating two chlorine atoms at C7, the C=O of the 
cyclobutanone were found to be prone to exist predominantly as a hydrate in water and as a hemiketal 
in methanol.  This tendency was especially pronounced for those compounds that possess a 
heteroatom in the α-orientation adjacent to the sulfur atom (Figure 5.2). 
It was envisaged that SBL inhibition would occur via hemiketal formation with the active site 
serine hydroxyl group of SBLs and MBL inhibition might arise through binding to the zinc ions as a 




Scheme 5.2 Parallells between the binding of penems and cyclobutanones to SBLs and MBLs. 
Proposed binding modes of tetrahedral intermediates in the β-lactamase-catalyzed hydrolysis of 
a penem (A) and the potential for cyclobutanones as broad-spectrum SBL and MBL inhibitors. 
In a collaborative study with the protein X-ray crystallography group of Natalie Strynadka at UBC 
it was possible to demonstrate the formation of a hemiketal linkage with the active site serine 
hydroxyl group of the Class D SBL OXA-10 (Figure 5.3A)  It was also possible to demonstrate that 
the cyclobutanone CYB-2 and the unsaturated cyclobutanone JJ05-1058 (Figure 5.1) exhibit 




Figure 5.3 X-Ray crystal structures of cyclobutanones bound to β-lactamases.  (A) CYB-2 
bound to OXA-10 as a serine hemiketal. (B)JJ05-1058 bound to the B1 MBL SPM-1 as a 
hydrate. This figure was generated using Chimera v. 1.12 from the protein databank files 3LCE 
and 5NDB respectively)391,392 
More recently, in a collaborative study with colleagues Christopher Schofield at the University of 
Oxford and James Spencer at the University of Bristol  in the UK, this group has been able to show 
that the unsaturated cyclobutanone JJ05-1058 binds in its hydrated form to the active site of the Class 
B1 MBL SPM-1 with the hydroxide ion that bridges between the two zinc ions retained rather than 
being displaced by one of the oxygens groups of the hydrate as had been speculated in earlier studies 
in this group (Figure 5.3B).392 
The goal of the present study of cyclobutanone-type β-lactamase inhibitors was to expand the 
understanding of the spectrum of activity of the unsaturated cyclobutanone-type inhibitor JJ05-1058 
as an inhibitor of clinically important SBLs and MBLs as well as to gain some initial insight into the 
possibility of binding to PBPs which might suggest possible antibacterial activity. 
5.2 Methods. 
5.2.1 β-Lactamase Enzyme Kinetics 
One of the most active cyclobutanone analogues from the Johnson 2010 paper seen in Figure 5.1 
was tested against a wider array of β-lactamases. Solid JJ05-1058 (compound 5)391 was provided by 
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chemists in the Dmitrienko lab, and the structure was confirmed using 1H NMR, 13C NMR, and ESI-
MS. The solid was dissolved in DMSO to make a 50 mM stock which was stored at -20 oC. 
Since previous work has been done on these compounds, screening of numerous cyclobutanone 
analogs was forgone and JJ05-1058 was directly used for IC50 determinations. All β-lactamases used 
in this thesis were tested using the conditions detailed in Table 5.1. Enzyme stocks for class A, B, and 
C β-lactamases were prepared in 50 mM HEPES pH 7.2 supplemented with 50 μg/mL BSA and 0.01 
% Triton X-100 whereas the stocks for class D enzymes were prepared in 100 mM NaPi, 2.1 mg/mL 
NaHCO3, pH 7.0 supplemented with 50 μg/mL BSA and 0.01 % Triton X-100. 









CTX-M-15 A NC 17.3 ± 0.8 150 pM 20 
KPC-2 A NC 8.1 ± 0.2453 211 pM 8 
IMP-1 B1 NC 3.5 ± 0.2453 186 pM 3.5 
NDM-1 B1 NC 0.88 ± 0.06453 620 pM 1 
SPM-1 B1 NC 1.2 ± 0.1453 8.17 nM 1 
VIM-1 B1 NC 19 ± 1 16.4 nM 30 
VIM-2 B1 NC 13.9 ± 0.3453 313 pM 15 
SFH-1 B2 UW-58 220 ± 10 1.86 nM 100 
L1 B3 NC 5.5 ± 0.5453 637 pM 5 
GC-1 C NC 15.4 ± 0.8453 41 pM 15 
OXA-23 D NC 51 ± 2 620 pM 100 
OXA-48 D NC 81 ± 2 79 pM 80 
 
Literature work was performed in the absence of detergent, so IC50 determinations here were done 
both in the presence and absence of Triton X-100. Two preincubation times were tested (10 min and 
30 min) to compare with other inhibitors using the standard 10 min pre-incubation as well as the 
literature values which were acquired with 30 min pre-incubation. The enzyme mix was incubated 
with either control DMSO or 7-14 dilutions of JJ05-1058 made in DMSO in triplicate for 10 or 30 
min at 30 oC in flat bottomed 96-well plates (Greiner, Monroe, NC) prior to addition to nitrocefin or 
UW-58 as appropriate to initiate the reaction. The reaction was shaken for 5 sec then monitored at 
482 nm (NC) or 534 nm (UW-58) every 5-7 sec for 5 min (30 min for SFH-1) using a SpectraMax 
190 (Molecular Devices, Sunnyvale, CA). Initial rates were determined using SoftMax 6.0 
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(Molecular Devices, Sunnyvale, CA) then normalized and fitted to Equation 3.1 using GraphPad 
Prism version 5.00 for Windows (GraphPad Software, San Diego, CA) by non-linear least squares 
regression. The concentration of DMSO present in the final assay mixture was kept under 2 % which 
set an upper limit for JJ05-1058 concentrations at 1000 μM. Due to this upper limit, the plateau at the 
high inhibitor concentration end was not always present or well defined.  
5.2.2 Penicillin Binding Protein Binding Assay 
Preparation of PBP Containing Membrane Fragments 
Procedures for PBP membrane preparation and Bocillin binding assay were adapted from Moyá et 
al..116 P. aeruginosa PA01 cells were obtained from Dr. Stephen Seah of the University of Guelph. 
An overnight culture of PA01 cells was prepared by inoculating two tubes containing 2 mL Luria 
Bertani (LB) broth with scrapings from a glycerol stock and shaking them at 250 rpm, 37 oC, 
overnight (16-20 hr). The 4 mL of PA01 overnight culture were used to inoculate 500 mL LB broth 
which was then incubated at 37 oC, shaking at 185 rpm until the OD600 reached 1 (~5 hr). Cells were 
then centrifuged in a JA-10 rotor at 4400 xg for 10 min at 4 oC and the supernatant was discarded. 
The pellets were washed in 150 mL of Buffer A (20 mM KH2PO4, 140 mM NaCl, pH 7.5) then 
centrifuged again at 4400 xg for 10 min at 4 oC and the supernatant was discarded. The cells in the 
pellet were then lysed using a large probe on a Heat Systems Ultrasonic processor W-255 sonicator 
set to 50 % cycle and 50 % power 5 times for 30 sec each with 1 min rest on ice between bursts. The 
lysate was then centrifuged in a JA-25.5 rotor at 12 000 xg for 10 min at 4 oC and the supernatant and 
pellets were retained separately and frozen on dry ice then stored at -80 oC. The supernatant was 
thawed and transferred into Oak Ridge polypropylene tubes with a nylon screw cap for use in a T-
1270 rotor of a Sorvall WX100 Ultra centrifuge. Samples were centrifuged at 150 000 xg for 1 h at 4 
oC and the supernatant was discarded. The pellets were resuspended in 1 mL Buffer A and pooled. 
Total membrane protein concentration was determined by Bradford assay as described in 2.2. The P. 
aeruginosa PBP membrane preparation was then aliquoted, frozen on dry ice, and stored at -80 oC.  
PBP Competitive Binding Assay 
Two-fold dilutions of JJ05-1058 ranging from 128 mg/L to 0.0039 mg/L were prepared in Buffer B 
(20 mM NaPi, 140 mM NaCl, pH 7.5) and DMSO such that the final concentration of DMSO in each 
sample was 1.28 % while aliquots of the PBP membrane preparation were thawed on ice. The PBP 
membrane preparation (10 μL) was incubated with a 3x concentrated stock of JJ05-1058 (5 μL) for 30 
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min at 37 oC after vortexing. In a darkened room, 5 μL of the fluorescent penicillin, Bocillin, was 
added and returned to the incubator for 30 min at 37 oC after vortexing. Samples were prepared for 
SDS-PAGE by adding 5 μL of 5x SDS-PAGE Buffer to each sample, vortexing, boiling for 3 min 
before spinning down any condensation. Each sample (20 μL) as well as 5 μL of low molecular 
weight marker was loaded onto a 10 % SDS-PAGE gel which were run at 80 V in the dark until the 
blue dye front had reached the bottom of the gel. Gels were uncased directly onto a Pharos (BioRad, 
Hercules, CA) gel reading system and visualized at λex= 488 nm and λem= 530 nm. Band densities 
were determined using Image Lab software (BioRad, Hercules, CA) and were normalized and fitted 
to Equation 3.1 using GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, CA) with 
the added constraint that the bottom plateau is set to 0 since it is not well defined. Gels were then 
stained with Coomassie Blue R-250 (BioRad, Hercules, CA) containing stain overnight then 
destained with 50 % methanol, 10 % acetic acid in water. Coomassie stained gels were visualized on 
a Gel Doc EZ Imager (BioRad, Hercules, CA). 
5.3 Results 
5.3.1 Inhibition of β-Lactamases 
The cyclobutanone JJ05-1058, was screened against 12 β-lactamases for inhibitory activity using a 
standardized IC50 assay. The effects of pre-incubation time and presence of detergent are best 





Figure 5.4 Inhibition of SBLs by JJ05-1058. Assays performed in the presence of 0.01 % Triton 
X-100 are displayed in blue while those performed in the absence of Triton X-100 are displayed 
in red; preincubation times of 10 min (▲) and 30 min (●) are shown. The graphs in this figure 
were generated using GraphPad Prism v. 5.03. 
From the graphs in Figure 5.4 it can be seen that the inhibition of KPC-2, GC-1, OXA-23, and 
OXA-48 by JJ05-1058 depends heavily on pre-incubation time with longer incubation times resulting 
in more potent inhibition whereas the presence or absence of detergent makes little difference. This 
trend is indicative of slow-binding that requires more than 10 min to achieve steady state. From these 
data, it cannot be conclusively stated whether or not steady state has even been achieved after 30 min 
pre-incubation. CTX-M-15 shows a similar trend as the other SBLs with respect to longer incubation 
times resulting in more inhibition but also shows a significant dependence on detergent which was not 
observed in other SBLs. In the presence of 0.01 % Triton X-100 (blue curves), inhibition is only 
observed at the highest concentrations for CTX-M-15, but by excluding Triton X-100 from the mix, 




Figure 5.5 Inhibition of MBLs by JJ05-1058. Assays performed in the presence of 0.01 % 
Triton X-100 are displayed in blue while those performed in the absence of Triton X-100 are 
displayed in red; preincubation times of 10 min (▲) and 30 min (●) are shown. The graphs in 
this figure were generated using GraphPad Prism v. 5.03. 
Unlike the SBLs, the inhibition of the MBLs by JJ05-1058 is largely unchanged regardless of both 
pre-incubation time and detergent. The major outlier in this group appears to be NDM-1 which is not 
inhibited by JJ05-1058 under any conditions, even at the highest concentrations. The values of the 




Table 5.2 IC50 of β-Lactamases with JJ05-1058 with variable pre-incubation times and 
detergent concentrations. 
  IC50 (μM) 
  0.01% Triton X-100 no Triton X-100 
β-Lactamase Class 10 min 30 min 10 min 30 min 
CTX-M-15 A NI >1000 170 ± 40 31 ± 10 
KPC-2 A NI 560 ± 210 NI 250 ± 50 
IMP-1 B1 14 ± 3 15 ± 3 15 ± 3 8.2 ± 2.1 
NDM-1 B1 NI NI NI NI 
SPM-1 B1 990 ± 960 1200 ± 800 380 ± 80 300 ± 50 
VIM-1 B1 480 ± 140 220 ± 150 10 ± 3 210 ± 70 
VIM-2 B1 60 ± 20 180 ± 70 70 ± 30 140 ± 60 
SFH-1 B2 210 ± 20 130 ± 10 120 ± 20 140 ± 20 
L1 B3 0.32 ± 0.03 0.33 ± 0.08 0.28 ± 0.03 0.29 ± 0.05 
GC-1 C 48 ± 3 3.1 ± 0.2 25 ± 3 2.7 ± 0.4 
OXA-23 D 440 ± 70 88 ± 7 680 ± 70 90 ± 12 
OXA-48 D 320 ± 30 100 ± 17 700 ± 70 108 ± 9 
NI – not inhibited 
From the data in Table 5.2, it is evident that L1 is the most potently inhibited by JJ05-1058 of the 
assayed β-lactamases and that NDM-1 is the least susceptible. IMP-1 is generally 10 times more 
potently inhibited by JJ05-1058 than other B1 MBLs, and this discrepancy along with the behavior of 
NDM-1 suggests that broad generalizations about the efficacy of this compound against any one class 
based on only a few enzymes may be erroneous. With that in mind, the class A enzymes that have 
been assayed were not very susceptible to inhibition by JJ05-1058 while the class C enzyme, GC-1, 
was reasonably susceptible although the same may not be true for other class A and C SBLs. The two 
assayed class D SBLs are very consistent with each other, demonstrating moderate inhibition at 30 
min pre-incubation. Many of the larger IC50 values in the table above have error values that greatly 
exceed 10 %. The relatively large error values are due to a lack of data points defining the lower 
plateau leading to increased uncertainty in the curve fitting. The lack of points at concentrations 
exceeding 1000 μM is due to the solubility limits of JJ05-1058 in 2 % DMSO. 
Previously, a trend with respect to incubation time in which inhibition increased with time, was 
observed from the graphs of SBLs; however, some MBLs (VIM-1 and VIM-2) show an opposite 
trend. Additionally, a more subtle trend with respect to detergent can be observed in the values of the 
IC50s. Generally, inhibition of both SBLs and MBLs is improved or not significantly changed when 
Triton X-100 is left out of the mix with the exception of the Class D SBLs. Both OXA-23 and OXA-
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48 have lower IC50 values, indicating more potent inhibition by JJ05-1058, when in the presence of 
0.01% Triton X-100; however, this effect is most pronounced at 10 min pre-incubation.  
5.3.2 Competitive binding to Penicillin binding proteins 
The structural similarity of penicillins and cyclobutanones suggest that the cyclobutanones may 
also bind to the active site of PBPs. This binding was assayed by incubating membrane fragments 
from P. aeruginosa PA01 with JJ05-1058 followed by Bocillin, a fluorescent penicillin. This method 
is advantageous as it allows selective assaying of an array of related proteins at physiological relative 
concentrations without purifying 6-7 individual membrane proteins. The gels from this assay are first 
read using the fluorescence of Bocillin (Figure 5.6A) then stained with Coomassie and read again 
(Figure 5.6B). 
  
Figure 5.6 SDS-PAGE of JJ05-1058 bound to P. aeruginosa PBPs competing with Bocillin. Gel 
A is the Bocillin fluorescent read, Gel B is the Coomassie stained read. The lanes correspond to 
the following concentrations of JJ05-1058: 2) 0 mg/L; 3) 128 mg/L; 4) 64 mg/L; 5) 32 mg/L; 6) 
16 mg/L – mistake when pipetting Bocillin; 7) 8 mg/L; 8) 4 mg/L; 9) 2 mg/L; 10) 1 mg/L; 11) 0.5 
mg/L; 12) 0.25 mg/L; 13) 0.125 mg/L; 14) 0.0625 mg/L; 15) 0.0313 mg/L; 16) 0.0156 mg/L; 17) 
0.0078 mg/L; 18) 0.0039 mg/L; 19) 0 mg/L. Lanes 1 and 20 contained low molecular weight 
marker. 
The visualization of the fluorescence shows the Bocillin covalently bound to the various PBPs, and 
a decrease in intensity of any band relative to the control is indicative of JJ05-1058 competing for the 
active site of that PBP. As can be seen in Figure 5.6A, JJ05-1058 binds to PBP 4 and PBP 5/6 at high 
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concentrations. Graphing the relative intensities of the bands gives a clearer picture of the binding 
(Figure 5.7).
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Figure 5.7 JJ05-1058 competition for PBP binding with Bocillin.  The graphs in this figure were 
generated using GraphPad Prism v. 5.03. 
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Again, the binding of JJ05-1058 to PBP 4 and PBP 5/6 is evident at high concentrations. The large 
amount of scatter in the graph of PBP 2 (Figure 5.7) is due to the low intensity of the band on the 
SDS PAGE gel (Figure 5.6A). Upon curve fitting, the IC50 values in Table 5.3 were determined and 
showed that JJ05-1058 binds best to PBP 4 with an IC50 of 47.3 mg/L. 
Table 5.3 IC50s of JJ05-1058 competing with Bocillin for binding to P. aeruginosa PBPs. 
PBP 1a 1b 2 3 4 5/6 
IC50 (mg/L) >128 >128 >128 >128 47.3 74.3 
 
When the PBP binding IC50s are converted into molar units, it is 198 μM for PBP 4 and 311 μM for 
PBP 5/6 making the binding comparable to that of many of the β-lactamases. The PBPs inhibited by 
JJ05-1058 are all non-essential LMM PBPs, so any potentiation of meropenem observed in bacterial 
experiments would be the result of β-lactamase inhibition rather than synergistic PBP inhibition. 
5.4 Discussion 
Three of the IC50s performed using the cyclobutanones were repeats of those presented by Johnson 
et al.: IMP-1, KPC-2, and GC-1 pre-incubated for 30 min in the absence of Triton X-100.391 
Comparison of the values determined in this work to the literature are presented in Table 5.4 and 
shows that the values for GC-1 were reproducible; however, those for KPC-2 and IMP-1 are not. 
Since the time that these values were initially determined, each of these enzyme stocks has been re-
made and the storage conditions have been changed to prolong their lifetime. When the original 
values were determined, enzyme stocks were being stored on ice at 4 oC in buffer and since then we 
have changed the storage conditions to -20 oC in 50 % glycerol. Additionally, the KPC-2 and IMP-1 
stocks that were used in the Johnson paper were purified from a different expression vector that did 
not include a His-tag. The slight differences in sequence and storage between the literature and this 
study should not be significant enough to cause the order of magnitude difference between these IC50 







Table 5.4 Comparison of literature values for JJ05-1058 IC50s to those presented in this study. 
 IC50 (μM) 
 KPC-2 IMP-1 GC-1 
Johnson et al. 26 ± 2 213 ± 21 4.5 ± 0.3 
This study 250 ± 50 8.2 ± 2.1 2.7 ± 0.4 
 
The effects of two variables on IC50 were examined in this study: pre-incubation time and presence 
of detergent. Detergent is generally used in enzyme kinetics to reduce the probability of non-specific 
inhibition by preventing aggregate formation.547–549 JJ05-1058 inhibition was significantly impaired 
by the presence of 0.01 % Triton X-100 against CTX-M-15, KPC-2, SPM-1, and to a lesser extent, 
L1 and GC-1. Inhibition of IMP-1 and VIM-2 was mostly unaffected by the presence or absence 
Triton X-100 while SFH-1 and VIM-1 were only affected when pre-incubated for 10 min. For SFH-1, 
the IC50 values suggest that the presence of Triton X-100 slowed the achievement of steady state; 
however, it is more likely that when incubated for 10 min in the absence of Triton X-100 some non-
specific binding occurred. Contrary to expectation, OXA-23 and OXA-48 were slightly more 
inhibited in the presence of Triton X-100 although with longer pre-incubation, this difference falls 
within the uncertainty of the values. It is also possible that a slight error occurred in pipetting and that 
additional replicates could change this observation as it is very slight. 
The time variable of JJ05-1058 inhibition produced much more consistent trends: in the majority of 
cases, longer pre-incubation resulted in more potent inhibition. This observation is indicative of time 
dependence in which steady-state takes more than 10 min to achieve. IMP-1, SPM-1, SFH-1, and L1 
did not demonstrate time dependence beyond the uncertainty of the IC50 values. The VIM β-
lactamases did yield higher IC50values with longer incubation times; however, there is a discrepancy 
in the control rates between the 10 min and 30 min incubation times in which the 30 min control rates 
are half again as fast as the 10 min control rates. If the faster turnover is a result of faster off rates 
(koff), then the inhibitor could also have higher off rates due to the structural similarity between JJ05-
1058 and substrates for β-lactamases. A higher off rate would result in a shorter EI complex half-life 
and consequently higher IC50s.  
In addition to inhibiting β-lactamases, JJ05-1058 also inhibits low molecular weight PBPs from P. 
aeruginosa. This dual mode of action suggests that compounds of this family should behave 
synergistically with β-lactam antibiotics to kill β-lactamase producing bacteria. 
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5.5 Future Work 
The cyclobutanone JJ05-1058 has been screened against 12 β-lactamases in this study; however, 
the IC50 values presented here are from a single experiment due to time constraints. Additional 
replicates of the experiments that demonstrated inhibition should be obtained to solidify trends and 
get more accurate values. Since the data suggests the inhibition of cyclobutanones is time dependent, 
it should be further characterized using methods similar to those described in 1113.2.1.3. The 
hypothesis regarding higher off rates for VIM β-lactamases at longer pre-incubation times could be 
tested by performing the experiment described in 3.2.1.3 using both the 10 min pre-heating described 
as well as a 30 min pre-heating to ascertain whether or not a difference in koff and t1/2 is observed. To 
date, only the only cyclobutanones that have been synthesized and tested are derived from the core 
structure of a penicillin.388  
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Appendix A 
Structures of β-Lactamase Inhibitors 
Compound 
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Statistical Methods for IC50 Averages 
Since we are working with values that have an associated uncertainty (the standard error), each 
value should contribute differently to the mean such that values with lower uncertainties are more 
strongly weighted. In order to do this, a weighted mean is used on the log (IC50) values so as to not 








      
Where pi is a property (in this case, each log(IC50) value) and wi is the weight as defined by 𝑤𝑖 =
1
𝑢𝑖
2 where ui is the log(SE) associated with each log(IC50) value. This makes Eq. 1 the same as the 
weighted mean equation in the Jones paper (except I used the log values of the IC50and SE).  






      




∑ (𝑝𝑖 − ?̅?)
2 ∗ 𝑤𝑖̅̅ ̅
𝑁
𝑖=1     
This gives the SE of the weighted mean, so we can convert this into the 95% confidence interval 
using the t-table equation: 
?̅? ± 𝑡 ∗ 𝑢(?̅?)      
From this point the values for the mean and the 95% confidence interval that were calculated could 





Clinical Isolates and Control Strains 
UWB Organism Isolate Identifier Known Resistance Source 
11 K. pneumoniae  KPC-3 Dr. Dylan Pillai 
16 K. pneumoniae  KPC-2 Dr. Dylan Pillai 
24 P. putida C10 VIM-2 Dr. Johann Pitout  
25 P. aeruginosa C7 VIM-2 Dr. Johann Pitout  
26 S. maltophilia 5563 L1, L2 Dr. Dylan Pillai 
27 P. aeruginosa 5564  Dr. Dylan Pillai 
28 P. aeruginosa 5566  Dr. Dylan Pillai 
29 S. maltophilia 5568  Dr. Dylan Pillai 
31 P. aeruginosa 5785 IMP-5 like Dr. Dylan Pillai 
33 S. maltophilia 6069 L1, L2 Dr. Dylan Pillai 
34 S. maltophilia 6081 L1, L2 Dr. Dylan Pillai 
35 P. aeruginosa 6225  Dr. Dylan Pillai 
39 S. maltophilia 6487 L1, L2 Dr. Dylan Pillai 
43 S. maltophilia 6773 L1, L2 Dr. Dylan Pillai 
44 S. maltophilia 6776 L1, L2 Dr. Dylan Pillai 
45 S. maltophilia 6779 L1, L2 Dr. Dylan Pillai 
46 S. maltophilia 6781 L1, L2 Dr. Dylan Pillai 
48 S. maltophilia 6924 L2 Dr. Dylan Pillai 
49 S. maltophilia 6952 L2 Dr. Dylan Pillai 
56 K. pneumoniae A7 AmpC ACC1 CMY-2 Dr. Johann Pitout  
57 E. coli A9 AmpC CMY-2 Dr. Johann Pitout  
59 E. coli 1175  Dr. Karen Pike 
60 K. pneumoniae   Dr. Karen Pike 
62 P. aeruginosa 27853  ATCC
551 
75 E. coli MH1 NDM-1, CTX-M-15 Dr. Johann Pitout  
78 P. aeruginosa Vim I-1 VIM-2 Dr. Johann Pitout  
82 K. pneumoniae KpSA01 VIM-1 Dr. Dylan Pillai 
83 K. pneumoniae Kp3VIM VIM-1 Dr. Dylan Pillai 
86 K. pneumoniae Kp5OXA OXA-48 Dr. Dylan Pillai 
87 K. pneumoniae Kp9OXA OXA-48, CTX-M-15 Dr. Dylan Pillai 
88 K. pneumoniae KpCG02 KPC-2, SHV-12 Dr. Dylan Pillai 
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91 E. coli MH01 NDM-1, CTX-M type 1 Dr. Dylan Pillai 
93 E. coli Ec7IMP IMP-1, CTX-M-15 Dr. Dylan Pillai 
94 A. baumannii AB01 OXA-23 Dr. Dylan Pillai 
95 A. baumannii AB02 OXA-23 Dr. Dylan Pillai 
96 P. aeruginosa PA01  Dr. Stephen Seah 
102 E. coli 25922  ATCC
552 







KI Graphs of DPA, PMPC-3, and PMPC-4 












































































































































KI = 1.1 ± 0.3
R2 = 0.9895
KI = 2.8 ± 0.4
R2 = 0.9968
KI = 3.3 ± 0.6
R2 = 0.9620





Figure 5.8 Time Dependent KI graphs for DPA against representative MBLs  IMP-1 (A), 
NDM-1 (B), VIM-2 (C), and L1 (D). 
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KI = 0.41 ± 0.10
R2 = 0.9789
KI = 1.5 ± 0.1
R2 = 0.9987
KI = 0.074 ± 0.008
R2 = 0.9961





Figure 5.9 Time Dependent KI graphs for PMPC-3 against representative MBLs  IMP-1 (A), 
NDM-1 (B), VIM-2 (C), and L1 (D). 
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KI = 0.40 ± 0.1
R2 = 0.9845
KI = 0.4 ± 0.2
R2 = 0.9463
KI = 0.034 ± 0.006
R2 = 0.9944





Figure 5.10 Time Dependent KI graphs for PMPC-4 against representative MBLs  IMP-1 (A), 





Protein Sequence Alignments 
Alignment of NDM variants relative to NDM-1 
                 10        20        30        40        50        60            
        ....|....|....|....|....|....|....|....|....|....|....|....| 
NDM-1   MELPNIMHPVAKLSTALAAALMLSGCMPGEIRPTIGQQMETGDQRFGD-----LVFRQLA  
NDM-2   ...........................A....................-----.......  
NDM-3   ................................................-----.......  
NDM-4   ................................................-----.......  
NDM-5   ................................................-----.......  
NDM-6   ................................................-----.......  
NDM-7   ................................................-----.......  
NDM-8   ................................................-----.......  
NDM-9   ................................................-----.......  
NDM-10  ...............................S...D............-----.......  
NDM-11  ................................................-----.......  
NDM-12  ................................................-----.......  
NDM-13  ................................................-----.......  
NDM-14  ................................................-----.......  
NDM-15  ................................................-----.......  
NDM-16  ................................................-----.......  
NDM-17  ................................................-----.......  
NDM-18  ................................................QRFGD.......  
NDM-19  ................................................-----.......  
 
                 70        80        90       100       110       120         
        ....|....|....|....|....|....|....|....|....|....|....|....| 
NDM-1   PNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTAWTDDQTAQILNWIKQEINLPVAL  
NDM-2   ............................................................  
NDM-3   .......................................N....................  
NDM-4   ............................................................  
NDM-5   ................................L...........................  
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NDM-6   ............................................................  
NDM-7   ............................................................  
NDM-8   ............................................................  
NDM-9   ............................................................  
NDM-10  .............S....T.........................................  
NDM-11  ............................................................  
NDM-12  ............................................................  
NDM-13  .......................................N....................  
NDM-14  ............................................................  
NDM-15  ............................................................  
NDM-16  ............................................................  
NDM-17  ................................L...........................  
NDM-18  ............................................................  




                130       140       150       160       170       180      
        ....|....|....|....|....|....|....|....|....|....|....|....| 
NDM-1   AVVTHAHQDKMGGMDALHAAGIATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAP  
NDM-2   ............................................................  
NDM-3   ............................................................  
NDM-4   ......................................L.....................  
NDM-5   ......................................L.....................  
NDM-6   ............................................................  
NDM-7   ..............N.......................L.....................  
NDM-8   ..............G.......................L.....................  
NDM-9   ....................................K.......................  
NDM-10  ............................................................  
NDM-11  ......................................V.....................  
NDM-12  ......................................L.....................  
NDM-13  ......................................L.....................  
NDM-14  ..............G.............................................  
NDM-15  ......................................L.....................  
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NDM-16  ............................................................  
NDM-17  ......................................L...............K.....  
NDM-18  ............................................................  
NDM-19  ..............N.......................L.....................  
 
                190       200       210       220       230       240      
        ....|....|....|....|....|....|....|....|....|....|....|....| 
NDM-1   NFGPLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARA  
NDM-2   ............................................................  
NDM-3   ............................................................  
NDM-4   ............................................................  
NDM-5   ............................................................  
NDM-6   .........................................................V..  
NDM-7   ............................................................  
NDM-8   ............................................................  
NDM-9   ............................................................  
NDM-10  ........................R...................................  
NDM-11  ............................................................  
NDM-12  ..............................................D.............  
NDM-13  ............................................................  
NDM-14  ............................................................  
NDM-15  .........................................................V..  
NDM-16  ............................................................  
NDM-17  ............................................................  
NDM-18  ............................................................  













                250       260       270         
        ....|....|....|....|....|....|....| 
NDM-1   FGAAFPKASMIVMSHSAPDSRAAITHTARMADKLR  
NDM-2   ...................................  
NDM-3   ...................................  
NDM-4   ...................................  
NDM-5   ...................................  
NDM-6   ...................................  
NDM-7   ...................................  
NDM-8   ...................................  
NDM-9   ...................................  
NDM-10  ...................................  
NDM-11  ...................................  
NDM-12  ...................................  
NDM-13  ...................................  
NDM-14  ...................................  
NDM-15  ...................................  
NDM-16  ............................H......  
NDM-17  ...................................  
NDM-18  ...................................  
NDM-19  ...................................  
 
Alignment of VIM Variants relative to VIM-2 
 
                 10        20        30        40        50        60            
        ....|....|....|....|....|....|....|....|....|....|....|....| 
VIM-02  MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATQ  
VIM-01  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-03  ...........................................................K  
VIM-04  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-05  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-06  ...........................................................R  
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VIM-07  ..Q-IRSF..GIS.FV..VLGSA.Y.AQPG......DD.........K.G..........  
VIM-08  ............................................................  
VIM-09  ............................................................  
VIM-10  ............................................................  
VIM-11  ............................................................  
VIM-12  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-13  .L.VI.S..F.M...L..V.....H.GE.R...................D.........H  
VIM-14  .L.VI.S....M...V..V.....H.GEP.S.....N.......................  
VIM-15  ............................................................  
VIM-16  ......................................................L.....  
VIM-17  ...............M............................................  
VIM-18  ...........................................................R  
VIM-19  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-20  ............................................................  
VIM-23  ............................................................  
VIM-24  ............................................................  
VIM-25  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-26  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-27  .L.VI.S....M...V..V.....H.GEP.......N....................S..  
VIM-28  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-29  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-30  ....................................N.......................  
VIM-31  ............................................................  
VIM-32  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-33  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-34  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-35  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-36  ...........................................................R  
VIM-37  .L.VI.S....M...V..V.....H.GEP.......N....................S..  
VIM-38  .L.VI.S........V..V.....H.GEP.......N.......................  
VIM-39  .L.VI.S....M...V..V.....H.GEP.....A.N.......................  
VIM-40  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-41  ............................................................  
VIM-42  .L.VI.S....M...V..V.....H.GEP.......N.......................  
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VIM-43  .L.VI.S....M...V..V....VH.GEP.......N.......................  
VIM-44  ............................................................  
VIM-45  ..................................I.........................  
VIM-46  ...F...............................A........................  
VIM-47  ...VV.S..F.M...L..V.....H.GE.R...................D.........H  
VIM-48  ............................................................  
VIM-49  .L.VI.S....M...V..V.....H.GEP.......N....................S..  
VIM-50  ............................................................  
VIM-51  ............................................................  
VIM-52  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-54  .L.VI.S....M...V..V.....H.GEP.......N.......................  
VIM-55  .L.VI.S....M...V..V.....H.GEP.......N.......................  
 
                 70        80        90       100       110       120         
        ....|....|....|....|....|....|....|....|....|....|....|....| 
VIM-02  SFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRV  
VIM-01  ............................................................  
VIM-03  ............................................................  
VIM-04  ............................................................  
VIM-05  ............................................................  
VIM-06  ............................................................  
VIM-07  KLGDT..S........A...............V................SI.........  
VIM-08  ............................................................  
VIM-09  ............................................................  
VIM-10  ............................................................  
VIM-11  ............................................................  
VIM-12  ............................................................  
VIM-13  T...V.......................T...V................S..........  
VIM-14  ............................................................  
VIM-15  ............................................................  
VIM-16  ............................................................  
VIM-17  ............................................................  
VIM-18  ............................................................  
VIM-19  ............................................................  
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VIM-20  ............................................................  
VIM-23  ............................................................  
VIM-24  ............................................................  
VIM-25  ............................................................  
VIM-26  ............................................................  
VIM-27  ............................................................  
VIM-28  ............................................................  
VIM-29  ............................................................  
VIM-30  ............................................................  
VIM-31  ............................................................  
VIM-32  ............................................................  
VIM-33  ............................................................  
VIM-34  ..................................................I.........  
VIM-35  ............................................................  
VIM-36  ............................................................  
VIM-37  ............................................................  
VIM-38  ............................................................  
VIM-39  ............................................................  
VIM-40  ............................................................  
VIM-41  ............................................................  
VIM-42  ............................................................  
VIM-43  ............................................................  
VIM-44  ............................................................  
VIM-45  ............................................................  
VIM-46  ............................................................  
VIM-47  T...V.......................T...V................S..........  
VIM-48  ............................................................  
VIM-49  ............................................................  
VIM-50  ............................................................  
VIM-51  ............................................................  
VIM-52  ............................................................  
VIM-54  ............................................................  




                130       140       150       160       170       180      
        ....|....|....|....|....|....|....|....|....|....|....|....| 
VIM-02  GGVDVLRAAGVATYASPSTRRLAEVEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHS  
VIM-01  ........................A...................................  
VIM-03  ...........................S................................  
VIM-04  ........................A...................................  
VIM-05  .......K................A...................................  
VIM-06  ...........................S................................  
VIM-07  ..............T..L..Q...AA...V.A...KA......V.......V........  
VIM-08  ..................A.........................................  
VIM-09  ..................I.........................................  
VIM-10  ............................................................  
VIM-11  ...........................S................................  
VIM-12  ........................A...................................  
VIM-13  ....A...................A....V..............................  
VIM-14  ........................A...................................  
VIM-15  ............................................................  
VIM-16  ............................................................  
VIM-17  ............................................................  
VIM-18  .......................----.................................  
VIM-19  ........................A...................................  
VIM-20  ............................................................  
VIM-23  ............................................................  
VIM-24  ............................................................  
VIM-25  .......K................A...................................  
VIM-26  ........................A...................................  
VIM-27  ........................A...................................  
VIM-28  ........................A...................................  
VIM-29  ........................A...................................  
VIM-30  ............................................................  
VIM-31  ............................................................  
VIM-32  ........................AA..................................  
VIM-33  ........................A...................................  
VIM-34  ........................A...................................  
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VIM-35  ........................A...................................  
VIM-36  ............................................................  
VIM-37  ........................A...................................  
VIM-38  .......K................A...................................  
VIM-39  ........................A...................................  
VIM-40  ......................V.A...................................  
VIM-41  ............................................................  
VIM-42  ........................A...................................  
VIM-43  ........................A...................................  
VIM-44  ............................................................  
VIM-45  ............................................................  
VIM-46  ............................................................  
VIM-47  ....A...................A....V..............................  
VIM-48  ............................................................  
VIM-49  .......K................A...................................  
VIM-50  ...........................S................................  
VIM-51  ............................................................  
VIM-52  ........................A...................................  
VIM-54  ........................A..S................................  
VIM-55  ........................A...................................  
 
                190       200       210       220       230       240      
        ....|....|....|....|....|....|....|....|....|....|....|....| 
VIM-02  TDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGH  
VIM-01  ...........N.......VH...S.................V....K.....EV.....  
VIM-03  ............................................................  
VIM-04  ...........N.......VH.....................V....K.....EV.....  
VIM-05  ...........N.......VLA....................V....K.....EV.....  
VIM-06  ............................................................  
VIM-07  G........AVR..F....VH.A..E........N.....AT.K....R....EV.....  
VIM-08  ............................................................  
VIM-09  ............................................................  
VIM-10  ......................................................Y.....  
VIM-11  ............................................................  
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VIM-12  ...........N.......VH...S...................................  
VIM-13  ...........N.......VL...................G.V..........EV.....  
VIM-14  ...........N.......VH.....................V....K.....EV.....  
VIM-15  ..............F.............................................  
VIM-16  ............................................................  
VIM-17  ............................................................  
VIM-18  ............................................................  
VIM-19  ...........K.......VH.....................V....K.....EV.....  
VIM-20  ................................................R...........  
VIM-23  ........................S...................................  
VIM-24  ........................L...................................  
VIM-25  ...........N.......VLA....................V....K............  
VIM-26  ...........N.......VL...S.................V....K.....EV.....  
VIM-27  ...........N.......VH...S.................V....K.....EV.....  
VIM-28  ...........N.......VL.....................V....K.....EV.....  
VIM-29  ...........K.......VH...S.................V....KR....EV.....  
VIM-30  ............................................................  
VIM-31  ....................H...........................R...........  
VIM-32  ...........N.......VH...S.................V....K.....EV.....  
VIM-33  ...........N..F....VH...S.................V....K.....EV.....  
VIM-34  ...........N.......VH...S.................V....K.....EV.....  
VIM-35  ...........N.......VH...S......T..........V....K.....EV.....  
VIM-36  ............................................................  
VIM-37  ...........N.......VH.....................V....K.....EV.....  
VIM-38  ...........N.......VLA....................V....K.....EV.....  
VIM-39  ...........N.......VL...S.................V....K.....EV.....  
VIM-40  ...........N.......VH.....................V....K.....EV.....  
VIM-41  ................................N...........................  
VIM-42  ...........N.......VH...S......................K.....EV.....  
VIM-43  ...........N.......VH.....................V....K.....EV.....  
VIM-44  ............................................................  
VIM-45  ............................................................  
VIM-46  ............................................................  
VIM-47  ...........N.......VL...................G.V..........EV.....  
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VIM-48  ............................................................  
VIM-49  ...........N.......VLA....................V....K.....EV.....  
VIM-50  ........................L...................................  
VIM-51  ...........................V................................  
VIM-52  ...........N.......VR...S.................V....K.....EV.....  
VIM-54  ...........N.......VH.....................V....K.....EV.....  
VIM-55  ...........K.......VH.....................V....KR....EV.....  
 
                250       260       270   
        ....|....|....|....|....|....|.. 
VIM-02  GLPGGLDLLKHTTNVVKAHTNRSVVE------  
VIM-01  .........Q..A......K....A.------  
VIM-03  ..........................------  
VIM-04  .........Q..A......K....A.------  
VIM-05  .........Q..A...T..K....A.------  
VIM-06  ..........................------  
VIM-07  ......E..Q.......T.KV.P.A.------  
VIM-08  ..........................------  
VIM-09  ..........................------  
VIM-10  ..........................------  
VIM-11  ..........................------  
VIM-12  ..........................------  
VIM-13  .........Q..A...........A.------  
VIM-14  .........Q..A......K....A.------  
VIM-15  ..........................------  
VIM-16  ..........................------  
VIM-17  ..........................------  
VIM-18  ..........................------  
VIM-19  .........Q..A......K....A.------  
VIM-20  ..........................------  
VIM-23  ..........................------  
VIM-24  ..........................------  
VIM-25  ..........................------  
VIM-26  .........Q..A......K....A.------  
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VIM-27  .........Q..A......K....A.------  
VIM-28  .........Q..A......K....A.------  
VIM-29  .........Q..A......K....A.------  
VIM-30  ..........................------  
VIM-31  ..........................------  
VIM-32  .........Q..A......K....A.------  
VIM-33  .........Q..A......K....A.------  
VIM-34  .........Q..A......K....A.------  
VIM-35  .........Q..A......K....A.------  
VIM-36  ..........................------  
VIM-37  .........Q..A......K....A.------  
VIM-38  .........Q..A...T..K......------  
VIM-39  .........Q..A......K....A.------  
VIM-40  .........Q..A......K....A.------  
VIM-41  ..........................------  
VIM-42  .........Q..A......K....A.------  
VIM-43  .........Q..A......K....A.------  
VIM-44  ................N.........------  
VIM-45  ..........................------  
VIM-46  ..........................------  
VIM-47  .........Q..A...........A.------  
VIM-48  ..................---G..AKIGGSQR  
VIM-49  .........Q..A...T..K....A.------  
VIM-50  ..........................------  
VIM-51  ..........................------  
VIM-52  .........Q..A......K....A.------  
VIM-54  .........Q..A......K....A.------  





 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 




VIM-3  Q60K, N148S 
VIM-4 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, I200V, Y201H, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A 
VIM-5 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, A128K, 
V145A, S192N, I200V, Y201L, E202A, I223V, Q228K, Q234E, F235V, K250Q, T253A, 
K257T, T260K, V265A 
VIM-6  Q60R, N148S 
VIM-7 
 K3Q, L4del, L5I, S6R, K7S, L8F, Y11G, L12I, T13S, S15F, I16V, I19V, A20L, S21G, 
P22S, L23A, F25Y, V27A, D28Q, S29P, S30G, S37D, E38D, Q48K, A50G, S61K, F62L, 
D63G, G64D, A65T, P68S, G77A, A93V, A110S, V111I, A135T, S138L, R141Q, V145A, 
E146A, I150V, T152A, E156K, G157A, A164V, L172V, T181G, S190A, A191V, S192R, 
Y195F, I200V, Y201H, L203A, T206E, D215N, T221A, S222T, E224K, H229R, Q234E, 
F235V, D247E, K250Q, A258T, T260K, N261V, S263P, V265A 
VIM-8  T139A 
VIM-9  T139I 
VIM-10  F235Y 
VIM-11  N148S 
VIM-12 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, I200V, Y201H, R205S 
VIM-13 
 F2L, L4V, L5I, K7S, V10F, L12M, I16L, I19V, F25H, V27G, D28E, S30R, A50D, Q60H, 
S61T, A65V, A89T, A93V, A110S, V125A, V145A, I150V, S192N, I200V, Y201L, T221G, 
Q234E, F235V, K250Q, T253A, V265A 
VIM-14 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, G31S, S37N, V145A, 
S192N, I200V, Y201H, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A 
VIM-15  Y195F 
VIM-16  S55L 
VIM-17  I16M 
VIM-18  Q60R, E144_G147del 
VIM-19 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192K, I200V, Y201H, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A 
VIM-20  H229R 
VIM-23  R205S 
VIM-24  R205L 
VIM-25 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, A128K, 




 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, I200V, Y201L, R205S, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, 
V265A 
VIM-27 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, A58S, V145A, 
S192N, I200V, Y201H, R205S, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, 
V265A 
VIM-28 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, I200V, Y201L, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A 
VIM-29 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192K, I200V, Y201H, R205S, I223V, Q228K, H229R, Q234E, F235V, K250Q, T253A, 
T260K, V265A 
VIM-30  S37N 
VIM-31  Y201H, H229R 
VIM-32 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
E146A, S192N, I200V, Y201H, R205S, I223V, Q228K, Q234E, F235V, K250Q, T253A, 
T260K, V265A 
VIM-33 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, Y195F, I200V, Y201H, R205S, I223V, Q288K, Q234E, F235V, K250Q, T253A, 
T260K, V265A 
VIM-34 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V111I, 
V145A, S192N, Y195F, I200V, Y201H, R205S, I223V, Q288K, Q234E, F235V, K250Q, 
T253A, T260K, V265A 
VIM-35 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, Y195F, I200V, Y201H, R205S, A212T, I223V, Q228K, Q234E, F235V, K250Q, 
T253A, T260K, V265A 
VIM-36  Q60R 
VIM-37 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, A58S, V145A, 
S192N, I200V, Y201H, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A 
VIM-38 
 F2L, L4V, L5I, K7S, I16V, I19V, F25H, V27G, D28E, S29P, S37N, A128K, V145A, 
S192N, I200V, Y201L, E202A, I223V, Q228K, Q234E, F235V, K250Q, T253A, K257T, 
T260K 
VIM-39 
  F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, T35A, S37N, 
V145A, S192N, I200V, Y201L, R205S, I223V, Q228K, Q234E, F235V, K250Q, T253A, 
T260K, V265A 
VIM-40 
 F2L, L4V, L5I, K7S, I16V, I19V, F25H, V27G, D28E, S29P, S37N, A143V, V145A, 
S192N, I200V, Y201H, I223V, Q228K, Q234E, F235V, K250W, T253A, T260K, V265A 
VIM-41  D213N 
VIM-42 
 F2L, L4V, L5I, K7S, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, S192N, 
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I200V, Y201H, R205S, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A 
VIM-43 
 F2L, L4V, L5I, K7S, I16V, I19V, A24V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, I200V, Y201H, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, V265A 
VIM-44  K257N 
VIM-45  T35I 
VIM-46  L4F, V36A 
VIM-47 
 L4V, L5V, K7S, V10F, L12M, I16L, I19V, F25H, V27G, D28E, S30R, A50D, Q60H, 
S61T, A65V, A89T, A93V, A110S, V125A, V145A, I150V, S192N, I200V, Y201L, T221G, 
I223V, Q234E, F235V, K250Q, T253A, V265A 
VIM-48  H259_N261del, R262G, V265A, E266K, E266_insIGGSQR 
VIM-49 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, A128K, 
V145A, S192N, I200V, Y201L, E202A, I223V, Q228K, Q234E, F235V, K250Q, T253A, 
K257T, T260K, V265A 
VIM-50  N148S, R205L 
VIM-51  A208V 
VIM-52 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192N, I200V, Y201R, R205S, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, 
V265A 
VIM-54 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
N148S, S192N, I200V, Y201H, I223V, Q228K, Q234E, F235V, K250Q, T253A, T260K, 
V265A 
VIM-55 
 F2L, L4V, L5I, K7S, L12M, I16V, I19V, F25H, V27G, D28E, S29P, S37N, V145A, 
S192K, I200V, Y201H, I223V, Q228K, H229R, Q234E, F235V, K250Q, T253A, T260K, 
V265A 
 
IMP Variant Sequence Alignment 
                 10        20        30        40        50        60            
        ....|....|....|....|....|....|....|....|....|....|....|....| 
IMP-01  MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVPKHGLVVLVNA  
IMP-02  .K..F.LCVCFL...TA.GAR.........E..................S.........T  
IMP-03  ............................................................  
IMP-04  ....................P.....................................D.  
IMP-05  ....F...M......TA..........................................T  
IMP-06  ............................................................  
IMP-07  .K......M.......ASG.A......................................T  
IMP-08  .K..F.LCVCFL...TA.GAA.........E..................S.........T  
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IMP-09  ....F...M......TA.G.............................I..........T  
IMP-10  ................................................F...........  
IMP-11  .K..F.LC.......TA.GA..........E..................S.........T  
IMP-12  .K..F.LC....L..TASG.V.........E....L.......S.....T.........N  
IMP-13  .K..F.LCVCF....TA.GAA.........E...F..............T.........T  
IMP-14  .K..F.LCV.F..N..V.E...........E............K..S..T........KN  
IMP-15  .N......M.M....TA.G........................................T  
IMP-16  .K..F.LC.......TA.G...........ED.................T.....F...T  
IMP-17  .K..F.LCVCF....TA.GAA.........E...F..............T.........T  
IMP-18  .K..F.LCV.FL.N..A.DD..........EK...........K.....T........KN  
IMP-19  .K..F.LCVCFL...TA.GAA.........E..................S.........T  
IMP-20  .K..F.LCVCFL...TA.GAA.........E.................FS.........T  
IMP-21  .K..F.LC.......TA.GA..........E.................AS.........T  
IMP-22  .K..F.LCV......TA.G...........E..................S.....I...T  
IMP-23  .K..F.LCVCFL...TA.GAA.........E.................FS.........T  
IMP-24  .K..F.LCVCFL...TA.GAA.........E..................S.........T  
IMP-25  ............................................................  
IMP-26  ....................P...........................F.........D.  
IMP-27  .K..F.LCV.V....TV.G.T..N.RV...E........Y...K.....T.......IG.  
IMP-28  ....F...M......TA...........R..............................T  
IMP-29  ....F..L.......TA..........................................T  
IMP-30  ........................................K...................  
IMP-31  .K.IF.L.V......TA.G.....I.......D........KIT....IT.........T  
IMP-32  .K..F.LCV.F..N..V.E...........E............K..S..T........KN  
IMP-33  .K..F.LCVCF....TA.GS..........E...F..............T.........T  
IMP-34  ............................................................  
IMP-35  .K.IF.L.V......TA.G.....I.......D.........D.....IT.........T  
IMP-37  .K..F.LCVCF....TA.GAA.........E...F..............T.........T  
IMP-38  ....................P.....................................D.  
IMP-40  ................................................F...........  
IMP-41  .K..F.LC.......TA.GA..........E.................FS.........T  
IMP-42  ............................................R...............  
IMP-43  .K......M.......ASG.A...........................F..........T  
IMP-44  .K..F.LC.......TA.GA..........E.................FS.........T  
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IMP-45  ....F...M......TA.G.............................I..........T  
IMP-48  .K..F.LCV.F..N..V.E...........E............K..S..T........KN  
IMP-49  .K..F.LCV.FL.N..A.DD..........EK...........K....FT........KN  
IMP-51  .K......M.......ASG.A......................................T  
IMP-52  ............................................................  
IMP-53  ....F...M......TA.G.............................I..........T  
IMP-54  .K..F.LCV.F..N..V.E...........E............K..S..T........KN  
IMP-55  ...........I..................E.........K...................  
IMP-56  .K..F.LCV.FL.N..A.DD..........EK...........K.....T........KN  
IMP-58  .K..F.LCV......TA.G...........E.................FS.....I...T  
IMP-59  ....................P.....................................D.  
IMP-60  ............................................................  
IMP-61  ............................................................  
IMP-62  .N......M.M....TA.G........................................T  
IMP-63  .K..F.LC....L..TASG.V.........E....L.......S.....T.........N  
IMP-64  .K..F.LCV.V....TV...T..N.RV...E........Y...K.....T.......IG.  
IMP-66  ...............................................F............  
IMP-67  .K..F.LCV.V....TV.G.T..N.RV...E........Y...K.....T.......IG.  
IMP-68  .K..F.LC.......TA.GA..........E..................S.........T  
IMP-69  .K..F.LCVCFL...TA.GAT.........E..................S.........T  
IMP-70  ............................................................  
 
                 70        80        90       100       110       120         
        ....|....|....|....|....|....|....|....|....|....|....|....| 
IMP-01  EAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELT  
IMP-02  D..........T......N...........T..................Q..........  
IMP-03  ............................................G...............  
IMP-04  .................................................Q..........  
IMP-05  .................................................Q..........  
IMP-06  ............................................................  
IMP-07  D................................................Q..........  
IMP-08  D..........T......N...........T..................Q..........  
IMP-09  D..............N..N.......R......................Q..........  
IMP-10  ............................................................  
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IMP-11  D.................N..............................Q.......V..  
IMP-12  D.........N.......A...G..FT....V.................Q..........  
IMP-13  D..........T......N.......E...T..................Q..........  
IMP-14  D.......I.........N..............T...G...A.......Q..........  
IMP-15  .................................................Q..........  
IMP-16  D........A........N.....................S........Q..........  
IMP-17  D..........T......N.......E...T..................Q..........  
IMP-18  D.......I.........N..I.H..R......T...G...A.......Q..S.......  
IMP-19  D..........T......N...........T..................Q..........  
IMP-20  D..........T......N...........T..................Q..........  
IMP-21  D.................N..............................Q.......V..  
IMP-22  D................................................Q..........  
IMP-23  D..........T......N...........T..................Q..........  
IMP-24  D..........T......N...........T..................Q..........  
IMP-25  ............................................................  
IMP-26  .................................................Q..........  
IMP-27  D.................N...........TV.................Q..........  
IMP-28  ......................G..........................Q..........  
IMP-29  .................................................Q..........  
IMP-30  ............................................................  
IMP-31  D..I..............R...G.................A........Q.......K..  
IMP-32  D.......I.........N..............T...G...A.......Q..........  
IMP-33  D..........T......N...........T..................Q..........  
IMP-34  ............................................G...............  
IMP-35  D..I..............R...G.................A........Q.......K..  
IMP-37  D..........T......N.......E...T..................Q..........  
IMP-38  .................................................Q..........  
IMP-40  ........S...................................................  
IMP-41  D.................N..............................Q.......V..  
IMP-42  ............................................................  
IMP-43  D................................................Q..........  
IMP-44  D.......S.........N..............................Q.......V..  
IMP-45  D..............N..N.......R......................Q..........  
IMP-48  D.......T.........N..............T...G...A.......Q..........  
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IMP-49  D.......I.........N..I.H..R......T...G...A.......Q..S.......  
IMP-51  D................................................Q..........  
IMP-52  ...I.............G..........................................  
IMP-53  D..............N..N.......R......................Q..........  
IMP-54  D.......V.........N..............T...G...A.......Q..........  
IMP-55  ............................................................  
IMP-56  D.......I.........N..I.H..R......T...G...A.......Q..S.......  
IMP-58  D................................................Q..........  
IMP-59  .................................................Q..........  
IMP-60  ............................................................  
IMP-61  ...............................................I............  
IMP-62  .................................................Q..........  
IMP-63  D.........N.......A...G..FT....V.................Q..........  
IMP-64  D.................N...........TV.................Q..........  
IMP-66  ............................................................  
IMP-67  D.................N...........TV.................Q..........  
IMP-68  D.................N..............................Q.......V..  
IMP-69  D..........T......N...........T..................Q..........  
IMP-70  ............................................................  
 
                130       140       150       160       170       180      
        ....|....|....|....|....|....|....|....|....|....|....|....| 
IMP-01  NELLKKDGKVQATNSFSGVNYWLVKNKIEVFYPGPGHTPDNVVVWLPERKILFGGCFIKP  
IMP-02  ............K......S..................Q.........K........V..  
IMP-03  ............................................................  
IMP-04  ............K...G........................L..................  
IMP-05  ............K.....AS.....K......................NRV......V..  
IMP-06  ............................................................  
IMP-07  ............K.....AS.....K...I..................HRV......V..  
IMP-08  ............K......S..................Q.........K........V..  
IMP-09  ............KY.....S.....K...........A..........NRV......V..  
IMP-10  ............................................................  
IMP-11  ............K......S..................Q........KN........V..  
IMP-12  ......N............S.........I........Q.........N........V..  
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IMP-13  ......S.....KY...E.S..................Q..L......S...........  
IMP-14  .......N....KH..N..S.S.I..............Q.........K........V..  
IMP-15  ............K.....GS....N.......................NRV......V..  
IMP-16  ......N.....K......S...L.....I........Q.........K........V..  
IMP-17  ......S.....KY.....S..................Q..L......SE..........  
IMP-18  .......N...........S.S.I..............Q.........K........V..  
IMP-19  ............K......S..................Q.........K........V..  
IMP-20  ............K......S..................Q.........K........V..  
IMP-21  ............K......S..................Q........KN........V..  
IMP-22  .D...QN.....K......S..................Q.........K........V..  
IMP-23  ............K......S..................Q.........K........V..  
IMP-24  ............K......S..................Q.........K........V..  
IMP-25  ............................................................  
IMP-26  ............K...G........................L..................  
IMP-27  ............K...D..S...A.D............Q.........KE.......V..  
IMP-28  ............K...G..S............................NRV......V..  
IMP-29  ......G.....K......S.....K......................NRV......V..  
IMP-30  ............................................................  
IMP-31  ......N.NA..E......S.....H............Q.........K...........  
IMP-32  .......N....KH..Y..S.S.I..............Q.........K........V..  
IMP-33  ......S.....KY...E.S..................Q..L......S........V..  
IMP-34  ............................................................  
IMP-35  ......N.NA..E......S.....H............Q.........K...........  
IMP-37  ......S.....KY...E.S..................Q..L......S...........  
IMP-38  ............K...G........................L..................  
IMP-40  ............................................................  
IMP-41  ............K......S..................Q........KN........V..  
IMP-42  ............................................................  
IMP-43  ............K.....AS.....K...I..................HRV......V..  
IMP-44  ............K......S..................Q........KN........V..  
IMP-45  ............KY.....S.....K...........A..........NRV......V..  
IMP-48  .......N....KH..N..S.S.I..............Q.........K........V..  
IMP-49  .......N...........S.S.I..............Q.........K........V..  
IMP-51  ............K.....AS.....K...I..................HRV......V..  
 
 232 
IMP-52  ............................................................  
IMP-53  ............KY.....S.....K........S..A..........NRV......V..  
IMP-54  .......N....KH..N..S.S.I..............Q.........K........V..  
IMP-55  ...................................................F........  
IMP-56  .......N...........S.S.I..............Q.........K........V..  
IMP-58  .D...QN.....K......S..................Q.........K........V..  
IMP-59  ............K...G........................L..................  
IMP-60  ...............................................K............  
IMP-61  ............................................................  
IMP-62  ............K.....GS....N.......................NRV......V..  
IMP-63  ......N............S.........I........Q.........N........V..  
IMP-64  ............K...D..S...A.D............Q.........KE.......V..  
IMP-66  ............................................................  
IMP-67  ............K...D..S...A.D............Q.........KE.......V..  
IMP-68  ............K......S..................Q........KN........V..  
IMP-69  ............K......S..................Q.........K........V..  
IMP-70  ............................................................  
 
                190       200       210       220       230       240      
        ....|....|....|....|....|....|....|....|....|....|....|....| 
IMP-01  YGLGNLGDANIEAWPKSAKLLKSKYGKAKLVVPSHSEVGDASLLKLTLEQAVKGLNESKK  
IMP-02  D.........L........I.M...V......S....I.......R.W............  
IMP-03  .................................G..........................  
IMP-04  ..........L..........I...............A......................  
IMP-05  ..........V..........M.......................R..............  
IMP-06  .................................G..........................  
IMP-07  ..........L..........V.......................R..............  
IMP-08  D.........L........I.M..........S....I.......R.W............  
IMP-09  ..........L..........M...S..........DI..S......W..T...F.....  
IMP-10  ............................................................  
IMP-11  ......D...V....H..EK.I....N.........DI.........W............  
IMP-12  D.....D...LK.......I.M..........SG...I.N.......W.......K....  
IMP-13  H.........L........I.M..........S....K.....M.R.W...L...K....  
IMP-14  D...Y.....L........I.M..........S...DI..V....R.W............  
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IMP-15  ..........L........I.M..........S....T.N.......W.......K....  
IMP-16  ......D...V....H..EI.M.R..N.........D..........W.......K....  
IMP-17  H.........L........I.M..........S....K.....M.R.W...L...K....  
IMP-18  D.........L........I.M..........S....I.N....QR.W............  
IMP-19  D.........L........I.M...V......S....I.......R.W............  
IMP-20  D.........L........I.M...V......S....I.......R.W............  
IMP-21  ......D...V....H..EK.I....N.........DI.........W............  
IMP-22  ......D...VV...H..EI.M.R..N.........DI.........W.......K....  
IMP-23  D.........L........I.M..........S....I.......R.W............  
IMP-24  D.........L........I.M..........S....I.......R.W..........R.  
IMP-25  ......S..........................G..........................  
IMP-26  ..........L..........I...............A......................  
IMP-27  H.........L....E...I.ME.........SG...T...TH..R.W.......K....  
IMP-28  ..........L..........M.......................R...H..........  
IMP-29  ......D...V....H..EI.M.R..N.........DI.N.......W.......K....  
IMP-30  ............................................................  
IMP-31  D...Y.....L.......ET.M....N.....S....I.G.....R.W.......K...N  
IMP-32  D...Y.....L........I.M..........S...DI..V....R.W............  
IMP-33  H.........L........I.M..........S....K.......R.W...L...K....  
IMP-34  ............................................................  
IMP-35  D...Y.....L.......ET.M....N.....S....I.G.....R.W.......K....  
IMP-37  H.........L........I.M..........S....K.....M.R.W...L...K....  
IMP-38  ..........L..........I...........G...A......................  
IMP-40  ............................................................  
IMP-41  ......D...V....H..EK.I....N.........DI.........W............  
IMP-42  ............................................................  
IMP-43  ..........L..........V.......................R..............  
IMP-44  ......D...V....H..EK.I....N.........DI.........W............  
IMP-45  ..........L..........M...S.......G..DI..S......W..T...F.....  
IMP-48  D...Y.....L........I.M..........S...DI..V....R.W............  
IMP-49  D.........L........I.M..........S....I.N....QR.W............  
IMP-51  ..........L..........V...........G...........R..............  
IMP-52  ............................................................  
IMP-53  ..........L..........M...S.......G..DI..S......W..T...F.....  
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IMP-54  D...Y.....L........I.M..........S...DI..V....R.W............  
IMP-55  ....K.......................................................  
IMP-56  D.........L........I.M..........SG...I.N....QR.W............  
IMP-58  ......D...VV...H..EI.M.R..N.........DI.........W.......K....  
IMP-59  ....Y.....L..........I...............A......................  
IMP-60  ............................................................  
IMP-61  ............................................................  
IMP-62  ..........L........I.M..........SG...T.N.......W.......K....  
IMP-63  D.....D...LK.......I.M..........S....I.N.......W.......K....  
IMP-64  H.........L....E...I.ME.........SG...T...TH..R.W.......K....  
IMP-66  ............................................................  
IMP-67  H.........L....E...I.ME.........SG...T..STH..R.W.......K....  
IMP-68  ......D...V....H..EK.I....N......G..DI.........W............  
IMP-69  D.........L........I.M..........S....I.......R.W............  
IMP-70  ...............................................I............  
 
               
        ....|... 
IMP-01  PSKPS--N  
IMP-02  ..Q..--.  
IMP-03  .....--.  
IMP-04  ...L.--.  
IMP-05  .....--.  
IMP-06  .....--.  
IMP-07  L....--.  
IMP-08  ..Q..--.  
IMP-09  -.TTA--H  
IMP-10  .....--.  
IMP-11  -.NTV--H  
IMP-12  .LL..--.  
IMP-13  T.S..--.  
IMP-14  S.Q..--D  
IMP-15  ..L..--.  
IMP-16  ..Q..--.  
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IMP-17  T.S..--.  
IMP-18  .LQ..--S  
IMP-19  ..Q..--.  
IMP-20  ..Q..--.  
IMP-21  -.NTV--H  
IMP-22  ..E..--.  
IMP-23  ..Q..--.  
IMP-24  ..Q..--.  
IMP-25  .....--.  
IMP-26  ...L.--.  
IMP-27  TLQ..--.  
IMP-28  .....--.  
IMP-29  ..Q..--.  
IMP-30  .....--.  
IMP-31  HHS.K---  
IMP-32  S.Q..--D  
IMP-33  T.S..--.  
IMP-34  .....--.  
IMP-35  ..Q.N--.  
IMP-37  T.SQ.TAS  
IMP-38  ...L.--.  
IMP-40  .....--.  
IMP-41  -.NTV--H  
IMP-42  .....--.  
IMP-43  L....--.  
IMP-44  -.NTV--H  
IMP-45  -.TTA--H  
IMP-48  S.Q..--D  
IMP-49  .LQ..--S  
IMP-51  L....--.  
IMP-52  .....--.  
IMP-53  -.TTA--H  
IMP-54  S.Q..--D  
IMP-55  .....--.  
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IMP-56  .LQ..--S  
IMP-58  ..E..--.  
IMP-59  ...L.--.  
IMP-60  .....--.  
IMP-61  .....--.  
IMP-62  ..L..--.  
IMP-63  .LL..--.  
IMP-64  TLQ..--.  
IMP-66  .....--.  
IMP-67  TLQ..--.  
IMP-68  -.NTV--H  
IMP-69  ..Q..--.  
IMP-70  .....--.  
 
Table of IMP variant amino acid differences relative to IMP-1 
IMP-2 S2K, S5F, F7L, F8C, I9V, F10C, L11F, F12L, A16T, T17A, A19G, E20A, S21R, D31E, 
P50S, A60T, E61D, K72T, T79N, S91T, R110Q, T133K, N140S, P159Q, R169K, I178V, 
Y181D, I191L, L200I, K202M, G206V, P213S, V218I, L226R, L228W, K243Q 
IMP-3 E105G, S214G 
IMP-4 S21P, N59D, R110Q, T133K, S137G, V162L, I191L, K202I, V218A, P244L 
IMP-5 S5F, I9M, A16T, T17A, A60T, R110Q, T133K, V139A, N140S, N146K, R169N, 
K170R, I171V, I178V, I191V, K202M, L226R 
IMP-6 S214G 
IMP-7 S2K, I9M, T17A, A18S, A19G, S21A, A60T, E61D, R110Q, T133K, V139A, N140S, 
N146K, V150I, R169H, K170R, I171V, I178V, I191L, K202V, L226R, P241L 
IMP-8 S2K, S5F, F7L, F8C, I9V, F10C, L11F, F12L, A16T, T17A, A19G, E20A, S21A, D31E, 
P50S, A60T, E61D, K72T, T79N, S91T, R110Q, T133K, N140S, P159Q, R169K, I178V, 
Y181D, I191L, L200I, K202M, P213S, V218I, L226R, L228W, K243Q 
IMP-9 S5F, I9M, A16T, T17A, A19G, V49I, A60T, E61D, K76N, T79N, K87R, R110Q, 
T133K, N134Y, N140S, N146K, T158A, R169N, K170R, I171V, I178V, I191L, K202M, 
G206S, E217D, V218I, A221S, L228W, A231T, L235F, P241del, K243T, P244T, 
S245A, N246H 
IMP-10 V49F 
IMP-11 S2K, S5F, F7L, F8C, A16T, T17A, A19G, E20A, D31E, P50S, A60T, E61D, T79N, 
R110Q, E118V, T133K, N140S, P159Q, E168K, R169N, I178V, G187D, I191V, K196H, 




IMP-12 S2K, S5F, F7L, F8C, C13L, A16T, T17A, A18S, A19G, S21V, D31E, V36L, N44S, 
P50T, A60N, E61D, A71N, T79A, E83G, Y86F, K87T, I92V, R110Q, D127N, N140S, 
V150I, P159Q, R169N, I178V, Y181D, G187D, I191L, E192K, L200I, L202M, P213S, 
S214G, V218I, D220N, L228W, N236K, S242L, K243L 
IMP-13 S2K, S5F, F7L, F8C, I9V, F10C, L11F, A16T, T17A, A19G, E20A, S21A, D31E, Y35F, 
P50T, A60T, E61D, K72T, T79N, K87E, S91T, R110Q, D127S, T133K, N134Y, G138E, 
N140S, P159Q, V162L, R169S, Y181H, I191L, L200I, K202M, P213S, V218K, L224M, 
L226R, L228W, V232L, N236K, P241T, K243S 
IMP-14 S2K, S5F, F7L, F8C, I9V, L11F, S14N, T17V, A19E, D31E, N44K, G47S, P50T, N59K, 
A60N, E61D, F69I, T79N, S94T, S98G, G102A, R110Q, G128N, T133K, N134H, 
S137N, N140S, W142S, V144I, P159Q, R169K, I178V, Y181D, N185Y, I191L, L200I, 
K202M, P213S, E217D, V218I, A221V, L226R, L228W, P241S, K243Q, N246D 
IMP-15 S2N, I9M, L11M, A16T, T17A, A19G, A60T, R110Q, T133K, V139G, N140S, K145N, 
R169N, K170R, I171V, I178V, I191L, L200I, K202M, P213S, V218T, D220N, L228W, 
N236K, K243L 
IMP-16 S2K, S5F, F7L, F8C, A16T, T17A, A19G, D31E, E32D, P50T, V56F, A60T, E61D, 
T70A, T79N, T101S, R110Q, D127N, T133K, N140S, V144L, V150I, P159Q, R169K, 
I178V, G187D, I191V, K196H, K199E, L200I, K202M, K204R, K207N, E217D, 
L228W, N236K, K243Q 
IMP-17 S2K, S5F, F7L, F8C, T9V, F10C, L11F, A16T, T17A, A19G, E20A, S21A, D31E, Y35F, 
P50T, A60T, E61D, K72T, T79N, K87E, S91T, R110Q, D127S, T133K, N134Y, N140S, 
P159Q, V162L, R169S, K170E, Y181H, I191L, L200I, K202M, P213S, V218K, L224M, 
L226R, L228W, V232L, N236K, P241T, K243S 
IMP-18 S2K, S5F, F7L, F8C, I9V, L11F, F12L, S14N, T17A, A19D, E20D, D31E, E32K, N44K, 
P50T, N59K, A60N, E61D, F69I, T79N, V82I, R84H, K87R, S94T, S98G, G102A, 
R110Q, P113S, G128N, N140S, W142S, V144I, P159Q, R169K, I178V, Y181D, I191L, 
L200I, K202M, P213S, V218I, D220N, K225Q, L226R, L228W, S242L, K243Q, N246S 
IMP-19 S2K, S5F, F7L, F8C, I9V, F10C, L11F, F12L, A16T, T17A, A19G, E20A, S21A, D31E, 
P50S, A60T, E61D, K72T, T79N, S91T, R110Q, T133K, N140S, P159Q, R169K, I178V, 
Y181D, I191L, L200I, K202M, G206V, P213S, V218I, L226R, L228W, K243Q 
IMP-20 S2K, S5F, F7L, F8C, I9V, F10C, L11F, F12L, A16T, T17A, A19G, E20A, S21A, D31E, 
V49F, P50S, A60T, E61D, K72T, T79N, S91T, R110Q, T133K, N140S, P159Q, R169K, 
I178V, Y181D, I191L, L200I, K202M, G206V, P213S, V218I, L226R, L228W, K243Q 
IMP-21 S2K, S5F, F7L, F8C, A16T, T17A, A19G, E20A, D31E, V49A, P50S, A60T, E61D, 
T79N, R110Q, E118V, T133K, N140S, P159Q, E168K, R169N, I178V, G187D, I191V, 
K196H, K199E, L200K, K202I, K207N, E217D, V218I, L228W, P241del, K243N, 
P244T, S245V, N246H 
IMP-22 S2K, S5F, F7L, F8C, I9V, A16T, T17A, A19G, D31E, P50S, V56I, A60T, E61D, 
R110Q, E122D, K126Q, D127N, T133K, N140S, P159Q, R169K, I178V, G187D, I191V, 




IMP-23 S2K, S5F, F7L, F8C, I9V, F10C, L11F, F12L, A16T, T17A, A19G, E20A, S21A, D31E, 
V49F, P50S, A60T, E61D, K72T, T79N, S91T, R110Q, T133K, N140S, P159Q, R169K, 
I178V, Y181D, I191L, L200I, K202M, P213S, V218I, L226R, L228W, K243Q 
IMP-24 S2K, S5F, F7L, F8C, I9V, F10C, L11F, F12L, A16T, T17A, A19G, E20A, S21A, D31E, 
P50S, A60T, E61D, K72T, T79N, S91T, R110Q, T133K, N140S, P159Q, R169K, I178V, 
Y181D, I191L, L200I, K202M, P213S, V218I, L226R, L228W, K239R, K243Q 
IMP-25 G187S, S214G 
IMP-26 S21P, V49F, N59D, R110Q, T133K, S137G, V162L, I191L, K202I, V218A, P244L 
IMP-27 S2K, S5F, F7L, F8C, I9V, L11V, A16T, T17V, A19G, S21T, D24N, K26R, I27V, D31E, 
F40Y, N44K, P50T, V58I, N59G, E61D, T79N, S91T, I92V, R110Q, T133K, S137D, 
N140S, V144A, N146D, D159Q, R169K, K170E, I178V, Y181H, I191L, K196E, L200I, 
K202M, S203E, P213S, S214G, V218T, S222T, L223H, L226R, L228W, N236K, P241T, 
S242L, K243Q 
IMP-28 S5F, I9M, A16T, T17A, K29R, A60T, E83G, R110Q, T133K, S137G, N140S, R169N, 
K170R, I171V, I178V, I191L, K202M, L226R, Q230H 
IMP-29 S5F, F8L, A16T, T17A, A60T, R110Q, D127G, T133K, N140S, N146K, R169N, K170R, 
I171V, I178V, G187D, I191V, K196H, K199E, L200I, K202M, K204R, K207N, E217D, 
V218I, D220N, L228W, N236K, K243Q 
IMP-30 E41K 
IMP-31 S2K, L4I, S5F, F7L, I9V, A16T, T17A, A19G, L25I, G33D, E42K, V43I, N44T, V49I, 
P50T, A60T, E61D, L64I, T79R, E83G, T101A, R110Q, E118K, D127N, K129N, 
V130A, T133S, N140S, N146H, P159Q, R169K, Y181D, N185Y, I191L, K199E, L200T, 
K202M, K207N, P213S, V218I, D220G, L226R, L228W, N236K, K240N, P241H, 
S242H, K243S, S245K 
IMP-32 S2K, S5F, F7L, F8C, I9V, L11F, S14N, T17V, A19E, D31E, N44K, G47S, P50T, N59K, 
A60N, E61D, F69I, T79N, S94T, S98G, G102A, R110Q, G128N, T133K, N134H, 
S137Y, N140S, W142S, V144I, P159Q, R169K, I178V, Y181D, N185Y, I191L, L200I, 
K202M, P213S, E217D, V218I, A221V, L226R, L228W, P241S, K243Q, N246D 
IMP-33 S2K, S5F, F7L, F8C, I9V, F10C, L11F, A16T, T17A, A19G, E20S, D31E, Y35F, P50T, 
A60T, E61D, K72T, T79N, S91T, R110Q, D127S, T133K, N134Y, G138E, N140S, 
P159Q, V162L, R169S, I178V, Y181H, I191L, L200I, K202M, P213S, V218K, L226R, 
L228W, V232L, N236K, P241T, K243S 
IMP-34 E105G 
IMP-35 S2K, L4I, S5F, F7L, I9V, A16T, T17A, A19G, L25I, G33D, V43D, V49I, P50T, A60T, 
E61D, L64I, T79R, E83G, T101A, R110Q, E118K, D127N, K129N, V130A, T133E, 
N140S, N146H, P159Q, R169K, Y181D, N185Y, I191L, K199E, L200T, K202M, 
K207N, P213S, V218I, D220G, L226R, L228W, N236K, K243Q, S245N 
IMP-37 S2K, S5F, F7L, F8C, I9V, F10C, L11F, A16T, T17A, A19G, E20A, S21A, D31E, Y35F, 
P50T, A60T, E61D, K72T, T79N, K87E, S91T, R110Q, D127S, T133K, N134Y, G138E, 
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N140S, P159Q, V162L, R169S, Y181H, I191L, L200I, K202M, P213S, V218K, L224M, 
L226R, L228W, V232L, N236K, P241T, K243S, P244Q, S245_N246insTA, N246S 
IMP-38 S21P, N59D, R110Q, T133K, S137G, V162L, I191L, K202I, S214G, V218A, P244L 
IMP-40 V49F, F69S 
IMP-41 S2K, S5F, F7L, F8C, A16T, T17A, A19G, E20A, D31E, V49F, P50S, A60T, E61D, 
T79N, R110Q, E118V, T133K, N140S, P159Q, E168K, R169N, I178V, G187D, I191V, 
K196H, K199E, L200K, K202I, K207N, E217D, V218I, L228W, P241del, K243N, 
P244T, S245V, N246H 
IMP-42 G45R 
IMP-43 S2K, I9M, T17A, A18S, A19G, S21A, V49F, A60T, E61D, R110Q, T133K, V139A, 
N140S, N146K, V150I, R169H, K170R, I171V, I178V, I191L, K202V, L226R, P241L 
IMP-44 S2K, S5F, F7L, F8C, A16T, T17A, A19G, E20A, D31E, V49F, P50S, A60T, E61D, 
F69S, T79N, R110Q, E118V, T133K, N140S, P159Q, E168K, R169N, I178V, G187D, 
I191V, K196H, K199E, L200K, K202I, K207N, E217D, V218I, L228W, P241del, 
K243N, P244T, S245V, N246H 
IMP-45 S5F, I9M, A16T, T17A, A19G, V49I, A60T, E61D, K76N, T79N, K87R, R110Q, 
T133K, N134Y, N140S, N146K, T158A, R169N, K170R, I171V, I178V, I191L, K202M, 
G206S, S214G, E217D, V218I, A221S, L228W, A231T, L235F, P241del, K243T, 
P244T, S245A, N246H 
IMP-48 S2K, S5F, F7L, F8C, I9V, L11F, S14N, T17V, A19E, D31E, N44K, G47S, P50T, N59K, 
A60N, E61D, F69T, T79N, S94T, S98G, G102A, R110Q, G118N, T133K, N134H, 
S137N, N140S, W142S, V144I, P159Q, R169K, I178V, Y181D, N185Y, I191L, L200I, 
K202M, P213S, E217D, V218I, A221V, L226R, L228W, P241S, K243Q, N246D 
IMP-49 S2K, S5F, F7L, F8C, I9V, L11F, F12L, S14N, T17A, A19D, E20D, D31E, E32K, N44K, 
V49F, P50T, N59K, A60N, E61D, F69I, T79N, V82I, R84H, K87R, S94T, S98G, 
G102A, R110Q, P113S, G128N, N140S, W142S, V144I, P159Q, R169K, I178V, Y181D, 
I191L, L200I, K202M, P213S, V218I, D220N, K225Q, L226R, L228W, S242L, K243Q, 
N246S 
IMP-51 S2K, I9M, T17A, A18S, A19G, S21A, A60T, E61D, R110Q, T133K, V139A, N140S, 
N146K, V150I, R169H, K170R, I171V, I178V, I191L, K202V, S214G, L226R, P241L 
IMP-52 L64I, V78G 
IMP-53 S5F, I9M, A16T, T17A, A19G, V49I, A60T, E61D, K76N, T79N, K87R, R110Q, 
T133K, N134Y, N140S, N146K, P155S, T158A, R169N, K170R, I171V, I178V, I191L, 
K202M, G206S, S214G, E217D, V218I, A211S, L228W, A231T, L235F, P241del, 
K243T, P244T, S245A, N246H 
IMP-54 S2K, S5F, F7L, F8C, I9V, L11F, S14N, T17V, A19E, D31E, N44K, G47S, P50T, N59K, 
A60N, E61D, F69V, T79N, S94T, S98G, G102A, R110Q, G128N, T133K, N134H, 
S137N, N140S, W142S, V144I, P159Q, R169K, I178V, Y181D, N185Y, I191L, L200I, 
K202M, P213S, E217D, V218I, A221V, L226R, L228W, P241S, K243Q, N246D 
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IMP-55 F12I, D31E, E41K, L172F, N185K 
IMP-56 S2K, S5F, F7L, F8C, I9V, L11F, F12L, S14N, T17A, A19D, E20D, D31E, E32K, N44K, 
P50T, N59K, A60N, E61D, F69I, T79N, V82I, R84H, K87R, S94T, S98G, G102A, 
R110Q, P113S, G128N, N140S, W142S, V144I, P159Q, R169K, I178V, Y181D, I191L, 
L200I, K202M, P213S, S214G, V218I, D220N, K225Q, L226R, L228W, S242L, K243Q, 
N246S 
IMP-58 S2K, S5F, F7L, F8C, I9V, A16T, T17A, A19G, D31E, V49F, P50S, V56I, A60T, E61D, 
R110Q, E122D, K126Q, D127N, T133K, N140S, P159Q, R169K, I178V, G187D, I191V, 
E192V, K196H, K199E, L200I, K202M, K204R, K207N, E217D, V218I, L228W, 
N236K, K243E 
IMP-59 S21P, N59D, R110Q, T133K, S137G, V162L, N185Y, I191L, K202I, V218A, P244L 
IMP-60 E168K 
IMP-61 N108I 
IMP-62 S2N, I9M, L11M, A16T, T17A, A19G, A60T, R110Q, T133K, V139G, N140S, K145N, 
R169N, K170R, I171V, I178V, I191L, L200I, K202M, P213S, S214G, V218T, D220N, 
L228W, N236K, K243L 
IMP-63 S2K, S5F, F7L, F8C, C13L, A16T, T17A, A18S, A19G, S21V, D31E, V36L, N44S, 
P50T, A60N, E61D, A71N, T79A, E83G, Y86F, K87T, I92V, R110Q, D127N, N140S, 
V150I, P159Q, R169N, I178V, Y181D, G187D, I191L, E192K, L200I, K202M, P213S, 
V218I, D220N, L228W, N236K, S242L, K243L 
IMP-64 S2K, S5F, F7L, F8C, T9V, L11V, A16T, T17V, S21T, D24N, K26R, I27V, D31E, F40Y, 
N44K, P50T, V58I, N59G, E61D, T79N, S91T, I92V, R110Q, T133K, S137D, N140S, 
V144A, N146D, P159Q, R169K, K170E, I178V, Y181H, I191L, K196E, L200I, K202M, 
S203E, P213S, S214G, V218T, S222T, L223H, L226R, L228W, N236K, P241T, S242L, 
K243Q 
IMP-66 V48F 
IMP-67 S2K, S5F, F7L, F8C, I9V, L11V, A16T, T17V, A19G, S21T, D24N, K26R, I27V, D31E, 
F40Y, N44K, P50T, V58I, N59G, E61D, T79N, S91T, I92V, R110Q, T133K, S137D, 
N140S, V144A, N146D, P159Q, R169K, K170E, I178V, Y181H, I191L, K196E, L200I, 
K202M, S203E, P213S, S214G, V218T, A221S, S222T, L223H, L226R, L228W, 
N236K, P241T, S242L, K243Q 
IMP-68 S2K, S5F, F7L, F8C, A16T, T17A, A19G, E20A, D31E, P50S, A60T, E61D, T79N, 
R110Q, E118V, T133K, N140S, P159Q, E168K, R169N, I178V, G187D, I191V, K196H, 
K199E, L200K, K202I, K207N, S214G, E217D, V218I, L228W, P241del, K243N, 
P244T, S245V, N246H 
IMP-69 S2K, S5F, F7L, F8C, I9V, F10C, L11F, F12L, A16T, T17A, A19G, E20A, S21T, D31E, 
P50S, A60T, E61D, K72T, T79N, S91T, R110Q, T133K, N140S, P159Q, R169K, I178V, 
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